Document:

Credit Agreement, dated August 26, 2008

 Exhibit 10.1 
  

			
	

	  	

 Published CUSIP Number: 27885FAA7 
  
  
  
 $125,000,000 
 CREDIT AGREEMENT 
 among 
 ECLIPSYS CORPORATION, 
 as Borrower 

CERTAIN DOMESTIC SUBSIDIARIES OF THE BORROWER 
 FROM TIME TO TIME PARTY HERETO, 
 as Guarantors, 
 THE LENDERS PARTY HERETO, 
 and 
 WACHOVIA BANK, NATIONAL ASSOCIATION, 
 as Administrative Agent, 
 BANK OF AMERICA, N.A., 
 as Co-Syndication
Agent 
 and 
 SUNTRUST BANK,

 as Co-Syndication Agent 
 Dated
as of August 26, 2008 
 WACHOVIA CAPITAL MARKETS, LLC 
 as Sole Lead Arranger and Joint Bookrunner 
 and 
 BANC OF AMERICA SECURITIES LLC, 
 as Joint Bookrunner 
  
  
  
  

	
	Prepared by:
	
	

 TABLE OF CONTENTS 
  

					
	  	    	 	  	Page
	 ARTICLE I DEFINITIONS
	  	6
	 Section 1.1
	    	Defined Terms	  	6
	 Section 1.2
	    	Other Definitional Provisions	  	37
	 Section 1.3
	    	Accounting Terms	  	38
	 Section 1.4
	    	Time References	  	39
	 Section 1.5
	    	Execution of Documents	  	39
		
	 ARTICLE II THE LOANS; AMOUNT AND TERMS
	  	39
	 Section 2.1
	    	Revolving Loans	  	39
	 Section 2.2
	    	Incremental Revolving Facility	  	41
	 Section 2.3
	    	Letter of Credit Subfacility	  	42
	 Section 2.4
	    	Swingline Loan Subfacility	  	46
	 Section 2.5
	    	Fees	  	48
	 Section 2.6
	    	Commitment Termination and Reductions	  	49
	 Section 2.7
	    	Prepayments	  	50
	 Section 2.8
	    	Default Rate and Payment Dates	  	51
	 Section 2.9
	    	Conversion Options	  	52
	 Section 2.10
	    	Computation of Interest and Fees; Usury	  	53
	 Section 2.11
	    	Pro Rata Treatment and Payments	  	54
	 Section 2.12
	    	Non-Receipt of Funds by the Administrative Agent	  	56
	 Section 2.13
	    	Inability to Determine Interest Rate	  	57
	 Section 2.14
	    	Yield Protection	  	58
	 Section 2.15
	    	Indemnity	  	59
	 Section 2.16
	    	Taxes	  	60
	 Section 2.17
	    	Indemnification in Respect of Letters of Credit; Nature of Issuing Lender’s Duties	  	62
	 Section 2.18
	    	Illegality	  	64
	 Section 2.19
	    	Mitigation Obligations; Replacement of Lenders	  	64
		
	 ARTICLE III REPRESENTATIONS AND WARRANTIES
	  	65
	 Section 3.1
	    	Financial Condition	  	65
	 Section 3.2
	    	No Material Adverse Effect	  	66
	 Section 3.3
	    	Corporate Existence; Compliance with Law	  	66
	 Section 3.4
	    	Corporate Power; Authorization; Enforceable Obligations	  	67
	 Section 3.5
	    	No Legal Bar; No Default	  	67
	 Section 3.6
	    	No Material Litigation	  	67
	 Section 3.7
	    	Investment Company Act; etc.	  	68
	 Section 3.8
	    	Margin Regulations	  	68
	 Section 3.9
	    	ERISA	  	68
	 Section 3.10
	    	Environmental Matters	  	69
	 Section 3.11
	    	Use of Proceeds	  	70
	 Section 3.12
	    	Subsidiaries; Joint Ventures; Partnerships	  	70
	 Section 3.13
	    	Ownership	  	70
	 Section 3.14
	    	Taxes	  	70
	 Section 3.15
	    	Intellectual Property Rights	  	71

  

 2 

					
	 Section 3.16
	    	Solvency	  	71
	 Section 3.17
	    	Location of Offices	  	72
	 Section 3.18
	    	No Burdensome Restrictions	  	72
	 Section 3.19
	    	Brokers’ Fees	  	72
	 Section 3.20
	    	Labor Matters	  	72
	 Section 3.21
	    	Accuracy and Completeness of Information	  	72
	 Section 3.22
	    	Insurance	  	73
	 Section 3.23
	    	Security Documents	  	73
	 Section 3.24
	    	Classification of Senior Indebtedness	  	73
	 Section 3.25
	    	Anti-Terrorism Laws	  	73
	 Section 3.26
	    	Compliance with OFAC Rules and Regulations	  	74
	 Section 3.27
	    	Compliance with FCPA	  	74
	 Section 3.28
	    	Consent; Governmental Authorizations	  	74
		
	 ARTICLE IV CONDITIONS PRECEDENT
	  	74
	 Section 4.1
	    	Conditions to Closing Date	  	74
	 Section 4.2
	    	Conditions to All Extensions of Credit	  	79
		
	 ARTICLE V AFFIRMATIVE COVENANTS
	  	80
	 Section 5.1
	    	Financial Statements	  	80
	 Section 5.2
	    	Certificates; Other Information	  	81
	 Section 5.3
	    	Payment of Taxes and Other Obligations	  	82
	 Section 5.4
	    	Conduct of Business and Maintenance of Existence	  	82
	 Section 5.5
	    	Maintenance of Property; Insurance	  	83
	 Section 5.6
	    	Inspection of Property; Books and Records; Discussions	  	83
	 Section 5.7
	    	Notices	  	83
	 Section 5.8
	    	Environmental Laws	  	85
	 Section 5.9
	    	Financial Covenants	  	85
	 Section 5.10
	    	Additional Guarantors	  	85
	 Section 5.11
	    	Compliance with Law	  	86
	 Section 5.12
	    	Pledged Assets	  	86
	 Section 5.13
	    	Further Assurances	  	87
		
	 ARTICLE VI NEGATIVE COVENANTS
	  	88
	 Section 6.1
	    	Indebtedness	  	88
	 Section 6.2
	    	Liens	  	89
	 Section 6.3
	    	Nature of Business	  	89
	 Section 6.4
	    	Consolidation, Merger, Sale or Purchase of Assets, etc.	  	89
	 Section 6.5
	    	Advances, Investments and Loans	  	91
	 Section 6.6
	    	Transactions with Affiliates	  	91
	 Section 6.8
	    	Limitation on Restricted Actions	  	92
	 Section 6.9
	    	Restricted Payments	  	92
	 Section 6.10
	    	Amendment of Subordinated Debt	  	92
	 Section 6.11
	    	No Further Negative Pledges	  	93
	 Section 6.12
	    	Account Control Agreements; Additional Bank Accounts	  	93
		
	 ARTICLE VII EVENTS OF DEFAULT
	  	94
	 Section 7.1
	    	Events of Default	  	94
	 Section 7.2
	    	Acceleration; Remedies	  	97

  

 3 

					
		
	 ARTICLE VIII THE ADMINISTRATIVE AGENT
	  	97
	 Section 8.1
	    	Appointment and Authority	  	97
	 Section 8.2
	    	Nature of Duties	  	97
	 Section 8.3
	    	Exculpatory Provisions	  	98
	 Section 8.4
	    	Reliance by Administrative Agent	  	99
	 Section 8.5
	    	Notice of Default	  	99
	 Section 8.6
	    	Non-Reliance on Administrative Agent and Other Lenders	  	99
	 Section 8.7
	    	Indemnification	  	100
	 Section 8.8
	    	Administrative Agent in Its Individual Capacity	  	100
	 Section 8.9
	    	Successor Administrative Agent	  	101
	 Section 8.10
	    	Other Agents	  	101
	 Section 8.11
	    	Collateral and Guaranty Matters	  	102
		
	 ARTICLE IX MISCELLANEOUS
	  	102
	 Section 9.1
	    	Amendments, Waivers and Release of Collateral	  	102
	 Section 9.2
	    	Notices	  	105
	 Section 9.3
	    	No Waiver; Cumulative Remedies	  	107
	 Section 9.4
	    	Survival of Representations and Warranties	  	107
	 Section 9.5
	    	Payment of Expenses and Taxes; Indemnity	  	107
	 Section 9.6
	    	Successors and Assigns; Participations	  	109
	 Section 9.7
	    	Right of Set-off; Sharing of Payments	  	113
	 Section 9.8
	    	Table of Contents and Section Headings	  	114
	 Section 9.9
	    	Counterparts; Integration; Effectiveness; Electronic Execution	  	114
	 Section 9.10
	    	Severability	  	115
	 Section 9.11
	    	Integration	  	115
	 Section 9.12
	    	Governing Law	  	115
	 Section 9.13
	    	Consent to Jurisdiction; Service of Process and Venue	  	115
	 Section 9.14
	    	Confidentiality	  	116
	 Section 9.15
	    	Acknowledgments	  	117
	 Section 9.16
	    	Waivers of Jury Trial	  	117
	 Section 9.17
	    	Patriot Act Notice	  	118
	 Section 9.18
	    	Resolution of Drafting Ambiguities	  	118
	 Section 9.19
	    	Continuing Agreement	  	118
		
	 ARTICLE X GUARANTY
	  	119
	 Section 10.1
	    	The Guaranty	  	119
	 Section 10.2
	    	Bankruptcy	  	120
	 Section 10.3
	    	Nature of Liability	  	120
	 Section 10.4
	    	Independent Obligation	  	120
	 Section 10.5
	    	Authorization	  	120
	 Section 10.6
	    	Reliance	  	121
	 Section 10.7
	    	Waiver	  	121
	 Section 10.8
	    	Limitation on Enforcement	  	122
	 Section 10.9
	    	Confirmation of Payment	  	123

  

 4 

 Schedules 
  

			
	Schedule 1.1(a)	  	Investments
	Schedule 1.1(b)	  	Liens
	Schedule 1.1(c)	  	Existing Letters of Credit
	Schedule 3.12	  	Subsidiaries
	Schedule 3.14	  	Taxes
	Schedule 3.15	  	Intellectual Property
	Schedule 3.17	  	Chief Executive Offices
	Schedule 3.20	  	Labor Matters
	Schedule 3.22	  	Insurance
	Schedule 6.1(b)	  	Indebtedness
	Schedule 6.12	  	Accounts

 Exhibits 
  

			
	Exhibit 1.1(a)	  	Form of Account Designation Notice
	Exhibit 1.1(b)	  	Form of Assignment and Assumption
	Exhibit 1.1(c)	  	Form of Deposit Account Control Agreement
	Exhibit 1.1(d)	  	Form of Joinder Agreement
	Exhibit 1.1(e)	  	Form of Notice of Borrowing
	Exhibit 1.1(f)	  	Form of Notice of Conversion/Extension
	Exhibit 1.1(g)	  	Form of Permitted Acquisition Certificate
	Exhibit 1.1(h)	  	Form of Securities Account Control Agreement
	Exhibit 2.1(a)	  	Form of Funding Indemnity Letter
	Exhibit 2.1(e)	  	Form of Revolving Note
	Exhibit 2.4(d)	  	Form of Swingline Note
	Exhibit 4.1(b)	  	Form of Officer’s Certificate
	Exhibit 4.1(f)	  	Form of Solvency Certificate
	Exhibit 4.1(o)	  	Form of Financial Condition Certificate
	Exhibit 4.1(p)	  	Form of Patriot Act Certificate
	Exhibit 5.2(a)	  	Form of Officer’s Compliance Certificate

  

 5 

 CREDIT AGREEMENT, dated as of August 26, 2008 among ECLIPSYS CORPORATION, a Delaware
corporation (the “Borrower”), each of those Domestic Subsidiaries of the Borrower identified as a “Guarantor” on the signature pages hereto and such other Domestic Subsidiaries of the Borrower as may from time to time
become a party hereto (such Subsidiaries, each a “Guarantor” and collectively, the “Guarantors”), the several banks and other financial institutions as are, or may from time to time become parties to this Agreement
(each a “Lender” and, collectively, the “Lenders”), and WACHOVIA BANK, NATIONAL ASSOCIATION, a national banking association, as administrative agent for the Lenders hereunder (in such capacity, the
“Administrative Agent”). 
 W I T N E S S E T H:

 WHEREAS, the Credit Parties (as hereinafter defined) have requested that the Lenders make loans and other financial
accommodations to the Credit Parties in an aggregate amount of up to $125,000,000, as more particularly described herein; and 
 WHEREAS, the Lenders have agreed to make such loans and other financial accommodations to the Credit Parties on the terms and conditions contained herein. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, such parties hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS

 Section 1.1 Defined Terms. 
 As used in this Agreement, terms defined in the preamble to this Agreement have the meanings therein indicated, and the following terms have the following meanings: 
 “Accessible Borrowing Availability” shall mean, as of any date of determination, the amount that the Borrower is able to borrow on such
date under the Revolving Committed Amount. 
 “Account Designation Notice” shall mean the Account Designation Notice dated
as of the Closing Date from the Borrower to the Administrative Agent in substantially the form attached hereto as Exhibit 1.1(a). 
 “Additional Credit Party” shall mean each Person that becomes a Guarantor by execution of a Joinder Agreement in accordance with Section 5.10. 
 “Additional Revolving Loan” shall have the meaning set forth in Section 2.2. 
  

 6 

 “Administrative Agent” or “Agent” shall have the meaning set forth in
the first paragraph of this Agreement and shall include any successors in such capacity. 
 “Administrative Questionnaire”
shall mean an Administrative Questionnaire in a form supplied by the Administrative Agent. 
 “Affiliate” shall mean, with
respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. 
 “Agreement” or “Credit Agreement” shall mean this Agreement, as amended, modified, extended, restated, replaced, or
supplemented from time to time in accordance with its terms. 
 “Alternate Base Rate” shall mean, for any day, a rate per
annum equal to the greater of (a) the Prime Rate in effect on such day and (b) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1%. For purposes hereof: “Prime Rate” shall mean, at any time, the
rate of interest per annum publicly announced or otherwise identified from time to time by Wachovia at its principal office in Charlotte, North Carolina as its prime rate. Each change in the Prime Rate shall be effective as of the opening of
business on the day such change in the Prime Rate occurs. The parties hereto acknowledge that the rate announced publicly by Wachovia as its Prime Rate is an index or base rate and shall not necessarily be its lowest or best rate charged to its
customers or other banks; and “Federal Funds Effective Rate” shall mean, for any day, the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds
brokers, as published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such rate is not so published on the next succeeding Business Day, the average of the quotations for the day of such transactions received by
the Administrative Agent from three federal funds brokers of recognized standing selected by it. If for any reason the Administrative Agent shall have determined (which determination shall be conclusive in the absence of manifest error) that it is
unable to ascertain the Federal Funds Effective Rate, for any reason, including the inability or failure of the Administrative Agent to obtain sufficient quotations in accordance with the terms above, the Alternate Base Rate shall be determined
without regard to clause (b) of the first sentence of this definition, as appropriate, until the circumstances giving rise to such inability no longer exist. Any change in the Alternate Base Rate due to a change in the Prime Rate or the Federal
Funds Effective Rate shall be effective on the opening of business on the date of such change. 
 “Alternate Base Rate
Loans” shall mean Loans that bear interest at an interest rate based on the Alternate Base Rate. 
  

 7 

 “Applicable Percentage” shall mean, for any day, the rate per annum set forth below
opposite the applicable level then in effect (based on the Leverage Ratio), it being understood that the Applicable Percentage for (a) Revolving Loans that are Alternate Base Rate Loans shall be the percentage set forth under the column
“Base Rate Margin”, (b) Revolving Loans that are LIBOR Rate Loans shall be the percentage set forth under the column “LIBOR Margin & L/C Fee”, (c) the Letter of Credit Fee shall be the percentage set forth
under the column “LIBOR Margin & L/C Fee”, and (d) the Commitment Fee shall be the percentage set forth under the column “Commitment Fee”: 
 Applicable Percentage 
  

												
	 Level
	  	 Leverage Ratio
	  	LIBOR Margin
& L/C Fee	 	 	Base Rate Margin	 	 	Commitment Fee	 
	I	  	>1.50 to 1.00	  	2.000	%	 	1.000	%	 	0.325	%
	II	  	 3 0.50 to 1.00 but £
 1.50 to 1.00
	  	1.750	%	 	0.750	%	 	0.300	%
	III	  	< 0.50 to 1.00	  	1.500	%	 	0.500	%	 	0.275	%

 The Applicable Percentage shall, in each case, be determined and adjusted quarterly on the date
five (5) Business Days after the date on which the Administrative Agent has received from the Borrower the quarterly financial information (in the case of the first three fiscal quarters of the Borrower’s fiscal year), the annual financial
information (in the case of the fourth fiscal quarter of the Borrower’s fiscal year) and the certifications required to be delivered to the Administrative Agent and the Lenders in accordance with the provisions of Sections 5.1(a), 5.1(b)
and 5.2(a) (each an “Interest Determination Date”). Such Applicable Percentage shall be effective from such Interest Determination Date until the next such Interest Determination Date. After the Closing Date, if the Credit Parties
shall fail to provide the financial information or certifications in accordance with the provisions of Sections 5.1(a), 5.1(b) and 5.2(a), the Applicable Percentage shall, on the date five (5) Business Days after the date by which the Credit
Parties were so required to provide such financial information or certifications to the Administrative Agent and the Lenders, be based on Level I until such time as such information or certifications or corrected information or corrected
certificates are provided, whereupon the Level shall be determined by the then current Consolidated Leverage Ratio. 
 Notwithstanding the
foregoing, the initial Applicable Percentages shall be set at Level II until the financial information and certificates required to be delivered pursuant to Section 5.1 and 5.2 for the first full fiscal quarter to occur following the Closing
Date have been delivered to the Administrative Agent. 
 In the event that any financial statement or certification delivered pursuant to
Sections 5.1 or 5.2(a) is shown to be inaccurate (regardless of whether this Agreement or the Commitments are in effect when such inaccuracy is discovered), and such inaccuracy, if corrected, would have led to the application of a higher Applicable
Percentage for any period (an “Applicable Period”) than the Applicable Percentage applied for such Applicable Period, the Borrower shall immediately (a) deliver to the Administrative Agent a corrected compliance certificate for
such Applicable Period, (b) determine the Applicable Percentage for such Applicable Period based upon the corrected compliance certificate, and (c) immediately pay to the Administrative Agent the accrued additional interest and the accrued
additional Letter of Credit Fees and Commitment Fees, as applicable, owing as a result of such increased Applicable Percentage for such Applicable Period, which payment shall be promptly distributed by the Administrative Agent to the Lenders
entitled thereto. It is acknowledged and agreed that nothing contained herein shall limit the rights of the Administrative Agent and the Lenders under the Credit Documents, including their rights under Sections 2.8 and 7.1. 
  

 8 

 “Approved Bank” shall have the meaning set forth in the definition of “Cash
Equivalents.” 
 “Approved Fund” shall mean any Fund that is administered, managed or underwritten by (a) a
Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender. 
 “Arranger” shall mean WCM. 
 “Asset Disposition” shall mean the disposition of any or all of the
assets (including, without limitation, the Capital Stock of a Subsidiary or any ownership interest in a Person) of any Credit Party or any Subsidiary whether by sale, lease, transfer or otherwise, in a single transaction or in a series of
transactions. The term “Asset Disposition” shall not include (a) the sale, lease, transfer or other disposition of assets permitted by Subsections 6.4(a)(i) through (viii) or (b) any Equity Issuance. 
 “Assignment and Assumption” shall mean an assignment and assumption entered into by a Lender and an Eligible Assignee (with the consent
of any party whose consent is required by Section 9.6), and accepted by the Administrative Agent, in substantially the form of Exhibit 1.1(b) or any other form approved by the Administrative Agent. 
 “Bankruptcy Code” shall mean the Bankruptcy Code in Title 11 of the United States Code, as amended, modified, succeeded or replaced from
time to time. 
 “Bankruptcy Event” shall mean any of the events described in Section 7.1(e). 
 “Bankruptcy Event of Default” shall mean an Event of Default specified in Section 7.1(e). 
 “Borrower” shall have the meaning set forth in the first paragraph of this Agreement. 
 “Borrowing Date” shall mean, in respect of any Loan, the date such Loan is made. 
 “Business” shall have the meaning set forth in Section 3.10. 
 “Business Day” shall mean any day other than a Saturday, Sunday or other day on which commercial banks in Charlotte, North Carolina or
New York, New York are authorized or required by law to close; provided, however, that when used in connection with a rate determination, borrowing or payment in respect of a LIBOR Rate Loan, the term “Business Day” shall
also exclude any day on which banks in London, England are not open for dealings in Dollar deposits in the London interbank market. 
  

 9 

 “Capital Lease” shall mean any lease of property, real or personal, the obligations with
respect to which are required to be capitalized on a balance sheet of the lessee in accordance with GAAP. 
 “Capital Lease
Obligations” shall mean the capitalized lease obligations relating to a Capital Lease determined in accordance with GAAP. 
 “Capital Stock” shall mean (a) in the case of a corporation, capital stock, (b) in the case of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however
designated) of capital stock, (c) in the case of a partnership, partnership interests (whether general or limited), (d) in the case of a limited liability company, membership interests and (e) any other interest or participation that
confers on a Person the right to receive a share of the profits and losses of, or distributions of assets of, the issuing Person. 
 “Cash Equivalents” shall mean (a) securities issued or directly and fully guaranteed or insured by the United States of America or any agency or instrumentality thereof (provided that the full faith and credit
of the United States of America is pledged in support thereof) having maturities of not more than twelve months from the date of acquisition (“Government Obligations”), (b) Dollar denominated time deposits, certificates of
deposit, Eurodollar time deposits and Eurodollar certificates of deposit of (i) any domestic commercial bank of recognized standing having capital and surplus in excess of $200,000,000 or (ii) any bank whose short-term commercial paper
rating at the time of the acquisition thereof is at least A-1 or the equivalent thereof from S&P or from Moody’s is at least P-1 or the equivalent thereof from Moody’s (any such bank being an “Approved Bank”), in each
case with maturities of not more than 364 days from the date of acquisition, (c) commercial paper issued by any Person incorporated under the laws of the United States of America or any state thereof at the time of acquisition rated at least
A-1 (or the equivalent thereof) or better by S&P or at least P-1 (or the equivalent thereof) or better by Moody’s and maturing within six months of the date of acquisition, (d) commercial paper or notes issued by any Approved Bank (or
by the parent company thereof) and maturing within six months of the date of acquisition, (e) notes issued by or guaranteed by any Person incorporated under the laws of the United States of America or any state thereof at the time of
acquisition rated at least A-1 (or the equivalent thereof) or better by S&P or at least P-1 (or the equivalent thereof) or better by Moody’s and maturing within six months of the date of acquisition, (f) repurchase agreements with a
bank or trust company (including a Lender) or a recognized securities dealer having capital and surplus in excess of $500,000,000 for direct obligations issued by or fully guaranteed by the United States of America, (g) obligations of any state
of the United States or any political subdivision thereof for the payment of the principal and redemption price of and interest on which there shall have been irrevocably deposited Government Obligations maturing as to principal and interest at
times and in amounts sufficient to provide such payment, (h) money market accounts subject to Rule 2a-7 of the Investment Company Act of 1940 (“SEC Rule 2a-7”) which consist primarily of cash and cash equivalents set forth in
clauses (a) through (g) above and of which 85% shall at all times be comprised of First Tier Securities (as defined in SEC Rule 2a-7) and any remaining amount shall at all times be comprised of Second Tier Securities (as defined in SEC
Rule 2a-7), (i) shares of any so-called “money market fund,” provided that such fund is registered under the Investment Company Act of 1940, has net assets of at least $100,000,000 and has an investment portfolio 

  

 10 

 
with an average maturity of 365 days or less and (j) instruments comparable to those referred to in clauses (a) through (i) above denominated
in Euros or any other foreign currency comparable in credit quality and tenor to those referred to above and customarily used by corporations for short term cash management purposes in jurisdictions outside the United States of America. 

“Change in Law” shall mean the occurrence, after the date of this Agreement, of any of the following: (a) the adoption or taking
effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the administration, interpretation or application thereof by any Governmental Authority or (c) the making or issuance of any
request, guideline or directive (whether or not having the force of law) by any Governmental Authority. 
 “Change of
Control” shall mean at any time the occurrence of any of the following events: (a) any “person” or “group” (as such terms are used in Section 13(d) and 14(d) of the Exchange Act), is or becomes the
“beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly, of thirty-five percent (35%) or more of the then outstanding Voting Stock of the Borrower; or (b) the majority of the Board
of Directors of the Borrower fails to consist of Continuing Directors. 
 “Closing Date” shall mean the date of this
Agreement. 
 “Code” shall mean the Internal Revenue Code of 1986, as amended from time to time. 
 “Collateral” shall mean a collective reference to the collateral which is identified in and subject to a security interest under the
Security Documents and any other property or assets of a Credit Party, whether tangible or intangible and whether real or personal, that may from time to time secure the Credit Party Obligations. For the avoidance of doubt, the term
“Collateral” shall not include any property excluded by the terms of the Security Documents from the collateral set forth therein. 
 “Commitment” shall mean the Revolving Commitments, the LOC Commitment, and the Swingline Commitment, individually or collectively, as appropriate. 
 “Commitment Fee” shall have the meaning set forth in Section 2.5(a). 
 “Commitment Period” shall mean (a) with respect to Revolving Loans and Swingline Loans, the period from and including the Closing
Date to but excluding the Maturity Date and (b) with respect to Letters of Credit, the period from and including the Closing Date to the Maturity Date. 
 “Commonly Controlled Entity” shall mean an entity, whether or not incorporated, which is under common control with the Borrower within the meaning of Section 4001(b)(1) of ERISA or is part of a
group which includes the Borrower and which is treated as a single employer under Section 414(b) or 414(c) of the Code or, solely for purposes of Section 412 of the Code to the extent required by such section, Section 414(m) or 414(o)
of the Code. 
  

 11 

 “Consolidated” shall mean, when used with reference to financial statements or financial
statement items of the Credit Parties and their Subsidiaries or any other Person, such statements or items on a consolidated basis in accordance with the consolidation principles of GAAP. 
 “Consolidated Assets” shall mean, as of any date of determination, the Consolidated assets of the Credit Parties and their Subsidiaries
at such date, as determined in accordance with GAAP. 
 “Consolidated Capital Expenditures” shall mean, as of any date of
determination for any period ending on such date, all expenditures of the Credit Parties and their Subsidiaries on a Consolidated basis for such period that in accordance with GAAP would be classified as capital expenditures, including, without
limitation, Capital Lease Obligations; provided, however, that the term “Consolidated Capital Expenditures” shall not include (a) any Permitted Acquisition; (b) capital expenditures in respect of the reinvestment of
proceeds from Recovery Events or (c) the reinvestment of proceeds of permitted Asset Dispositions. 
 “Consolidated Cash
Taxes” shall mean, as of any date of determination for any period ending on such date, the aggregate of all federal, state, local and foreign income, value added and similar taxes actually paid by the Credit Parties and their Subsidiaries
on a Consolidated basis during such period. 
 “Consolidated EBITDA” shall mean, with respect to the Credit Parties and
their Subsidiaries on a Consolidated basis, as of any date of determination for any specified period ending on such date, without duplication, (a) Consolidated Net Income for such period plus (b) the sum of the following to the
extent deducted in calculating Consolidated Net Income for such period: (i) Consolidated Interest Expense (net of any interest income) of the Credit Parties and their Subsidiaries on a Consolidated basis for such period, (ii) federal,
state, local and foreign income, value added and similar tax expense (but net of any tax credits and rebates) of the Credit Parties and their Subsidiaries for such period, (iii) depreciation and amortization expense of the Credit Parties and
their Subsidiaries for such period, (iv) other non-cash charges of the Credit Parties and their Subsidiaries for such period (including without limitation (x) stock-based awards compensation expense, including without limitation any such
charges arising from stock options, restricted stock grants or other equity incentive grants and (y) any impairment charge or asset write-offs related to assets (including goodwill) and excluding any such non-cash charge that represents an
accrual of or reserve for cash expenditures in any future period), (v) any non-recurring cash charges or losses of the Credit Parties and their Subsidiaries not to exceed (A) for any four fiscal quarter period ending on
or before June 30, 2009, $15,000,000 and (B) for any four fiscal quarter period ending thereafter, the greater of (1) $10,000,000 and (2) 20% of Consolidated EBITDA for the previous four fiscal
quarter period (which for the purposes of this clause (v)(B)(2), Consolidated EBITDA shall include addbacks of all non-recurring cash charges or losses of the Credit Parties and their Subsidiaries for such prior four fiscal quarter
period) and (vi) one-time transaction related expenses incurred in connection with Permitted Acquisitions, asset dispositions, financing transactions and other strategic initiatives in an aggregate amount not to exceed $2,500,000 during
any Fiscal Year minus (c) any other non-recurring cash gains during such period. 
  

 12 

 “Consolidated Funded Debt” shall mean, as of any date of determination, Funded Debt of
the Credit Parties and their Subsidiaries on a Consolidated basis. 
 “Consolidated Interest Expense” shall mean, as of any
date of determination for any period ending on such date, all interest expense (excluding amortization of debt discount and premium to the extent not paid in cash, but including the interest component under Capital Leases and synthetic leases, tax
retention operating leases, off-balance sheet loans and similar off-balance sheet financing products) for such period of the Credit Parties and their Subsidiaries on a Consolidated basis. 
 “Consolidated Net Income” shall mean, as of any date of determination for any specified period ending on such date, the net income
(excluding extraordinary losses and gains) of the Credit Parties and their Subsidiaries on a Consolidated basis for such period, all as determined in accordance with GAAP. 
 “Continuing Director” shall mean, with respect to any Person as of any date of determination, any member of the board of directors of
such Person who (a) was a member of such board of directors on the Closing Date, or (b) was nominated for election or elected to such board of directors with the approval of a majority of the Continuing Directors who were members of such
board at the time of such nomination or election. 
 “Contractual Obligation” shall mean, as to any Person, any provision of
any security issued by such Person or of any contract, agreement, instrument or undertaking to which such Person is a party or by which it or any of its property is bound. 
 “Control” shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies
of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto. 
 “Copyright License” shall mean any agreement, whether written or oral, providing for the grant by or to a Person of any right under any
Copyright, including, without limitation, any thereof referred to in Schedule 3.15. 
 “Copyrights” shall mean all
copyrights of the Credit Parties and their Subsidiaries in all Works, now existing or hereafter created or acquired, all registrations and recordings thereof, and all applications in connection therewith, including, without limitation,
registrations, recordings and applications in the United States Copyright Office or in any similar office or agency of the United States, any state thereof or any other country or any political subdivision thereof, or otherwise, including, without
limitation, any thereof referred to in Schedule 3.15 and all renewals thereof. 
 “Credit Documents” shall mean this
Agreement, each of the Notes, any Joinder Agreement, the Letters of Credit, LOC Documents and the Security Documents and all other agreements, documents, certificates and instruments delivered to the Administrative Agent or any Lender by any Credit
Party in connection therewith (other than any agreement, document, certificate or instrument related to a Hedging Agreement). 
  

 13 

 “Credit Party” shall mean any of the Borrower or the Guarantors. 
 “Credit Party Intellectual Property” shall mean, collectively, all Copyrights, Patents, Trademarks and all material Copyright Licenses,
Patent Licenses and Trademark Licenses of the Credit Parties and their Subsidiaries, all goodwill associated therewith and all rights to sue for infringement thereof. 
 “Credit Party Obligations” shall mean, without duplication, (a) all of the obligations, indebtedness and liabilities of the Credit Parties to the Lenders (including the Issuing Lender) and the
Administrative Agent, whenever arising, under this Agreement, the Notes or any of the other Credit Documents, including principal, interest, fees, reimbursements and indemnification obligations and other amounts (including, but not limited to, any
interest accruing after the occurrence of a filing of a petition of bankruptcy under the Bankruptcy Code with respect to any Credit Party, regardless of whether such interest is an allowed claim under the Bankruptcy Code) and (b) all
liabilities and obligations, whenever arising, owing from any Credit Party or any of their Subsidiaries to any Hedging Agreement Provider arising under any Secured Hedging Agreement. 
 “Default” shall mean any of the events specified in Section 7.1, whether or not any requirement for the giving of notice or the
lapse of time, or both, or any other condition, has been satisfied. 
 “Default Rate” shall mean (a) when used with
respect to the Obligations, other than Letter of Credit Fees, an interest rate equal to (i) for Alternate Base Rate Loans (A) the Alternate Base Rate plus (B) the Applicable Percentage, if any, applicable to Alternate Base Rate
Loans plus (C) 2% per annum and (ii) for LIBOR Rate Loans, (A) the LIBOR Rate plus (B) the Applicable Percentage applicable to LIBOR Rate Loans plus (C) 2% per annum and (b) when used with respect
to Letter of Credit Fees, a rate equal to the Applicable Percentage plus 2% per annum. 
 “Defaulting Lender”
shall mean, at any time, any Lender that, at such time (a) has failed to make a Loan required pursuant to the terms of this Agreement or failed to fund a Participation Interest in accordance with the terms of this Agreement, (b) has failed
to pay to the Administrative Agent or any Lender an amount owed by such Lender pursuant to the terms of this Agreement and such default remains uncured, or (c) has been deemed insolvent or has become subject to a bankruptcy or insolvency
proceeding or to a receiver, trustee or similar official. 
 “Deposit Account Control Agreement” shall mean an agreement,
among a Credit Party, a depository institution, and the Administrative Agent, which agreement is either substantially in the form of Exhibit 1.1(c) or in a form reasonably acceptable to the Administrative Agent and which provides the
Administrative Agent with “control” (as such term is used in Article 9 of the UCC) over the deposit account(s) described therein, as the same may be amended, modified, extended, restated, replaced, or supplemented from time to time.

  

 14 

 “Dollars” and “$” shall mean dollars in lawful currency of the United
States of America. 
 “Domestic Lending Office” shall mean, initially, the office of each Lender designated as such
Lender’s Domestic Lending Office shown in such Lender’s Administrative Questionnaire, and thereafter, such other office of such Lender as such Lender may from time to time specify to the Administrative Agent and the Borrower as the office
of such Lender at which Alternate Base Rate Loans of such Lender are to be made. 
 “Domestic Subsidiary” shall mean any
Subsidiary that is not a Foreign Subsidiary. 
 “Eligible Assignee” shall mean (a) a Lender, (b) an Affiliate of a
Lender, (c) an Approved Fund, and (d) any other Person (other than a natural person) approved by (i) the Administrative Agent, (ii) in the case of any assignment of a Revolving Commitment, the Issuing Lender, and
(iii) unless an Event of Default has occurred and is continuing, the Borrower (each such approval not to be unreasonably withheld or delayed); provided that notwithstanding the foregoing, “Eligible Assignee” shall not include
the Borrower or any of the Borrower’s Affiliates or Subsidiaries. 
 “Engagement Letter” shall mean the letter
agreement dated July 1, 2008, addressed to the Borrower from Wachovia and WCM, as amended, modified, extended, restated, replaced, or supplemented from time to time. 
 “Environmental Laws” shall mean any and all applicable foreign, federal, state, local or municipal laws, rules, orders, regulations, statutes, ordinances, codes, decrees, requirements of any
Governmental Authority or other Requirement of Law (including common law) regulating, relating to or imposing liability or standards of conduct concerning protection of human health or the environment, as now or may at any time be in effect during
the term of this Agreement. 
 “EPSI Account” shall mean that certain deposit account numbered 0000312694 maintained at The
Private Bank. 
 “Equity Issuance” shall mean any issuance by any Credit Party or any Subsidiary to any Person which
is not a Credit Party or a Subsidiary of (a) shares or interests of its Capital Stock, (b) any shares or interests of its Capital Stock pursuant to the exercise of options or warrants or similar rights, (c) any shares or interests of
its Capital Stock pursuant to the conversion of any debt securities to equity or (d) warrants or options or similar rights that are exercisable or convertible into shares or interests of its Capital Stock.  
 “ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time. 
  

 15 

 “Event of Default” shall mean any of the events specified in Section 7.1;
provided, however, that any requirement for the giving of notice or the lapse of time, or both, or any other condition, has been satisfied. 
 “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended. 
 “Excluded Account” shall have the meaning set forth in Section 6.12(b). 
 “Excluded
Subsidiary” shall mean (a) any Subsidiary (other than a Subsidiary described in clause (a) of the definition of “Foreign Subsidiary”) (i) substantially all the assets of which consist, directly or indirectly, of
Subsidiaries described in clause (a) of the definition of “Foreign Subsidiary”, (ii) which engages in no material business operations other than in the ordinary course of its business as a holding company (which such permitted
activities shall include the ownership of assets described in clause (a)(i) of this definition, the payment of required taxes, the receipt of Restricted Payments and Investments permitted under this Agreement, the declaration and making of
Restricted Payments and Investments permitted under this Agreement, other activities required to maintain its separate corporate or other legal structure and such other business, operations and activities consented to by the Agent) and
administrative functions related thereto and (iii) which has no Indebtedness at any time outstanding in excess of $100,000 (other than Indebtedness in respect of Credit Party Obligations or Indebtedness owed to a Credit Party) or (b) any
entity disregarded as separate from its owner for United States federal income tax purposes that owns more than 65% of the Voting Stock of a Subsidiary described in either clause (a) of the definition of “Foreign Subsidiary” or clause
(a) of this definition so long as such entity (i) engages in no material business operations other than in the ordinary course of its business as a holding company (which such permitted activities shall include the ownership of Capital
Stock of its Subsidiaries, the payment of required taxes, the receipt of Restricted Payments and Investments permitted under this Agreement, the declaration and making of Restricted Payments and Investments permitted under this Agreement, other
activities required to maintain its separate corporate or other legal structure and such other business, operations and activities consented to by the Agent) and administrative functions related thereto and (ii) has no Indebtedness at any time
outstanding in excess of $100,000 (other than Indebtedness in respect of Credit Party Obligations or Indebtedness owed to a Credit Party). 
 “Excluded Taxes” shall mean, with respect to the Administrative Agent, any Lender, the Issuing Lender or any other recipient of any payment to be made by or on account of any obligation of the Borrower hereunder,
(a) taxes imposed on or measured by its overall net income (however denominated), and franchise taxes imposed on it (in lieu of net income taxes), by any jurisdiction (or any political subdivision thereof) under the laws of which such recipient
is organized or in which its principal office is located or, in the case of any Lender, in which its applicable lending office is located, (b) any branch profits taxes imposed by the United States of America or any similar tax imposed by any
other jurisdiction in which the Borrower is located, (c) in the case of a Foreign Lender, any withholding tax that is imposed on amounts payable to such Foreign Lender at the time such Foreign Lender becomes a party hereto (or designates a new
lending office) or is attributable to such Foreign Lender’s failure or inability (other than as a result of a Change in Law) to comply with Section 2.16, except to the extent that such Foreign Lender (or its assignor, if any) was entitled,
at the time of designation of a new lending office (or 

  

 16 

 
assignment), to receive additional amounts from the Borrower with respect to such withholding tax pursuant to Section 2.16 and (d) any additional
withholding tax that is imposed on amounts payable as a result of such Lender’s specification of (i) a Domestic Lending Office other than the office specified in such Lender’s Administrative Questionnaire or (ii) a LIBOR Lending
Office other than the office specified in such Lender’s Administrative Questionnaire, except to the extent that such Lender was entitled, at the time of designation of such other lending office, to receive additional amounts from the Borrower
with respect to such withholding tax pursuant to Section 2.16. 
 “Existing Letter of Credit” shall mean each of the
letters of credit described by applicant, date of issuance, letter of credit number, amount, beneficiary and the date of expiry on Schedule 1.1(c) hereto. 
 “Extension of Credit” shall mean, as to any Lender, the making of a Loan by such Lender, any conversion of a Loan from one Type to another Type, any extension of any Loan or the issuance of, or
participation in, a Letter of Credit or Swingline Loan by such Lender. 
 “Federal Funds Effective Rate” shall have the
meaning set forth in the definition of “Alternate Base Rate”. 
 “Fiscal Year” shall mean any fiscal year of the
Borrower. 
 “Fixed Charge Coverage Ratio” shall mean, as of the last day of any fiscal quarter of the Borrower, for the
Credit Parties and their Subsidiaries on a Consolidated basis, determined for the four consecutive fiscal quarter period ending on such date, the ratio of (a) (i) Consolidated EBITDA for such period minus (ii) Consolidated
Capital Expenditures for such period to the extent permitted hereunder and not financed with Funded Debt minus (iii) capitalized software expenses of the Credit Parties and their Subsidiaries on a Consolidated basis during such period to
(b) the sum of (i) Consolidated Interest Expense paid in cash during such period, (ii) Consolidated Cash Taxes during such period and (iii) Scheduled Funded Debt Payments during such period (including the principal component of
payments due on Capital Leases). 
 “Foreign Lender” shall mean any Lender that is organized under the laws of a
jurisdiction other than that in which the Borrower is resident for tax purposes. For purposes of this definition, the United States of America, each State thereof and the District of Columbia shall be deemed to constitute a single jurisdiction.

 “Foreign Subsidiary” shall mean (a) any Subsidiary that is treated as a corporation for United States federal income
tax purposes and that is formed or incorporated outside the United States and (b) any Excluded Subsidiary. 
 “Fund”
shall mean any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business. 
  

 17 

 “Funded Debt” shall mean, with respect to any Person, without duplication, (a) all
obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person under conditional sale or other title retention agreements
relating to property purchased by such Person (other than customary reservations or retentions of title under agreements with suppliers entered into in the ordinary course of business), (d) all obligations (including, without limitation,
earnout obligations) of such Person incurred, issued or assumed as the deferred purchase price of property or services purchased by such Person (other than trade and other ordinary course payables and accrued expenses incurred in the ordinary course
of business and due within six months of the incurrence thereof) which would appear as liabilities on a balance sheet of such Person prepared in accordance with GAAP, (e) the principal portion of all obligations of such Person under Capital
Leases, (f) the unreimbursed amount of all letters of credit issued or bankers’ acceptances facilities created for the account of such Person, (g) all preferred Capital Stock (other than Qualified Preferred Stock) or other equity
interests issued by such Person and which by the terms thereof could be (at the request of the holders thereof or otherwise) subject to mandatory sinking fund payments, redemption or other acceleration, (h) the principal balance outstanding
under any Synthetic Lease, (i) all Indebtedness of others of the type described in clauses (a) through (h) hereof secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured
by) any Lien on property owned or acquired by such Person, whether or not the obligations secured thereby have been assumed (provided, that if such Indebtedness has not been so assumed, the amount of Indebtedness of any Person for purposes of this
clause (i) shall be deemed to be equal to the lesser of (i) the aggregate unpaid amount of such Indebtedness and (ii) the fair market value of the property encumbered thereby as determined by such Person in good faith), (j) all
Guaranty Obligations of such Person with respect to Indebtedness of another Person of the type described in clauses (a) through (h) hereof, and (k) all Indebtedness of any partnership in which such Person is a general partner to the
extent such Indebtedness is recourse to such Person. 
 “GAAP” shall mean generally accepted accounting principles in effect
in the United States of America (or, in the case of Foreign Subsidiaries with significant operations outside the United States of America, generally accepted accounting principles in effect from time to time in their respective jurisdictions of
organization or formation) applied on a consistent basis, subject, however, in the case of determination of compliance with the financial covenants set out in Section 5.9 to the provisions of Section 1.3. 
 “Government Acts” shall have the meaning set forth in Section 2.17. 
 “Government Obligations” shall have the meaning set forth in the definition of “Cash Equivalents.” 
 “Governmental Authority” shall mean the government of the United States of America or any other nation, or of any political subdivision
thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining
to government (including any supra-national bodies such as the European Union or the European Central Bank). 
  

 18 

 “Guarantor” shall have the meaning set forth in the first paragraph of this Agreement.

 “Guaranty” shall mean the guaranty of the Guarantors set forth in Article X. 
 “Guaranty Obligations” shall mean, with respect to any Person, without duplication, any obligations of such Person (other than
endorsements in the ordinary course of business of negotiable instruments for deposit or collection) guaranteeing or intended to guarantee any Indebtedness of any other Person in any manner, whether direct or indirect, and including without
limitation any obligation, whether or not contingent, (a) to purchase any such Indebtedness, (b) to advance or provide funds or other support for the payment or purchase of any such Indebtedness or to maintain working capital, solvency or
other balance sheet condition of such other Person (including without limitation keep well agreements, maintenance agreements, comfort letters or similar agreements or arrangements) for the benefit of any holder of Indebtedness of such other Person,
(c) to lease or purchase property, securities or services primarily for the purpose of assuring payment to the holder of such Indebtedness, or (d) to otherwise assure or hold harmless the holder of such Indebtedness against loss in respect
thereof. The amount of any Guaranty Obligation hereunder shall (subject to any limitations set forth therein) be deemed to be an amount equal to the outstanding principal amount (or maximum principal amount, if larger) of the Indebtedness in respect
of which such Guaranty Obligation is made. 
 “Hedging Agreement Provider” shall mean any Person that enters into a Hedging
Agreement with a Credit Party or any of its Subsidiaries to the extent that (i) such Person is (A) a Lender, (B) an Affiliate of a Lender or (C) any other Person that was a Lender (or an Affiliate of a Lender) at the time it
entered into the Hedging Agreement but has ceased to be a Lender (or whose Affiliate has ceased to be a Lender) under the Credit Agreement or (ii) such Person is a Lender or Affiliate of a Lender on the Closing Date and the Hedging Agreement
was entered into on or prior to the Closing Date (even if such Person ceases to be a Lender or such Person’s Affiliate ceases to be a Lender); provided, in the case of a Secured Hedging Agreement with a Person who is no longer a Lender,
such Person shall be considered a Hedging Agreement Provider only through the stated maturity date (without extension or renewal) of such Secured Hedging Agreement. 
 “Hedging Agreement” shall mean, with respect to any Person, any agreement entered into to protect such Person against fluctuations in interest rates, or currency or raw materials values, including,
without limitation, any interest rate swap, cap or collar agreement or similar arrangement between such Person and one or more counterparties, any foreign currency exchange agreement, currency protection agreements, commodity purchase or option
agreements or other interest or exchange rate hedging agreements. 
 “Incremental Revolving Facility” shall have the meaning
set forth in Section 2.2. 
 “Indebtedness” shall mean, with respect to any Person, without duplication, (a) all
obligations of such Person for borrowed money, (b) all obligations of such Person evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person under 

  

 19 

 
conditional sale or other title retention agreements relating to property purchased by such Person (other than customary reservations or retentions of title
under agreements with suppliers entered into in the ordinary course of business), (d) all obligations (including, without limitation, earnout obligations) of such Person incurred, issued or assumed as the deferred purchase price of property or
services purchased by such Person (other than trade and other ordinary course payables and accrued expenses incurred in the ordinary course of business and due within six months of the incurrence thereof) which, in each case, would appear as
liabilities on a balance sheet of such Person prepared in accordance with GAAP, (e) all obligations of such Person under take-or-pay or similar arrangements, (f) all Indebtedness of others secured by (or for which the holder of such
Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed by such Person (provided, that if such
Indebtedness has not been so assumed, the amount of Indebtedness of any Person for purposes of this clause (f) shall be deemed to be equal to the lesser of (i) the aggregate unpaid amount of such Indebtedness and (ii) the fair market
value of the property encumbered thereby as determined by such Person in good faith), (g) all Guaranty Obligations of such Person with respect to Indebtedness of another Person, (h) the principal portion of all Capital Lease Obligations,
(i) all net obligations of such Person under Hedging Agreements (valued as the net termination value thereof computed in accordance with a method approved by the International Swap Dealers Association and agreed to by such Person in the
applicable Hedging Agreement, if applicable), excluding any portion thereof which would be accounted for as interest expense under GAAP, (j) the unreimbursed amount of all letters of credit issued or bankers’ acceptances facilities created
for the account of such Person, (k) all preferred Capital Stock (other than Qualified Preferred Stock) issued by such Person and which by the terms thereof could be (at the request of the holders thereof or otherwise) subject to mandatory
sinking fund payments, redemption or other acceleration, (l) the principal balance outstanding under any Synthetic Lease, and (m) all indebtedness of the type described in clauses (a) through (i) of any partnership in which such
Person is a general partner to the extent such Indebtedness is recourse to such Person. 
 “Indemnified Taxes” shall mean
Taxes other than Excluded Taxes. 
 “Indemnitee” shall have the meaning set forth in Section 9.5(b). 
 “Insolvency” shall mean, with respect to any Multiemployer Plan, the condition that such Plan is insolvent within the meaning of such
term as used in Section 4245 of ERISA. 
 “Intellectual Property” shall mean, collectively, all Copyrights, Copyright
Licenses, Patents, Patent Licenses, Trademarks and Trademark Licenses of the Credit Parties and their Subsidiaries, all goodwill associated therewith and all rights to sue for infringement thereof. 
 “Interest Determination Date” shall have the meaning specified in the definition of “Applicable Percentage”. 
 “Interest Payment Date” shall mean (a) as to any Alternate Base Rate Loan, the last Business Day of each March, June, September and
December and on the Maturity Date, (b) as to any LIBOR Rate Loan having an Interest Period of three months or less, the last day of such 

  

 20 

 
Interest Period, (c) as to any LIBOR Rate Loan having an Interest Period longer than three months, (i) each three (3) month anniversary
following the first day of such Interest Period and (ii) the last day of such Interest Period and (d) as to any Loan which is the subject of a mandatory prepayment required pursuant to Section 2.7(b), the date on which such mandatory
prepayment is due. 
 “Interest Period” shall mean, with respect to any LIBOR Rate Loan, 
 (a) initially, the period commencing on the Borrowing Date or conversion date, as the case may be, with respect to such LIBOR Rate Loan
and ending one, two, three, six, nine or twelve months thereafter, subject to availability to all applicable Lenders, as selected by the Borrower in the Notice of Borrowing or Notice of Conversion given with respect thereto; and 
 (b) thereafter, each period commencing on the last day of the immediately preceding Interest Period applicable to such LIBOR Rate Loan and
ending one, two, three, six, nine or twelve months thereafter, subject to availability to all applicable Lenders, as selected by the Borrower by irrevocable notice to the Administrative Agent not less than three Business Days prior to the last day
of the then current Interest Period with respect thereto; provided that the foregoing provisions are subject to the following: 
 (i) if any Interest Period pertaining to a LIBOR Rate Loan would otherwise end on a day that is not a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless the result of such
extension would be to carry such Interest Period into another calendar month in which event such Interest Period shall end on the immediately preceding Business Day; 
 (ii) any Interest Period pertaining to a LIBOR Rate Loan that begins on the last Business Day of a calendar month (or on a day for which
there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the relevant calendar month; 
 (iii) if the Borrower shall fail to give notice as provided above, the Borrower shall be deemed to have selected an Alternate Base Rate
Loan to replace the affected LIBOR Rate Loan; 
 (iv) no Interest Period in respect of any Loan shall extend beyond the
applicable Maturity Date; and 
 (v) no more than six (6) LIBOR Rate Loans may be in effect at any time. For purposes
hereof, LIBOR Rate Loans with different Interest Periods shall be considered as separate LIBOR Rate Loans, even if they shall begin on the same date and have the same duration, although borrowings, extensions and conversions may, in accordance with
the provisions hereof, be combined at the end of existing Interest Periods to constitute a new LIBOR Rate Loan with a single Interest Period. 
  

 21 

 “International Holding Company” shall mean a first tier Subsidiary of (a) a Credit
Party or (b) an Excluded Subsidiary described in clause (b) of the definition of “Excluded Subsidiary”, in each case to which Offshore Rights are transferred. 
 “International Holding Company Note” shall have the meaning set forth in Section 6.1(h). 
 “Investment” shall mean, with respect to any Person, (a) the acquisition (whether for cash, property, services, assumption of
Indebtedness, securities or otherwise) of shares of Capital Stock, other ownership interests or other securities of any other Person or bonds, notes, debentures or all or substantially all of the assets of any other Person, (b) any deposit
with, or advance, loan or other extension of credit to, any other Person (other than deposits made in the ordinary course of business) or (c) any other capital contribution to or investment in any other Person, including, without limitation,
any Guaranty Obligation (including any support for a letter of credit issued on behalf of such Person with respect to Indebtedness of such other Person; provided that, in the event that any Investment is made by the Borrower or any
Subsidiary in any Person through substantially concurrent interim transfers through one or more other Subsidiaries, then such other substantially concurrent interim transfers shall be disregarded for purposes of Section 6.5. For purposes of
covenant compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment (other than adjustments for the repayment of, or the refund of capital
with respect to, the original amount of any such Investment). 
 “Issuing Lender” shall mean Wachovia Bank, National
Association, together with any successor. 
 “Issuing Lender Fees” shall have the meaning set forth in Section 2.3(c).

 “Joinder Agreement” shall mean a Joinder Agreement in substantially the form of Exhibit 1.1(d), executed and
delivered by an Additional Credit Party in accordance with the provisions of Section 5.10. 
 “Lender” shall have the
meaning set forth in the first paragraph of this Agreement and shall include the Revolving Lenders and the Issuing Lender. 
 “Lender
Commitment Letter” shall mean, with respect to any Lender, the letter (or other correspondence) to such Lender from the Administrative Agent notifying such Lender of its LOC Commitment or Revolving Commitment Percentage. 
 “Letter of Credit” shall mean (a) any letter of credit issued by the Issuing Lender pursuant to the terms hereof, as such letter of
credit may be amended, modified, restated, extended, renewed, increased, replaced or supplemented from time to time and (b) any Existing Letter of Credit, in each case as such letter of credit may be amended, modified, extended, renewed or
replaced from time to time. 
  

 22 

 “Letter of Credit Facing Fee” shall have the meaning set forth in Section 2.3(c).

 “Letter of Credit Fee” shall have the meaning set forth in Section 2.3(b). 
 “Leverage Ratio” shall mean, as of the last day of any fiscal quarter of the Borrower, for the Credit Parties and their Subsidiaries on
a Consolidated basis, the ratio of (a) Consolidated Funded Debt of the Credit Parties and their Subsidiaries on such date to (b)(i) Consolidated EBITDA determined for the four consecutive fiscal quarter period ending on such date minus
(ii) to the extent greater than $10,000,000 during any four (4) fiscal quarter period, capitalized software expenses of the Credit Parties and their Subsidiaries on a Consolidated basis determined for the four (4) consecutive fiscal
quarter period. 
 “LIBOR Lending Office” shall mean, initially, the office(s) of each Lender designated as such
Lender’s LIBOR Lending Office in such Lender’s Administrative Questionnaire; and thereafter, such other office of such Lender as such Lender may from time to time specify to the Administrative Agent and the Borrower as the office of such
Lender at which the LIBOR Rate Loans of such Lender are to be made. 
 “LIBOR Rate” shall mean, for any LIBOR Rate Loan for
any Interest Period therefor, the rate per annum (rounded upwards, if necessary, to the nearest 1/100 of 1%) appearing on Reuters Screen LIBOR01 Page (or any successor page) as the London interbank offered rate for deposits in Dollars at
approximately 11:00 A.M. (London time) two (2) Business Days prior to the first day of such Interest Period for a term comparable to such Interest Period. If for any reason such rate is not available, then “LIBOR Rate” shall mean the
rate per annum at which, as determined by the Administrative Agent in accordance with its customary practices, Dollars in an amount comparable to the Loans then requested are being offered to leading banks at approximately 11:00 A.M. London
time, two (2) Business Days prior to the commencement of the applicable Interest Period for settlement in immediately available funds by leading banks in the London interbank market for a period equal to the Interest Period selected.

 “LIBOR Rate Loan” shall mean Loans the rate of interest applicable to which is based on the LIBOR Rate. 
 “LIBOR Tranche” shall mean the collective reference to LIBOR Rate Loans whose Interest Periods begin and end on the same day.

 “Lien” shall mean any mortgage, pledge, hypothecation, collateral assignment, collateral deposit arrangement,
encumbrance, lien (statutory or other), charge or other security interest or any security agreement of any kind or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement and any Capital Lease having
substantially the same economic effect as any of the foregoing). 
 “Liquidity” shall mean, as of any date of determination,
the sum of following for the Credit Parties and their Subsidiaries on a Consolidated basis: (a) the Accessible Borrowing Availability plus (b) cash and Cash Equivalents. 
  

 23 

 “Loan” shall mean a Revolving Loan and/or a Swingline Loan, as appropriate. 

“LOC Commitment” shall mean the commitment of the Issuing Lender to issue Letters of Credit and with respect to each Revolving
Lender, the commitment of such Revolving Lender to purchase Participation Interests in the Letters of Credit up to such Lender’s Revolving Commitment Percentage of the LOC Committed Amount. 
 “LOC Committed Amount” shall have the meaning set forth in Section 2.3(a). 
 “LOC Documents” shall mean, with respect to each Letter of Credit, such Letter of Credit, any amendments thereto, any documents
delivered in connection therewith, any application therefor, and any agreements, instruments, guarantees or other documents (whether general in application or applicable only to such Letter of Credit) governing or providing for (a) the rights
and obligations of the parties concerned or (b) any Collateral for such obligations. 
 “LOC Obligations” shall mean,
at any time, the sum of (a) the maximum amount which is, or at any time thereafter may become, available to be drawn under Letters of Credit then outstanding, assuming compliance with all requirements for drawings referred to in such Letters of
Credit plus (b) the aggregate amount of all drawings under Letters of Credit honored by the Issuing Lender but not theretofore reimbursed. 
 “Mandatory LOC Borrowing” shall have the meaning set forth in Section 2.3(e). 
 “Mandatory Swingline Borrowing” shall have the meaning set forth in Section 2.4(b)(ii). 
 “Material
Adverse Effect” shall mean a material adverse effect on (a) the business, properties, operations or financial condition of the Borrower and its Subsidiaries taken as a whole, (b) the ability of the Borrower and the Guarantors,
taken as a whole, to perform their payment and other material obligations, when such obligations are required to be performed, under this Agreement, any of the Notes or any other Credit Document or (c) the validity or enforceability of this
Agreement, any of the Notes or any of the other Credit Documents (to the extent constituting agreements) or the rights or remedies of the Administrative Agent or the Lenders hereunder or thereunder. 
 “Material Domestic Subsidiary” shall mean, as of any date of determination, any Domestic Subsidiary of the Borrower that, together with
such Domestic Subsidiary’s Subsidiaries, (a) generates more than 5% of Consolidated EBITDA for the four (4) fiscal quarter period most recently ended or (b) owns more than 5% of the Consolidated Assets as of the last day of the
most recently ended fiscal quarter of the Borrower. For purposes of determining whether the Target of any Permitted Acquisition qualifies as a Material Domestic Subsidiary pursuant to clause (a) above, the foregoing calculations shall be made
after giving effect to such acquisition on a Pro Forma Basis. 
 “Materials of Environmental Concern” shall mean any
gasoline or petroleum (including crude oil or any extraction thereof) or petroleum products or any hazardous or toxic substances, materials or wastes, defined or regulated as such in or under any Environmental Law, including, without limitation,
asbestos, perchlorate, polychlorinated biphenyls and urea-formaldehyde insulation. 
  

 24 

 “Maturity Date” shall mean the date that is three (3) years following the Closing
Date. 
 “Moody’s” shall mean Moody’s Investors Service, Inc. 
 “Multiemployer Plan” shall mean a Plan that is a multiemployer plan as defined in Section 4001(a)(3) of ERISA. 
 “Net Cash Proceeds” shall mean the aggregate cash proceeds received by any Credit Party or any Subsidiary in respect of any Asset
Disposition, net of (a) direct costs (including, without limitation, legal, accounting and investment banking fees, and sales commissions) associated therewith, (b) amounts held in escrow to be applied as part of the purchase price of any
Asset Disposition and (c) taxes paid or payable as a result thereof, (d) the principal amount of, premium, if any, and interest on any Indebtedness secured by a Lien on the asset (or a portion thereof) sold, which Indebtedness is required
to be repaid in connection with such sale; it being understood that “Net Cash Proceeds” shall include (when received by a Credit Party or Subsidiary as cash), without limitation, any cash received upon the sale or other disposition of any
non-cash consideration received by any Credit Party or any Subsidiary in any Asset Disposition and any cash released from escrow to any Credit Party or Subsidiary as part of the purchase price in connection with any Asset Disposition. 
 “Note” or “Notes” shall mean the Revolving Notes and/or the Swingline Note, collectively, separately or individually,
as appropriate. 
 “Notice of Borrowing” shall mean a request for a Revolving Loan borrowing pursuant to
Section 2.1(b)(i) or a request for a Swingline Loan borrowing pursuant to Section 2.4(b)(i), as appropriate. A Form of Notice of Borrowing is attached as Exhibit 1.1(e). 
 “Notice of Conversion/Extension” shall mean the written notice of conversion of a LIBOR Rate Loan to an Alternate Base Rate Loan or an
Alternate Base Rate Loan to a LIBOR Rate Loan, or extension of a LIBOR Rate Loan, in each case substantially in the form of Exhibit 1.1(f). 
 “Obligations” shall mean, collectively, Loans, LOC Obligations, and all other obligations of the Credit Parties to the Administrative Agent and the Lenders under the Credit Documents. 
 “OFAC” shall mean the U.S. Department of the Treasury’s Office of Foreign Assets Control. 
 “Off-Shore Rights” shall mean all rights to Intellectual Property outside the United States. 
 “Operating Lease” shall mean, as applied to any Person, any lease (including, without limitation, leases which may be terminated by the
lessee at any time) of any property (whether real, personal or mixed) which is not a Capital Lease other than any such lease in which that Person is the lessor. 
  

 25 

 “Other Taxes” shall mean all present or future stamp or documentary taxes or any other
excise or property taxes, charges or similar levies arising from any payment made hereunder or under any other Credit Document or from the execution, delivery or enforcement of, or otherwise with respect to, this Agreement or any other Credit
Document. 
 “Outside LC Account” shall mean that certain deposit account numbered 1009353460 maintained at Wachovia Bank.

 “Owned Intellectual Property” shall mean, collectively, all Copyrights, Patents and Trademarks owned by the Credit
Parties and their Subsidiaries, all goodwill associated therewith and all rights to sue for infringement thereof. 
 “Participant” has the meaning assigned to such term in clause (d) of Section 9.6. 
 “Participation Interest” shall mean a participation interest purchased by a Revolving Lender in LOC Obligations as provided in Section 2.3(c) and in Swingline Loans as provided in Section 2.4. 
 “Patent Licenses” shall mean all agreements, whether written or oral, providing for the grant by or to a Person of any right to
manufacture, use or sell any invention covered by a Patent, including, without limitation, any thereof referred to in Schedule 3.15. 
 “Patents” shall mean (a) all letters patent of the United States or any other country, now existing or hereafter arising, and all improvement patents, reissues, reexaminations, patents of additions, renewals and
extensions thereof, including, without limitation, any thereof referred to in Schedule 3.15, and (b) all applications for letters patent of the United States or any other country, now existing or hereafter arising, and all provisionals,
divisions, continuations and continuations-in-part and substitutes thereof, including, without limitation, any thereof referred to in Schedule 3.15. 
 “Patriot Act” shall mean The Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Title III of Pub. L. No. 107-56
(signed into law October 26, 2001)), as amended or modified from time to time. 
 “Payment Event of Default” shall mean
an Event of Default specified in Section 7.1(a). 
 “PBGC” shall mean the Pension Benefit Guaranty Corporation
established pursuant to Subtitle A of Title IV of ERISA. 
 “Permitted Acquisition” shall mean an acquisition or any series
of related acquisitions by a Credit Party or a Subsidiary of a Credit Party of (a) all or substantially all of the assets or a majority of the outstanding Voting Stock or economic interests of a Person, (b) a Person by a merger,
amalgamation or consolidation or any other combination with such Person or (c) any 

  

 26 

 
division, line of business or other business unit (such assets or such Person or such division, line of business or other business unit of such Person shall
be referred to herein as the “Target”), in each case that is a type of business (or assets used in a type of business) permitted to be engaged in by the Credit Parties and their Subsidiaries pursuant to Section 6.3, in each
case so long as: 
 (i) no Default or Event of Default shall then exist or would exist after giving effect thereto;

 (ii) the Credit Parties shall demonstrate to the reasonable satisfaction of the Administrative Agent that, after giving
effect to the acquisition on a Pro Forma Basis (including giving pro forma effect to any earnout payments and any deferred purchase price to be paid in connection with such acquisition, in each case if the aggregate amount of all such payments with
respect to such Permitted Acquisition reasonably anticipated to be made within fifteen (15) months of the consummation of such Permitted Acquisition exceeds $5,000,000), the Credit Parties are in compliance with each of the financial covenants
set forth in Section 5.9; 
 (iii)(A) to the extent required as of the consummation of such Permitted Acquisition by, and
in accordance with the terms of, Sections 5.10 and 5.12 hereof, the Administrative Agent, on behalf of the Secured Parties, shall have received (or shall receive in connection with the closing of such acquisition) a first priority (subject to
Permitted Liens) perfected security interest in substantially all Collateral acquired with respect to the Target and (B) to the extent required as of the consummation of such Permitted Acquisition by, and in accordance with the terms of,
Section 5.10 hereof, the Target, if a Person, shall have executed a Joinder Agreement; 
 (iv) with respect to any
Permitted Acquisition with a cash purchase price in excess of $20,000,000, the Administrative Agent and the Lenders shall have received, not less than ten (10) days prior to the consummation of such Permitted Acquisition, (A) a description
of the material terms of such acquisition, (B) audited financial statements (or, if unavailable, management-prepared financial statements) of the Target for its two most recent fiscal years and for any fiscal quarters ended for more than 45
days within the fiscal year to date, (C) Consolidated projected income statements for the period of four fiscal quarters from the date of consummation of the acquisition of the Credit Parties and their Subsidiaries on a Consolidated basis
(giving effect to such acquisition), and (D) a certificate substantially in the form of Exhibit 1.1(g), executed by a Responsible Officer of the Borrower certifying that such Permitted Acquisition complies with the requirements of this
Agreement; and 
 (v) such acquisition shall not be a “hostile” acquisition and shall have been approved by the
Board of Directors (or equivalent) and/or shareholders (or equivalent), if required by law, of the applicable Credit Party or Subsidiary and the Target. 
 “Permitted Investments” shall mean: 
 (a) cash and Cash Equivalents;

  

 27 

 (b) Investments set forth on Schedule 1.1(a); 
 (c) receivables owing to the Credit Parties or any of their Subsidiaries or any receivables and advances to suppliers, in each case if
created, acquired or made in the ordinary course of business and payable or dischargeable in accordance with customary trade terms; 
 (d) Investments in and loans to any Credit Party; 
 (e) loans and advances to officers, directors and employees in
an aggregate amount not to exceed $2,000,000 at any time outstanding; provided that such loans and advances shall comply with all applicable Requirements of Law (including Sarbanes-Oxley); 
 (f) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of suppliers and customers and
in settlement of delinquent obligations of, and other disputes with, customers and suppliers arising in the ordinary course of business; 
 (g) Investments, acquisitions or transactions permitted under Section 6.4(b); 
 (h)
Permitted Acquisitions; 
 (i) Hedging Agreements to the extent permitted hereunder; 
 (j) Investments of assets made pursuant to any non-qualified deferred compensation plan sponsored by the Borrower or its Subsidiaries;

 (k)(i) Investments by the Credit Parties in any Foreign Subsidiary, to the extent necessary for such Foreign Subsidiary to
meet its tax, payroll and operating expense requirements in the ordinary course of its business, but only to the extent such tax, payroll and operating expenses exceed the revenues of such Foreign Subsidiary, (ii) additional Investments by the
Credit Parties in Foreign Subsidiaries (including, to the extent applicable, Eclipsys (Mauritius) Limited and Eclipsys (India) Private Limited) in an amount not to exceed $10,000,000 during any Fiscal Year and (iii) Investments by Foreign
Subsidiaries in other Foreign Subsidiaries; 
 (l)(i) Investments by any Credit Party or an Excluded Subsidiary described in
clause (b) of the definition of “Excluded Subsidiary” in any International Holding Company in the form of any capital contribution by such Person to such International Holding Company of the shares of Capital Stock owned by such
Person in a Foreign Subsidiary and in the form of a transfer of Off-Shore Rights to such International Holding Company and (ii) Investments by any Credit Party consisting of Offshore Rights in any International Holding Company and
(iii) Investments consisting of any International Holding Company Note; and 
  

 28 

 (m) additional loans and/or Investments; provided that such loans, advances and/or
Investments made after the Closing Date pursuant to this clause shall not exceed an aggregate amount of $10,000,000 at any one time outstanding. 
 “Permitted Liens” shall mean: 
 (a) Liens created by or otherwise existing under or in connection
with this Agreement or the other Credit Documents in favor of the Administrative Agent on behalf of the Secured Parties; 
 (b) Liens under the Credit Documents in favor of a Hedging Agreement Provider in connection with a Secured Hedging Agreement under the Credit Documents; 
 (c) Liens securing purchase money Indebtedness and Capital Lease Obligations to the extent permitted under Section 6.1(c);
provided, that (i) any such Lien attaches to such property concurrently with or within ninety (90) days after the acquisition, construction, repair, replacement or improvement (as applicable) thereof and (ii) such Lien attaches
solely to the property so acquired in such transaction (and proceeds and products thereof and proceeds of insurance maintained with respect thereto); provided, that individual financings of equipment provided by one lender may be cross
collateralized to other financings of equipment provided by such lender; 
 (d) Liens for taxes, assessments, charges or other
governmental levies not yet due or as to which the period of grace, if any, related thereto has not expired or which are being contested in good faith by appropriate proceedings; provided that adequate reserves with respect thereto are
maintained on the books of any Credit Party or its Subsidiaries, as the case may be, in conformity with GAAP; 
 (e) statutory
Liens such as carriers’, warehousemen’s, mechanics’, materialmen’s, landlords’, repairmen’s or other like Liens arising in the ordinary course of business which are not overdue for a period of more than sixty
(60) days or which are being contested in good faith by appropriate proceedings; provided that a reserve or other appropriate provision shall have been made therefor to the extent required by GAAP and the aggregate amount of such Liens
could not reasonably be expected to have a Material Adverse Effect; and Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods; 
 (f) pledges or deposits in connection with workers’ compensation, unemployment insurance and other social security legislation (other
than any Lien imposed by ERISA) and deposits securing liability to insurance carriers under insurance or self-insurance arrangements arising in the ordinary course of business; 
 (g) deposits to secure the performance of bids, trade contracts (other than for borrowed money), leases, statutory obligations, surety and
appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of business; 
  

 29 

 (h) easements, rights of way, restrictions and other similar encumbrances affecting real
property which, in the aggregate, are not substantial in amount, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the applicable
Person; 
 (i) leases, licenses, subleases or sublicenses granted to others not interfering in any material respect with the
business of Borrower and its Subsidiaries, taken as a whole; and Liens arising from precautionary Uniform Commercial Code financing statements or similar filings made in respect of Operating Leases entered into by the Borrower or any of its
Subsidiaries; 
 (j) Liens existing on the Closing Date and, to the extent securing obligations in excess of $10,000 as of the
Closing Date, set forth on Schedule 1.1(b); provided that (i) no such Lien shall at any time be extended to cover property or assets other than the property or assets subject thereto on the Closing Date and improvements thereon
and (ii) the principal amount of the Indebtedness secured by such Lien shall not be extended, renewed, refunded or refinanced, except as permitted hereunder; 
 (k) any extension, renewal or replacement (or successive extensions, renewals or replacements), in whole or in part, of any Lien referred
to in this definition); provided that such extension, renewal or replacement Lien shall be limited to all or a part of the property which secured the Lien so extended, renewed or replaced (plus improvements on such property); 
 (l) Liens arising in the ordinary course of business by virtue of any contractual, statutory or common law provision relating to
banker’s Liens, rights of set-off or similar rights and remedies covering deposit or securities accounts (including funds or other assets credited thereto) or other funds or assets maintained with a depository institution or securities
intermediary; and Liens of a collecting bank arising under Section 4-210 of the UCC on items in the course of collection; 
 (m) any zoning, building or similar laws or rights reserved to or vested in any Governmental Authority; 
 (n)
restrictions on transfers of securities imposed by applicable Securities Laws; 
 (o) Liens arising out of judgments or awards
not resulting in an Event of Default; 
 (p) Liens on property acquired pursuant to a Permitted Acquisition or on the property
of a Person existing at the time such Person becomes a Subsidiary of a Credit Party (or is a Subsidiary that survives a merger with such a Person) securing Indebtedness or other obligations in an aggregate amount not to exceed $5,000,000 for all
such Liens; provided, however, that any such Lien may not extend to any other property of any Credit 

  

 30 

 
Party (other than proceeds of such property and after-acquired property that is affixed or incorporated into the property covered by such Lien);
provided, further, that any such Lien was not created in anticipation of or in connection with the applicable Permitted Acquisition or the transaction or series of transactions pursuant to which such Person became a Subsidiary of a
Credit Party; 
 (q) any interest or title of a lessor, licensor or sublessor under any lease, license or sublease entered
into by any Credit Party or any Subsidiary thereof in the ordinary course of its business and covering only the assets so leased, licensed or subleased (and proceeds and products thereof and proceeds of insurance maintained with respect thereto);

 (r) assignments of insurance or condemnation proceeds provided to landlords (or their mortgagees) pursuant to the terms of
any lease and Liens or rights reserved in any lease for rent or for compliance with the terms of such lease; 
 (s) Liens
securing Indebtedness or other obligations or any Subsidiary that is not a Credit Party to any other Subsidiary; 
 (t) Liens
(i) on cash advances in favor of the seller of any property to be acquired in a Permitted Acquisition to be applied against the purchase price of such Permitted Acquisition, and (ii) consisting of an agreement to sell, transfer, lease or
otherwise dispose of any property in a transaction permitted hereunder, in each case, solely to the extent such Permitted Acquisition, sale, disposition, transfer or lease, as the case may be, would have been permitted on the date of the creation of
such Lien; 
 (u) Liens on assets not constituting Collateral so long as the amount of Indebtedness and other obligations
secured thereby does not exceed $5,000,000 outstanding at any time; and 
 (v) additional Liens so long as the principal
amount of Indebtedness and other obligations secured thereby does not exceed $5,000,000 outstanding at any time. 
 “Person”
shall mean any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity. 
 “Plan” shall mean, as of any date of determination, any employee benefit plan which is subject to Title IV of ERISA and in respect of which any Credit Party or a Commonly Controlled Entity is (or, if
such plan were terminated at such time, would under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA. 
 “Pledge Agreement” shall mean the Pledge Agreement dated as of the Closing Date executed by the Credit Parties in favor of the Administrative Agent, for the benefit of the Secured Parties, as the same
may from time to time be amended, modified, extended, restated, replaced, or supplemented from time to time in accordance with the terms hereof and thereof. 
  

 31 

 “Prime Rate” shall have the meaning set forth in the definition of Alternate Base Rate.

 “Pro Forma Basis” shall mean, with respect to any transaction, that such transaction shall be deemed to have occurred as
of the first day of the four-quarter period ending as of the most recent quarter end preceding the date of such transaction. 
 “Properties” shall have the meaning set forth in Section 3.10(a). 
 “Qualified Preferred
Stock” shall mean, with respect to any Person, any Capital Stock of such Person so long as the terms of any such Capital Stock (a) (i) do not contain any mandatory put, redemption, repayment, sinking fund
or other similar provision and (ii) do not permit such Capital Stock to be converted into Indebtedness, in each case prior to the date which is six (6) months after the Maturity Date and (b) do not require the cash payment of
dividends, distributions or other Restricted Payments that would otherwise be prohibited by the terms of this Agreement. 
 “Recovery
Event” shall mean the receipt by the Credit Parties or any of their Subsidiaries of any cash insurance proceeds or condemnation or expropriation award payable by reason of theft, loss, physical destruction or damage, taking or similar event
with respect to any of their respective property or assets other than obsolete property or assets no longer used or useful in the business of the Credit Parties or any of their Subsidiaries. 
 “Register” shall have the meaning set forth in Section 9.6(c). 
 “Reimbursement Obligation” shall mean the obligation of the Borrower to reimburse the Issuing Lender pursuant to Section 2.3(d) for
amounts drawn under Letters of Credit. 
 “Related Parties” shall mean, with respect to any Person, such Person’s
Affiliates and the partners, directors, officers, employees, agents and advisors of such Person and of such Person’s Affiliates. 
 “Reorganization” shall mean, with respect to any Multiemployer Plan, the condition that such Plan is in reorganization within the meaning of such term as used in Section 4241 of ERISA. 
 “Reportable Event” shall mean any of the events set forth in Section 4043(c) of ERISA, other than those events as to which the
thirty-day notice period is waived under PBGC Reg. §4043. 
 “Required Lenders” shall mean, as of any date of
determination, Lenders holding at least a majority of (a) the outstanding Revolving Commitments or (b) if the Revolving Commitments have been terminated, the outstanding Loans and Participation Interests; provided, however,
that if any Lender shall be a Defaulting Lender at such time, then there shall be excluded from the determination of Required Lenders, Obligations (including Participation Interests) owing to such Defaulting Lender and such Defaulting Lender’s
Commitments. 
  

 32 

 “Requirement of Law” shall mean, as to any Person, (a) the articles or certificate
of incorporation, by-laws or other organizational or governing documents of such Person, and (b) all international, foreign, Federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes, executive orders, and
administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative
orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority (in each case whether or not having the force of law); in each case applicable to or binding upon such Person or any of its
property or to which such Person or any of its property is subject. 
 “Responsible Officer” shall mean, for any Credit
Party, any duly authorized officer thereof and with respect to which the Administrative Agent has an incumbency certificate indicating such officer is a duly authorized officer thereof. 
 “Restricted Payment” shall mean (a) any dividend or other distribution, direct or indirect, on account of any shares (or
equivalent) of any class of Capital Stock of any Credit Party or any of its Subsidiaries, now or hereafter outstanding (other than a stock split effected as a dividend or distribution of purchase rights pursuant to a stockholder rights plan (poison
pill)), (b) any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or indirect, of any shares (or equivalent) of any class of Capital Stock of any Credit Party or any of its Subsidiaries,
now or hereafter outstanding (c) any payment made to retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Capital Stock of any Credit Party or any of its Subsidiaries, now or
hereafter outstanding and (d) any payment or prepayment of principal of, premium, if any, or interest on, redemption, purchase, retirement, defeasance, sinking fund or similar payment with respect to, any Subordinated Debt of any Credit Party
or any of its Subsidiaries; provided, that the following will be deemed not to be Restricted Payments: (i) the repurchase, redemption, or other acquisition for value of Capital Stock held by present or former officers, directors or employees
(or their transferees, estates or beneficiaries under their estates) of any Credit Party or any of its Subsidiaries upon their death, disability, retirement, severance or termination of employment or service or pursuant to any management equity plan
or stock option plan or any other management or employee benefit plan, agreement or arrangement; provided that the aggregate cash consideration paid for all such repurchases, redemptions and acquisitions shall not exceed, without duplication, in any
calendar year, $2,000,000; (ii) tax payments made by any Credit Party or any of its Subsidiaries to any taxing authority related to the vesting of Capital Stock issued to employees or directors for compensatory purposes (and the surrender of
shares of Capital Stock to any Credit Party or any of its Subsidiaries by any such employees or directors in connection therewith); (iii) non-cash repurchases of Capital Stock deemed to occur upon the exercise of stock options if the Capital
Stock represents a portion of the exercise price thereof and (iv) cash payments in lieu of the issuance of fractional shares in connection with the exercise of warrants, options or other securities convertible into or exchangeable for Capital
Stock of any Credit Party or any of its Subsidiaries. 
  

 33 

 “Revolving Commitment” shall mean, with respect to each Revolving Lender, the commitment
of such Revolving Lender to make Revolving Loans in an aggregate principal amount at any time outstanding up to an amount equal to such Revolving Lender’s Revolving Commitment Percentage of the Revolving Committed Amount. The Revolving
Commitment of all Lenders on the Closing Date shall be One Hundred Twenty-Five Million Dollars ($125,000,000). 
 “Revolving
Commitment Percentage” shall mean, for each Lender, the percentage identified as its Revolving Commitment Percentage in its Lender Commitment Letter or in the Register or the applicable Assignment and Assumption pursuant to which such
Lender became a Lender hereunder, as such percentage may be modified in connection with any assignment made in accordance with the provisions of Section 9.6(b). 
 “Revolving Committed Amount” shall have the meaning set forth in Section 2.1(a). 
 “Revolving Lender” shall mean, as of any date of determination, a Lender holding a Revolving Commitment, a Revolving Loan or a Participation Interest on such date. 
 “Revolving Loan” shall have the meaning set forth in Section 2.1. 
 “Revolving Note” or “Revolving Notes” shall mean the promissory notes of the Borrower provided pursuant to
Section 2.1(e) in favor of any of the Revolving Lenders evidencing the Revolving Loan provided by any such Revolving Lender pursuant to Section 2.1(a), individually or collectively, as appropriate, as such promissory notes may be amended,
modified, extended, restated, replaced, or supplemented from time to time. 
 “S&P” shall mean Standard &
Poor’s Ratings Services, a division of The McGraw Hill Companies, Inc. 
 “Sanctioned Country” shall mean a country
subject to a sanctions program identified on the list maintained by OFAC and made publicly available from time to time. 
 “Sanctioned Person” shall mean (a) a Person named on the list of “Specially Designated Nationals and Blocked Persons” maintained by OFAC and made publicly available from time to time, or (b) (i) an
agency of the government of a Sanctioned Country, (ii) an organization controlled by a Sanctioned Country, or (iii) a person resident in a Sanctioned Country, to the extent subject to a sanctions program administered by OFAC. 

“Sarbanes-Oxley” shall mean the Sarbanes-Oxley Act of 2002. 
 “Scheduled Funded Debt Payments” shall mean, without duplication, as of any date of determination for the four consecutive fiscal
quarter period ending on such date, the sum of all regularly scheduled payments of principal on Funded Debt of the Credit Parties and their Subsidiaries for the applicable period ending on the date of determination ((i) including the principal
component of payments due on Capital Leases during the applicable period ending on the date of determination but (ii) excluding any principal payments due with respect to Funded Debt owed by the Borrower or any Subsidiary to the Borrower or any
Subsidiary during the applicable period ending on the date of determination). 
  

 34 

 “SEC” shall mean the Securities and Exchange Commission or any successor Governmental
Authority. 
 “Secured Hedging Agreement” shall mean any Hedging Agreement between a Credit Party or a Subsidiary thereof
and a Hedging Agreement Provider, as amended, modified, extended, restated, replaced, or supplemented from time to time. 
 “Secured
Parties” shall mean the Administrative Agent, the Lenders and the Hedging Agreement Providers. 
 “Securities Account
Control Agreement” shall mean an agreement, among a Credit Party, a securities intermediary, and the Administrative Agent, which agreement is either substantially in the form of Exhibit 1.1(h) or in a form acceptable to the
Administrative Agent and which provides the Administrative Agent with “control” (as such term is used in Articles 8 and 9 of the Uniform Commercial Code) over the securities account(s) described therein, as the same may be as amended,
modified, extended, restated, replaced, or supplemented from time to time. 
 “Securities Act” shall mean the Securities Act
of 1933, together with any amendment thereto or replacement thereof and any rules or regulations promulgated thereunder. 
 “Securities Laws” shall mean the Securities Act, the Exchange Act, Sarbanes-Oxley and the applicable accounting and auditing principles, rules, standards and practices promulgated, approved or incorporated by the SEC or the
Public Company Accounting Oversight Board, as each of the foregoing may be amended and in effect on any applicable date hereunder. 
 “Security Agreement” shall mean the Security Agreement dated as of the Closing Date executed by the Credit Parties in favor of the Administrative Agent, for the benefit of the Secured Parties, as amended, modified,
extended, restated, replaced, or supplemented from time to time in accordance with its terms. 
 “Security Documents” shall
mean the Security Agreement, the Pledge Agreement and all other agreements, documents and instruments relating to, arising out of, or in any way connected with any of the foregoing documents granting to the Administrative Agent, Liens or security
interests to secure, the Credit Party Obligations whether now or hereafter executed and/or filed, each as may be amended from time to time in accordance with the terms hereof, including, without limitation, UCC financing statements, Deposit Account
Control Agreements and Securities Account Control Agreements. 
 “Single Employer Plan” shall mean any Plan that is not a
Multiemployer Plan. 
 “Subordinated Debt” shall mean any Indebtedness incurred by any Credit Party which by its terms
is specifically subordinated in right of payment to the prior payment of the Credit Party Obligations and contains subordination and other terms reasonably acceptable to the Administrative Agent. 
  

 35 

 “Subsidiary” shall mean, as to any Person, a corporation, partnership, limited liability
company or other entity of which shares of stock or other ownership interests having ordinary voting power (other than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of
the board of directors or other managers of such corporation, limited liability company, partnership or other entity are at the time owned, directly or indirectly through one or more intermediaries, by such Person. Unless otherwise qualified, all
references to a “Subsidiary” or to “Subsidiaries” in this Agreement shall refer to a Subsidiary or Subsidiaries of the Borrower. 
 “Swingline Commitment” shall mean the commitment of the Swingline Lender to make Swingline Loans in an aggregate principal amount at any time outstanding up to the Swingline Committed Amount, and the
commitment of the Revolving Lenders to purchase participation interests in the Swingline Loans as provided in Section 2.4(b)(ii), as such amounts may be reduced from time to time in accordance with the provisions hereof. 
 “Swingline Committed Amount” shall mean the amount of the Swingline Lender’s Swingline Commitment as specified in
Section 2.4(a). 
 “Swingline Lender” shall mean Wachovia and any successor swingline lender. 
 “Swingline Loan” shall have the meaning set forth in Section 2.4(a). 
 “Swingline Note” shall mean the promissory note of the Borrower in favor of the Swingline Lender evidencing the Swingline Loans provided
pursuant to Section 2.4(d), as such promissory note may be amended, modified, extended, restated, replaced, or supplemented from time to time. 
 “Synthetic Lease” shall mean any synthetic lease, tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing product where such transaction is considered borrowed money indebtedness for tax
purposes but is classified as an Operating Lease in accordance with GAAP. 
 “Target” shall have the meaning set forth in
the definition of “Permitted Acquisition”. 
 “Taxes” shall mean all present or future taxes, levies, imposts,
duties, deductions, withholdings, assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto. 
 “Trademark License” shall mean any agreement, whether written or oral, providing for the grant by or to a Person of any right to use any
Trademark, including, without limitation, any thereof referred to in Schedule 3.15. 
 “Trademarks” shall mean
(a) all trademarks, trade names, corporate names, company names, business names, fictitious business names, service marks, elements of package or trade dress of goods or services, logos and other source or business identifiers, together with
the goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations 

  

 36 

 
and recordings thereof, and all applications in connection therewith, whether in the United States Patent and Trademark Office or in any similar office or
agency of the United States, any State thereof or any other country or any political subdivision thereof, including, without limitation, any thereof referred to in Schedule 3.15 and (b) all renewals thereof including, without limitation,
any thereof referred to in Schedule 3.15. 
 “Tranche” shall mean the collective reference to (a) LIBOR Rate
Loans whose Interest Periods begin and end on the same day and (b) Alternate Base Rate Loans made on the same day. 
 “Transactions” shall mean the closing of this Agreement and the other Credit Documents and the consummation of the other transactions contemplated hereby to occur in connection with such closing (including, without
limitation, the initial borrowings under the Credit Documents and the payment of fees and expenses in connection with all of the foregoing). 
 “Transfer Effective Date” shall have the meaning set forth in each Assignment and Assumption. 
 “Type” shall mean, as to any Loan, its nature as an Alternate Base Rate Loan or LIBOR Rate Loan, as the case may be. 
 “UCC” shall mean the Uniform Commercial Code from time to time in effect in any applicable jurisdiction. 
 “Voting Stock” shall mean, with respect to any Person, Capital Stock issued by such Person the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons
performing similar functions) of such Person, even though the right so to vote may be or have been suspended by the happening of such a contingency. 
 “Wachovia” shall mean Wachovia Bank, National Association, a national banking association, together with its successors and/or assigns. 
 “WCM” shall mean Wachovia Capital Markets, LLC, together with its successors and assigns. 
 “Works” shall mean all works which are subject to copyright protection pursuant to Title 17 of the United States Code. 

Section 1.2 Other Definitional Provisions. 
 The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter
forms. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “without limitation.” The word “will” shall be construed to have the same meaning and effect as the
word “shall.” Unless the context requires otherwise (a) any definition of or reference to any agreement, instrument or other document herein shall be 

  

 37 

 
construed as referring to such agreement, instrument or other document as from time to time amended, restated, supplemented, amended and restated or
otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (b) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (c) the
words “herein,” “hereof” and “hereunder,” and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (d) all references herein to
Articles, Sections, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Exhibits and Schedules to, this Agreement, (e) any reference to any law or regulation herein shall, unless otherwise specified, refer to
such law or regulation as amended, modified or supplemented from time to time, (f) the words “asset” and “property” shall be construed to have the same meaning and effect and to refer to any and all tangible and intangible
assets and properties, including cash, securities, accounts and contract rights and (g) all terms defined in this Agreement shall have the defined meanings when used in any other Credit Document or any certificate or other document made or
delivered pursuant hereto. 
 Section 1.3 Accounting Terms. 
 Unless otherwise specified herein, all accounting terms used herein shall be interpreted, all accounting determinations hereunder shall be made, and all
financial statements required to be delivered hereunder shall be prepared in accordance with GAAP applied on a basis consistent with the most recent audited Consolidated financial statements of the Borrower delivered to the Lenders; provided
that, if the Borrower shall notify the Administrative Agent that it wishes to amend any definitions or covenant incorporated in Section 5.9 to eliminate the effect of any change in GAAP on the operation of any such definition or provision (or
if the Administrative Agent notifies the Borrower that the Required Lenders wish to amend any such definition or provision for such purpose), then the Borrower’s compliance with such provisions shall be determined on the basis of GAAP in effect
immediately before the relevant change in GAAP became effective, until either such notice is withdrawn or such definition or provision is amended in a manner satisfactory to the Borrower and the Required Lenders. 
 The Borrower shall deliver to the Administrative Agent and each Lender at the same time as the delivery of any annual or quarterly financial statements
given in accordance with the provisions of Section 5.1, (a) a description in reasonable detail of any material change in the application of accounting principles employed in the preparation of such financial statements from those applied
in the most recently preceding quarterly or annual financial statements as to which no objection shall have been made in accordance with the provisions above and (b) a reasonable estimate of the effect on the financial statements on account of
such changes in application. 
 For purposes of computing the financial covenants set forth in Section 5.9 for any applicable test
period, any Permitted Acquisition or permitted sale of a Subsidiary, division, line of business or other business unit (including the incurrence or repayment of Indebtedness in connection with any such Permitted Acquisition or permitted sale) shall
be given pro forma effect as if such transaction had taken place as of the first day of such applicable test period. 
  

 38 

 Section 1.4 Time References. 
 Unless otherwise specified, all references herein to times of day shall be references to Eastern time (daylight or standard, as applicable). 

Section 1.5 Execution of Documents. 
 Unless otherwise specified, all Credit Documents and all other certificates executed in connection therewith must be signed by a Responsible Officer. 
 ARTICLE II 
 THE LOANS; AMOUNT AND TERMS 
 Section 2.1 Revolving Loans. 
 (a) Revolving Commitment. During the Commitment Period, subject to the terms and conditions hereof, each Revolving Lender severally, but not jointly, agrees to make revolving credit loans in Dollars
(“Revolving Loans”) to the Borrower from time to time in an aggregate principal amount of up to ONE HUNDRED TWENTY-FIVE MILLION DOLLARS ($125,000,000) (as increased from time to time as provided in Section 2.2 and as
such aggregate maximum amount may be reduced from time to time as provided in Section 2.6, the “Revolving Committed Amount”) for the purposes hereinafter set forth; provided, however, that (i) with regard to
each Revolving Lender individually, the sum of such Revolving Lender’s Revolving Commitment Percentage of the aggregate principal amount of outstanding Revolving Loans plus such Revolving Lender’s Revolving Commitment Percentage of
outstanding Swingline Loans plus such Revolving Lender’s Revolving Commitment Percentage of outstanding LOC Obligations shall not exceed such Revolving Lender’s Revolving Commitment and (ii) with regard to the Revolving Lenders
collectively, the sum of the aggregate principal amount of outstanding Revolving Loans plus outstanding LOC Obligations shall not exceed the Revolving Committed Amount then in effect. Revolving Loans may consist of Alternate Base Rate Loans
or LIBOR Rate Loans, or a combination thereof, as the Borrower may request, and may be repaid and reborrowed in accordance with the provisions hereof; provided, however, that the Revolving Loans made on the Closing Date or any of the
three (3) Business Days following the Closing Date, may only consist of Alternate Base Rate Loans unless the Borrower delivers a funding indemnity letter, substantially in the form of Exhibit 2.1(a), reasonably acceptable to the
Administrative Agent not less than three (3) Business Days prior to the Closing Date. LIBOR Rate Loans shall be made by each Revolving Lender at its LIBOR Lending Office and Alternate Base Rate Loans at its Domestic Lending Office. 

(b) Revolving Loan Borrowings. 
 (i) Notice of Borrowing. The Borrower shall request a Revolving Loan borrowing by delivering a written Notice of Borrowing (or telephone notice 

  

 39 

 
promptly confirmed in writing by delivery of a written Notice of Borrowing, which delivery may be by fax) to the Administrative Agent not later than
11:00 A.M. on the Business Day prior to the date of the requested borrowing in the case of Alternate Base Rate Loans, and on the third Business Day prior to the date of the requested borrowing in the case of LIBOR Rate Loans. Each such Notice
of Borrowing shall be irrevocable and shall specify (A) that a Revolving Loan is requested, (B) the date of the requested borrowing (which shall be a Business Day), (C) the aggregate principal amount to be borrowed and
(D) whether the borrowing shall be comprised of Alternate Base Rate Loans, LIBOR Rate Loans or a combination thereof, and if LIBOR Rate Loans are requested, the Interest Period(s) therefor. If the Borrower shall fail to specify in any such
Notice of Borrowing (1) an applicable Interest Period in the case of a LIBOR Rate Loan, then such notice shall be deemed to be a request for an Interest Period of one month, or (2) the Type of Revolving Loan requested, then such notice
shall be deemed to be a request for an Alternate Base Rate Loan hereunder. The Administrative Agent shall give notice to each Revolving Lender promptly upon receipt of each Notice of Borrowing, the contents thereof and each such Revolving
Lender’s share thereof. 
 (ii) Minimum Amounts. Each Revolving Loan that is made as an Alternate Base Rate Loan
shall be in a minimum aggregate amount of $500,000 and in integral multiples of $500,000 in excess thereof (or the remaining amount of the Revolving Committed Amount, if less). Each Revolving Loan that is made as a LIBOR Rate Loan shall be in a
minimum aggregate amount of $1,000,000 and in integral multiples of $1,000,000 in excess thereof (or the remaining amount of the Revolving Committed Amount, if less). 
 (iii) Advances. Each Revolving Lender will make its Revolving Commitment Percentage of each Revolving Loan borrowing available to
the Administrative Agent for the account of the Borrower at the office of the Administrative Agent specified in Section 9.2, or at such other office as the Administrative Agent may designate in writing, upon reasonable advance notice by 1:00
P.M. on the date specified in the applicable Notice of Borrowing, in Dollars and in funds immediately available to the Administrative Agent. Such borrowing will then be made available to the Borrower by the Administrative Agent by crediting the
account of the Borrower on the books of such office (or such other account that the Borrower may designate in writing to the Administrative Agent) with the aggregate of the amounts made available to the Administrative Agent by the Revolving Lenders
and in like funds as received by the Administrative Agent. 
 (c) Repayment. Subject to the terms of this Agreement,
Revolving Loans may be borrowed, repaid and reborrowed during the Commitment Period. The principal amount of all Revolving Loans shall be due and payable in full on the Maturity Date, unless accelerated sooner pursuant to Section 7.2. The
Borrower shall have the right to repay Revolving Loans in whole or in part from time to time without penalty; provided, 

  

 40 

 
however; that each partial repayment of a Revolving Loan shall be in a minimum principal amount of (i) in the case of Alternate Base Rate Loans,
$500,000 and integral multiples of $500,000 in excess thereof (or the remaining outstanding principal amount) and (ii) in the case of LIBOR Rate Loans, $1,000,000 and integral multiples of $1,000,000 in excess thereof (or the remaining
outstanding principal amount). 
 (d) Interest. Subject to the provisions of Section 2.8, Revolving Loans shall
bear interest as follows: 
 (i) Alternate Base Rate Loans. During such periods as any Revolving Loans shall be
comprised of Alternate Base Rate Loans, each such Alternate Base Rate Loan shall bear interest at a per annum rate equal to the sum of the Alternate Base Rate plus the Applicable Percentage; and 
 (ii) LIBOR Rate Loans. During such periods as Revolving Loans shall be comprised of LIBOR Rate Loans, each such LIBOR Rate Loan
shall bear interest at a per annum rate equal to the sum of the LIBOR Rate plus the Applicable Percentage. 
 (e)
Revolving Notes; Covenant to Pay. The Borrower’s obligation to pay each Revolving Lender shall be evidenced by this Agreement and, upon such Revolving Lender’s request, by a duly executed promissory note of the Borrower to such
Revolving Lender in substantially the form of Exhibit 2.1(e). The Borrower covenants and agrees to pay the Revolving Loans in accordance with the terms of this Agreement. 
 Section 2.2 Incremental Revolving Facility. 
 Subject to the terms and conditions set forth herein and so long as no Default or Event of Default has occurred and is continuing, the Borrower shall have the right, up to three times prior to the Maturity Date, to
incur additional Indebtedness under this Credit Agreement in the form of an increase to the Revolving Committed Amount (each an “Incremental Revolving Facility” and collectively the “Incremental Revolving
Facilities”). The following terms and conditions shall apply to each Incremental Revolving Facility: (i) the loans made under each Incremental Revolving Facility (each an “Additional Revolving Loan”) shall constitute
Credit Party Obligations and will be secured and guaranteed with the other Credit Party Obligations on a pari passu basis, (ii) each Incremental Revolving Facility shall have the same terms (including interest rate and maturity date) as the
existing Revolving Loans (provided, however, that the Borrower may at its discretion pay additional fees to the Lenders providing such Incremental Revolving Facilities), (iii) each Incremental Revolving Facility shall be entitled to the same
voting rights as the existing Revolving Loans, voting as one class, and shall be entitled to receive a pro rata share of proceeds of prepayments on the same basis as the existing Revolving Loans, (iv) each Incremental Revolving Facility shall
be obtained from existing Lenders or from other banks, financial institutions or investment funds, in each case in accordance with the terms set forth below, (v) the proceeds of the Additional Revolving Loans will be used for the purposes set
forth in Section 3.11, (vi) the Borrower shall execute a Revolving Note in favor of any new Lender or any existing Lender requesting a Revolving Note whose Revolving Commitment is 

  

 41 

 
increased, (vii) the conditions to Extensions of Credit in Section 4.2 shall have been satisfied, (viii) each such Incremental Revolving
Facility shall be in a minimum amount of $5,000,000 (and $1,000,000 increments in excess thereof), (ix) the aggregate amount of all Incremental Revolving Facilities shall not exceed $25,000,000 at any time and (x) the Administrative Agent
shall have received from the Borrower (A) resolutions, legal opinions and other corporate authority documents with respect to each Incremental Revolving Facility requested by the Administrative Agent, substantially the same in form and
substance as those delivered on the Closing Date pursuant to Section 4.1 and (B) updated financial projections and an officer’s certificate, in each case in form and substance reasonably satisfactory to the Administrative Agent,
demonstrating that, after giving effect to such Incremental Revolving Facility on a Pro Forma Basis, the Credit Parties will be in compliance with the financial covenants set forth in Section 5.9 and no Default or Event of Default shall exist.
The Borrower may invite other banks, financial institutions and investment funds reasonably acceptable to the Administrative Agent to join this Credit Agreement as Lenders hereunder, provided that such other banks, financial institutions and
investment funds shall enter into such joinder agreements to give effect thereto as the Administrative Agent may reasonably request. The Administrative Agent is authorized to enter into, on behalf of the Lenders, any amendment to this Credit
Agreement or any other Credit Document as may be necessary to solely incorporate the terms of each Incremental Revolving Facility therein. 
 In connection with the closing of any Incremental Revolving Facility, the outstanding Revolving Loans and Participation Interests shall be reallocated by causing such fundings and repayments (which shall not be subject to any processing
and/or recordation fees) among the Revolving Lenders (which the Borrowers shall be responsible for any costs arising under Section 2.15 resulting from such reallocation and repayments; provided, that the Administrative Agent will use its
reasonable efforts to minimize any such costs) of Revolving Loans as necessary such that, after giving effect to such Incremental Revolving Facility, each Revolving Lender will hold Revolving Loans and Participation Interests based on its Revolving
Commitment Percentage (after giving effect to such Incremental Revolving Facility). 
 Section 2.3 Letter of Credit
Subfacility. 
 (a) Issuance. Subject to the terms and conditions hereof and of the LOC Documents, if any, and
any other terms and conditions which the Issuing Lender may reasonably require which are not inconsistent with the terms of this Agreement, during the Commitment Period the Issuing Lender shall issue, and the Revolving Lenders shall participate in,
standby Letters of Credit for the account of the Borrower from time to time upon request in a form reasonably acceptable to the Issuing Lender; provided, however, that (i) the aggregate amount of outstanding LOC Obligations shall
not at any time exceed TEN MILLION DOLLARS ($10,000,000) (the “LOC Committed Amount”), (ii) the sum of the aggregate principal amount of outstanding Revolving Loans plus outstanding Swingline Loans plus
outstanding LOC Obligations shall not at any time exceed the Revolving Committed Amount then in effect, (iii) all Letters of Credit shall be denominated in Dollars and (iv) Letters of Credit shall be issued for any lawful corporate
purposes and shall be issued as standby letters of credit, including in connection with workers’ compensation and other insurance programs. Except as otherwise expressly 

  

 42 

 
agreed upon by all the Revolving Lenders, no Letter of Credit shall have an original expiry date more than twelve (12) months from the date of
issuance; provided, however, so long as no Default or Event of Default has occurred and is continuing and subject to the other terms and conditions to the issuance of Letters of Credit hereunder, the expiry dates of Letters of
Credit may be extended annually or periodically from time to time on the request of the Borrower or by operation of the terms of the applicable Letter of Credit to a date not more than twelve (12) months from the date of extension;
provided, further, that no Letter of Credit, as originally issued or as extended, shall have an expiry date extending beyond the Maturity Date. Each Letter of Credit shall comply with the related LOC Documents. The issuance and expiry
date of each Letter of Credit shall be a Business Day. Each Letter of Credit issued hereunder shall be in a minimum original face amount of $100,000 or such lesser amount as approved by the Issuing Lender. The Borrower’s Reimbursement
Obligations in respect of each Existing Letter of Credit, and each Revolving Lender’s participation obligations in connection therewith, shall be governed by the terms of this Credit Agreement. Wachovia shall be the Issuing Lender on all
Letters of Credit issued after the Closing Date. The Existing Letters of Credit shall, as of the Closing Date, be deemed to have been issued as Letters of Credit hereunder and subject to and governed by the terms of this Agreement. 
 (b) Notice and Reports. The request for the issuance of a Letter of Credit shall be submitted to the Issuing Lender at least five
(5) Business Days prior to the requested date of issuance. The Issuing Lender will promptly upon request provide to the Administrative Agent for dissemination to the Revolving Lenders a detailed report specifying the Letters of Credit which are
then issued and outstanding and any activity with respect thereto which may have occurred since the date of any prior report, and including therein, among other things, the account party, the beneficiary, the face amount, expiry date as well as any
payments or expirations which may have occurred. The Issuing Lender will further provide to the Administrative Agent promptly upon request copies of the Letters of Credit. The Issuing Lender will provide to the Administrative Agent promptly upon
request a summary report of the nature and extent of LOC Obligations then outstanding. 
 (c) Participations. Each
Revolving Lender, (i) on the Closing Date with respect to each Existing Letter of Credit and (ii) upon issuance of a Letter of Credit, shall be deemed to have purchased without recourse a risk participation from the Issuing Lender in such
Letter of Credit and the obligations arising thereunder and any collateral relating thereto, in each case in an amount equal to its Revolving Commitment Percentage of the obligations under such Letter of Credit and shall absolutely, unconditionally
and irrevocably assume, as primary obligor and not as surety, and be obligated to pay to the Issuing Lender therefor and discharge when due, its Revolving Commitment Percentage of the obligations arising under such Letter of Credit; provided
that any Person that becomes a Revolving Lender after the Closing Date shall be deemed to have purchased a Participation Interest in all outstanding Letters of Credit on the date it becomes a Lender hereunder and any Letter of Credit issued on or
after such date, in each case in accordance with the foregoing terms. Without limiting the scope and nature of each Revolving Lender’s participation in any Letter of Credit, to the extent that the 

  

 43 

 
Issuing Lender has not been reimbursed as required hereunder or under any LOC Document, each such Revolving Lender shall pay to the Issuing Lender its
Revolving Commitment Percentage of such unreimbursed drawing in same day funds pursuant to and in accordance with the provisions of subsection (d) hereof. The obligation of each Revolving Lender to so reimburse the Issuing Lender shall be
absolute and unconditional and shall not be affected by the occurrence of a Default, an Event of Default or any other occurrence or event. Any such reimbursement shall not relieve or otherwise impair the obligation of the Borrower to reimburse the
Issuing Lender under any Letter of Credit, together with interest as hereinafter provided. 
 (d) Reimbursement. In the
event of any drawing under any Letter of Credit, the Issuing Lender will promptly notify the Borrower and the Administrative Agent. The Borrower shall reimburse the Issuing Lender on the day of drawing under any Letter of Credit if notified prior to
3:00 P.M. on a Business Day or, if after 3:00 P.M., on the following Business Day (either with the proceeds of a Revolving Loan obtained hereunder or otherwise) in same day funds as provided herein or in the LOC Documents. If the Borrower shall fail
to reimburse the Issuing Lender as provided herein, the unreimbursed amount of such drawing shall bear interest at a per annum rate equal to the Default Rate until reimbursed. Unless the Borrower shall immediately notify the Issuing Lender and the
Administrative Agent of its intent to otherwise reimburse the Issuing Lender, the Borrower shall be deemed to have requested a Mandatory LOC Borrowing in the amount of the drawing as provided in subsection (e) hereof, the proceeds of which will
be used to satisfy the Reimbursement Obligations. The Borrower’s Reimbursement Obligations hereunder shall be absolute and unconditional under all circumstances irrespective of any rights of set-off, counterclaim or defense to payment the
Borrower may claim or have against the Issuing Lender, the Administrative Agent, the Lenders, the beneficiary of the Letter of Credit drawn upon or any other Person, including without limitation any defense based on any failure of the Borrower to
receive consideration or the legality, validity, regularity or unenforceability of the Letter of Credit; provided that the foregoing shall not exonerate any Issuing Lender, the Administrative Agent or any other Lender from any liability to
the Borrower or any other Credit Party or Subsidiary thereof resulting from such Issuing Lender’s, the Administrative Agent’s or such Lender’s gross negligence or willful misconduct. The Issuing Lender will promptly notify the other
Revolving Lenders of the amount of any unreimbursed drawing and each Revolving Lender shall promptly pay to the Administrative Agent for the account of the Issuing Lender, in Dollars and in immediately available funds, the amount of such Revolving
Lender’s Revolving Commitment Percentage of such unreimbursed drawing. Such payment shall be made on the Business Day such notice is received by such Revolving Lender from the Issuing Lender if such notice is received at or before 2:00 P.M.,
otherwise such payment shall be made at or before 12:00 Noon on the Business Day next succeeding the Business Day such notice is received. If such Revolving Lender does not pay such amount to the Issuing Lender in full upon such request, such
Revolving Lender shall, on demand, pay to the Administrative Agent for the account of the Issuing Lender interest on the unpaid amount during the period from the date of such drawing until such Revolving Lender pays such amount to the Issuing Lender
in full at a rate per annum equal to, if paid within two (2) Business Days of the date of drawing, the Federal 

  

 44 

 
Funds Effective Rate and thereafter at a rate equal to the Alternate Base Rate. Each Revolving Lender’s obligation to make such payment to the Issuing
Lender, and the right of the Issuing Lender to receive the same, shall be absolute and unconditional, shall not be affected by any circumstance whatsoever and without regard to the termination of this Agreement or the Commitments hereunder, the
existence of a Default or Event of Default or the acceleration of the Credit Party Obligations hereunder and shall be made without any offset, abatement, withholding or reduction whatsoever. 
 (e) Repayment with Revolving Loans. On any day on which the Borrower shall have requested, or been deemed to have requested, a
Revolving Loan to reimburse a drawing under a Letter of Credit, the Administrative Agent shall give notice to the Revolving Lenders that a Revolving Loan has been requested or deemed requested in connection with a drawing under a Letter of Credit,
in which case a Revolving Loan borrowing comprised entirely of Alternate Base Rate Loans (each such borrowing, a “Mandatory LOC Borrowing”) shall be made (without giving effect to any termination of the Commitments pursuant to
Section 7.2) pro rata based on each Revolving Lender’s respective Revolving Commitment Percentage (determined before giving effect to any termination of the Commitments pursuant to Section 7.2) and the proceeds thereof shall be paid
directly to the Issuing Lender for application to the respective LOC Obligations. Each Revolving Lender hereby irrevocably agrees to make such Revolving Loans on the day such notice is received by the Revolving Lenders from the Administrative Agent
if such notice is received at or before 2:00 P.M., otherwise such payment shall be made at or before 12:00 Noon on the Business Day next succeeding the day such notice is received, in each case notwithstanding (i) the amount of Mandatory
LOC Borrowing may not comply with the minimum amount for borrowings of Revolving Loans otherwise required hereunder, (ii) whether any conditions specified in Section 4.2 are then satisfied, (iii) whether a Default or an Event of
Default then exists, (iv) failure for any such request or deemed request for Revolving Loan to be made by the time otherwise required in Section 2.1(b), (v) the date of such Mandatory LOC Borrowing, or (vi) any reduction in the
Revolving Committed Amount after any such Letter of Credit may have been drawn upon. In the event that any Mandatory LOC Borrowing cannot for any reason be made on the date otherwise required above (including, without limitation, as a result of the
occurrence of a Bankruptcy Event), then each such Revolving Lender hereby agrees that it shall forthwith fund as of the date the Mandatory LOC Borrowing would otherwise have occurred, but adjusted for any payments received from the Borrower on or
after such date and prior to such purchase) its Participation Interests in the outstanding LOC Obligations; provided, further, that in the event any Revolving Lender shall fail to fund its Participation Interest on the day the
Mandatory LOC Borrowing would otherwise have occurred, then the amount of such Revolving Lender’s unfunded Participation Interest therein shall bear interest payable by such Revolving Lender to the Issuing Lender upon demand, at the rate equal
to, if paid within two (2) Business Days of such date, the Federal Funds Effective Rate, and thereafter at a rate equal to the Alternate Base Rate. 
 (f) Modification, Extension. The issuance of any supplement, modification, amendment, renewal, or extension to any Letter of Credit shall, for purposes hereof, be treated in all respects the same as the
issuance of a new Letter of Credit hereunder. 
  

 45 

 (g) ISP98. Unless otherwise expressly agreed by the Issuing Lender and the
Borrower, when a Letter of Credit is issued, the rules of the “International Standby Practices 1998,” published by the Institute of International Banking Law & Practice (or such later version thereof as may be in effect at the
time of issuance) shall apply to each standby Letter of Credit. 
 (h) Conflict with LOC Documents. In the event of any
conflict between this Agreement and any LOC Document (including any letter of credit application and any LOC Documents relating to the Existing Letters of Credit), this Agreement shall control. 
 (i) Designation of Subsidiaries as Account Parties. Notwithstanding anything to the contrary set forth in this Agreement, including
without limitation Section 2.3(a), a Letter of Credit issued hereunder may contain a statement to the effect that such Letter of Credit is issued for the account of a Subsidiary of the Borrower; provided that, notwithstanding such
statement, the Borrower shall be the actual account party for all purposes of this Agreement for such Letter of Credit and such statement shall not affect the Borrower’s Reimbursement Obligations hereunder with respect to such Letter of Credit.

 Section 2.4 Swingline Loan Subfacility. 
 (a) Swingline Commitment. During the Commitment Period, subject to the terms and conditions hereof, the Swingline Lender, in its
individual capacity, agrees to make certain revolving credit loans to the Borrower (each a “Swingline Loan” and, collectively, the “Swingline Loans”) for the purposes hereinafter set forth; provided,
however, (i) the aggregate principal amount of Swingline Loans outstanding at any time shall not exceed FIVE MILLION DOLLARS ($5,000,000) (the “Swingline Committed Amount”), and (ii) the sum of the aggregate
principal amount of outstanding Revolving Loans plus outstanding Swingline Loans plus outstanding LOC Obligations shall not exceed the Revolving Committed Amount then in effect. Swingline Loans hereunder may be repaid and reborrowed in
accordance with the provisions hereof. 
 (b) Swingline Loan Borrowings. 
 (i) Notice of Borrowing and Disbursement. Upon receiving a Notice of Borrowing from the Borrower not later than 12:00 P.M. on any
Business Day requesting that a Swingline Loan be made, the Swingline Lender will make Swingline Loans available to the Borrower on the same Business Day such request is received by the Administrative Agent. Swingline Loan borrowings hereunder shall
be made in minimum amounts of $100,000 (or the remaining available amount of the Swingline Committed Amount if less) and in integral amounts of $100,000 in excess thereof. 
  

 46 

 (ii) Repayment of Swingline Loans. Each Swingline Loan borrowing shall be due and
payable on the earlier of (A) the Maturity Date and (B) fifteen (15) days following such borrowing. The Swingline Lender may, at any time, in its sole discretion, by written notice to the Borrower and the Administrative Agent, demand
repayment of its Swingline Loans by way of a Revolving Loan borrowing, in which case the Borrower shall be deemed to have requested a Revolving Loan borrowing comprised entirely of Alternate Base Rate Loans in the amount of such Swingline Loans;
provided, however, that, in the following circumstances, any such demand shall also be deemed to have been given one Business Day prior to each of (A) the Maturity Date, (B) the occurrence of any Bankruptcy Event,
(C) upon acceleration of the Credit Party Obligations hereunder, whether on account of a Bankruptcy Event or any other Event of Default, and (D) the exercise of remedies in accordance with the provisions of Section 7.2 hereof (each
such Revolving Loan borrowing made on account of any such deemed request therefor as provided herein being hereinafter referred to as “Mandatory Swingline Borrowing”). Each Revolving Lender hereby irrevocably agrees to make such
Revolving Loans promptly upon any such request or deemed request on account of each Mandatory Swingline Borrowing in the amount and in the manner specified in the preceding sentence on the date such notice is received by the Revolving Lenders from
the Administrative Agent if such notice is received at or before 2:00 P.M., otherwise such payment shall be made at or before 12:00 P.M. on the Business Day next succeeding the date such notice is received notwithstanding (1) the amount
of Mandatory Swingline Borrowing may not comply with the minimum amount for borrowings of Revolving Loans otherwise required hereunder, (2) whether any conditions specified in Section 4.2 are then satisfied, (3) whether a Default or
an Event of Default then exists, (4) failure of any such request or deemed request for Revolving Loans to be made by the time otherwise required in Section 2.1(b)(i), (5) the date of such Mandatory Swingline Borrowing, or (6) any
reduction in the Revolving Committed Amount or termination of the Revolving Commitments immediately prior to such Mandatory Swingline Borrowing or contemporaneously therewith. In the event that any Mandatory Swingline Borrowing cannot for any reason
be made on the date otherwise required above (including, without limitation, as a result of the commencement of a proceeding under the Bankruptcy Code), then each Revolving Lender hereby agrees that it shall forthwith purchase (as of the date the
Mandatory Swingline Borrowing would otherwise have occurred, but adjusted for any payments received from the Borrower on or after such date and prior to such purchase) from the Swingline Lender such Participation Interest in the outstanding
Swingline Loans as shall be necessary to cause each such Revolving Lender to share in such Swingline Loans ratably based upon its respective Revolving Commitment Percentage (determined before giving effect to any termination of the Commitments
pursuant to Section 7.2); provided that (x) all interest payable on the Swingline Loans shall be for the account of the Swingline Lender until the date as of which the respective Participation Interest is purchased, and (y) at
the time any purchase of a Participation Interest pursuant to this sentence is actually made, the purchasing Revolving Lender shall be required to pay to the Swingline Lender interest on the principal amount of such Participation Interest purchased
for each day from and including the day upon 

  

 47 

 
which the Mandatory Swingline Borrowing would otherwise have occurred to but excluding the date of payment for such Participation Interest, at the rate equal
to, if paid within two (2) Business Days of the date of the Mandatory Swingline Borrowing, the Federal Funds Effective Rate, and thereafter at a rate equal to the Alternate Base Rate. The Borrower shall have the right to repay the Swingline
Loan in whole or in part from time to time; provided, however; that each partial repayment of a Swingline Loan shall be in a minimum principal amount of $100,000 and integral multiples of $100,000 in excess thereof (or the remaining
outstanding principal amount). 
 (c) Interest on Swingline Loans. Subject to the provisions of Section 2.8,
Swingline Loans shall bear interest at a per annum rate equal to the Alternate Base Rate plus the Applicable Percentage for Revolving Loans that are Alternate Base Rate Loans. Interest on Swingline Loans shall be payable in arrears on each
Interest Payment Date. 
 (d) Swingline Note; Covenant to Pay. The Swingline Loans shall be evidenced by this Agreement
and, upon request of the Swingline Lender, by a duly executed promissory note of the Borrower in favor of the Swingline Lender in the original amount of the Swingline Committed Amount and substantially in the form of Exhibit 2.4(d). The
Borrower covenants and agrees to pay the Swingline Loans in accordance with the terms of this Agreement. 
 Section 2.5 Fees.

 (a) Commitment Fee. In consideration of the Revolving Commitments, the Borrower agrees to pay to the
Administrative Agent, for the ratable benefit of the Revolving Lenders, a commitment fee (the “Commitment Fee”) in an amount equal to the Applicable Percentage per annum on the average daily unused amount of the Revolving Committed
Amount; provided, that no Commitment Fee shall accrue or be payable on any of the Revolving Commitments of a Defaulting Lender so long as such Lender shall be a Defaulting Lender. For purposes of computation of the Commitment Fee, LOC Obligations
shall be considered usage of the Revolving Committed Amount but Swingline Loans shall not be considered usage of the Revolving Committed Amount. The Commitment Fee shall be payable quarterly in arrears on the last Business Day of each calendar
quarter. 
 (b) Letter of Credit Fees. In consideration of the LOC Commitments, the Borrower agrees to pay to the
Administrative Agent, for the ratable benefit of the Revolving Lenders, a fee (the “Letter of Credit Fee”) equal to the Applicable Percentage for Revolving Loans that are LIBOR Rate Loans per annum on the average daily maximum
amount available to be drawn under each Letter of Credit from the date of issuance to the date of expiration. The Letter of Credit Fee shall each be payable quarterly in arrears on the last Business Day of each calendar quarter. 
  

 48 

 (c) Issuing Lender Fees. In addition to the Letter of Credit Fees payable pursuant
to subsection (b) hereof, the Borrower shall pay to the Issuing Lender for its own account without sharing by the other Lenders the reasonable and customary charges from time to time of the Issuing Lender with respect to the amendment,
transfer, administration, cancellation and conversion of, and drawings under, such Letters of Credit (collectively, the “Issuing Lender Fees”). The Issuing Lender may charge, and retain for its own account without sharing by the
other Lenders, an additional facing fee (the “Letter of Credit Facing Fee”) of 0.25% per annum on the average daily maximum amount available to be drawn under each such Letter of Credit issued by it. The Issuing Lender Fees and
the Letter of Credit Facing Fee shall be payable quarterly in arrears on the last Business Day of each calendar quarter. 
 (d) Administrative Fee. The Borrower agrees to pay to the Administrative Agent the annual administrative fee as described in the Engagement Letter. 
 Section 2.6 Commitment Termination and Reductions. 
 (a) Voluntary
Termination and Reductions. The Borrower shall have the right to terminate or permanently reduce the unused portion of the Revolving Committed Amount at any time or from time to time upon not less than five (5) Business Days’ prior
written notice to the Administrative Agent (which shall notify the Lenders thereof as soon as practicable) of each such termination or reduction, which notice shall specify the effective date thereof and the amount of any such reduction which shall
be in a minimum amount of $500,000 or a whole multiple of $500,000 in excess thereof or the entire remaining amount of the Revolving Committed Amount and shall be irrevocable (other than as set forth in the last sentence of this paragraph
(a) below) and effective upon receipt by the Administrative Agent; provided that no such reduction or termination shall be permitted if after giving effect thereto, and to any prepayments of the Revolving Loans made on the effective date
thereof, the sum of the aggregate principal amount of outstanding Revolving Loans plus outstanding Swingline Loans plus outstanding LOC Obligations would exceed the Revolving Committed Amount then in effect. Any notice of termination
given by the Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities or capital raising, in which case such notice may be revoked by the Borrower (by notice to Administrative Agent on or prior to the
specified effective date) if such condition is not satisfied. 
 (b) Swingline Committed Amount and LOC Committed
Amount. If the Revolving Committed Amount is reduced below the then current Swingline Committed Amount and/or LOC Committed Amount, the Swingline Committed Amount and/or the LOC Committed Amount, as applicable, shall automatically be reduced by
an amount such that the Swingline Committed Amount and/or the LOC Committed Amount, as applicable, equals the Revolving Committed Amount. 
 (c) Maturity Date. The Revolving Commitments, the Swingline Commitment and the LOC Commitment shall automatically terminate on the Maturity Date. 
  

 49 

 Section 2.7 Prepayments. 
 (a) Optional Prepayments. The Borrower shall have the right to prepay Loans in whole or in part from time to time without penalty;
provided, that each partial prepayment (i) of Alternate Base Rate Loans shall be in a minimum principal amount of $500,000 and integral multiples of $100,000 in excess thereof or the remaining outstanding principal amount and (ii) LIBOR
Rate Loans shall be in a minimum principal amount of $1,000,000 and integral multiples of $100,000 in excess thereof (or the remaining outstanding principal amount). The Borrower shall give three Business Days’ irrevocable notice of prepayment
in case of LIBOR Rate Loans and same-day irrevocable notice on any Business Day in the case of the Alternate Base Rate Loans to the Administrative Agent (which shall notify the Lenders thereof as soon as practicable). Within the foregoing
parameters, prepayments under this Section shall be applied first to Alternate Base Rate Loans and then to LIBOR Rate Loans in direct order of Interest Period maturities. All prepayments under this Section shall be subject to Section 2.15,
but otherwise without premium or penalty. Interest on the principal amount prepaid shall be payable on the next occurring Interest Payment Date that would have occurred had such loan not been prepaid or, at the request of the Administrative Agent,
interest on the principal amount prepaid shall be payable on any date that a prepayment is made hereunder through the date of prepayment. Any notice of prepayment given by the Borrower may state that such notice is conditioned upon the effectiveness
of other credit facilities or capital raising, in which case such notice may be revoked by the Borrower (by notice to Administrative Agent on or prior to the specified effective date) if such condition is not satisfied. 
 (b) Mandatory Prepayments. 
 (i) Revolving Committed Amount. If at any time after the Closing Date, the sum of the aggregate principal amount of outstanding Revolving Loans plus outstanding LOC Obligations plus outstanding
Swingline Loans shall exceed the Revolving Committed Amount, the Borrower shall immediately prepay the Revolving Loans and Swingline Loans and (after all Revolving Loans and Swingline Loans have been repaid) cash collateralize the LOC Obligations in
an amount sufficient to eliminate such excess (such prepayment to be applied as set forth in clause (vi) below. 
 (ii)
Asset Dispositions. Promptly following any Asset Disposition (or related series of Asset Dispositions), the Borrower shall prepay the Loans and/or cash collateralize the LOC Obligations in an aggregate amount equal to one hundred percent
(100%) of the Net Cash Proceeds derived from such Asset Disposition (or related series of Asset Dispositions) (such prepayment to be applied as set forth in clause (iii) below); provided, however, that, so long as no Default
or Event of Default has occurred and is continuing, such Net Cash Proceeds shall not be required to be so applied (A) until the aggregate amount of Asset Dispositions during any Fiscal Year not previously applied to prepayments is equal to or
greater than $35,000,000 and (B) to the extent the Borrower delivers to the Administrative Agent a certificate stating that the Credit Parties intend to 

  

 50 

 
use such Net Cash Proceeds to acquire assets useful to the business of the Credit Parties within 365 days of the receipt of such Net Cash Proceeds, it
being expressly agreed that Net Cash Proceeds not so reinvested within such 365 day period shall be applied to prepay the Loans and/or cash collateralize the LOC Obligations immediately thereafter (such prepayment to be applied as set forth in
clause (iii) below). 
 (iii) Application of Mandatory Prepayments. All amounts required to be paid pursuant to
this Section shall be applied as follows: 
 (A) with respect to all amounts prepaid pursuant to Section 2.7(b)(i),
(1) first to the outstanding Swingline Loans, (2) second to the outstanding Revolving Loans and (3) third to cash collateralize the LOC Obligations; and 
 (B) with respect to all amounts prepaid pursuant to Section 2.7(b)(ii), (1) first to the Swingline Loans (with a
corresponding reduction of the Revolving Committed Amount) and (2) second to the Revolving Loans (with a corresponding reduction of the Revolving Committed Amount) and (3) third to a cash collateral account in respect of LOC
Obligations (with a corresponding reduction of the Revolving Committed Amount). Within the parameters of the applications set forth above, prepayments shall be applied first to Alternate Base Rate Loans and then to LIBOR Rate Loans in direct order
of Interest Period maturities. All prepayments under this Section shall be subject to Section 2.15 and be accompanied by interest on the principal amount prepaid through the date of prepayment, but otherwise without premium or penalty.

 (c) Hedging Obligations Unaffected. Any repayment or prepayment made pursuant to this Section shall not affect the
Borrower’s obligation to continue to make payments under any Secured Hedging Agreement, which shall remain in full force and effect notwithstanding such repayment or prepayment, subject to the terms of such Secured Hedging Agreement.

 Section 2.8 Default Rate and Payment Dates. 
 (a) If all or a portion of the principal amount of any Loan which is a LIBOR Rate Loan shall not be paid when due or continued as a LIBOR
Rate Loan in accordance with the provisions of Section 2.9 (whether at the stated maturity, by acceleration or otherwise), such overdue principal amount of such Loan shall be converted to an Alternate Base Rate Loan at the end of the Interest
Period applicable thereto. 
 (b) Upon the occurrence and during the continuance of a Bankruptcy Event of Default or a Payment
Event of Default, the principal of and, to the extent permitted by law, interest on the Loans and any other amounts owing hereunder or under the other 

  

 51 

 
Credit Documents shall bear interest at a rate per annum which is equal to the Default Rate. Upon the occurrence, and during the continuance, of any other
Event of Default hereunder, at the option of the Required Lenders, the principal of and, to the extent permitted by law, interest on the Loans and any other amounts owing hereunder or under the other Credit Documents shall bear interest at the
Default Rate (after as well as before judgment). 
 (c) Interest on each Loan shall be payable in arrears on each Interest
Payment Date; provided that interest accruing pursuant to paragraph (a) of this Section shall be payable from time to time on demand. 
 Section 2.9 Conversion Options. 
 (a) The Borrower may, in the case of Revolving Loans, elect from
time to time to convert Alternate Base Rate Loans to LIBOR Rate Loans or to continue LIBOR Rate Loans, by delivering a Notice of Conversion/Extension to the Administrative Agent at least three (3) Business Days prior to the proposed date of
conversion or continuation. In addition, the Borrower may elect from time to time to convert all or any portion of a LIBOR Rate Loan to an Alternate Base Rate Loan by giving the Administrative Agent irrevocable written notice thereof by 11:00 A.M.
one (1) Business Day prior to the proposed date of conversion. If the date upon which an Alternate Base Rate Loan is to be converted to a LIBOR Rate Loan is not a Business Day, then such conversion shall be made on the next succeeding Business
Day and during the period from such last day of an Interest Period to such succeeding Business Day such Loan shall bear interest as if it were an Alternate Base Rate Loan. LIBOR Rate Loans may only be converted to Alternate Base Rate Loans on the
last day of the applicable Interest Period. If the date upon which a LIBOR Rate Loan is to be converted to an Alternate Base Rate Loan is not a Business Day, then such conversion shall be made on the next succeeding Business Day and during the
period from such last day of an Interest Period to such succeeding Business Day such Loan shall bear interest as if it were an Alternate Base Rate Loan. All or any part of outstanding Alternate Base Rate Loans may be converted as provided herein;
provided that (i) no Loan may be converted into a LIBOR Rate Loan when any Default or Event of Default has occurred and is continuing and (ii) partial conversions shall be in an aggregate principal amount of $1,000,000 or a whole
multiple of $100,000 in excess thereof. All or any part of outstanding LIBOR Rate Loans may be converted as provided herein; provided that partial conversions shall be in an aggregate principal amount of $1,000,000 or a whole multiple of
$100,000 in excess thereof. 
 (b) Any LIBOR Rate Loans may be continued as such upon the expiration of an Interest Period
with respect thereto by compliance by the Borrower with the notice provisions contained in Section 2.9(a); provided, that no LIBOR Rate Loan may be continued as such when any Default or Event of Default has occurred and is continuing, in
which case such Loan shall be automatically converted to an Alternate Base Rate Loan at the end of the applicable Interest Period with respect thereto. If the Borrower shall fail to give timely notice of an election to continue a LIBOR Rate Loan, or
the continuation of LIBOR Rate Loans is not permitted hereunder, such LIBOR Rate Loans shall be automatically converted to Alternate Base Rate Loans at the end of the applicable Interest Period with respect thereto. 
  

 52 

 Section 2.10 Computation of Interest and Fees; Usury. 
 (a) Interest payable hereunder with respect to any Alternate Base Rate Loan based on the Prime Rate shall be calculated on the basis of a
year of 365 days (or 366 days, as applicable) for the actual days elapsed. All other fees, interest and all other amounts payable hereunder shall be calculated on the basis of a 360-day year for the actual days elapsed. The Administrative Agent
shall as soon as practicable notify the Borrower and the Lenders of each determination of a LIBOR Rate on the Business Day of the determination thereof. Any change in the interest rate on a Loan resulting from a change in the Alternate Base Rate
shall become effective as of the opening of business on the day on which such change in the Alternate Base Rate shall become effective. The Administrative Agent shall as soon as practicable notify the Borrower and the Lenders of the effective date
and the amount of each such change. 
 (b) Each determination of an interest rate by the Administrative Agent pursuant to any
provision of this Agreement shall be conclusive and binding on the Borrower and the Lenders in the absence of manifest error. The Administrative Agent shall, at the request of the Borrower, deliver to the Borrower a statement showing the
computations used by the Administrative Agent in determining any interest rate. 
 (c) It is the intent of the Lenders and the
Credit Parties to conform to and contract in strict compliance with applicable usury law from time to time in effect. All agreements between the Lenders and the Credit Parties are hereby limited by the provisions of this subsection which shall
override and control all such agreements, whether now existing or hereafter arising and whether written or oral. In no way, nor in any event or contingency (including but not limited to prepayment or acceleration of the maturity of any Credit Party
Obligation), shall the interest taken, reserved, contracted for, charged, or received under this Agreement, under the Notes or otherwise, exceed the maximum nonusurious amount permissible under applicable law. If, from any possible construction of
any of the Credit Documents or any other document, interest would otherwise be payable in excess of the maximum nonusurious amount, any such construction shall be subject to the provisions of this paragraph and such interest shall be automatically
reduced to the maximum nonusurious amount permitted under applicable law, without the necessity of execution of any amendment or new document. If any Lender shall ever receive anything of value which is characterized as interest on the Loans under
applicable law and which would, apart from this provision, be in excess of the maximum nonusurious amount, an amount equal to the amount which would have been excessive interest shall, without penalty, be applied to the reduction of the principal
amount owing on the Loans and not to the payment of interest, or refunded to the Borrower or the other payor thereof if and to the extent such amount which would have been excessive exceeds such unpaid principal amount of the Loans. The right to
demand payment of the Loans or any other Indebtedness evidenced by any of the Credit Documents does not include the right to receive any interest which has not otherwise 

  

 53 

 
accrued on the date of such demand, and the Lenders do not intend to charge or receive any unearned interest in the event of such demand. All interest paid
or agreed to be paid to the Lenders with respect to the Loans shall, to the extent permitted by applicable law, be amortized, prorated, allocated, and spread throughout the full stated term (including any renewal or extension) of the Loans so that
the amount of interest on account of such Indebtedness does not exceed the maximum nonusurious amount permitted by applicable law. 
 Section 2.11 Pro Rata Treatment and Payments. 
 (a) Allocation of Payments Prior to Exercise
of Remedies. Each borrowing of Revolving Loans and any reduction of the Revolving Commitments shall be made pro rata according to the respective Revolving Commitment Percentages of the Revolving Lenders. Unless otherwise required by the terms of
this Agreement, each payment under this Agreement or any Note shall be applied, first, to any fees then due and owing by the Borrower pursuant to Section 2.5, second, to interest then due and owing hereunder and under the Notes of
the Borrower and, third, to principal then due and owing hereunder and under the Notes of the Borrower. Each payment on account of any fees pursuant to Section 2.5 shall be made pro rata in accordance with the respective amounts due and
owing (except as to the Letter of Credit Facing Fees and the Issuing Lender Fees). Each payment (other than prepayments) by the Borrower on account of principal of and interest on the Revolving Loans shall be applied to such Loans, as applicable, on
a pro rata basis in accordance with the terms of Section 2.7(a) hereof. Each optional prepayment on account of principal of the Loans shall be applied in accordance with Section 2.7(a). Each mandatory prepayment on account of principal of
the Loans shall be applied in accordance with Section 2.7(b). All payments (including prepayments) to be made by the Borrower on account of principal, interest and fees shall be made without defense, set-off or counterclaim (except as provided
in Section 2.16(b)) and shall be made to the Administrative Agent for the account of the Lenders at the Administrative Agent’s office specified on Section 9.2 in Dollars and in immediately available funds not later than 1:00 P.M. on
the date when due. The Administrative Agent shall distribute such payments to the Lenders entitled thereto promptly upon receipt in like funds as received. If any payment hereunder (other than payments on the LIBOR Rate Loans) becomes due and
payable on a day other than a Business Day, such payment shall be extended to the next succeeding Business Day, and, with respect to payments of principal, interest thereon shall be payable at the then applicable rate during such extension. If any
payment on a LIBOR Rate Loan becomes due and payable on a day other than a Business Day, such payment date shall be extended to the next succeeding Business Day unless the result of such extension would be to extend such payment into another
calendar month, in which event such payment shall be made on the immediately preceding Business Day. 
 (b) Allocation of
Payments After Exercise of Remedies. Notwithstanding any other provisions of this Agreement to the contrary, after the exercise of remedies (other than the invocation of default interest pursuant to Section 2.8) by the Administrative Agent
or the Lenders pursuant to Section 7.2 (or after the Commitments shall 

  

 54 

 
automatically terminate and the Loans (with accrued interest thereon) and all other amounts under the Credit Documents (including without limitation the
maximum amount of all outstanding contingent liabilities under Letters of Credit) shall automatically become due and payable in accordance with the terms of such Section), all amounts collected or received by the Administrative Agent or any Lender
on account of the Credit Party Obligations or any other amounts outstanding under any of the Credit Documents or in respect of the Collateral shall be paid over or delivered as follows (irrespective of whether the following costs, expenses, fees,
interest, premiums, scheduled periodic payments or Credit Party Obligations are allowed, permitted or recognized as a claim in any proceeding resulting from the occurrence of a Bankruptcy Event): 
 FIRST, to the payment of all reasonable out-of-pocket costs and expenses (including without limitation reasonable attorneys’ fees) of
the Administrative Agent in connection with enforcing the rights of the Lenders under the Credit Documents and any protective advances made by the Administrative Agent with respect to the Collateral under or pursuant to the terms of the Security
Documents; 
 SECOND, to the payment of any fees owed to the Administrative Agent and the Issuing Lender 
 THIRD, to the payment of all reasonable out-of-pocket costs and expenses (including without limitation, reasonable attorneys’ fees)
of each of the Lenders in connection with enforcing its rights under the Credit Documents or otherwise with respect to the Credit Party Obligations owing to such Lender; 
 FOURTH, to the payment of all of the Credit Party Obligations consisting of accrued fees and interest, and including, with respect to any
Secured Hedging Agreement, any fees, premiums and scheduled periodic payments due under such Secured Hedging Agreement and any interest accrued thereon; 
 FIFTH, to the payment of the outstanding principal amount of the Credit Party Obligations and the payment or cash collateralization of the outstanding LOC Obligations, and including with respect to any Secured Hedging
Agreement, any breakage, termination or other payments due under such Secured Hedging Agreement and any interest accrued thereon; 
 SIXTH, to all other Credit Party Obligations and other obligations which shall have become due and payable under the Credit Documents or otherwise and not repaid pursuant to clauses “FIRST” through “FIFTH” above;
and 
 SEVENTH, to the payment of the surplus, if any, to whoever may be lawfully entitled to receive such surplus.

 In carrying out the foregoing, (a) amounts received shall be applied in the numerical order provided until exhausted
prior to application to the next succeeding 

  

 55 

 
category; (b) each of the Lenders and any Hedging Agreement Provider shall receive an amount equal to its pro rata share (based on the proportion that
the then outstanding Loans and LOC Obligations held by such Lender or the outstanding obligations payable to such Hedging Agreement Provider bears to the aggregate then outstanding Loans and LOC Obligations and obligations payable under all Secured
Hedging Agreements) of amounts available to be applied pursuant to clauses “THIRD”, “FOURTH”, “FIFTH” and “SIXTH” above; and (c) to the extent that any amounts available for distribution pursuant to
clause “FIFTH” above are attributable to the issued but undrawn amount of outstanding Letters of Credit, such amounts shall be held by the Administrative Agent in a cash collateral account and applied (i) first, to reimburse the
Issuing Lender from time to time for any drawings under such Letters of Credit and (ii) then, following the expiration of all Letters of Credit, to all other obligations of the types described in clauses “FIFTH” and
“SIXTH” above in the manner provided in this Section. Notwithstanding the foregoing terms of this Section, only Collateral proceeds and payments under the Guaranty (as opposed to ordinary course principal, interest and fee payments
hereunder) shall be applied to obligations under any Secured Hedging Agreement. 
 Section 2.12 Non-Receipt of Funds by the
Administrative Agent. 
 (a) Funding by Lenders; Presumption by Administrative Agent. Unless the Administrative
Agent shall have received written notice from a Lender prior to the proposed date of any Extension of Credit that such Lender will not make available to the Administrative Agent such Lender’s share of such Extension of Credit, the
Administrative Agent may assume that such Lender has made such share available on such date in accordance with this Agreement and may, in reliance upon such assumption, make available to the Borrower a corresponding amount. In such event, if a
Lender has not in fact made its share of the applicable Extension of Credit available to the Administrative Agent, then the applicable Lender and the Borrower severally agree to pay to the Administrative Agent forthwith on demand such corresponding
amount with interest thereon, for each day from and including the date such amount is made available to the Borrower to but excluding the date of payment to the Administrative Agent, at (i) in the case of a payment to be made by such Lender,
the greater of the Federal Funds Effective Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation and (ii) in the case of a payment to be made by the Borrower, the interest
rate applicable to Alternate Base Rate Loans. If the Borrower and such Lender shall pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent shall promptly remit to the Borrower the amount of such
interest paid by the Borrower for such period. If such Lender pays its share of the applicable Extension of Credit to the Administrative Agent, then the amount so paid shall constitute such Lender’s Loan included in such Extension of Credit.
Any payment by the Borrower shall be without prejudice to any claim the Borrower may have against a Lender that shall have failed to make such payment to the Administrative Agent. 
  

 56 

 (b) Payments by Borrower; Presumptions by Administrative Agent. Unless the
Administrative Agent shall have received notice from the Borrower prior to the date on which any payment is due to the Administrative Agent for the account of the Lenders or the Issuing Lender hereunder that the Borrower will not make such payment,
the Administrative Agent may assume that the Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the Issuing Lender, as the case may be, the amount due. In such
event, if the Borrower has not in fact made such payment, then each of the Lenders or the Issuing Lender, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender or the
Issuing Lender, with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the greater of the Federal Funds Effective Rate and a rate
determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. 
 A notice of the
Administrative Agent to any Lender or the Borrower with respect to any amount owing under subsections (a) and (b) of this Section shall be conclusive, absent manifest error. 
 (c) Failure to Satisfy Conditions Precedent. If any Lender makes available to the Administrative Agent funds for any Loan to be
made by such Lender as provided in the foregoing provisions of this Article II, and such funds are not made available to the Borrower by the Administrative Agent because the conditions to the applicable Extension of Credit set forth in Article IV
are not satisfied or waived in accordance with the terms thereof, the Administrative Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest. 
 (d) Obligations of Lenders Several. The obligations of the Lenders hereunder to make Revolving Loans, to fund participations in
Letters of Credit and Swingline Loans and to make payments pursuant to Section 9.5(c) are several and not joint. The failure of any Lender to make any Loan, to fund any such participation or to make any such payment under Section 9.5(c) on
any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan, to purchase its participation or to
make its payment under Section 9.5(c). 
 (e) Funding Source. Nothing herein shall be deemed to obligate any
Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner. 
 Section 2.13 Inability to Determine Interest Rate. 
 Notwithstanding any other provision of this Agreement, if (a) the Required Lenders shall reasonably determine that, by reason of circumstances affecting the relevant market, reasonable and adequate means do not
exist for ascertaining the LIBOR Rate for such Interest Period, or 

  

 57 

 
(b) the Required Lenders shall reasonably determine that the LIBOR Rate does not adequately and fairly reflect the cost to such Lenders of funding LIBOR
Rate Loans that the Borrower has requested be outstanding as a LIBOR Tranche during such Interest Period, the Administrative Agent shall forthwith give telephone notice of such determination, confirmed in writing, to the Borrower, and the Lenders at
least two (2) Business Days prior to the first day of such Interest Period. Unless the Borrower shall have notified the Administrative Agent upon receipt of such telephone notice that it wishes to rescind or modify its request regarding such
LIBOR Rate Loans, any Loans that were requested to be made as LIBOR Rate Loans shall be made as Alternate Base Rate Loans and any Loans that were requested to be converted into or continued as LIBOR Rate Loans shall remain as or be converted into
Alternate Base Rate Loans. Until any such notice has been withdrawn by the Administrative Agent, no further Loans shall be made as, continued as, or converted into, LIBOR Rate Loans for the Interest Periods so affected. 
 Section 2.14 Yield Protection. 
 (a) Increased Costs Generally. If any Change in Law shall: 
 (i) impose, modify or
deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender or the Issuing Lender; 
 (ii) subject any Lender or the Issuing Lender to any tax of any kind whatsoever with respect to this Agreement, any Letter of Credit, any
participation in a Letter of Credit or any Loan made by it, or change the basis of taxation of payments to such Lender or the Issuing Lender in respect thereof (except for Indemnified Taxes or Other Taxes covered by Section 2.16 and the
imposition of, or any change in the rate of, any Excluded Tax payable by such Lender or the Issuing Lender); or 
 (iii)
impose on any Lender or the Issuing Lender or the London interbank market any other condition, cost or expense affecting this Agreement or Loans made by such Lender or any Letter of Credit or participation therein; 
 and the result of any of the foregoing shall be to increase the cost to such Lender of making or maintaining any Loan (or of maintaining its obligation to
make any such Loan), or to increase the cost to such Lender or the Issuing Lender of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate in or to issue any Letter of Credit), or to reduce
the amount of any sum received or receivable by such Lender or the Issuing Lender hereunder (whether of principal, interest or any other amount) then, upon request of such Lender or the Issuing Lender, the Borrower will pay to such Lender or the
Issuing Lender, as the case may be, such additional amount or amounts as will compensate such Lender or the Issuing Lender, as the case may be, for such additional costs incurred or reduction suffered. 
  

 58 

 (b) Capital Requirements. If any Lender or the Issuing Lender determines that any
Change in Law affecting such Lender or the Issuing Lender or any lending office of such Lender or such Lender’s or the Issuing Lender’s holding company, if any, regarding capital requirements has or would have the effect of reducing the
rate of return on such Lender’s or the Issuing Lender’s capital or on the capital of such Lender’s or the Issuing Lender’s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the Loans
made by, or participations in Letters of Credit held by, such Lender, or the Letters of Credit issued by the Issuing Lender, to a level below that which such Lender or the Issuing Lender or such Lender’s or the Issuing Lender’s holding
company could have achieved but for such Change in Law (taking into consideration such Lender’s or the Issuing Lender’s policies and the policies of such Lender’s or the Issuing Lender’s holding company with respect to capital
adequacy), then from time to time the Borrower will pay to such Lender or the Issuing Lender, as the case may be, such additional amount or amounts as will compensate such Lender or the Issuing Lender or such Lender’s or the Issuing
Lender’s holding company for any such reduction suffered. 
 (c) Certificates for Reimbursement. A certificate of
a Lender or the Issuing Lender setting forth the amount or amounts (and setting forth in reasonable detail the calculation thereof) necessary to compensate such Lender or the Issuing Lender or its holding company, as the case may be, as specified in
paragraph (a) or (b) of this Section and delivered to the Borrower shall be conclusive absent manifest error. The Borrower shall pay such Lender or the Issuing Lender, as the case may be, the amount shown as due on any such certificate
within ten (10) days after receipt thereof. 
 (d) Delay in Requests. Failure or delay on the part of any Lender
or the Issuing Lender to demand compensation pursuant to this Section shall not constitute a waiver of such Lender’s or the Issuing Lender’s right to demand such compensation, provided that the Borrower shall not be required to
compensate a Lender or the Issuing Lender pursuant to this Section for any increased costs incurred or reductions suffered more than nine months prior to the date that such Lender or the Issuing Lender, as the case may be, notifies the Borrower of
the Change in Law giving rise to such increased costs or reductions and of such Lender’s or the Issuing Lender’s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions
is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof). 
 Section 2.15 Indemnity. 
 (a) The Credit Parties hereby agree to indemnify each Lender and to
hold such Lender harmless from any funding loss or expense which such Lender may sustain or incur as a consequence of (i) the failure by the Borrower to pay the principal amount of or interest on any Loan by such Lender in accordance with the
terms hereof, (ii) the failure by the Borrower to accept a borrowing after the Borrower has given a notice in accordance with the terms hereof, (iii) default by the Borrower in making any prepayment after the Borrower has given a notice in
accordance with the terms hereof and/or (iv) the making by the Borrower of a prepayment of a Loan, or the conversion thereof, on a day which is not the last day of the Interest Period with respect thereto, in each case including, but not
limited to, any such loss or expense arising from 

  

 59 

 
interest or fees payable by such Lender to lenders of funds obtained by it in order to maintain its Loans hereunder. A certificate setting forth in
reasonable detail the calculation of any additional amounts payable pursuant to this Section submitted by any Lender, through the Administrative Agent, to the Borrower (which certificate must be delivered to the Administrative Agent within thirty
days following such default, prepayment or conversion) shall be conclusive in the absence of manifest error. The agreements in this Section shall survive termination of this Agreement and payment of the Credit Party Obligations. 
 (b) The Borrower shall pay to each Lender, as long as such Lender shall be required to maintain reserves under Regulation D with respect
to “Eurocurrency liabilities” within the meaning of Regulation D, or under any similar or successor regulation with respect to Eurocurrency liabilities or Eurocurrency funding, additional interest on the unpaid principal amount of each
LIBOR Rate Loan equal to the actual costs of such reserves allocated to such LIBOR Rate Loan by such Lender (as determined by such Lender in good faith, which determination shall be conclusive in the absence of manifest error), which shall be due
and payable on each date on which interest is payable on such LIBOR Rate Loan, provided the Borrower shall have received at least fifteen (15) days prior notice (with a copy to the Administrative Agent) of such additional interest from such
Lender. If a Lender fails to give notice fifteen (15) days prior to the relevant interest payment date, such additional interest shall be due and payable fifteen (15) days from receipt of such notice. 
 Section 2.16 Taxes. 
 (a) Payments Free of Taxes. Any and all payments by or on account of any obligation of the Borrower hereunder or under any other Credit Document shall be made free and clear of and without reduction or
withholding for any Indemnified Taxes or Other Taxes, provided that if the Borrower shall be required by applicable law to deduct any Indemnified Taxes (including any Other Taxes) from such payments, then (i) the sum payable shall be
increased as necessary so that after making all required deductions (including deductions applicable to additional sums payable under this Section) the Administrative Agent, Lender or Issuing Lender, as the case may be, receives an amount equal to
the sum it would have received had no such deductions been made, (ii) the Borrower shall make such deductions and (iii) the Borrower shall timely pay the full amount deducted to the relevant Governmental Authority in accordance with
applicable law. 
 (b) Payment of Other Taxes by the Borrower. Without limiting the provisions of paragraph
(a) above, the Borrower shall timely pay any Other Taxes to the relevant Governmental Authority in accordance with applicable law. 
 (c) Indemnification by the Borrower. The Borrower shall indemnify the Administrative Agent, each Lender and the Issuing Lender, within ten (10) days after demand therefor, for the full amount of any
Indemnified Taxes or Other Taxes (including Indemnified Taxes or Other Taxes imposed or asserted on or attributable to amounts payable under this Section) paid by the Administrative Agent, such Lender or the Issuing 

  

 60 

 
Lender, as the case may be, and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified
Taxes or Other Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate setting forth in reasonable detail the calculation of the amount of such payment or liability delivered to the Borrower by a
Lender or the Issuing Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender or the Issuing Lender, shall be conclusive absent manifest error. 
 (d) Evidence of Payments. As soon as practicable after any payment of Indemnified Taxes or Other Taxes pursuant to Sections
2.16(a), (b) or (c) above by the Borrower to a Governmental Authority, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a
copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent. 
 (e) Status of Lenders. Any Foreign Lender that is entitled to an exemption from or reduction of withholding tax under the law of the jurisdiction in which the Borrower is resident for tax purposes, or any treaty to which such
jurisdiction is a party, with respect to payments hereunder or under any other Credit Document shall deliver to the Borrower (with a copy to the Administrative Agent), at the time or times prescribed by applicable law or reasonably requested by the
Borrower or the Administrative Agent, such properly completed and executed documentation prescribed by applicable law as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if
requested by the Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower or the Administrative Agent as will enable the Borrower or the Administrative Agent to
determine whether or not such Lender is subject to backup withholding or information reporting requirements. 
 Without limiting the
generality of the foregoing, in the event that the Borrower is resident for tax purposes in the United States of America, any Foreign Lender shall deliver to the Borrower and the Administrative Agent (in such number of copies as shall be requested
by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the request of the Borrower or the Administrative Agent, but only if such Foreign Lender is legally
entitled to do so), whichever of the following is applicable: 
 (i) duly completed copies of Internal Revenue Service Form
W-8BEN claiming eligibility for benefits of an income tax treaty to which the United States of America is a party, 
 (ii)
duly completed copies of Internal Revenue Service Form W-8ECI, 
 (iii) in the case of a Foreign Lender claiming the benefits
of the exemption for portfolio interest under section 881(c) of the Code, (i) a certificate to the effect that such Foreign Lender is not (A) a “bank” within the meaning of 

  

 61 

 
section 881(c)(3)(A) of the Code, (B) a “10 percent shareholder” of the Borrower within the meaning of section 881(c)(3)(B) of the Code, or
(C) a “controlled foreign corporation” described in section 881(c)(3)(C) of the Code and (ii) duly completed copies of Internal Revenue Service Form W-8BEN, or 
 (iv) any other form prescribed by applicable law as a basis for claiming exemption from or a reduction in United States Federal
withholding tax duly completed together with such supplementary documentation as may be prescribed by applicable law to permit the Borrower to determine the withholding or deduction required to be made. 
 (f) Treatment of Certain Refunds. If the Administrative Agent, a Lender or the Issuing Lender determines, in its reasonable
discretion, that it has received a refund of any Taxes or Other Taxes as to which it has been indemnified by the Borrower or with respect to which the Borrower has paid additional amounts pursuant to this Section, it shall pay to the Borrower an
amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by the Borrower under this Section with respect to the Taxes or Other Taxes giving rise to such refund), net of all out-of-pocket expenses of
the Administrative Agent directly related to receipt of such refund, such Lender or the Issuing Lender, as the case may be, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund),
provided that the Borrower, upon the request of the Administrative Agent, such Lender or the Issuing Lender, agrees to repay the amount paid over to the Borrower (plus any penalties, interest or other charges imposed by the relevant
Governmental Authority with respect to the amount paid over to the Borrower) to the Administrative Agent, such Lender or the Issuing Lender in the event the Administrative Agent, such Lender or the Issuing Lender is required to repay such refund to
such Governmental Authority. This paragraph shall not be construed to require the Administrative Agent, any Lender or the Issuing Lender to make available its tax returns (or any other information relating to its taxes that it reasonably deems
confidential) to the Borrower or any other Person. 
 Section 2.17 Indemnification in Respect of Letters of Credit; Nature of
Issuing Lender’s Duties. 
 (a) In addition to its other obligations under Section 2.3, the Credit Parties
hereby agree to protect, indemnify, pay and save the Issuing Lender and each Lender harmless from and against any and all claims, demands, liabilities, damages, losses, costs, charges and expenses (including reasonable attorneys’ fees) that the
Issuing Lender or such Lender may incur or be subject to as a consequence, direct or indirect, of (i) the issuance of any Letter of Credit or (ii) the failure of the Issuing Lender to honor a drawing under a Letter of Credit as a result of
any act or omission, whether rightful or wrongful, of any present or future de jure or de facto government or Governmental Authority (all such acts or omissions, herein called “Government Acts”). 
  

 62 

 (b) As between the Credit Parties, the Issuing Lender and each Lender, the Credit Parties
shall assume all risks of the acts, omissions or misuse of any Letter of Credit by the beneficiary thereof. Neither the Issuing Lender nor any Lender shall be responsible: (i) for the form, validity, sufficiency, accuracy, genuineness or legal
effect of any document submitted by any party in connection with the application for and issuance of any Letter of Credit, even if it should in fact prove to be in any or all respects invalid, insufficient, inaccurate, fraudulent or forged;
(ii) for the validity or sufficiency of any instrument transferring or assigning or purporting to transfer or assign any Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, that may prove to be
invalid or ineffective for any reason; (iii) for failure of the beneficiary of a Letter of Credit to comply fully with conditions required in order to draw upon a Letter of Credit; (iv) for errors, omissions, interruptions or delays in
transmission or delivery of any messages, by mail, cable, telegraph, telex or otherwise, whether or not they be in cipher; (v) for errors in interpretation of technical terms; (vi) for any loss or delay in the transmission or otherwise of
any document required in order to make a drawing under a Letter of Credit or of the proceeds thereof; and (vii) for any consequences arising from causes beyond the control of the Issuing Lender or any Lender, including, without limitation, any
Government Acts. None of the above shall affect, impair, or prevent the vesting of the Issuing Lender’s rights or powers hereunder. 
 (c) In furtherance and extension and not in limitation of the specific provisions hereinabove set forth, any action taken or omitted by the Issuing Lender or any Lender, under or in connection with any Letter of
Credit or the related certificates, if taken or omitted in the absence of gross negligence or willful misconduct, shall not put such Issuing Lender or such Lender under any resulting liability to the Credit Parties. It is the intention of the
parties that this Agreement shall be construed and applied to protect and indemnify the Issuing Lender and each Lender against any and all risks involved in the issuance of the Letters of Credit, all of which risks are hereby assumed by the Credit
Parties, including, without limitation, any and all risks of the acts or omissions, whether rightful or wrongful, of any Government Authority. The Issuing Lender and the Lenders shall not, in any way, be liable for any failure by the Issuing Lender
or anyone else to pay any drawing under any Letter of Credit as a result of any Government Acts or any other cause beyond the control of the Issuing Lender and the Lenders. 
 (d) Nothing in this Section is intended to limit the Reimbursement Obligation of the Borrower contained in Section 2.3(d) hereof. The
obligations of the Credit Parties under this Section shall survive the termination of this Agreement. No act or omissions of any current or prior beneficiary of a Letter of Credit shall in any way affect or impair the rights of the Issuing Lender
and the Lenders to enforce any right, power or benefit under this Agreement. 
 (e) Notwithstanding anything to the contrary
contained in this Section or any other provision of any Credit Document or LOC Document, the Credit Parties shall have no obligation to indemnify the Issuing Lender or any Lender in respect of any liability incurred by the Issuing Lender or such
Lender arising out of the gross negligence or willful misconduct of the Issuing Lender (including action not taken by the Issuing Lender or such Lender), as determined by a court of competent jurisdiction or pursuant to arbitration. 
  

 63 

 Section 2.18 Illegality. 
 Notwithstanding any other provision of this Credit Agreement, if any Change in Law shall make it unlawful for such Lender or its LIBOR Lending Office to
make or maintain LIBOR Rate Loans as contemplated by this Credit Agreement or to obtain in the interbank eurodollar market through its LIBOR Lending Office the funds with which to make such Loans, (a) such Lender shall promptly notify the
Administrative Agent and the Borrower thereof, (b) the commitment of such Lender hereunder to make LIBOR Rate Loans or continue LIBOR Rate Loans as such shall forthwith be suspended until the Administrative Agent shall give notice that the
condition or situation which gave rise to the suspension shall no longer exist, and (c) such Lender’s Loans then outstanding as LIBOR Rate Loans, if any, shall be converted on the last day of the Interest Period for such Loans or within
such earlier period as required by law as Alternate Base Rate Loans. The Borrower hereby agrees to promptly pay any Lender, upon its demand, any additional amounts necessary to compensate such Lender for actual and direct costs (but not including
anticipated profits) reasonably incurred by such Lender in making any repayment in accordance with this Section including, but not limited to, any interest or fees payable by such Lender to lenders of funds obtained by it in order to make or
maintain its LIBOR Rate Loans hereunder. A certificate (which certificate shall include a description of the basis for the computation) as to any additional amounts payable pursuant to this Section submitted by such Lender, through the
Administrative Agent, to the Borrower shall be conclusive in the absence of manifest error. Each Lender agrees to use reasonable efforts (including reasonable efforts to change its LIBOR Lending Office) to avoid or to minimize any amounts which may
otherwise be payable pursuant to this Section; provided, however, that such efforts shall not cause the imposition on such Lender of any additional costs or legal or regulatory burdens deemed in good faith by such Lender to be
material. 
 Section 2.19 Mitigation Obligations; Replacement of Lenders. 
 (a) Designation of a Different Lending Office. If any Lender requests compensation under Section 2.14, or requires the
Borrower to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 2.16, then such Lender shall use reasonable efforts to designate a different lending office for funding or
booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable
pursuant to Section 2.14 or Section 2.16, as the case may be, in the future and (ii) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby
agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment. 
 (b) Replacement of Lenders. If any Lender requests compensation under Sections 2.14 or 2.18, or if the Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender
pursuant to Section 2.16, or if any Lender ceases to make LIBOR Rate Loans as a result of any 

  

 64 

 
condition described in Section 2.18, or if any Lender is a Defaulting Lender, or if any Lender shall refuse to consent to a waiver or amendment to, or a
departure from the provisions of this Agreement or any other Credit Document which requires the consent of all Lenders or all Lenders directly affected thereby and that has been consented to by the Required Lenders, then the Borrower may, at its
sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by,
Section 9.6), all of its interests, rights and obligations under this Agreement and the related Credit Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment),
provided that: 
 (i) the Borrower shall have paid to the Administrative Agent the assignment fee specified in
Section 9.6; 
 (ii) such Lender shall have received payment of an amount equal to the outstanding principal of its Loans
and funded participations in Letters of Credit, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Credit Documents (including any amounts under Section 2.15) from the assignee (to the
extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts); 
 (iii) in the case of any such assignment resulting from a claim for compensation under Section 2.14 or payments required to be made pursuant to Section 2.16, such assignment will result in a reduction in such compensation or
payments thereafter; and 
 (iv) such assignment does not conflict with applicable law. 
 A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the
circumstances entitling the Borrower to require such assignment and delegation cease to apply. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES 
 To
induce the Lenders to enter into this Agreement and to make the Extensions of Credit herein provided for, the Credit Parties hereby represent and warrant to the Administrative Agent and to each Lender that: 
 Section 3.1 Financial Condition. 
 (a)(i) The audited Consolidated financial statements of the Credit Parties and their Subsidiaries for the fiscal years ended December 31, 2005 (as restated), 2006 and 

  

 65 

 
2007, together with the related Consolidated statements of income or operations, equity and cash flows for the fiscal years ended on such dates,
(ii) the unaudited Consolidated financial statements of the Credit Parties and their Subsidiaries for the year-to-date period for the most recent month ending at least 30 days prior to the Closing Date, together with the related Consolidated
statements of income or operations, equity and cash flows for the year-to-date period ending on such date and (iii) a pro forma balance sheet of the Credit Parties and their Subsidiaries as of the last day of the month that ended at least
thirty (30) days prior to the Closing Date: 
 (A) were prepared in accordance with GAAP consistently applied throughout
the period covered thereby, except as otherwise expressly noted therein; 
 (B) fairly present the financial condition of the
Credit Parties and their Subsidiaries in all material respects, as applicable, as of the date thereof (subject, in the case of the unaudited financial statements, to normal year-end adjustments) and results of operations for the period covered
thereby; and 
 (C) reflect all material Indebtedness and other material liabilities, direct or contingent, of the Credit
Parties and their Subsidiaries as of the date thereof, including material liabilities for taxes, material commitments and material contingent obligations (to the extent required to be disclosed by GAAP). 
 (b) The three-year projections of the Credit Parties and their Subsidiaries delivered to the Lenders on or prior to the Closing Date have
been prepared in good faith based upon assumptions believed by the Borrower at the time of the preparation thereof to be reasonable (it being understood that projections are subject to significant uncertainties and contingencies, many of which are
beyond the Borrower’s control, and that no assurance can be given that the projections will be realized). 
 Section 3.2 No
Material Adverse Effect. 
 Since December 31, 2007, there has been no development or event which, individually or in the
aggregate, has had or could reasonably be expected to have a Material Adverse Effect. 
 Section 3.3 Corporate Existence;
Compliance with Law. 
 Each of the Credit Parties (a) is duly organized, validly existing and in good standing under the laws of
the jurisdiction of its incorporation, organization or formation, (b) has the requisite power and authority and the legal right to own and operate all its property, to lease the property it operates as lessee and to conduct the business in
which it is currently engaged and (except as could not reasonably be expected to have a Material Adverse Effect), has taken all actions necessary to maintain all rights, privileges, licenses and franchises necessary or required in the normal conduct
of its business, (c) is duly qualified to conduct business and in good 

  

 66 

 
standing under the laws of (i) the jurisdiction of its incorporation, organization or formation, (ii) the jurisdiction where its chief executive
office is located and (iii) each other jurisdiction where its ownership, lease or operation of property or the conduct of its business requires such qualification except to the extent that the failure to so qualify or be in good standing in any
such other jurisdiction could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect and (d) is in compliance with all Requirements of Law, organizational documents, government permits and government
licenses except to the extent such non-compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 Section 3.4 Corporate Power; Authorization; Enforceable Obligations. 
 Each of the Credit
Parties has full organizational power and authority to execute, deliver and perform the Credit Documents to which it is party and has taken all necessary limited liability company, partnership or corporate action to authorize the execution, delivery
and performance by it of the Credit Documents to which it is party. Each Credit Document to which it is a party has been duly executed and delivered on behalf of each Credit Party. Each Credit Document that is an agreement to which it is a party
constitutes a legal, valid and binding obligation of each Credit Party, enforceable against such Credit Party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles (whether enforcement is sought by proceedings in equity or at law). 
 Section 3.5 No Legal Bar; No Default. 
 The execution, delivery and performance by each Credit Party of the Credit Documents to which such Credit Party is a party, the borrowings thereunder and the use of the proceeds of the Loans (a) will not violate
any material Requirement of Law, (b) except as could not reasonably be expected to have a Material Adverse Effect, will not conflict with, result in a breach of or constitute a default under the articles of incorporation, bylaws, articles
of organization, operating agreement or other organization documents of the Credit Parties or any material approval or material consent from any Governmental Authority relating to such Person, and (c) will not result in, or require, the
creation or imposition of any Lien on any Credit Party’s properties or revenues pursuant to any Requirement of Law or Contractual Obligation other than the Liens arising under or contemplated in connection with the Credit Documents or Permitted
Liens. Except as could not reasonably be expected to have a Material Adverse Effect, no Credit Party is in default under or with respect to any of its Contractual Obligations. No Default or Event of Default has occurred and is continuing.

 Section 3.6 No Material Litigation. 
 No litigation, investigation, claim, criminal prosecution, civil investigative demand, imposition of criminal or civil fines and penalties, or any other proceeding of or before any arbitrator or Governmental Authority
is pending or, to the knowledge of the Credit Parties, threatened in writing by or against any Credit Party or any of its Subsidiaries or against any of its 

  

 67 

 
or their respective properties or revenues (a) with respect to the Credit Documents or any Extension of Credit or any of the transactions contemplated
hereby, or (b) which could reasonably be expected to have a Material Adverse Effect. To the knowledge of the Credit Parties, no permanent injunction, temporary restraining order or similar decree has been issued against any Credit Party or any
of its Subsidiaries which could reasonably be expected to have a Material Adverse Effect. 
 Section 3.7 Investment Company Act;
etc. 
 No Credit Party is an “investment company”, or a company “controlled” by an “investment
company”, within the meaning of the Investment Company Act of 1940, as amended. No Credit Party is a subject to regulation under the Federal Power Act, the Interstate Commerce Act, or any federal or state statute or regulation limiting its
ability to incur the Credit Party Obligations. 
 Section 3.8 Margin Regulations. 
 No part of the proceeds of any Extension of Credit hereunder will be used directly or indirectly for any purpose that violates the provisions of
Regulation T, U or X of the Board of Governors of the Federal Reserve System as now and from time to time hereafter in effect. The Credit Parties and their Subsidiaries (a) are not engaged, principally or as one of their important
activities, in the business of extending credit for the purpose of “purchasing” or “carrying” “margin stock” within the respective meanings of each of such terms under Regulation U and (b) as of the Closing Date,
taken as a group do not own “margin stock” except as identified in the financial statements referred to in Section 3.1. The aggregate value of all “margin stock” within the meaning of such term under Regulation U owned by
the Credit Parties and their Subsidiaries taken as a group does not exceed 25% of the value of their assets. 
 Section 3.9
ERISA. 
 Except as, individually or in the aggregate, could not reasonably be expected to have a Material Adverse Effect, neither
a Reportable Event nor an “accumulated funding deficiency” (within the meaning of Section 412 of the Code or Section 302 of ERISA) has occurred during the five-year period prior to the date on which this representation is made or
deemed made with respect to any Plan, and each Plan has complied with the applicable provisions of ERISA and the Code. No termination of a Single Employer Plan has occurred resulting in any material liability that has not be satisfied in full, and
no Lien in favor of the PBGC or a Plan has arisen, during such five-year period. Neither any Credit Party nor any Commonly Controlled Entity is currently subject to any material liability for a complete or partial withdrawal from a Multiemployer
Plan. 
  

 68 

 Section 3.10 Environmental Matters. 
 Except as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect: 
 (a) To the knowledge of the Credit Parties, the facilities and properties owned, leased or operated by the Credit Parties or any of their
Subsidiaries (the “Properties”) do not contain any Materials of Environmental Concern in amounts or concentrations which (i) constitute a violation of, or (ii) could give rise to liability on behalf of any Credit Party
under, any Environmental Law. 
 (b) All operations of the Credit Parties and/or their Subsidiaries at the Properties are in
compliance, and have in the last five years been in compliance, with all applicable Environmental Laws, and to the knowledge of the Credit Parties there is no contamination at, under or about the Properties or violation of any Environmental Law with
respect to the Properties or the business operated by the Credit Parties or any of their Subsidiaries (the “Business”). 
 (c) Neither the Credit Parties nor their Subsidiaries have received any written or actual notice of violation, alleged violation, non-compliance, liability or potential liability on behalf of any Credit Party with
respect to environmental matters or Environmental Laws regarding any of the Properties or the Business, nor do the Credit Parties or their Subsidiaries have knowledge or reason to believe that any such notice will be received or is being threatened.

 (d) To the knowledge of the Credit Parties, Materials of Environmental Concern have not been transported or disposed of
from the Properties in violation of, or in a manner or to a location that could give rise to liability on behalf of any Credit Party under any Environmental Law, and no Materials of Environmental Concern have been generated, treated, stored or
disposed of at, on or under any of the Properties in violation of, or in a manner that could give rise to liability on behalf of any Credit Party under, any applicable Environmental Law. 
 (e) No judicial proceeding or governmental or administrative action is pending or, to the knowledge of the Credit Parties and their
Subsidiaries, threatened, under any Environmental Law to which any Credit Party or any Subsidiary is a party with respect to the Properties or the Business, nor are there any consent decrees or other decrees, consent orders, administrative orders or
other orders, or other administrative or judicial requirements outstanding, in each case, to the extent binding on the Credit Parties or their Subsidiaries, under any Environmental Law with respect to the Properties or the Business. 
 (f) There has been no release or threat of release of Materials of Environmental Concern at or from the Properties arising from or related
to the operations of any Credit Party or any Subsidiary in connection with the Properties or otherwise in connection with the Business, in violation of or in amounts or in a manner that could give rise to liability on behalf of any Credit Party
under Environmental Laws. 
  

 69 

 Section 3.11 Use of Proceeds. 
 The proceeds of the Extensions of Credit shall be used by the Borrower solely (a) to pay any costs, fees and expenses associated with this Agreement
on the Closing Date, (b) to refinance certain existing Indebtedness of the Credit Parties and their Subsidiaries, and (c) for working capital and other general corporate purposes of the Credit Parties and their Subsidiaries, including,
without limitation, Permitted Acquisitions. 
 Section 3.12 Subsidiaries; Joint Ventures; Partnerships. 
 Set forth on Schedule 3.12 is a complete and accurate list of all Subsidiaries of the Credit Parties and partnerships in which any of the
Credit Parties owns any partnership interest as of the Closing Date or as of the date such Schedule was last updated in accordance with the terms of Section 5.2. Information on the attached Schedule includes the following: (a) the number
of shares of each class of Capital Stock or other equity interests of each Subsidiary outstanding; (b) the number and percentage of outstanding shares of each class of Capital Stock owned by the Borrower or any of its Subsidiaries; and
(c) the number and effect, if exercised, of all outstanding options, warrants, rights of conversion or purchase and similar rights regarding the Capital Stock or other equity interests of each Subsidiary. The outstanding Capital Stock and other
equity interests of all such Subsidiaries is validly issued, fully paid and non-assessable and is owned free and clear of all Liens (other than those arising under or contemplated in connection with the Credit Documents). There are no outstanding
subscriptions, options, warrants, calls, rights or other agreements or commitments (other than stock options granted to employees or directors and directors’ qualifying shares) of any nature relating to any Capital Stock of the Subsidiary,
except as contemplated in connection with the Credit Documents. 
 Section 3.13 Ownership. 
 Each of the Credit Parties and its Subsidiaries is the owner of, and has good and marketable title to or a valid leasehold interest in, all of its
respective assets, which, together with assets leased or licensed by the Credit Parties and their Subsidiaries, represents all assets in the aggregate material to the conduct of the business of the Credit Parties and their Subsidiaries, and (after
giving effect to the Transactions) none of such assets is subject to any Lien other than Permitted Liens. Except as could not reasonably be expected to have a Material Adverse Effect, each Credit Party and its Subsidiaries enjoys peaceful and
undisturbed possession under all of its leases and all such leases are valid and subsisting and in full force and effect. 
 Section 3.14 Taxes. 
 Except as set forth in Schedule 3.14, each of the Credit Parties and its
Subsidiaries has filed, or caused to be filed, all federal income tax returns and all other material tax returns (federal, state, local and foreign) required to be filed and paid (a) all amounts of taxes shown thereon to be due (including
interest and penalties) and (b) all other taxes, fees, assessments and other governmental charges (including mortgage recording taxes, documentary stamp taxes and intangibles taxes) owing by it, except for such taxes (i) that are not yet
delinquent or (ii) that are being contested in good faith and by proper proceedings, and against which adequate reserves are being maintained in accordance with GAAP. None of the Credit Parties or their Subsidiaries is aware as of the Closing
Date of any proposed tax assessments against it or any of its Subsidiaries. 
  

 70 

 Section 3.15 Intellectual Property Rights. 
 Each of the Credit Parties and its Subsidiaries owns, or has the legal right to use, all material Owned Intellectual Property, tradenames, technology,
know-how and processes necessary for each of them to conduct its business as currently conducted. Set forth on Schedule 3.15 is a list of all registered or issued Credit Party Intellectual Property (including all applications for
registration and issuance) as of the Closing Date, excluding any software licenses commercially available on terms comparable to the terms currently applicable to the applicable Credit Party, as of the Closing Date (including name/title, current
owner, registration or application number, and registration or application date). Except as could not reasonably be expected to have a Material Adverse Effect, (a) each Credit Party has the right to use its Owned Intellectual Property in
perpetuity and without payment of royalties and (b) all registrations with and applications to Governmental Authorities in respect of such Owned Intellectual Property are valid and in full force and effect and are not subject to the payment of
any taxes or maintenance fees (other than ordinary filing and administrative fees) or the taking of any interest therein, held by any of the Credit Parties to maintain their validity or effectiveness. Except as could not reasonably be expected to
have a Material Adverse Effect, none of the Credit Parties is in default (or with the giving of notice or lapse of time or both, would be in default) under any license to use its Credit Party Intellectual Property. Except as could not reasonably be
expected to have a Material Adverse Effect, no claim has been asserted and is pending by any Person challenging or questioning the use of any such Owned Intellectual Property or the validity or effectiveness of any such Owned Intellectual Property,
nor do the Credit Parties or any of their Subsidiaries know of any such claim; and, to the knowledge of the Credit Parties or any of their Subsidiaries, the use of such Owned Intellectual Property by any of the Credit Parties or any of its
Subsidiaries does not infringe on the rights of any Person. Except as could not reasonably be expected to have a Material Adverse Effect, the Credit Parties have recorded or deposited with and paid to the United States Copyright Office, the Register
of Copyrights, the Copyrights Royalty Tribunal or other Governmental Authority, all notices, statements of account, royalty fees and other documents and instruments required under the terms and conditions of any Contractual Obligation of the Credit
Parties and/or under Title 17 of the United States Code and the rules and regulations issued thereunder (collectively, the “Copyright Act”), and are not liable to any Person for copyright infringement under the Copyright Act or any
other law, rule, regulation, contract or license as a result of their business operations. 
 Section 3.16 Solvency.

 After giving effect to the Transactions, (a) the Credit Parties taken as a whole are solvent and are able to pay their debts and
other liabilities, contingent obligations and other commitments as they mature in the normal course of business, and (b) the fair saleable value of the Credit Parties’ assets taken as a whole, measured on a going concern basis, exceeds all
probable liabilities, including those to be incurred pursuant to this Agreement. After giving effect to the Transactions, none of the Credit Parties (i) has unreasonably small capital in relation to the business in which it is or proposes to be
engaged or (ii) has incurred, or believes that it will 

  

 71 

 
incur debts beyond its ability to pay such debts as they become due. In executing the Credit Documents and consummating the Transactions, none of the Credit
Parties intends to hinder, delay or defraud either present or future creditors or other Persons to which one or more of the Credit Parties is or will become indebted. 
 Section 3.17 Location of Offices. 
 Set forth on Schedule 3.17 is the state of
incorporation or organization, the chief executive office, the principal place of business, the federal tax identification number and organization identification number of each of the Credit Parties and their Subsidiaries as of the Closing Date.

 Section 3.18 No Burdensome Restrictions. 
 None of the Credit Parties or their Subsidiaries is a party to any agreement or instrument or subject to any other obligation or any charter or corporate restriction or any provision of any applicable law, rule or
regulation which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. 
 Section 3.19
Brokers’ Fees. 
 None of the Credit Parties or their Subsidiaries has any obligation to any Person in respect of any
finder’s, broker’s, investment banking or other similar fee in connection with any of the transactions contemplated under the Credit Documents other than the closing and other fees payable pursuant to this Agreement and as set forth in the
Engagement Letter. 
 Section 3.20 Labor Matters. 
 There are no collective bargaining agreements or Multiemployer Plans covering the employees of the Credit Parties or any of their Subsidiaries as
of the Closing Date, other than as set forth in Schedule 3.20 hereto. Except as could not reasonably be expected to have a Material Adverse Effect, no unfair labor practice complaint is pending against any Credit Party or any of its
Subsidiaries. Except as could not reasonably be expected to have a Material Adverse Effect, there are no strikes, walkouts, work stoppages or other material labor difficulty pending or threatened by any employees of any Credit Party.

 Section 3.21 Accuracy and Completeness of Information. 
 All written factual information (taken as a whole) heretofore, contemporaneously or hereafter furnished by or on behalf of any Credit Party or any of its
Subsidiaries to the Administrative Agent or any Lender for purposes of or in connection with this Agreement or any other Credit Document, or any transaction contemplated hereby or thereby, is or will be true and accurate in all material respects and
not incomplete by omitting to state any material fact necessary to make such information not misleading (taken as a whole) as of the date provided in light of the circumstances under which such factual information was furnished; it being understood
and agreed that for purposes of this Section 3.21, such factual information and data shall not include proforma financial information, projections or estimates (including financial estimates, forecasts and other forward-looking information) and
information of a general economic or general industry nature). 
  

 72 

 Section 3.22 Insurance. 
 The insurance coverage of the Credit Parties and their Subsidiaries as of the Closing Date (or as of the date Schedule 3.22 was last updated in
accordance with the terms of Section 5.2) is outlined as to carrier, policy number, expiration date, type and amount on Schedule 3.22 and such insurance coverage complies with the requirements set forth in Section 5.5(b).

 Section 3.23 Security Documents. 
 The Security Documents create valid security interests in, and Liens on, the Collateral purported to be covered thereby. Except as set forth in the Security Documents, such security interests and Liens are currently
(or will be, upon (a) the filing of appropriate financing statements with the Secretary of State of the state of incorporation or organization for each Credit Party, and the filing of appropriate assignments or notices with the United States
Patent and Trademark Office and the United States Copyright Office, in each case in favor of the Administrative Agent, on behalf of the Lenders, and (b) the Administrative Agent obtaining Control (as defined in the Security Agreement) or
possession over those items of Collateral in which a security interest is perfected through Control or possession) perfected security interests and Liens, prior to all other Liens other than Permitted Liens. 
 Section 3.24 Classification of Senior Indebtedness. 
 The Credit Party Obligations constitute “Senior Indebtedness”, “Designated Senior Indebtedness” or any similar designation under and as defined in any agreement governing any Subordinated Debt and
the subordination provisions set forth in each such agreement are legally valid and enforceable against the parties thereto. 
 Section 3.25 Anti-Terrorism Laws. 
 Neither any Credit Party nor any of its Subsidiaries is an “enemy”
or an “ally of the enemy” within the meaning of Section 2 of the Trading with the Enemy Act of the United States of America (50 U.S.C. App. §§ 1 et seq.), as amended. Neither any Credit Party nor any or its
Subsidiaries is in violation of (a) the Trading with the Enemy Act, as amended, (b) any of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) or any enabling
legislation or executive order relating thereto or (c) the Patriot Act. None of the Credit Parties (i) is a blocked person described in Section 1 of the Anti-Terrorism Order or (ii) to the best of its knowledge, engages in any
dealings or transactions, or is otherwise associated, with any such blocked person. 
  

 73 

 Section 3.26 Compliance with OFAC Rules and Regulations. 
 To the best of their knowledge, none of the Credit Parties or their Subsidiaries or their respective Affiliates (a) is a Sanctioned Person,
(b) has more than 15% of its assets in Sanctioned Countries, or (c) derives more than 15% of its operating income from investments in, or transactions with Sanctioned Persons or Sanctioned Countries. No part of the proceeds of any
Extension of Credit hereunder will be used directly or indirectly to fund any operations in, finance any investments or activities in or make any payments to, a Sanctioned Person or a Sanctioned Country. 
 Section 3.27 Compliance with FCPA. 
 Each of the Credit Parties and their Subsidiaries is in compliance with the Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq., and any foreign counterpart thereto. None of the Credit Parties
or their Subsidiaries has made a payment, offering, or promise to pay, or authorized the payment of, money or anything of value (a) in order to assist in obtaining or retaining business for or with, or directing business to, any foreign
official, foreign political party, party official or candidate for foreign political office, (b) to a foreign official, foreign political party or party official or any candidate for foreign political office, and (c) with the intent to
induce the recipient to misuse his or her official position to direct business wrongfully to such Credit Party or its Subsidiary or to any other Person, in violation of the Foreign Corrupt Practices Act, 15 U.S.C. §§ 78dd-1, et seq.
 
 Section 3.28 Consent; Governmental Authorizations. 
 No approval, consent or authorization of, filing with, notice to or other act by or in respect of, any Governmental Authority or any other Person is
required in connection with acceptance of Extensions of Credit by the Borrower or the making of the Guaranty hereunder or with the execution, delivery or performance of any Credit Document by the Credit Parties (other than those which have been
obtained) or with the validity or enforceability of any Credit Document against the Credit Parties (except such filings as are necessary in connection with the perfection of the Liens created by such Credit Documents). 
 ARTICLE IV 
 CONDITIONS PRECEDENT

 Section 4.1 Conditions to Closing Date. 
 This Agreement shall become effective upon, and the obligation of each Lender to make the initial Revolving Loans on the Closing Date is subject to, the
satisfaction or waiver of the following conditions precedent: 
 (a) Execution of Credit Agreement; Credit Documents.
The Administrative Agent shall have received (i) counterparts of this Agreement, executed by a duly authorized officer of each party hereto, (ii) for the account of each Revolving Lender requesting a promissory note, a Revolving Note,
(iii) for the account of each Swingline 

  

 74 

 
Lender requesting a promissory note, the Swingline Note, (iv) counterparts of the Security Agreement and the Pledge Agreement, in each case conforming
to the requirements of this Agreement and executed by duly authorized officers of the Credit Parties or other Person, as applicable and (v) counterparts of any other Credit Document required to be delivered on the Closing Date, executed by the
duly authorized officers of the parties thereto. 
 (b) Authority Documents. The Administrative Agent shall have
received the following: 
 (i) Articles of Incorporation/Charter Documents. Certified copies of articles of
incorporation or other charter documents, as applicable, of each Credit Party certified (A) by an officer of such Credit Party (pursuant to an officer’s certificate in substantially the form of Exhibit 4.1(b) attached hereto) as of
the Closing Date to be true and correct and in force and effect as of such date, and (B) to be true and complete as of a recent date by the appropriate Governmental Authority of the state of its incorporation or organization, as applicable.

 (ii) Resolutions. Copies of resolutions of the board of directors or comparable managing body of each Credit Party
approving and adopting the Credit Documents, the transactions contemplated therein and authorizing execution and delivery thereof, certified by an officer of such Credit Party (pursuant to an officer’s certificate in substantially the form of
Exhibit 4.1(b) attached hereto) as of the Closing Date to be true and correct and in force and effect as of such date. 
 (iii) Bylaws/Operating Agreement. A copy of the bylaws or comparable operating agreement of each Credit Party certified by an officer of such Credit Party (pursuant to an officer’s certificate in substantially the form of
Exhibit 4.1(b) attached hereto) as of the Closing Date to be true and correct and in force and effect as of such date. 
 (iv) Good Standing. Original certificates of good standing, existence or its equivalent with respect to each Credit Party certified as of a recent date by the appropriate Governmental Authorities of the state of incorporation or
organization and each other state in which the failure to so qualify and be in good standing could reasonably be expected to have a Material Adverse Effect. 
 (v) Incumbency. An incumbency certificate of each Credit Party certified by an officer (pursuant to an officer’s certificate
in substantially the form of Exhibit 4.1(b) attached hereto) to be true and correct as of the Closing Date. 
 (c)
Legal Opinion of Counsel. The Administrative Agent shall have received an opinion or opinions of counsel (which, for certain opinions, may be internal counsel) for the Credit Parties, dated the Closing Date and addressed to the Administrative
Agent and the Lenders, in form and substance reasonably acceptable to the Administrative 

  

 75 

 
Agent (which shall include, without limitation, opinions with respect to the due organization and valid existence of each Credit Party, opinions as to
perfection of the Liens granted to the Administrative Agent pursuant to the Security Documents and opinions as to the non-contravention of the Credit Parties’ organizational documents). 
 (d) Personal Property Collateral. The Administrative Agent shall have received, in form and substance satisfactory to the
Administrative Agent: 
 (i)(A) searches of UCC filings in the jurisdiction of incorporation or formation, as applicable,
of each Credit Party and copies of the financing statements on file in such jurisdictions and (B) tax lien, judgment and pending litigation searches; 
 (ii) completed UCC financing statements for each appropriate jurisdiction as is necessary, in the Administrative Agent’s sole discretion, to perfect the Administrative Agent’s security interest in the
Collateral; 
 (iii) stock or membership certificates, if any, evidencing the Capital Stock pledged to the Administrative
Agent pursuant to the Pledge Agreement, and duly executed in blank undated stock or transfer powers; 
 (iv) duly executed
consents as are necessary, in the Administrative Agent’s sole discretion, to perfect the Lenders’ security interest in the Collateral; 
 (v) to the extent constituting Collateral, all instruments and chattel paper with an individual face amount in excess of $1,000,000 in the possession of any of the Credit Parties, together with allonges or assignments
as may be necessary or appropriate to perfect the Administrative Agent’s and the Lenders’ security interest in the Collateral; 
 (vi) searches of ownership of Credit Party Intellectual Property in the appropriate governmental offices and such patent/trademark/copyright filings as reasonably requested by the Administrative Agent in order to
perfect the Administrative Agent’s security interest in the Intellectual Property; 
 (vii) Deposit Account Control
Agreements reasonably satisfactory to the Administrative Agent with respect to each deposit account, except Excluded Accounts and to the extent otherwise determined by the Administrative Agent; and 
 (viii) Securities Account Control Agreements satisfactory to the Administrative Agent with respect to each securities account, except
Excluded Accounts and to the extent otherwise determined by the Administrative Agent. 
  

 76 

 (e) Liability, Casualty, Property and Business Interruption Insurance. The
Administrative Agent shall have received copies of insurance policies or certificates and endorsements of insurance evidencing liability, casualty, property and business interruption insurance meeting the requirements set forth herein or in the
Security Documents. The Administrative Agent shall be named as additional insured, as its interest may appear, with respect to any such insurance providing liability coverage, and the Borrower will use its commercially reasonable efforts to have
each provider of any such insurance agree, by endorsement upon the policy or policies issued by it or by independent instruments to be furnished to the Administrative Agent, that it will endeavor to give the Administrative Agent thirty
(30) days prior written notice before any such policy or policies shall be altered or cancelled. 
 (f) Solvency
Certificate. The Administrative Agent shall have received an officer’s certificate prepared by the chief financial officer of the Borrower as to the financial condition, solvency and related matters of the Credit Parties and their
Subsidiaries, after giving effect to the Transactions and the initial borrowings under the Credit Documents, in substantially the form of Exhibit 4.1(f) hereto. 
 (g) Account Designation Notice. The Administrative Agent shall have received the executed Account Designation Notice in the form of
Exhibit 1.1(a) hereto. 
 (h) Notice of Borrowing. The Administrative Agent shall have received a Notice of
Borrowing with respect to the Loans to be made on the Closing Date. 
 (i) Consents. The Administrative Agent shall
have received evidence that all boards of directors, governmental, shareholder and material third party consents and approvals necessary in connection with the Transactions have been obtained. 
 (j) Compliance with Laws. The financings and other Transactions contemplated hereby shall be in compliance with all applicable laws
and regulations (including all applicable securities and banking laws, rules and regulations). 
 (k) Bankruptcy. There
shall be no bankruptcy or insolvency proceedings pending with respect to any Credit Party or any Subsidiary thereof. 
 (l)
Existing Indebtedness of the Credit Parties. All of the existing Indebtedness for borrowed money of the Credit Parties and their Subsidiaries (other than Indebtedness permitted to exist pursuant to Section 6.1) shall be repaid in full
and all security interests related thereto shall be terminated on or prior to the Closing Date. 
 (m) Financial
Statements. The Administrative Agent and the Lenders shall have received copies of the financial statements referred to in Section 3.1, each in form and substance satisfactory thereto. 
 (n) No Material Adverse Change. Since December 31, 2007, no material adverse change shall have occurred in the business,
properties, operations or condition (financial or otherwise) of the Credit Parties and their Subsidiaries, taken as a whole other than the impact of any development or event with respect to the market for auction rate securities. 
  

 77 

 (o) Financial Condition Certificate. The Administrative Agent shall have received
a certificate or certificates executed by a Responsible Officer of the Borrower as of the Closing Date, substantially in the form of Exhibit 4.1(o) stating that (i) there exists no pending or, to such Responsible Officer’s
knowledge, threatened litigation, injunction, order or claim with respect to the Borrower or its Subsidiaries, in each case that could reasonably be expected to have a Material Adverse Effect, (ii) immediately after giving effect to this
Agreement, the other Credit Documents, and all the Transactions contemplated to occur on such date, (A) no Default or Event of Default exists, (B) all representations and warranties contained herein and in the other Credit
Documents shall (x) with respect to representations and warranties that contain a materiality qualification, are true and correct and (y) with respect to representations and warranties that do not contain a materiality qualification, are
true and correct in all material respects; (C) the Credit Parties are in pro forma compliance with each of the initial financial covenants set forth in Section 5.9 (as evidenced through reasonably detailed calculations of such
financial covenants on a schedule to such certificate) as of the most recent month ending at least 30 days prior to the Closing Date and (iii) each of the other conditions precedent in Section 4.1 have been satisfied, except to the extent
the satisfaction of any such condition is subject to the judgment or discretion of the Administrative Agent or any Lender. 
 (p) Patriot Act Certificate. At least five (5) Business Days prior to the Closing Date, the Administrative Agent shall have received a certificate satisfactory thereto, substantially in the form of Exhibit 4.1(p), for
benefit of itself and the Lenders, provided by the Borrower that sets forth information required by the Patriot Act including, without limitation, the identity of the Credit Parties, the name and address of the Credit Parties and other information
that will allow the Administrative Agent or any Lender, as applicable, to identify the Credit Parties in accordance with the Patriot Act. 
 (q) Corporate Structure. The number of shares of each class of Capital Stock issued and outstanding and the ownership thereof of the Credit Parties and their Subsidiaries as of the Closing Date shall be as
described in Schedule 3.12. 
 (r) Fees and Expenses. The Administrative Agent and the Lenders shall have
received all fees and expenses, if any, owing pursuant to the Engagement Letter and Section 2.5. 
 (s)
Litigation. There shall exist no pending or threatened litigation, injunction, order or claim with respect to the Borrower or its Subsidiaries, in each case that could reasonably be expected to have a Material Adverse Effect. 
 (t) Additional Matters. All other documents and legal matters in connection with the transactions contemplated by this Agreement
shall be reasonably satisfactory in form and substance to the Administrative Agent and its counsel. 
  

 78 

 Without limiting the generality of the provisions of Section 8.4, for purposes of determining
compliance with the conditions specified in this Section 4.1, each Lender that has executed this Credit Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required
hereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto. 
 Section 4.2 Conditions to All Extensions of Credit. 
 The obligation of each Lender to make any Extension of Credit hereunder is subject to the satisfaction of the following conditions precedent on the date of making such Extension of Credit: 
 (a) Representations and Warranties. The representations and warranties made by the Credit Parties herein, in the Security Documents
and which are contained in any certificate furnished at any time under or in connection herewith shall (i) with respect to representations and warranties that contain a materiality qualification, be true and correct and (ii) with respect
to representations and warranties that do not contain a materiality qualification, be true and correct in all material respects, in each case with the same effect as though such representations and warranties had been made on and as of the date of
such Extension of Credit as if made on and as of such date, except to the extent that such representations and warranties expressly related solely to an earlier date (in which case such representations and warranties shall have been true and
accurate on such earlier date); 
 (b) No Default or Event of Default. No Default or Event of Default shall have
occurred and be continuing on such date or after giving effect to the Extension of Credit to be made on such date unless such Default or Event of Default shall have been waived in accordance with this Agreement. 
 (c) Compliance with Commitments. Immediately after giving effect to the making of any such Extension of Credit (and the application
of the proceeds thereof), (i) the sum of the aggregate principal amount of outstanding Revolving Loans plus outstanding Swingline Loans plus outstanding LOC Obligations shall not exceed the Revolving Committed Amount then in
effect, (ii) the outstanding LOC Obligations shall not exceed the LOC Committed Amount and (iii) the outstanding Swingline Loans shall not exceed the Swingline Committed Amount. 
 (d) Additional Conditions to Revolving Loans. If a Revolving Loan is requested, all conditions set forth in Section 2.1 shall
have been satisfied. 
 (e) Incremental Facility. If an Incremental Facility is requested, all conditions set forth in
Section 2.2 shall have been satisfied. 
  

 79 

 (f) Additional Conditions to Letters of Credit. If the issuance of a Letter of
Credit is requested, all conditions set forth in Section 2.3 shall have been satisfied. 
 (g) Additional Conditions
to Swingline Loans. If a Swingline Loan is requested, all conditions set forth in Section 2.4 shall have been satisfied. 
 Each
request for an Extension of Credit and each acceptance by the Borrower of any such Extension of Credit shall be deemed to constitute representations and warranties by the Credit Parties as of the date of such Extension of Credit that the conditions
set forth above in paragraphs (a) through (g), as applicable, have been satisfied. 
 ARTICLE V 
 AFFIRMATIVE COVENANTS 
 Each of the
Credit Parties hereby covenants and agrees that on the Closing Date, and thereafter (a) for so long as this Agreement is in effect, (b) until the Commitments have terminated, and (c) until no Note remains outstanding and unpaid and
the Credit Party Obligations (other than contingent indemnity obligations) are paid in full, such Credit Party shall, and shall cause each of their Subsidiaries, to: 
 Section 5.1 Financial Statements. 
 Furnish to the Administrative Agent for prompt further
distribution to each Lender: 
 (a) Annual Financial Statements. As soon as available and in any event no later than
the earlier of (i) to the extent applicable, the date the Borrower is required by the SEC to deliver its Form 10-K for each fiscal year of the Borrower and (ii) one hundred twenty (120) days after the end of each fiscal year of the
Borrower, a copy of the Consolidated balance sheet of the Credit Parties and their Subsidiaries as at the end of such fiscal year and the related Consolidated statements of income and shareholders’ equity and of cash flows of the Credit Parties
and their Subsidiaries for such year, which shall be audited by PricewaterhouseCoopers or another firm of independent certified public accountants of nationally recognized standing, setting forth in each case in comparative form the figures for the
previous year, reported on without a “going concern” or like qualification or exception, or qualification indicating that the scope of the audit was inadequate to permit such independent certified public accountants to certify such
financial statements without such qualification; 
 (b) Quarterly Financial Statements. As soon as available and in any
event no later than the earlier of (i) to the extent applicable, the date the Borrower is required by the SEC to deliver its Form 10-Q for any fiscal quarter of the Borrower and (ii) forty-five (45) days after the end of each fiscal
quarter of the Borrower, a copy of the Consolidated balance sheet of the Credit Parties and their Subsidiaries as at the end of such period and 

  

 80 

 
related Consolidated statements of income and retained earnings and of cash flows for the Credit Parties and their Subsidiaries for such quarterly period and
for the portion of the fiscal year ending with such period, in each case setting forth in comparative form Consolidated figures for the corresponding period or periods of the preceding fiscal year (subject to normal recurring year-end audit
adjustments) and including a management discussion and analysis; and 
 (c) Annual Operating Budget and Cash Flow. As
soon as available, but in any event within seventy-five (75) days after the end of each Fiscal Year, a copy of the detailed annual operating budget or plan including cash flow projections of the Credit Parties and their Subsidiaries for the
next four fiscal quarter period prepared on a quarterly basis, in form and detail reasonably acceptable to the Administrative Agent and the Lenders, together with a summary of the material assumptions made in the preparation of such annual budget or
plan (it being understood that operating budgets or plans and projections are subject to significant uncertainties and contingencies, many of which are beyond the Borrower’s control, and that no assurance can be given that any operating budget
or plan or projections will be realized); 
 all such financial statements to be complete and correct in all material respects (subject, in the case of
interim statements, to normal recurring year-end audit adjustments) and to be prepared in reasonable detail and, in the case of the annual and quarterly financial statements provided in accordance with subsections (a) and (b) above, in
accordance with GAAP applied consistently throughout the periods reflected therein and further accompanied by a description of, and an estimation of the effect on the financial statements on account of, a change, if any, in the application of
accounting principles as provided in Section 1.3. 
 Notwithstanding the foregoing, financial statements and reports required to be
delivered pursuant to the foregoing provisions of this Section may be delivered electronically and if so, shall be deemed to have been delivered on the date on which either (i) such financial statements and reports are filed by the Borrower
with the SEC or (ii) the Administrative Agent receives such reports from the Borrower through electronic mail; provided that, upon the Administrative Agent’s request, the Borrower shall provide paper copies of any documents required
hereby to the Administrative Agent. 
 Section 5.2 Certificates; Other Information. 
 Furnish to the Administrative Agent for prompt further distribution to each Lender: 
 (a) concurrently with the delivery of the financial statements referred to in Sections 5.1(a) and 5.1(b) above, a certificate of a
Responsible Officer substantially in the form of Exhibit 5.2(a) stating that (i) (A) such financial statements present fairly the financial position of the Credit Parties and their Subsidiaries for the periods indicated in
conformity with GAAP applied on a consistent basis, (B) each of the Credit Parties during such period observed or performed all of its covenants and other agreements, and satisfied every condition, contained in this Agreement to be observed,
performed or satisfied by it, and (C) such Responsible Officer has obtained no knowledge of any Default or Event of Default except as specified in such certificate and such certificate shall include the calculations in reasonable detail
required to indicate compliance with Section 5.9 as of the last day of such period; 
  

 81 

 (b) concurrently with or prior to the delivery of the financial statements referred to in
Sections 5.1(a) and 5.1(b) above, (i) an updated copy of Schedule 3.12 if the Credit Parties or any of their Subsidiaries has formed or acquired a new Subsidiary since the Closing Date or since such Schedule was last updated, as
applicable, (ii) an updated copy of Schedule 3.22 if the Credit Parties or any of their Subsidiaries has materially altered or acquired any material insurance policies since the Closing Date or since Schedule 3.22 was last updated
and (iii) an updated copy of Schedule 6.12 if any Credit Party opens, maintains or otherwise has any checking, savings or other account (including securities accounts) other than Excluded Accounts not set forth on Schedule 6.12;

 (c) promptly upon their becoming available, (i) all material regulatory reports and (ii) copies of all Form 8-K
reports and all registration statements and prospectuses (other than Form S-8 registration statements), if any, which any Credit Party may file with the SEC (or any successor or analogous Governmental Authority); 
 (d) within ninety (90) days after the end of each Fiscal Year of the Borrower, a certificate containing information including a
calculation of the amount of all acquisitions, all dividends paid and Asset Dispositions that were made during the prior fiscal year; and 
 (e) promptly, such additional financial and other information as the Administrative Agent or any Lender may from time to time reasonably request. 
 Section 5.3 Payment of Taxes and Other Obligations. 
 Pay, discharge or otherwise satisfy at or before maturity or before they become delinquent, as the case may be, subject, where applicable, to specified grace periods, (a) all of its Federal and other material
taxes and (b) any material additional costs that are imposed as a result of any failure to so pay, discharge or otherwise satisfy such taxes, except when the amount or validity of any such taxes is currently being contested in good faith by
appropriate proceedings and reserves, if applicable, in conformity with GAAP with respect thereto have been provided on the books of the Credit Parties. 
 Section 5.4 Conduct of Business and Maintenance of Existence. 
 Continue to engage in
business of the same general type as now conducted by it on the Closing Date and preserve, renew and keep in full force and effect its corporate or other formative existence and good standing in its jurisdiction of formation, except as permitted by
this Agreement. Except as could not reasonably be expected to have a Material Adverse Effect, (a) keep in full force and effect good standing in all jurisdictions where required, other than the jurisdiction of formation and (b) take all
reasonable action to maintain all rights, privileges and franchises necessary or desirable in the normal conduct of its business. 
  

 82 

 Section 5.5 Maintenance of Property; Insurance. 
 (a) Keep all material property useful and necessary in its business in good working order and condition (ordinary wear and tear and
obsolescence excepted), except as could not reasonably be expected to have a Material Adverse Effect. 
 (b) Maintain with
financially sound and reputable insurance companies liability, casualty, property and business interruption insurance (including, without limitation, insurance with respect to its tangible Collateral) in at least such amounts and against at least
such risks as are usually insured against in the same general area by companies engaged in the same or a similar business; and furnish to the Administrative Agent, upon the request of the Administrative Agent, full information as to the insurance
carried. The Administrative Agent shall be named as additional insured, as its interest may appear, with respect to any such liability insurance, and each provider of any such insurance shall agree, by endorsement upon the policy or policies issued
by it or by independent instruments to be furnished to the Administrative Agent, that it will endeavor to give the Administrative Agent thirty (30) days prior written notice before any such policy or policies shall be altered or canceled.

 Section 5.6 Inspection of Property; Books and Records; Discussions. 
 Keep proper books, records and accounts in conformity with GAAP and all material Requirements of Law; and permit, during regular business hours and upon
reasonable notice by the Administrative Agent, the Administrative Agent or any Lender to visit and inspect any of its properties and examine and make abstracts from any of its books and records at any reasonable time and as often as may reasonably
be desired, and to discuss the business, operations, properties, financial conditions and other conditions of the Credit Parties and their Subsidiaries with officers and employees of the Credit Parties and their Subsidiaries and with its independent
certified public accountants, in each case at the reasonable expense of the Borrower. 
 Section 5.7 Notices. 

Give notice in writing to the Administrative Agent (which shall promptly transmit such notice to each Lender): 
 (a) promptly, but in any event within two (2) Business Days after any Credit Party knows thereof, the occurrence of any Default or
Event of Default; 
 (b) promptly, any default or event of default under any Contractual Obligation of any Credit Party or any
of its Subsidiaries which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect; 
  

 83 

 (c) promptly, any litigation, or any investigation or proceeding known to any Credit
Party (i) affecting any Credit Party or any of its Subsidiaries which, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect or involve a monetary claim in excess of $5,000,000 or involving injunctions
or requesting injunctive relief by or against any Credit Party or any Subsidiary of any Credit Party, (ii) affecting or with respect to this Agreement, any other Credit Document or any security interest or Lien created thereunder,
(iii) involving an environmental claim or potential liability under Environmental Laws which could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, or (iv) by any Governmental Authority relating
to the Borrower or any Subsidiary thereof and alleging fraud, deception or willful misconduct by such Person; 
 (d) of any
labor controversy that has resulted in, or threatens to result in, a strike or other work action against any Credit Party which could reasonably be expected to have a Material Adverse Effect; 
 (e) of any attachment, judgment, lien, levy or order exceeding $1,000,000 that may be assessed against any Credit Party other than
Permitted Liens; 
 (f) as soon as possible and in any event within thirty (30) days after any Credit Party knows or has
reason to know thereof: (i) the occurrence or expected occurrence of any Reportable Event with respect to any Plan, a failure to make any required contribution to a Plan, the creation of any Lien in favor of the PBGC (other than a Permitted
Lien) or a Plan or any withdrawal from, or the termination, Reorganization or Insolvency of, any Multiemployer Plan or (ii) the institution of proceedings or the taking of any other action by the PBGC or any Credit Party, any Commonly
Controlled Entity or any Multiemployer Plan, with respect to the withdrawal from, or the terminating, Reorganization or Insolvency of, any Plan; 
 (g) promptly, any notice of any violation received by any Credit Party from any Governmental Authority including, without limitation, any notice of violation of Environmental Laws, that could reasonably be expected to
have a Material Adverse Effect; and 
 (h) promptly, any other development or event which could reasonably be expected to have
a Material Adverse Effect. 
 Each notice pursuant to this Section shall be accompanied by a statement of a Responsible Officer setting forth details of the
occurrence referred to therein and stating what action the Credit Parties propose to take with respect thereto. In the case of any notice of a Default or Event of Default, the Borrower shall specify that such notice is a Default or Event of Default
notice on the face thereof. 
  

 84 

 Section 5.8 Environmental Laws. 
 (a) Except as could not reasonably be expected to have a Material Adverse Effect (i) comply in all material respects with, and ensure
compliance in all material respects by all tenants and subtenants, if any, with, all applicable Environmental Laws and (ii) and obtain and comply in all material respects with and maintain, and ensure that all tenants and subtenants obtain and
comply in all material respects with and maintain, any and all licenses, approvals, notifications, registrations or permits required by applicable Environmental Laws; and 
 (b) Except as could not reasonably be expected to have a Material Adverse Effect (i) conduct and complete all investigations,
studies, sampling and testing, and all remedial, removal and other actions required to be conducted by a Credit Party under Environmental Laws and (ii) promptly comply in all material respects with all lawful orders and directives of all
Governmental Authorities regarding Environmental Laws except to the extent that the same are being contested in good faith by appropriate proceedings. 
 Section 5.9 Financial Covenants. 
 Comply with the following financial covenants:

 (a) Leverage Ratio. The Leverage Ratio, measured as of the last day of each fiscal quarter of the Borrower shall be
less than or equal to (a) for each such date occurring on or before June 30, 2009, 2.50 to 1.00 and (b) for each such date thereafter, 2.25 to 1.00: 
 (b) Fixed Charge Coverage Ratio. The Fixed Charge Coverage Ratio, measured as of the last day of each fiscal quarter of the
Borrower shall be greater than or equal to 1.25 to 1.00. 
 (c) Minimum Liquidity. Liquidity shall, at all times, be
greater than or equal to $35,000,000. 
 Section 5.10 Additional Guarantors. 
 The Credit Parties will cause each of their Material Domestic Subsidiaries, whether newly formed, after acquired or otherwise existing to promptly (and in
any event within thirty (30) days after such Material Domestic Subsidiary is formed or acquired (or such longer period of time as agreed to by the Administrative Agent in its reasonable discretion)) become a Guarantor hereunder by way of
execution of a Joinder Agreement. In addition, if the Domestic Subsidiaries of the Borrower that are not Guarantors (the “Non-Guarantor Domestic Subsidiaries”) shall, as of the last day of any fiscal quarter of the Borrower,
collectively (a) generate more than 10% of Consolidated EBITDA for the four (4) fiscal quarter period ending as of such date or (b) own more than 10% of the Consolidated Assets as of such date (clause (a) and (b), the
“Additional Guarantor Criteria”), then the Borrower shall cause one or more of such Non-Guarantor Domestic Subsidiaries to promptly (and in any event within thirty 

  

 85 

 
(30) days after the end of the applicable fiscal quarter of the Borrower) become Guarantors hereunder by way of execution of Joinder Agreements so that,
after such Non-Guarantor Domestic Subsidiaries become Guarantors, neither of the Additional Guarantor Criteria will be met. In connection with the foregoing, the Credit Parties shall give notice to the Administrative Agent not less than
ten (10) days after creating a Domestic Subsidiary (or such larger period of time as agreed to by the Administrative Agent in its reasonable discretion), or acquiring a majority of the Capital Stock of any other Person. 
 The Credit Party Obligations shall be secured by, among other things, a first priority perfected security interest in the Collateral of such new
Guarantor and a pledge of 100% of the Capital Stock of such new Guarantor and its Domestic Subsidiaries (unless such Domestic Subsidiary is not owned directly by a Domestic Subsidiary and is owned, directly or indirectly, by a Subsidiary described
in clause (a) of the definition of “Foreign Subsidiary”) and 65% of the voting Capital Stock and 100% of the non-voting Capital Stock of (a) the first-tier Foreign Subsidiaries of such new Guarantor and (b) the first-tier
Foreign Subsidiaries of each Excluded Subsidiary of such new Guarantor (unless such Excluded Subsidiary is owned, directly or indirectly, by a Subsidiary described in clause (a) of the definition of “Foreign Subsidiary”), in each case
to the extent set forth in, and as provided in, the Security Documents. In connection with the foregoing, the Credit Parties shall, except to the extent, if any, waived by the Administrative Agent, deliver to the Administrative Agent, with respect
to each new Guarantor to the extent applicable, substantially the same documentation required pursuant to Sections 4.1(b), (c) and (d)(iii) and 5.12 and such other documents or agreements as the Administrative Agent may reasonably request.
The Credit Parties shall also cause each Excluded Subsidiary of such new Guarantor to become a party to the Pledge Agreement. Notwithstanding the foregoing, with respect to any checking, savings, or other account (including securities accounts)
acquired directly or indirectly by the Credit Parties as part of a Permitted Acquisition, Section 6.12(b) shall not apply until thirty (30) days following the consummation of such Permitted Acquisition. 
 Section 5.11 Compliance with Law. 
 (a) Comply with all Requirements of Law and orders (including Environmental Laws), and all applicable restrictions imposed by all Governmental Authorities, applicable to it and the Collateral if noncompliance with any
such Requirements of Law, order or restriction could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. 
 (b) Comply with all Contractual Obligations, except to the extent that failure to comply could not reasonably be expected to have a Material Adverse Effect. 
 Section 5.12 Pledged Assets. 
 (a) Each Credit Party will cause 100% of the Capital Stock in each of its direct or indirect Domestic Subsidiaries (unless such Domestic Subsidiary is not owned directly by a Domestic Subsidiary and is owned, directly
or indirectly, by a Subsidiary described in clause (a) of the definition of “Foreign Subsidiary”) and 65% of the voting 

  

 86 

 
Capital Stock and 100% of the non-voting Capital Stock of (i) the first-tier Foreign Subsidiaries of such Credit Party and (ii) the first-tier
Foreign Subsidiaries of each Excluded Subsidiary of such Credit Party (unless such Excluded Subsidiary is owned, directly or indirectly, by a Subsidiary described in clause (a) of the definition of “Foreign Subsidiary”), in each case
to the extent owned by such Credit Party, to be subject at all times to a first priority, perfected Lien in favor of the Administrative Agent pursuant to the terms and conditions of the Security Documents or such other security documents as the
Administrative Agent shall reasonably request; provided, that with respect to the Capital Stock of Eclipsys International Holding, LLC, such Lien shall be limited to 65% of its voting Capital Stock and 100% of its non-voting Capital Stock.

 (b) Each Credit Party will cause all Collateral now owned or hereafter acquired to be subject at all times to a first
priority, perfected Lien (subject in each case to Permitted Liens) in favor of the Administrative Agent, in each case pursuant to the terms and conditions of the Security Documents. 
 (c) Notwithstanding the foregoing, with respect to any checking, savings, or other account (including securities accounts) acquired
directly or indirectly by the Credit Parties as part of a Permitted Acquisition, Section 5.12(b) shall not apply until thirty (30) days following the consummation of such Permitted Acquisition. 
 (d) The Credit Parties will cause all Off-Shore Rights transferred to an International Holding Company after the date hereof to at all
times be owned by a Credit Party or by an International Holding Company. 
 Section 5.13 Further Assurances. 

(a) Public/Private Designation. Borrower will cooperate with the Administrative Agent in connection with the publication of
certain written materials and/or written information provided by or on behalf of the Borrower to the Administrative Agent and Lenders (collectively, “Information Materials”) pursuant to this Article V and will designate Information
Materials (i) that are either available to the public or not material with respect to the Credit Parties and their Subsidiaries or any of their respective securities for purposes of United States federal and state securities laws, as
“Public Information”. Any Information Materials that are not Public Information so marked shall be deemed to be “Private Information”. 
 (b) Further Assurances. Upon the reasonable request of the Administrative Agent, promptly perform or cause to be performed any and
all acts and execute or cause to be executed any and all documents for filing under the provisions of the Uniform Commercial Code or any other Requirement of Law which are necessary or advisable to maintain in favor of the Administrative Agent, for
the benefit of the Secured Parties, Liens on the Collateral that are duly perfected in accordance with the requirements of, or the obligations of the Credit Parties under, the Credit Documents and all applicable Requirements of Law. 
  

 87 

 ARTICLE VI 
 NEGATIVE COVENANTS 
 Each of the Credit Parties hereby covenants and agrees that on the Closing Date,
and thereafter (a) for so long as this Agreement is in effect, (b) until the Commitments have terminated, and (c) until no Note remains outstanding and unpaid and the Credit Party Obligations (other than contingent indemnity
obligations) are paid in full that: 
 Section 6.1 Indebtedness. 
 No Credit Party will, nor will it permit any Subsidiary to, create, incur, assume or permit to exist any Indebtedness, except: 
 (a) Indebtedness arising or existing under this Agreement and the other Credit Documents; 
 (b) Indebtedness of the Credit Parties and their Subsidiaries existing as of the Closing Date (and set out more specifically in
Schedule 6.1(b) hereto) and any renewals, refinancings or extensions thereof in a principal amount not in excess of that outstanding as of the date of such renewal, refinancing or extension; 
 (c) Indebtedness of the Credit Parties and their Subsidiaries incurred after the Closing Date consisting of Capital Leases or Indebtedness
incurred to provide all or a portion of the purchase price or cost of construction or improvement of an asset and any renewals, refinancings or extensions thereof; provided that (i) such Indebtedness when incurred shall not exceed the
purchase price or cost of construction or improvement of such asset plus applicable transaction costs; (ii) no such Indebtedness shall be renewed, refinanced or extended for a principal amount in excess of the principal balance outstanding
thereon at the time of such renewal, refinancing or extension plus applicable transaction costs; and (iii) the total amount of all such Indebtedness shall not exceed $5,000,000 at any time outstanding; 
 (d)(i) Intercompany Indebtedness among the Credit Parties; (ii) intercompany Indebtedness owed to a Credit Party by an Excluded
Subsidiary; (iii) Indebtedness of an Excluded Subsidiary in respect of the Credit Party Obligations; and (iv) intercompany Indebtedness among Foreign Subsidiaries; 
 (e) Indebtedness and obligations owing under Secured Hedging Agreements and other Hedging Agreements entered into in order to manage
existing or anticipated interest rate, exchange rate or commodity price risks and not for speculative purposes; 
 (f)
Guaranty Obligations in respect of Indebtedness of a Credit Party to the extent such Indebtedness is permitted to exist or be incurred pursuant to this Section; 
  

 88 

 (g) to the extent constituting Indebtedness, surety bonds and appeal bonds required in
the ordinary course of business or in connection with the enforcement of rights or claims of the Borrower or any Restricted Subsidiary or in connection with judgments that do not result in a Default or Event of Default; 
 (h) Indebtedness owing to any Credit Party by an International Holding Company in the form of a note issued solely in whole or partial
consideration for Off-Shore Rights (an “International Holding Company Note”); and 
 (i) other Indebtedness
of Credit Parties and their Subsidiaries which does not exceed $30,000,000 in the aggregate at any time outstanding (of which up to $5,000,000 in the aggregate at any time outstanding may be secured Indebtedness). 
 Section 6.2 Liens. 
 The
Credit Parties will not, nor will they permit any Subsidiary to, create, incur, assume or permit to exist any Lien with respect to any of their respective property or assets of any kind (whether real or personal, tangible or intangible), whether now
owned or hereafter acquired, except for Permitted Liens. 
 Section 6.3 Nature of Business. 
 The Borrower and its Subsidiaries, taken as a whole, will not substantively alter in any material respect the character of their business from that
conducted as of the Closing Date (and others reasonably related, supplemental, ancillary and/or incidental thereto). 
 Section 6.4
Consolidation, Merger, Sale or Purchase of Assets, etc. 
 The Credit Parties will not, nor will they permit any Subsidiary to,

 (a) dissolve or liquidate or sell, transfer, lease or otherwise dispose of its property or assets or agree to do so at a
future time (other than agreements to dispose of property or assets with a fair market value less than $1,000,000 individually or $5,000,000 in the aggregate during the term of this Agreement), except the following, without duplication, shall be
expressly permitted: 
 (i)(A) the sale, transfer, lease, sublease or other disposition of property in the ordinary
course of business; (B) the conversion of cash into Cash Equivalents and of Cash Equivalents into cash and (C) (1) the licensing out of intellectual property and other rights and (2) the sale, transfer, licensing or other
disposition of Off-Shore Rights to an International Holding Company; 
 (ii) Recovery Events for which such Credit Party or
such Subsidiary has received any cash insurance proceeds or condemnation or expropriation award with respect to such property or assets; 
  

 89 

 (iii) the sale, lease, sublease, transfer or other disposition of property, machinery,
parts and equipment and other goods no longer used or useful in, or consistent with the Borrower’s plans for, the conduct of the business of the Credit Parties or any of their Subsidiaries; 
 (iv) the sale, lease or transfer of property or assets from the Borrower or any Subsidiary to a Credit Party or from one Credit Party to
another Credit Party or from any Subsidiary that is not a Credit Party to any other Subsidiary that is not a Credit Party; 
 (v) the termination of any Hedging Agreement; 
 (vi) the sale of Investments held in securities accounts;

 (vii) the liquidation or dissolution of any Subsidiary that is not a Credit Party if the assets of such Subsidiary are
transferred to a Credit Party after the repayment of all Indebtedness and other obligations of such Subsidiary upon liquidation or dissolution; 
 (viii) the disposition of any property or assets for purposes of making a Permitted Investment; and 
 (ix) the sale, lease or transfer of property or assets not to exceed (A) $50,000,000 in net cash proceeds in the aggregate during any Fiscal Year and (B) $100,000,000 in net cash proceeds in the aggregate during the term of the
Agreement; 
 provided that (A) with respect to clauses (i)(A), (ii), (iii), (vi) and (ix) above, except for transactions involving
assets with a fair market value (as determined by a Responsible Officer) not exceeding $2,000,000 in any fiscal year, at least 75% of the consideration received therefor by the Credit Parties or any such Subsidiary shall be in the form of cash or
Cash Equivalents, (B) after giving effect to any Asset Disposition pursuant to clause (ix) above, the Credit Parties shall be in compliance on a Pro Forma Basis with the financial covenants set forth in Section 5.9 hereof,
recalculated for the most recently ended quarter for which information is available, and (C) no Default or Event of Default shall exist or shall result therefrom; provided, further, that with respect to dispositions of assets
permitted hereunder only, the Administrative Agent shall be entitled, without the consent of any Lender, to release its Liens relating to the particular assets subject to such disposition; or 
 (b)(i) purchase, lease or otherwise acquire (in a single transaction or a series of related transactions) all or substantially all of
the property or assets of any Person, other than (A) Permitted Acquisitions and (B) except as otherwise limited or prohibited herein, purchases or other acquisitions of inventory, materials, property and equipment in the ordinary course of
business, or (ii) enter into any transaction of merger or consolidation, except for (A) in connection with Investments or acquisitions permitted pursuant to Section 6.5 so long as the Credit Party subject to such merger or 

  

 90 

 
consolidation is the surviving entity or the surviving entity will become a Credit Party concurrently with effectiveness of the merger or consolidation,
(B) (y) the merger or consolidation of a Subsidiary that is not a Credit Party with and into a Credit Party; provided that such Credit Party will be the surviving entity and (z) the merger or consolidation of a Credit Party
with and into another Credit Party; provided that if the Borrower is a party thereto, the Borrower will be the surviving corporation, (C) the merger or consolidation of a Subsidiary that is not a Credit Party with and into another
Subsidiary that is not a Credit Party and (D) any merger or consolidation, the purpose or effect of which is to effect, all or in part, a disposition permitted pursuant to Section 6.4(a) or an Investment permitted pursuant to
Section 6.5. 
 Section 6.5 Advances, Investments and Loans. 
 The Credit Parties will not, nor will they permit any Subsidiary to, make any Investment except for Permitted Investments. 
 Section 6.6 Transactions with Affiliates. 
 The Credit Parties will not, nor will they permit any Subsidiary to, enter into any transaction or series of transactions, whether or not in the ordinary course of business, with any officer, director, shareholder or
Affiliate other than on terms and conditions substantially as favorable as would be obtainable in a comparable arm’s-length transaction with a Person other than an officer, director, shareholder or Affiliate; provided, that the foregoing
shall not prohibit (a) transactions among the Credit Parties, (b) Investments in Foreign Subsidiaries to the extent permitted pursuant to Section 6.5 and Investments by Foreign Subsidiaries in Credit Parties; (c) Restricted
Payments to the extent permitted pursuant to Section 6.9; (d) employment and severance arrangements between the Borrower or any of its Subsidiaries and their respective officers and employees and transactions pursuant to stock option plans
and employee benefit plans and arrangements, in each case in the ordinary course of business and (e) the payment of customary fees and reasonable out-of-pocket costs to, and indemnities provided on behalf of, directors, officers, employees and
consultants of the Borrower and its Subsidiaries in the ordinary course of business. 
 Section 6.7 Corporate Changes. 

 The Borrower will not change its fiscal year. No Credit Party will, nor will it permit any of its Subsidiaries to, (a) change its
fiscal year (other than to conform its fiscal year to the Borrower’s), (b) amend, modify or change its articles of incorporation, certificate of designation (or corporate charter or other similar organizational document) operating
agreement or bylaws (or other similar document) in any material respect adverse to the interests of the Lenders without the prior written consent of the Administrative Agent; provided that no Credit Party shall (i) alter its legal
existence in any way materially adverse to the Lenders, or, in one transaction or a series of transactions, merge into or consolidate with any other entity (other than, in each case, as permitted by Section 6.4), or sell all or substantially
all of its assets (other than as permitted by Section 6.4), (ii) change its state of incorporation or organization, or (iii) change its registered legal name, without providing thirty (30) days prior written notice to the
Administrative Agent 

  

 91 

 
and without filing (or confirming that the Administrative Agent has filed) such financing statements and amendments to any previously filed financing
statements as the Administrative Agent may require, (c) change its state of incorporation, organization or formation without the consent of the Administrative Agent without providing thirty (30) days prior written notice to the
Administrative Agent and without filing (or confirming that the Administrative Agent has filed) such financing statements and amendments to any previously filed financing statements as the Administrative Agent may require or have more than one state
of incorporation, organization or formation or (d) change its accounting method (except in accordance with GAAP) in any manner materially adverse to the interests of the Lenders without the prior written consent of the Required Lenders.

 Section 6.8 Limitation on Restricted Actions. 
 The Credit Parties will not, nor will they permit any Domestic Subsidiary to, directly or indirectly, create or otherwise cause or suffer to exist or
become effective any contractual encumbrance or restriction on the ability of any such Person to act as a Guarantor and pledge its Collateral pursuant to the Credit Documents. 
 Section 6.9 Restricted Payments. 
 The Credit Parties will not, nor will they permit any Subsidiary to, directly or indirectly, declare, order, make or set apart any sum for or pay any Restricted Payment, except (a) dividends payable solely in the same class of Capital
Stock of such Person, (b) dividends or other distributions payable to the Credit Parties (directly or indirectly through their Subsidiaries), (c) dividends or other distributions by a Subsidiary that is not a Credit Party to another
Subsidiary that is not a Credit Party and (d) other Restricted Payments so long as after giving effect to each such payment made pursuant to this clause (d) on a Pro Forma Basis (i) no Default or Event of Default shall then exist or
would result therefrom, (ii) the Credit Parties shall be in compliance with each of the financial covenants set forth in Section 5.9 hereof and (iii) as of the date such Restricted Payment is made, the aggregate amount of all such
Restricted Payments during the period beginning July 1, 2008 through the date of such Restricted Payment does not exceed 50% of Consolidated Net Income of the Borrower during such period beginning July 1, 2008 through the most recent
fiscal quarter ended prior to such Restricted Payment for which financial statements are available (treating such period as a single accounting period). 
 Section 6.10 Amendment of Subordinated Debt. 
 The Credit Parties will not, nor will they
permit any Subsidiary to, without the prior written consent of the Required Lenders, amend, modify, waive or extend or permit the amendment, modification, waiver or extension of any term of any document governing or relating to any Subordinated Debt
in a manner that is adverse to the interests of the Lenders. 
  

 92 

 Section 6.11 No Further Negative Pledges. 
 The Credit Parties will not, nor will they permit any Subsidiary to, enter into, assume or become subject to any agreement prohibiting or otherwise
restricting the creation or assumption of any Lien upon the Collateral to secure the Credit Party Obligations. 
 Section 6.12
Account Control Agreements; Additional Bank Accounts. 
 (a) Set forth on Schedule 6.12 is a complete and
accurate list of all checking, savings or other accounts (including securities accounts) other than Excluded Accounts of the Credit Parties at any bank or other financial institution, or any other account where money is or may be deposited or
maintained with any Person as of the Closing Date or as of the date such Schedule was last updated in accordance with the terms of Section 5.2. 
 (b) Each of the Credit Parties will not open, maintain or otherwise have any checking, savings or other accounts (including securities accounts) at any bank or other financial institution, or any other account where
money is or may be deposited or maintained with any Person, other than (i) deposit accounts that are subject to a Deposit Account Control Agreement, (ii) securities accounts that are subject to a Securities Account Control Agreement and
other securities accounts so long as the aggregate balance in all such other securities accounts does not exceed $500,000, (iii) the EPSI Account, the Outside LC Account, deposit accounts established solely as payroll and other zero balance
accounts and other deposit accounts so long as at any time the balance in any such other deposit account (other than the EPSI Account and the Outside LC Account) does not exceed $500,000 and the aggregate balance in all such other deposit accounts
(excluding the EPSI Account and the Outside LC Account) does not exceed $2,500,000 (such payroll, zero balance, EPSI Account, Outside LC Account and other deposit accounts are referred to herein as “Excluded Accounts”). The EPSI
Account shall be transferred to Wachovia no later than June 30, 2009. The Outside LC Account shall be closed no later than thirty (30) days after the Closing Date or by such other date as may be agreed to by the Borrower and the
Administrative Agent. 
 (c) Notwithstanding the foregoing, with respect to any checking, savings or other account (including
securities accounts) acquired directly or indirectly by the Credit Parties as part of a Permitted Acquisition, Section 6.12(b) shall not apply until thirty (30) days following the consummation of such Permitted Acquisition. 
  

 93 

 ARTICLE VII 
 EVENTS OF DEFAULT 
 Section 7.1 Events of Default. 
 An Event of Default shall exist upon the occurrence of any of the following specified events (each an “Event of Default”): 
 (a) Payment. (i) The Borrower shall fail to pay any principal on any Loan or Note when due (whether at maturity, by reason of
acceleration or otherwise) in accordance with the terms hereof or thereof; or (ii) the Borrower shall fail to reimburse the Issuing Lender for any LOC Obligations when due (whether at maturity, by reason of acceleration or otherwise) in
accordance with the terms hereof; or (iii) the Borrower shall fail to pay any interest on any Loan or any fee or other amount payable hereunder when due (whether at maturity, by reason of acceleration or otherwise) in accordance with the terms
hereof and such failure shall continue unremedied for three (3) Business Days; or (iv) or any Guarantor shall fail to pay after written demand therefor on the Guaranty in respect of any of the foregoing or in respect of any other Guaranty
Obligations hereunder (after giving effect to the grace period in clause (iii)); or 
 (b) Misrepresentation. Any
representation or warranty made or deemed made herein, in the Security Documents or in any of the other Credit Documents or which is contained in any certificate, document or financial or other statement furnished at any time under or in connection
with this Agreement shall (i) with respect to representations and warranties that contain a materiality qualification, prove to have been incorrect, false or misleading on or as of the date made or deemed made and (ii) with respect to
representations and warranties that do not contain a materiality qualification, prove to have been incorrect, false or misleading in any material respect on or as of the date made or deemed made; or 
 (c) Covenant Default. (i) Any Credit Party shall fail to perform, comply with or observe any term, covenant or agreement
applicable to it contained in Sections 5.1, 5.2, 5.4 (as to maintenance of the Borrower’s existence), 5.7, 5.9, or 5.11 or Article VI hereof; or (ii) any Credit Party shall fail to comply with any other covenant contained in this
Agreement or the other Credit Documents or any other agreement, document or instrument among any Credit Party, the Administrative Agent and the Lenders or executed by any Credit Party in favor of the Administrative Agent or the Lenders (other than
as described in Sections 7.1(a) or 7.1(c)(i) above), and such breach or failure to comply is not cured within thirty (30) days of its occurrence; or 
 (d) Indebtedness Cross-Default. (i) Any Credit Party shall default in any payment of principal of or interest on any Indebtedness (other than the Loans, Reimbursement Obligations and the Guaranty) in a
principal amount outstanding of at least $10,000,000 for the Credit Parties and any of their Subsidiaries in the aggregate beyond any applicable grace period (not to exceed sixty (60) days), if any, provided in the instrument or agreement under
which such Indebtedness was created; or (ii) any Credit Party shall default in the observance or performance of any other agreement or condition relating to any Indebtedness (other than the Loans, Reimbursement Obligations and the Guaranty) in
a principal amount outstanding of at least $10,000,000 in the aggregate for the Credit Parties and their Subsidiaries or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event shall occur or condition
exist, the effect of which default or other event or condition is to cause, or to permit the holder or holders of such Indebtedness or beneficiary or beneficiaries of such Indebtedness (or a trustee or agent on behalf of such holder or holders or
beneficiary or 

  

 94 

 
beneficiaries) to cause, with the giving of notice if required, such Indebtedness to become due prior to its stated maturity or to be repurchased, prepaid,
deferred or redeemed (automatically or otherwise); or (iii) any Credit Party shall have liability greater than $10,000,000 resulting from a termination event under any Secured Hedging Agreement; or 
 (e) Bankruptcy Default. (i) A Credit Party or any of its material Subsidiaries shall commence any case, proceeding or other
action (A) under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for relief entered with respect to it, or seeking to
adjudicate it a bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts, or (B) seeking appointment of a receiver, trustee,
custodian, conservator or other similar official for it or for all or any substantial part of its assets, or a Credit Party or any of its Subsidiaries shall make a general assignment for the benefit of its creditors; or (ii) there shall be
commenced against a Credit Party or any of its material Subsidiaries any case, proceeding or other action of a nature referred to in clause (i) above which (A) results in the entry of an order for relief or any such adjudication or
appointment or (B) remains undismissed, undischarged or unbonded for a period of sixty (60) days; or (iii) there shall be commenced against a Credit Party or any of its material Subsidiaries any case, proceeding or other action
seeking issuance of a warrant of attachment, execution, distraint or similar process against all or any substantial part of their assets which results in the entry of an order for any such relief which shall not have been vacated, discharged, or
stayed or bonded pending appeal within sixty (60) days from the entry thereof; or (iv) a Credit Party or any of its material Subsidiaries shall take any action in furtherance of, or indicating its consent to, approval of, or acquiescence
in, any of the acts set forth in clause (i), (ii), or (iii) above; or (v) a Credit Party or any of its material Subsidiaries shall generally not, or shall be unable to, or shall admit in writing their inability to, pay its debts as
they become due; or 
 (f) Judgment Default. (i) One or more judgments or decrees shall be entered against a
Credit Party or any of its material Subsidiaries involving in the aggregate a liability (to the extent not covered by insurance) of $10,000,000 or more or (ii) any injunction, temporary restraining order or similar decree shall be issued
against a Credit Party or any of its Subsidiaries that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect, and, in the case of either (i) or (ii), such judgment, injunction, temporary
restraining order or decree shall not have been paid or satisfied, vacated, discharged, stayed or bonded pending appeal within twenty (20) Business Days from the entry thereof; or 
 (g) ERISA Default. Except as could not, either individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect: (i) any Person shall engage in any “prohibited transaction” (as defined in Section 406 of ERISA or Section 4975 of the Code) involving any Plan, (ii) any “accumulated funding deficiency” (as defined in
Section 302 of ERISA), whether or not waived, shall exist with respect to any Plan or any Lien in favor of the PBGC or a Plan (other than a Permitted Lien) shall 

  

 95 

 
arise on the assets of the Credit Parties or any Commonly Controlled Entity, (iii) a Reportable Event shall occur with respect to, or proceedings shall
commence to have a trustee appointed, or a trustee shall be appointed, to administer or to terminate, any Single Employer Plan, which Reportable Event or commencement of proceedings or appointment of a trustee is, in the reasonable opinion of the
Required Lenders, likely to result in the termination of such Plan for purposes of Title IV of ERISA, (iv) any Single Employer Plan shall terminate for purposes of Title IV of ERISA, (v) a Credit Party or any Commonly Controlled
Entity shall incur any liability in connection with a withdrawal from, or the Insolvency or Reorganization of, any Multiemployer Plan; 
 (h) Change of Control. There shall occur a Change of Control; or 
 (i) Invalidity
of Guaranty. At any time after the execution and delivery thereof, the Guaranty, for any reason other than the satisfaction in full of all Credit Party Obligations, shall cease to be in full force and effect (other than in accordance with its
terms) or shall be declared to be null and void, or any Credit Party shall contest the validity, enforceability, perfection or priority of the Guaranty, any Credit Document, or any Lien granted thereunder in writing or deny in writing
that it has any further liability, including with respect to future advances by the Lenders, under any Credit Document to which it is a party; or 
 (j) Invalidity of Credit Documents. Any other Credit Document shall fail to be in full force and effect or to give the Administrative Agent and/or the Lenders the security interests, liens, material rights,
material powers, priority and material privileges purported to be created thereby (except as such documents may be terminated or no longer in force and effect in accordance with the terms thereof, other than those indemnities and provisions which by
their terms shall survive) or any Lien shall, subject to Permitted Liens, fail to be a first priority, perfected Lien on a material portion of the Collateral; or 
 (k) Subordinated Debt. Any default (which is not waived or cured within the applicable period of grace) or event of default shall
occur under any Subordinated Debt or the subordination provisions contained therein shall cease to be in full force and effect or shall cease to give the Lenders the material rights, material powers and material privileges purported to be created
thereby; or 
 (l) Classification as Senior Debt. The Credit Party Obligations shall cease to be classified as
“Senior Indebtedness,” “Designated Senior Indebtedness” or any similar designation under any Subordinated Debt instrument. 
 Once a Default occurs under the Credit Documents, then such Default will continue to exist until it either is cured (to the extent specifically permitted) in accordance with the Credit Documents or is otherwise expressly waived by
Administrative Agent (with the approval of requisite Lenders (in their sole and absolute discretion) as determined in accordance with Section 9.1); and once an Event of Default occurs under the Credit Documents, then such Event of Default will
continue to exist until it is expressly waived by Administrative Agent with the approval of the requisite Lenders, as required hereunder (in their sole and absolute discretion) in Section 9.1. 
  

 96 

 Section 7.2 Acceleration; Remedies. 
 Upon the occurrence and during the continuance of an Event of Default, then, and in any such event, (a) if such event is a Bankruptcy Event of
Default, automatically the Commitments shall immediately terminate and the Loans (with accrued interest thereon), and all other amounts under the Credit Documents (including without limitation the maximum amount of all contingent liabilities under
Letters of Credit, which shall be cash collateralized) shall immediately become due and payable, and (b) if such event is any other Event of Default, any or all of the following actions may be taken: (i) with the written consent of the
Required Lenders, the Administrative Agent may, or upon the written request of the Required Lenders, the Administrative Agent shall, declare the Commitments to be terminated forthwith, whereupon the Commitments shall immediately terminate;
(ii) the Administrative Agent may, or upon the written request of the Required Lenders, the Administrative Agent shall, declare the Loans (with accrued interest thereon) and all other amounts owing under this Agreement and the Notes to be due
and payable forthwith and direct the Borrower to pay to the Administrative Agent cash collateral as security for the LOC Obligations for subsequent drawings under then outstanding Letters of Credit an amount equal to the maximum amount of which may
be drawn under Letters of Credit then outstanding, whereupon the same shall immediately become due and payable; and/or (iii) with the written consent of the Required Lenders, the Administrative Agent may, or upon the written request of the
Required Lenders, the Administrative Agent shall, exercise such other rights and remedies as provided under the Credit Documents and under applicable law. 
 ARTICLE VIII 
 THE ADMINISTRATIVE AGENT 
 Section 8.1 Appointment and Authority. 
 Each of the Lenders and the Issuing Lender hereby irrevocably appoints Wachovia to act on its behalf as the Administrative Agent hereunder and under the other Credit Documents and authorizes the Administrative Agent
to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this Article
(other than those provisions in Sections 8.9 and 8.11) are solely for the benefit of the Administrative Agent, the Lenders and the Issuing Lender, and neither the Borrower nor any other Credit Party shall have rights as a third party beneficiary of
any of such provisions. 
 Section 8.2 Nature of Duties. 
 The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Credit Document by or
through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such 

  

 97 

 
sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions
of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for
herein as well as activities as Administrative Agent. 
 Section 8.3 Exculpatory Provisions. 
 The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Credit Documents. Without
limiting the generality of the foregoing, the Administrative Agent: 
 (a) shall not be subject to any fiduciary or other
implied duties, regardless of whether a Default has occurred and is continuing; 
 (b) shall not have any duty to take any
discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Credit Documents that the Administrative Agent is required to exercise as directed in writing by the
Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Credit Documents), provided that the Administrative Agent shall not be required to take any action that, in its
opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Credit Document or applicable law; and 
 (c) shall not, except as expressly set forth herein and in the other Credit Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrower or any of
its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity. 
 The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the
Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 9.1 and 7.2) or (ii) in the absence of its own gross negligence or willful misconduct. The Administrative Agent shall be
deemed not to have knowledge of any Default unless and until notice describing such Default is given to the Administrative Agent by the Borrower, a Lender or the Issuing Lender. 
 The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation
made in or in connection with this Agreement or any other Credit Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or
observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Credit
Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Article IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative
Agent. 
  

 98 

 Section 8.4 Reliance by Administrative Agent. 
 The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent,
statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper
Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any
condition hereunder to the making of a Loan, or the issuance of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or the Issuing Lender, the Administrative Agent may presume that such condition is satisfactory
to such Lender or the Issuing Lender unless the Administrative Agent shall have received notice to the contrary from such Lender or the Issuing Lender prior to the making of such Loan or the issuance of such Letter of Credit. The Administrative
Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel,
accountants or experts. 
 Section 8.5 Notice of Default. 
 The Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default hereunder unless the
Administrative Agent has received written notice from a Lender or the Borrower referring to this Agreement, describing such Default or Event of Default and stating that such notice is a “notice of default”. In the event that the
Administrative Agent receives such a notice, the Administrative Agent shall give prompt notice thereof to the Lenders. The Administrative Agent shall take such action with respect to such Default or Event of Default as shall be reasonably directed
by the Required Lenders; provided, however, that unless and until the Administrative Agent shall have received such directions, the Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such
action, with respect to such Default or Event of Default as it shall deem advisable in the best interests of the Lenders except to the extent that this Agreement expressly requires that such action be taken, or not taken, only with the consent or
upon the authorization of the Required Lenders, or all of the Lenders, as the case may be. 
 Section 8.6 Non-Reliance on
Administrative Agent and Other Lenders. 
 Each Lender and the Issuing Lender expressly acknowledges that neither the Administrative
Agent nor any of its officers, directors, employees, agents, attorneys-in-fact or affiliates has made any representation or warranty to it and that no act by the Administrative Agent hereinafter taken, including any review of the affairs of any
Credit Party, shall be deemed to constitute any representation or warranty by the Administrative Agent to any Lender. Each Lender and the Issuing Lender acknowledges that it has, independently and without reliance 

  

 99 

 
upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate,
made its own credit analysis and decision to enter into this Agreement. Each Lender and the Issuing Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related
Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Credit Document or any related
agreement or any document furnished hereunder or thereunder. 
 Section 8.7 Indemnification. 
 The Lenders agree to indemnify the Administrative Agent, Issuing Lender and the Swingline Lender in its capacity hereunder and their Affiliates and their
respective officers, directors, agents and employees (to the extent not reimbursed by the Borrower and without limiting the obligation of the Borrower to do so), ratably according to their respective Revolving Commitment Percentages in effect on the
date on which indemnification is sought under this Section, from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind whatsoever which may at any time
(including, without limitation, at any time following the payment of the Credit Party Obligations) be imposed on, incurred by or asserted against any such indemnitee in any way relating to or arising out of any Credit Document or any documents
contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by any such indemnitee under or in connection with any of the foregoing; provided, however, that no
Lender shall be liable for the payment of any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements to the extent resulting from such indemnitee’s gross negligence or
willful misconduct, as determined by a court of competent jurisdiction. The agreements in this Section shall survive the termination of this Agreement and payment of the Notes, any Reimbursement Obligation and all other amounts payable hereunder.

 Section 8.8 Administrative Agent in Its Individual Capacity. 
 The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may
exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the
Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with
the Borrower or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders. 
  

 100 

 Section 8.9 Successor Administrative Agent. 
 The Administrative Agent may at any time give notice of its resignation to the Lenders, the Issuing Lender and the Borrower. Upon receipt of any such
notice of resignation, the Required Lenders shall have the right, in consultation with the Borrower, to appoint a successor, or an Affiliate of any such bank. If no such successor shall have been so appointed by the Required Lenders and shall have
accepted such appointment within thirty (30) days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may on behalf of the Lenders and the Issuing Lender, appoint a successor
Administrative Agent meeting the qualifications set forth above provided that if the Administrative Agent shall notify the Borrower and the Lenders that no qualifying Person has accepted such appointment, then such resignation shall nonetheless
become effective in accordance with such notice and (a) the retiring Administrative Agent shall be discharged from its duties and obligations hereunder and under the other Credit Documents solely in its capacity as Administrative Agent and not
as Lender (except that in the case of any Collateral held by the Administrative Agent on behalf of the Lenders or the Issuing Lender under any of the Credit Documents, the retiring Administrative Agent shall continue to hold such Collateral until
such time as a successor Administrative Agent is appointed) and (b) all payments, communications and determinations provided to be made by, to or through the Administrative Agent shall instead be made by or to each Lender and the Issuing Lender
directly, until such time as the Required Lenders appoint a successor Administrative Agent as provided for above in this paragraph. Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor shall succeed
to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Administrative Agent, and the retiring Administrative Agent shall be discharged from all of its duties and obligations hereunder or under the
other Credit Documents solely in its capacity as Administrative Agent and not as Lender (if not already discharged therefrom as provided above in this paragraph). The fees payable by the Borrower to a successor Administrative Agent shall be the same
as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After the retiring Administrative Agent’s resignation hereunder and under the other Credit Documents, the provisions of this Article and
Section 9.5 shall continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while the retiring
Administrative Agent was acting as Administrative Agent. 
 Section 8.10 Other Agents. 
 None of the Lenders or other Persons identified on the facing page or signature pages of this Agreement as a “syndication agent,”
“documentation agent,” “co–agent,” “joint book runner” or “joint lead arranger” shall have any right, power, obligation, liability, responsibility or duty under this Agreement other than, in the case of
such Lenders, those applicable to all Lenders as such. Without limiting the foregoing, none of the Lenders or other Persons so identified shall have or be deemed to have any fiduciary relationship with any Lender. Each Lender acknowledges that it
has not relied, and will not rely, on any of the Lenders or other Persons so identified in deciding to enter into this Agreement or in taking or not taking action hereunder. 
  

 101 

 Section 8.11 Collateral and Guaranty Matters. 
 (a) The Lenders irrevocably authorize and direct the Administrative Agent to, and the Administrative Agent shall: 
 (i) release any Lien on any Collateral granted to or held by the Administrative Agent under any Credit Document (i) upon termination
of the Revolving Commitments and payment in full of all Credit Party Obligations (other than contingent indemnification obligations) and the expiration or termination of all Letters of Credit, (ii) that is transferred or to be transferred as
part of or in connection with any sale or other disposition not prohibited under Section 6.4, (iii) consisting of property owned by any Subsidiary of the Borrower that ceases to be a Guarantor pursuant to a transaction permitted hereunder
or (iv) subject to Section 9.1, if approved, authorized or ratified in writing by the Required Lenders; 
 (ii)
subordinate any Lien on any Collateral granted to or held by the Administrative Agent under any Credit Document to the holder of any Lien on such Property that is permitted described under clause (c) of the definition of Permitted Lien and
permitted by Section 6.2; and 
 (iii) release any Guarantor from its obligations under the applicable Guaranty if such
Person ceases to be a Subsidiary as a result of a transaction permitted hereunder. 
 (b) In connection with a termination or
release pursuant to this Section, the Administrative Agent shall promptly execute and deliver to the applicable Credit Party, at the Borrower’s expense, all documents that the applicable Credit Party shall reasonably request to evidence such
termination or release. Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent’s authority to release or subordinate its interest in particular types or items of Collateral,
or to release any Guarantor from its obligations under the Guaranty pursuant to this Section. 
 ARTICLE IX 
 MISCELLANEOUS 
 Section 9.1
Amendments, Waivers and Release of Collateral. 
 Neither this Agreement nor any of the other Credit Documents, nor any terms
hereof or thereof may be amended, modified, extended, restated, replaced, or supplemented (by amendment, waiver, consent or otherwise) except in accordance with the provisions of this Section nor may Collateral be released except as specifically
provided herein or in the Security Documents or in accordance with the provisions of this Section. The Required Lenders may or, with the written consent of the Required Lenders, the Administrative Agent may, from time to 

  

 102 

 
time, (a) enter into with the Borrower written amendments, supplements or modifications hereto and to the other Credit Documents for the purpose of
adding any provisions to this Agreement or the other Credit Documents or changing in any manner the rights of the Lenders or of the Borrower hereunder or thereunder or (b) waive or consent to the departure from, on such terms and conditions as
the Required Lenders may specify in such instrument, any of the requirements of this Agreement or the other Credit Documents or any Default or Event of Default and its consequences; provided, however, that no such amendment,
supplement, modification, release, waiver or consent shall: 
 (i) reduce the amount or extend the scheduled date of maturity
of any Loan or Note or any installment thereon, or reduce the stated rate of any interest or fee payable hereunder (except in connection with a waiver of interest at the increased post-default rate set forth in Section 2.8 which shall be
determined by a vote of the Required Lenders) or extend the scheduled date of any payment thereof or increase the amount or extend the expiration date of any Lender’s Commitment, in each case without the written consent of each Lender directly
affected thereby; provided that, it is understood and agreed that no waiver, reduction or deferral of a mandatory prepayment required pursuant to Section 2.7(b)(ii), nor any amendment of Section 2.7(b)(ii) or the definitions of
Asset Disposition, shall constitute a reduction of the amount of, or an extension of the scheduled date of, the scheduled date of maturity of, or any installment of, any Loan or Revolving Note; or 
 (ii) amend, modify or waive any provision of this Section or reduce the percentage specified in the definition of Required Lenders,
without the written consent of all the Lenders; or 
 (iii) release the Borrower or all or substantially all of the Guarantors
from obligations under the Guaranty, without the written consent of all of the Lenders and Hedging Agreement Providers; or 
 (iv) except as set forth in Section 8.11, release all or substantially all of the Collateral without the written consent of all of the Lenders and Hedging Agreement Providers; or 
 (v) subordinate the Loans to any other Indebtedness without the written consent of all of the Lenders; or 
 (vi) permit a Letter of Credit to have an original expiry date more than twelve (12) months from the date of issuance without the
consent of each of the Revolving Lenders; provided, that the expiry date of any Letter of Credit may be extended in accordance with the terms of Section 2.3(a); or 
 (vii) permit the Borrower to assign or transfer any of its rights or obligations under this Agreement or other Credit Documents without
the written consent of all of the Lenders; or 
  

 103 

 (viii) amend, modify or waive any provision of the Credit Documents requiring consent,
approval or request of the Required Lenders or all Lenders without the written consent of the Required Lenders or all the Lenders as appropriate; or 
 (ix) amend, modify or waive the order in which Credit Party Obligations are paid or in a manner that would alter the pro rata sharing of payments by and among the Lenders in Section 2.11 without the written
consent of each Lender and each Hedging Agreement Provider directly affected thereby; or 
 (x) amend, modify or waive any
provision of Article VIII without the written consent of the then Administrative Agent; or 
 (xi) amend or modify the
definition of Credit Party Obligations to delete or exclude any obligation or liability described therein without the written consent of each Lender and each Hedging Agreement Provider directly affected thereby; or 
 (xii) amend the definitions of “Hedging Agreement,” “Secured Hedging Agreement,” or “Hedging Agreement
Provider” without the consent of any Hedging Agreement Provider that would be adversely affected thereby. 
 provided, further, that no
amendment, waiver or consent affecting the rights or duties of the Administrative Agent, the Issuing Lender or the Swingline Lender under any Credit Document shall in any event be effective, unless in writing and signed by the Administrative Agent,
the Issuing Lender and/or the Swingline Lender, as applicable, in addition to the Lenders required hereinabove to take such action. 
 Any
such waiver, any such amendment, supplement or modification and any such release shall apply equally to each of the Lenders and shall be binding upon the Borrower, the other Credit Parties, the Lenders, the Administrative Agent and all future
holders of the Notes. In the case of any waiver, the Borrower, the other Credit Parties, the Lenders and the Administrative Agent shall be restored to their former position and rights hereunder and under the outstanding Loans and Notes and other
Credit Documents, and any Default or Event of Default waived shall be deemed to be cured and not continuing; but no such waiver shall extend to any subsequent or other Default or Event of Default, or impair any right consequent thereon. 

Notwithstanding any of the foregoing to the contrary, the consent of the Borrower and the other Credit Parties shall not be required for any
amendment, modification or waiver of the provisions of Article VIII that is in no way adverse to the Borrower or any other Credit Party (other than the provisions of Sections 8.9 and 8.11, as to which any amendment, modification or waiver will
require the consent of the Borrower and the other Credit Parties). 
  

 104 

 Notwithstanding the fact that the consent of all the Lenders is required in certain circumstances as set
forth above, (a) each Lender is entitled to vote as such Lender sees fit on any bankruptcy reorganization plan that affects the Loans, and each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code supersedes
the unanimous consent provisions set forth herein and (b) the Required Lenders may consent to allow a Credit Party to use cash collateral in the context of a bankruptcy or insolvency proceeding. 
 For the avoidance of doubt and notwithstanding any provision to the contrary contained in this Section 9.1, this Agreement may be amended (or
amended and restated) with the written consent of the Credit Parties and the Administrative Agent in accordance with Section 2.2. 
 Section 9.2 Notices. 
 (a) Notices Generally. Except in the case of notices and other
communications expressly permitted to be given by telephone (and except as provided in paragraph (b) below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier
service, mailed by certified or registered mail or sent by telecopier as follows: 
  

	 	(i)	If to the Borrower or any other Credit Party: 

 Eclipsys
Corporation 
 Three Ravinia Drive 
 Atlanta, Georgia 30346 
 Attention: Chief Financial Officer 
 Telephone: 
 Fax: 
 With a copy to: 
 Eclipsys Corporation

 18201 Von Karman Avenue, Suite 120 
 Irvine, California 92612 
 Attention: General Counsel 
 Telephone: (949) 885-1022 
 Fax:
(949) 258-5320 
  

	 	(ii)	If to the Administrative Agent: 

 Wachovia Bank, National
Association, as Administrative Agent 
 201 South College Street 
 Charlotte, NC 28288-0680 
 Attn: Syndication
Agency Services 
 Telephone: (704) 715-9297 
 Fax: (704) 383-0288 
  

 105 

 With a copy to: 
 Wachovia Bank, National Association, as Administrative Agent 
 980 N. Federal Hwy, Suite 100 
 Boca Raton, FL 33432 
 Mail Code: FL 7322

 Attn: Alina Cannon 
 Telephone: (561) 393-3470 
 Fax: (561) 393-9867 
 (iii) if to a Lender, to it at its address (or telecopier number) set forth in its Administrative Questionnaire. 
 Notices sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when
received; notices sent by telecopier shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next business day for
the recipient). Notices delivered through electronic communications to the extent provided in paragraph (b) below, shall be effective as provided in said paragraph (b). 
 (b) Electronic Communications. Notices and other communications to the Lenders and the Issuing Lender hereunder may be delivered or
furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing shall not apply to notices to any Lender or the Issuing Lender
pursuant to Article II if such Lender or the Issuing Lender, as applicable, has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication. The Administrative Agent or the Borrower may,
in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, provided that approval of such procedures may be limited to particular notices or
communications. 
 Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an
e-mail address shall be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement),
provided that if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication shall be deemed to have been sent at the opening of business on the next business day for the
recipient, and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of
notification that such notice or communication is available and identifying the website address therefor. 
  

 106 

 (c) Change of Address, Etc. Any party hereto may change its address or telecopier
number for notices and other communications hereunder by notice to the other parties hereto. 
 Section 9.3 No Waiver; Cumulative
Remedies. 
 No failure to exercise and no delay in exercising, on the part of the Administrative Agent or any Lender, any right,
remedy, power or privilege hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right,
remedy, power or privilege. The rights, remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law. 
 Section 9.4 Survival of Representations and Warranties. 
 All representations and warranties made hereunder and in any document, certificate or statement delivered pursuant hereto or in connection herewith shall survive the execution and delivery of this Agreement and the
Notes and the making of the Loans; provided that all such representations and warranties shall terminate on the date upon which the Commitments have been terminated and all amounts owing hereunder (other than contingent indemnity obligations)
and under any Notes have been paid in full. 
 Section 9.5 Payment of Expenses and Taxes; Indemnity. 
 (a) Costs and Expenses. The Borrower shall pay (i) all reasonable out-of-pocket expenses incurred by the Administrative Agent
and its Affiliates (including the reasonable fees, charges and disbursements of counsel for the Administrative Agent, limited to one counsel), and shall pay all reasonable fees and time charges and disbursements for attorneys who may be employees of
the Administrative Agent, in connection with the syndication of the credit facilities provided for herein, the preparation, negotiation, execution, delivery and administration of this Agreement and the other Credit Documents or any amendments,
modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated), (ii) all reasonable out-of-pocket expenses incurred by the Issuing Lender and the Swingline
Lender in connection with the issuance, amendment, renewal or extension of any Letter of Credit or Swingline Loan or any demand for payment thereunder and (iii) all reasonable out-of-pocket expenses incurred by the Administrative Agent, any
Lender, the Issuing Lender or the Swingline Lender (including the fees, charges and disbursements of any counsel for the Administrative Agent, any Lender or the Issuing Lender), and including all reasonable fees and time charges for attorneys who
may be employees of the Administrative Agent, any Lender, the Issuing Lender or the Swingline Lender, in connection with the enforcement of its rights (A) in connection with this Agreement and the other Credit Documents, including its rights
under this Section, or (B) in connection with the Loans made or Letters of Credit issued hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans or Letters of
Credit. 
  

 107 

 (b) Indemnification by the Borrower. The Borrower shall indemnify the
Administrative Agent (and any sub-agent thereof), each Lender, the Issuing Lender and the Swingline Lender, and each Related Party of any of the foregoing Persons (each such Person being called an “Indemnitee”) against, and hold
each Indemnitee harmless from, any and all losses, claims, penalties, damages, liabilities and related expenses (including the reasonable fees, charges and disbursements of any counsel for any Indemnitee), and shall indemnify and hold harmless each
Indemnitee from all reasonable fees and time charges and disbursements for attorneys who may be employees of any Indemnitee, incurred by any Indemnitee or asserted against any Indemnitee by any third party or by the Borrower or any other Credit
Party arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Credit Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their
respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, (ii) any Loan or Letter of Credit or the use or proposed use of the proceeds therefrom (including any refusal by the Issuing
Lender to honor a demand for payment under a Letter of Credit if the documents presented in connection with such demand do not strictly comply with the terms of such Letter of Credit), (iii) any actual or alleged presence or release of
Materials of Environmental Concern on or from any property owned or operated by the Borrower or any of its Subsidiaries, or any liability under Environmental Law related in any way to the Borrower or any of its Subsidiaries, or (iv) any actual
or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower or any other Credit Party, and regardless of
whether any Indemnitee is a party thereto, provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (A) are determined by a court of
competent jurisdiction to have resulted from the willful misconduct, bad faith or gross negligence of such Indemnitee or (B) are determined by a court of competent jurisdiction to have resulted from a material breach of the obligations of such
Indemnitee hereunder or (C) arise out of, or in connection with, any proceeding that does not involve an act or omission by the Credit Parties or any of their Subsidiaries or Affiliates and that is brought by an Indemnitee against any other
Indemnitee, other than claims against any Indemnitee in its capacity or in fulfilling its role as Administrative Agent, Issuing Lender, Swingline Lender or any other similar role hereunder. To the extent that any prepayment made by the Borrower to
or for an Indemnitee is determined by a court of competent jurisdiction to have been improper or not required by reason of the foregoing exceptions to the Borrower’s indemnity obligations, such Indemnitee shall promptly refund such payment to
the Borrower. In matters that involve claims against the Borrower that also name an Indemnitee, such Indemnitee will instruct its counsel, if any, to cooperate with the Borrower and its counsel in an effort to work efficiently and minimize overall
legal expense, to the extent possible without compromising any legal position either party may have. 
  

 108 

 (c) Reimbursement by Lenders. To the extent that the Borrower for any reason fails
to indefeasibly pay any amount required under paragraph (a) or (b) of this Section to be paid by it to the Administrative Agent (or any sub-agent thereof), the Issuing Lender, the Swingline Lender or any Related Party of any of the
foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent), the Issuing Lender, the Swingline Lender or such Related Party, as the case may be, such Lender’s Revolving Commitment Percentage (determined as
of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount, provided that the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was
incurred by or asserted against the Administrative Agent (or any such sub-agent), the Issuing Lender or the Swingline Lender in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent (or any
such sub-agent), the Issuing Lender or the Swingline Lender in connection with such capacity. The obligations of the Lenders under this paragraph (c) are subject to the provisions of Section 2.12. 
 (d) Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable law, the Borrower shall not assert, and
hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any
other Credit Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or Letter of Credit or the use of the proceeds thereof. No Indemnitee referred to in paragraph (b) above shall
(in the absence of gross negligence or willful misconduct by such Indemnitee) be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or
other information transmission systems in connection with this Agreement or the other Credit Documents or the transactions contemplated hereby or thereby. 
 (e) Payments. All amounts due under this Section shall be payable promptly/not later than five (5) days after written demand therefor. 
 Section 9.6 Successors and Assigns; Participations. 
 (a) Successors and Assigns Generally. The provisions of this Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and assigns permitted hereby, except that neither the Borrower nor any other Credit Party may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of
the Administrative Agent and each Lender, and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of paragraph (b) of this Section, (ii) by
way of participation in accordance with the provisions of paragraph (d) of this Section or (iii) by way of pledge or assignment of a security interest subject to the restrictions of paragraph (f) of this Section (and any other
attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns
permitted hereby, Participants to the extent provided in paragraph (d) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right,
remedy or claim under or by reason of this Agreement. 
  

 109 

 (b) Assignments by Lenders. Any Lender may at any time assign to one or more
Eligible Assignees all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans at the time owing to it); provided that any such assignment shall be subject to the following
conditions: 
 (i) Minimum Amounts. 
 (A) in the case of an assignment of the entire remaining amount of the assigning Lender’s Commitment and the Loans at the time owing
to it or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and 
 (B) in any case not described in paragraph (b)(i)(A) of this Section, the aggregate amount of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the applicable Commitment is not then
in effect, the principal outstanding balance of the Loans of the assigning Lender subject to each such assignment (determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or,
if “Trade Date” is specified in the Assignment and Assumption, as of the Trade Date) shall not be less than $5,000,000, in the case of any assignment in respect of a revolving facility, or $1,000,000, in the case of any assignment in
respect of a term facility (provided, however, that simultaneous assignments shall be aggregated in respect of a Lender and its Approved Funds), unless each of the Administrative Agent and, so long as no Event of Default has occurred and is
continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed). 
 (ii)
Proportionate Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement with respect to the Loan or the Commitment assigned, except
that this clause (ii) shall not prohibit any Lender from assigning all or a portion of its rights and obligations among separate Tranches on a non-pro rata basis. 
 (iii) Assignment and Assumption. The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment
and Assumption, together with a processing and recordation fee of $3,500 (provided that only one (1) such fee shall be payable in respect of simultaneous assignments by a Lender and its Approved Funds), and the assignee, if it is not a Lender,
shall deliver to the Administrative Agent and the Borrower an Administrative Questionnaire. 
  

 110 

 (iv) No Assignment to Borrower. No such assignment shall be made to the Borrower
or any of the Borrower’s Affiliates or Subsidiaries. 
 (v) No Assignment to Natural Persons. No such assignment
shall be made to a natural person. 
 Subject to acceptance and recording thereof by the Administrative Agent pursuant to
paragraph (c) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and
Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement
(and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of
Sections 2.14 and 9.5 with respect to facts and circumstances occurring prior to the effective date of such assignment. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this
paragraph shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph (d) of this Section. 
 (c) Register. The Administrative Agent, acting solely for this purpose as an agent of the Borrower, shall maintain at one of its
offices in Charlotte, North Carolina a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts of the Loans owing to, each
Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders may treat each Person whose
name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Borrower and any Lender, at any
reasonable time and from time to time upon reasonable prior notice. 
 (d) Participations. Any Lender may at any time,
without the consent of, or notice to, the Borrower or the Administrative Agent, sell participations to any Person (other than a natural person or the Borrower or any of the Borrower’s Affiliates or Subsidiaries) (each, a
“Participant”) in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the Loans owing to it); provided that (i) such Lender’s
obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent and the Lenders,
Issuing Lender and Swingline Lender shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement. Each Lender that sells such a participation shall maintain a register
on which it enters the name and address of each of its 

  

 111 

 
Participants and the principal amount of each such Participant’s participation interest in the Loans (or other rights or obligations) held by it (the
“Participant Register”). The entries in the Participant Register shall be conclusive, absent manifest error, and such Lender shall treat each person whose name is recorded in its Participant Register as the owner of such
participation interest as the owner thereof for all purposes notwithstanding any notice to the contrary. In maintaining a Participant Register, a Lender shall be acting as the agent of the Borrower solely for purposes of applicable United States
federal income tax law and Treasury regulations promulgated thereunder; provided, however, that such Lender thereby undertakes no duty, responsibility or obligation to the Borrower (without limitation, in no event shall such Lender be a
fiduciary of the Borrower for any purpose, except that such Lender shall maintain the Participant Register and, upon request by the Borrower, such Lender shall show the Participant Register to the Borrower). 
 Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole
right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant,
agree to any amendment, modification or waiver that affects such Participant except to the extent that such amendment, modification or waiver would (i) extend the scheduled maturity of any Loan or Note or any installment thereon in which such
Participant is participating (it is understood and agreed that no waiver, reduction or deferral of a mandatory prepayment required pursuant to Section 2.7(b), nor any amendment of Section 2.7(b) or the definitions of Asset Disposition,
shall constitute a reduction of the amount of, or an extension of the scheduled date of, any principal installment of any Loan or Note), or reduce the stated rate or extend the time of payment of interest or fees thereon (except in connection with a
waiver of interest at the increased post-default rate) or reduce the principal amount thereof, or increase the amount of the Participant’s participation of the amount thereof then in effect (it being understood that a waiver of any Default or
Event of Default shall not constitute a change in the terms of such participation, and that an increase in any Commitment or Loan shall be permitted without consent of a Participant if such Participant’s participation is not increased as a
result thereof), (ii) release the Borrower or all or substantially all of the Guarantors from its or their obligations under the Guaranty, (iii) release all or substantially all of the Collateral, or (iv) consent to the assignment or
transfer by a Borrower of any of its rights and obligations under this Credit Agreement. Subject to paragraph (e) of this Section, the Borrower agrees that each Participant shall be entitled to the benefits of Sections 2.14 and 2.16 to the same
extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b) of this Section. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 9.7 as though it were a
Lender, provided such Participant agrees to be subject to Section 2.11 as though it were a Lender. 
 (e) Limitations
upon Participant Rights. A Participant shall not be entitled to receive any greater payment under Sections 2.14 and 2.16 than the applicable Lender would have been entitled to receive with respect to the participation sold to such 

  

 112 

 
Participant, unless the sale of the participation to such Participant is made with the Borrower’s prior written consent. A Participant that would be a
Foreign Lender if it were a Lender shall not be entitled to the benefits of Section 2.16 unless the Borrower is notified of the participation sold to such Participant and such Participant agrees, for the benefit of the Borrower, to comply with
Section 2.16 as though it were a Lender. 
 (f) Certain Pledges. Any Lender may at any time pledge or assign a
security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment
shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. 
 Section 9.7 Right of Set-off; Sharing of Payments. 
 (a) If an Event of Default shall have
occurred and be continuing, each Lender, the Issuing Lender, and each of their respective Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable law, to set off and apply any and all deposits
(general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender, the Issuing Lender or any such Affiliate to or for the credit or the
account of the Borrower or any other Credit Party against any and all of the obligations of the Borrower or such Credit Party now or hereafter existing under this Agreement or any other Credit Document to such Lender or the Issuing Lender,
irrespective of whether or not such Lender or the Issuing Lender shall have made any demand under this Agreement or any other Credit Document and although such obligations of the Borrower or such Credit Party may be unmatured or are owed to a branch
or office of such Lender or the Issuing Lender different from the branch or office holding such deposit or obligated on such indebtedness. The rights of each Lender, the Issuing Lender and their respective Affiliates under this Section are in
addition to other rights and remedies (including other rights of setoff) that such Lender, the Issuing Lender or their respective Affiliates may have. Each Lender and the Issuing Lender agrees to notify the Borrower and the Administrative Agent
promptly after any such setoff and application, provided that the failure to give such notice shall not affect the validity of such setoff and application. 
 (b) If any Lender shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or
interest on any of its Loans or other obligations hereunder resulting in such Lender’s receiving payment of a proportion of the aggregate amount of its Loans and accrued interest thereon or other such obligations greater than its pro
rata share thereof as provided herein, then the Lender receiving such greater proportion shall (i) notify the Administrative Agent of such fact, and (ii) purchase (for cash at face value) participations in the Loans and such other
obligations of the other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on
their respective Loans and other amounts owing them, provided that: 
 (i) if any such participations are purchased and
all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price restored to the extent of such recovery, without interest; and 
  

 113 

 (ii) the provisions of this paragraph shall not be construed to apply to (A) any
payment made by the Borrower pursuant to and in accordance with the express terms of this Agreement or (B) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Loans or participations
in Letters of Credit to any assignee or participant, other than to the Borrower or any Subsidiary thereof (as to which the provisions of this paragraph shall apply). 
 (c) Each Credit Party consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender
acquiring a participation pursuant to the foregoing arrangements may exercise against each Credit Party rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of each Credit Party in
the amount of such participation. 
 Section 9.8 Table of Contents and Section Headings. 
 The table of contents and the Section and subsection headings herein are intended for convenience only and shall be ignored in construing this Agreement.

 Section 9.9 Counterparts; Integration; Effectiveness; Electronic Execution. 
 (a) Counterparts; Integration; Effectiveness. This Agreement may be executed in counterparts (and by different parties hereto in
different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement and the other Credit Documents, and any separate letter agreements with respect to fees
payable to the Administrative Agent, constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof.
Except as provided in Section 4.1, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof that, when taken together, bear the
signatures of each of the other parties hereto. Delivery of an executed counterpart of a signature page of this Agreement by telecopy or email shall be effective as delivery of a manually executed counterpart of this Agreement. 
 (b) Electronic Execution of Assignments. The words “execution,” “signed,” “signature,” and words of
like import in any Assignment and Assumption shall be deemed to include electronic signatures or the keeping of records in electronic form, each 

  

 114 

 
of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as
the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws
based on the Uniform Electronic Transactions Act. 
 Section 9.10 Severability. 
 Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of
such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

 Section 9.11 Integration. 
 This Agreement and the other Credit Documents represent the agreement of the Borrower, the other Credit Parties, the Administrative Agent and the Lenders with respect to the subject matter hereof, and there are no
promises, undertakings, representations or warranties by the Administrative Agent, the Borrower, the other Credit Parties, or any Lender relative to the subject matter hereof not expressly set forth or referred to herein or therein. 
 Section 9.12 Governing Law. 
 This Credit Agreement and, unless otherwise specified therein, each other Credit Document and the rights and obligations of the parties under this Credit Agreement and such other Credit Document shall be governed by, and construed and
interpreted in accordance with, the law of the State of New York without regard to conflict of laws principles thereof (other than Sections 5-1401 and 5-1402 of The New York General Obligations Law). 
 Section 9.13 Consent to Jurisdiction; Service of Process and Venue. 
 (a) Consent to Jurisdiction. The Borrower and each other Credit Party irrevocably and unconditionally submits, for itself and its
property, to the nonexclusive jurisdiction of the courts of the State of New York sitting in New York County and of the United States District Court of the Southern District of New York, and any appellate court from any thereof, in any action or
proceeding arising out of or relating to this Agreement or any other Credit Document, or for recognition or enforcement of any judgment, and each of the parties hereto irrevocably and unconditionally agrees that all claims in respect of any such
action or proceeding may be heard and determined in such New York sitting State court or, to the fullest extent permitted by applicable law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or
proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement or in any other Credit Document shall affect any right that the Administrative Agent,
any 

  

 115 

 
Lender or the Issuing Lender may otherwise have to bring any action or proceeding relating to this Agreement or any other Credit Document against the
Borrower or any other Credit Party or its properties in the courts of any jurisdiction. 
 (b) Service of Process. Each
party hereto irrevocably consents to service of process in the manner provided for notices in Section 9.2. Nothing in this Agreement will affect the right of any party hereto to serve process in any other manner permitted by applicable law.

 (c) Venue. The Borrower and each other Credit Party irrevocably and unconditionally waives, to the fullest extent
permitted by applicable law, any objection that it may now or hereafter have to the laying of venue of any action or proceeding arising out of or relating to this Agreement or any other Credit Document in any court referred to in paragraph (a)
of this Section. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 
 Section 9.14 Confidentiality. 
 Each of the Administrative Agent, the Lenders and the Issuing Lender agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its
Affiliates’ respective partners, directors, officers, employees, agents, advisors and other representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information
and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any self-regulatory authority, such as the National Association of Insurance
Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder, under any other
Credit Document or Secured Hedging Agreement or any action or proceeding relating to this Agreement, any other Credit Document or Secured Hedging Agreement or the enforcement of rights hereunder or thereunder, (f) subject to an agreement
containing provisions substantially the same as those of this Section, to any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement, (g) (i) any actual or
prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Borrower and its obligations, (ii) an investor or prospective investor in securities issued by an Approved Fund that also agrees that Information
shall be used solely for the purpose of evaluating an investment in such securities issued by the Approved Fund, (iii) a trustee, collateral manager, servicer, backup servicer, noteholder or secured party in connection with the administration,
servicing and reporting on the assets serving as collateral for securities issued by an Approved Fund, or (iv) a nationally recognized rating agency that requires access to information regarding the Credit Parties, the Loans and Credit
Documents in connection with ratings issued in respect of securities issued by an Approved Fund (in each case, it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such information and
instructed to keep such information confidential), (h) with the consent of the Borrower or (i) to the extent such Information (x) becomes publicly 

  

 116 

 
available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any Lender, the Issuing Lender or any
of their respective Affiliates on a nonconfidential basis from a source other than the Borrower. Further, the foregoing notwithstanding, the Credit Parties agree that the Administrative Agent, any Lender or any Affiliate of the Administrative Agent
or such Lender may use any Credit Party’s name or logo in connection with reasonable and customary advertising, marketing or other similar purposes. 
 For purposes of this Section, “Information” means all information received from the Borrower of any of its Subsidiaries relating to the Borrower or any of its Subsidiaries or any of their respective
businesses, other than any such information that is available to the Administrative Agent, any Lender or the Issuing Lender on a nonconfidential basis prior to disclosure by the Borrower or any of its Subsidiaries. Any Person required to maintain
the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person
would accord to its own confidential information. 
 Section 9.15 Acknowledgments. 
 The Borrower and the other Credit Parties each hereby acknowledges that: 
 (a) it has been advised by counsel in the negotiation, execution and delivery of each Credit Document; 
 (b) neither the Administrative Agent nor any Lender has any fiduciary relationship with or duty to the Borrower or any other Credit Party
arising out of or in connection with this Agreement and the relationship between the Administrative Agent and the Lenders, on one hand, and the Borrower and the other Credit Parties, on the other hand, in connection herewith is solely that of debtor
and creditor; and 
 (c) no joint venture exists among the Lenders or among the Borrower or the other Credit Parties and the
Lenders. 
 Section 9.16 Waivers of Jury Trial. 
 EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL
PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER CREDIT DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO
(A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES
THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER CREDIT DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 
  

 117 

 Section 9.17 Patriot Act Notice. 
 Each Lender and the Administrative Agent (for itself and not on behalf of any other party) hereby notifies the Borrower that, pursuant to the requirements
of the Patriot Act, it is required to obtain, verify and record information that identifies the Borrower and the other Credit Parties, which information includes the name and address of the Borrower and the other Credit Parties and other information
that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrower and the other Credit Parties in accordance with the Patriot Act. 
 Section 9.18 Resolution of Drafting Ambiguities. 
 Each Credit Party acknowledges and
agrees that it was represented by counsel in connection with the execution and delivery of this Agreement and the other Credit Documents to which it is a party, that it and its counsel reviewed and participated in the preparation and negotiation
hereof and thereof and that any rule of construction to the effect that ambiguities are to be resolved against the drafting party shall not be employed in the interpretation hereof or thereof. 
 Section 9.19 Continuing Agreement. 
 This Credit Agreement shall be a continuing agreement and shall remain in full force and effect until all Loans, LOC Obligations, interest, fees and other Credit Party Obligations (other than those obligations that
expressly survive the termination of this Credit Agreement) have been paid in full and all Commitments and Letters of Credit have been terminated. Upon termination, the Credit Parties shall have no further obligations (other than those obligations
that expressly survive the termination of this Credit Agreement) under the Credit Documents and the Administrative Agent shall, at the request and expense of the Borrower, deliver all the Collateral in its possession to the Borrower and release all
Liens on the Collateral and sign, deliver and file all documents reasonably requested by the Borrower in connection with such release; provided that should any payment, in whole or in part, of the Credit Party Obligations be rescinded or
otherwise required to be restored or returned by the Administrative Agent or any Lender, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, then to the extent permitted by applicable law, the Credit Documents shall
automatically be reinstated and all Liens of the Administrative Agent shall reattach to the Collateral and all amounts required to be restored or returned and all costs and expenses incurred by the Administrative Agent or any Lender in connection
therewith shall be deemed included as part of the Credit Party Obligations. 
 Section 9.20 Lender Consent. 
 Each Lender executing this Credit Agreement (a) approves the Credit Agreement and acknowledges and agrees that all of the conditions set forth in
Section 4.1 have been satisfied, (b) authorizes and appoints the Administrative Agent as its agent in accordance with the terms of Article VIII, (c) is a Lender hereunder and therefore shall have all the rights and obligations of a
Lender under this Agreement and (d) has consented to, approved or accepted or is satisfied with, each document or other matter required under Section 4.1 to be consented to or approved by or be acceptable or satisfactory to a Lender.

  

 118 

 ARTICLE X 
 GUARANTY 
 Section 10.1 The Guaranty. 
 In order to induce the Lenders to enter into this Agreement and any Hedging Agreement Provider to enter into any Secured Hedging Agreement and to extend
credit hereunder and thereunder and in recognition of the direct benefits to be received by the Guarantors from the Extensions of Credit hereunder and any Secured Hedging Agreement, each of the Guarantors hereby agrees with the Administrative Agent,
the Lenders and the Hedging Agreement Providers as follows: each Guarantor hereby unconditionally and irrevocably jointly and severally guarantees as primary obligor and not merely as surety the full and prompt payment when due, whether upon
maturity, by acceleration or otherwise, of any and all Credit Party Obligations. If any or all of the indebtedness becomes due and payable hereunder or under any Secured Hedging Agreement, each Guarantor unconditionally promises to pay such
indebtedness to the Administrative Agent, the Lenders, the Hedging Agreement Providers, or their respective order, on demand, together with any and all reasonable expenses which may be incurred by the Administrative Agent or the Lenders in
collecting any of the Credit Party Obligations. The Guaranty set forth in this Article X is a guaranty of timely payment and not of collection. The word “indebtedness” is used in this Article X in its most
comprehensive sense and includes any and all advances, debts, obligations and liabilities of the Borrower, including specifically all Credit Party Obligations, arising in connection with this Agreement, the other Credit Documents or any Secured
Hedging Agreement, in each case, heretofore, now, or hereafter made, incurred or created, whether voluntarily or involuntarily, absolute or contingent, liquidated or unliquidated, determined or undetermined, whether or not such indebtedness is from
time to time reduced, or extinguished and thereafter increased or incurred, whether the Borrower may be liable individually or jointly with others, whether or not recovery upon such indebtedness may be or hereafter become barred by any statute of
limitations, and whether or not such indebtedness may be or hereafter become otherwise unenforceable. 
 Notwithstanding any provision to the
contrary contained herein or in any other of the Credit Documents, to the extent the obligations of a Guarantor shall be adjudicated to be invalid or unenforceable for any reason (including, without limitation, because of any applicable state or
federal law relating to fraudulent conveyances or transfers) then the obligations of each such Guarantor hereunder shall be limited to the maximum amount that is permissible under applicable law (whether federal or state and including, without
limitation, the Bankruptcy Code). 
  

 119 

 Section 10.2 Bankruptcy. 
 Additionally, each of the Guarantors unconditionally and irrevocably guarantees jointly and severally the payment of any and all Credit Party Obligations
of the Borrower to the Lenders and any Hedging Agreement Provider whether or not due or payable by the Borrower upon the occurrence of any Bankruptcy Event and unconditionally promises to pay such Credit Party Obligations to the Administrative Agent
for the account of the Lenders and to any such Hedging Agreement Provider, or order, on demand, in lawful money of the United States. Each of the Guarantors further agrees that to the extent that the Borrower or a Guarantor shall make a payment or a
transfer of an interest in any property to the Administrative Agent, any Lender or any Hedging Agreement Provider, which payment or transfer or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, or otherwise is
avoided, and/or required to be repaid to the Borrower or a Guarantor, the estate of the Borrower or a Guarantor, a trustee, receiver or any other party under any bankruptcy law, state or federal law, common law or equitable cause, then to the extent
of such avoidance or repayment, the obligation or part thereof intended to be satisfied shall be revived and continued in full force and effect as if said payment had not been made. 
 Section 10.3 Nature of Liability. 
 The liability of each Guarantor hereunder is exclusive and independent of any security for or other guaranty of the Credit Party Obligations of the Borrower whether executed by any such Guarantor, any other guarantor or by any other party,
and no Guarantor’s liability hereunder shall be affected or impaired by (a) any direction as to application of payment by the Borrower or by any other party, or (b) any other continuing or other guaranty, undertaking or maximum
liability of a guarantor or of any other party as to the Credit Party Obligations of the Borrower, or (c) any reduction of any such other guaranty or undertaking, or (d) any dissolution, termination or increase, decrease or change in
personnel by the Borrower, or (e) any payment made to the Administrative Agent, the Lenders or any Hedging Agreement Provider on the Credit Party Obligations which the Administrative Agent, such Lenders or such Hedging Agreement Provider repay
the Borrower pursuant to court order in any bankruptcy, reorganization, arrangement, moratorium or other debtor relief proceeding, and each of the Guarantors waives to the extent permitted by law any right to the deferral or modification of its
obligations hereunder by reason of any such proceeding. 
 Section 10.4 Independent Obligation. 
 The obligations of each Guarantor hereunder are independent of the obligations of any other Guarantor or the Borrower, and a separate action or actions
may be brought and prosecuted against each Guarantor whether or not action is brought against any other Guarantor or the Borrower and whether or not any other Guarantor or the Borrower is joined in any such action or actions. 
 Section 10.5 Authorization. 
 Each of the Guarantors authorizes the Administrative Agent, each Lender and each Hedging Agreement Provider without notice or demand (except as shall be required by applicable law and cannot be waived), and without affecting or impairing
its liability hereunder, 

  

 120 

 
from time to time to (a) renew, compromise, extend, increase, accelerate or otherwise change the time for payment of, or otherwise change the terms of
the Credit Party Obligations or any part thereof in accordance with this Agreement and any Secured Hedging Agreement, as applicable, including any increase or decrease of the rate of interest thereon, (b) take and hold security from any
Guarantor or any other party for the payment of this Guaranty or the Credit Party Obligations and exchange, enforce waive and release any such security, (c) apply such security and direct the order or manner of sale thereof as the
Administrative Agent and the Lenders in their discretion may determine, (d) release or substitute any one or more endorsers, Guarantors, the Borrower or other obligors and (e) to the extent otherwise permitted herein, release or substitute
any Collateral. 
 Section 10.6 Reliance. 
 It is not necessary for the Administrative Agent, the Lenders or any Hedging Agreement Provider to inquire into the capacity or powers of the Borrower or the officers, directors, members, partners or agents acting or
purporting to act on its behalf, and any Credit Party Obligations made or created in reliance upon the professed exercise of such powers shall be guaranteed hereunder. 
 Section 10.7 Waiver. 
 (a) Each of the Guarantors waives any right (except
as shall be required by applicable law and cannot be waived) to require the Administrative Agent, any Lender or any Hedging Agreement Provider to (i) proceed against the Borrower, any other guarantor or any other party, (ii) proceed
against or exhaust any security held from the Borrower, any other guarantor or any other party, or (iii) pursue any other remedy in the Administrative Agent’s, any Lender’s or any Hedging Agreement Provider’s power whatsoever.
Each of the Guarantors waives any defense based on or arising out of any defense of the Borrower, any other guarantor or any other party other than payment in full of the Credit Party Obligations (other than contingent indemnity obligations),
including without limitation any defense based on or arising out of the disability of the Borrower, any other guarantor or any other party, or the unenforceability of the Credit Party Obligations or any part thereof from any cause, or the cessation
from any cause of the liability of the Borrower other than payment in full of the Credit Party Obligations. The Administrative Agent may, at its election, foreclose on any security held by the Administrative Agent or a Lender by one or more judicial
or nonjudicial sales, whether or not every aspect of any such sale is commercially reasonable (to the extent such sale is permitted by applicable law), or exercise any other right or remedy the Administrative Agent or any Lender may have against the
Borrower or any other party, or any security, without affecting or impairing in any way the liability of any Guarantor hereunder except to the extent the Credit Party Obligations have been paid in full and the Commitments have been terminated. Each
of the Guarantors waives any defense arising out of any such election by the Administrative Agent or any of the Lenders, even though such election operates to impair or extinguish any right of reimbursement or subrogation or other right or remedy of
the Guarantors against the Borrower or any other party or any security. 
  

 121 

 (b) Each of the Guarantors waives all presentments, demands for performance, protests and
notices, including without limitation notices of nonperformance, notice of protest, notices of dishonor, notices of acceptance of this Guaranty, and notices of the existence, creation or incurring of new or additional Credit Party Obligations. Each
Guarantor assumes all responsibility for being and keeping itself informed of the Borrower’s financial condition and assets, and of all other circumstances bearing upon the risk of nonpayment of the Credit Party Obligations and the nature,
scope and extent of the risks which such Guarantor assumes and incurs hereunder, and agrees that neither the Administrative Agent nor any Lender shall have any duty to advise such Guarantor of information known to it regarding such circumstances or
risks. 
 (c) Each of the Guarantors hereby agrees it will not exercise any rights of subrogation which it may at any time
otherwise have as a result of this Guaranty (whether contractual, under Section 509 of the U.S. Bankruptcy Code, or otherwise) to the claims of the Lenders or any Hedging Agreement Provider against the Borrower or any other guarantor of the
Credit Party Obligations of the Borrower owing to the Lenders or such Hedging Agreement Provider (collectively, the “Other Parties”) and all contractual, statutory or common law rights of reimbursement, contribution or indemnity
from any Other Party which it may at any time otherwise have as a result of this Guaranty until such time as the Credit Party Obligations (other than contingent indemnity obligations) shall have been paid in full and the Commitments have been
terminated. Each of the Guarantors hereby further agrees not to exercise any right to enforce any other remedy which the Administrative Agent, the Lenders or any Hedging Agreement Provider now have or may hereafter have against any Other Party, any
endorser or any other guarantor of all or any part of the Credit Party Obligations of the Borrower and any benefit of, and any right to participate in, any security or collateral given to or for the benefit of the Lenders and/or the Hedging
Agreement Providers to secure payment of the Credit Party Obligations of the Borrower until such time as the Credit Party Obligations (other than contingent indemnity obligations) shall have been paid in full and the Commitments have been
terminated. 
 Section 10.8 Limitation on Enforcement. 
 The Lenders and the Hedging Agreement Providers agree that this Guaranty may be enforced only by the action of the Administrative Agent acting upon the
instructions of the Required Lenders or such Hedging Agreement Provider (only with respect to obligations under the applicable Secured Hedging Agreement) and that no Lender or Hedging Agreement Provider shall have any right individually to seek to
enforce or to enforce this Guaranty, it being understood and agreed that such rights and remedies may be exercised by the Administrative Agent for the benefit of the Lenders under the terms of this Agreement and for the benefit of any Hedging
Agreement Provider under any Secured Hedging Agreement. The Lenders and the Hedging Agreement Providers further agree that this Guaranty may not be enforced against any director, officer, employee or stockholder of the Guarantors. 
  

 122 

 Section 10.9 Confirmation of Payment. 
 The Administrative Agent and the Lenders will, upon request after payment of the Credit Party Obligations which are the subject of this Guaranty and
termination of the Commitments relating thereto, confirm to the Borrower, the Guarantors or any other Person that such indebtedness and obligations have been paid and the Commitments relating thereto terminated, subject to the provisions of
Section 10.2. 
 [Signature Pages Follow] 
  

 123 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by
its proper and duly authorized officers as of the day and year first above written. 
  

							
	BORROWER:	 		 	 ECLIPSYS CORPORATION,
 a Delaware
corporation

				
		 		 	By:	 	/s/ Robert J. Colletti
		 		 	Name:	 	Robert J. Colletti
		 		 	Title:	 	SVP and Chief Financial Officer
			
	GUARANTOR:	 		 	 ENTERPRISE PERFORMANCE SYSTEMS,
 INC., a Missouri corporation

				
		 		 	By:	 	/s/ Robert J. Colletti
		 		 	Name:	 	Robert J. Colletti
		 		 	Title:	 	SVP and Chief Financial Officer

 ADMINISTRATIVE AGENT: 
  

			
	 WACHOVIA BANK, NATIONAL
 ASSOCIATION, as Administrative Agent and as a Lender

		
	By:	 	/s/ Robin B. Henderson
	Name:	 	Robin B. Henderson
	Title:	 	Senior Vice President

							
	LENDER:	 		 	RBC Bank (USA), 
		 		 	as a Lender
				
		 		 	By:	 	/s/ James R. Payer
		 		 	Name:	 	James R. Payer
		 		 	Title:	 	Managing Director

							
	LENDER:	 		 	 SunTrust Bank,
 as a
Lender

				
		 		 	By:	 	/s/ David Dupuy
		 		 	Name:	 	David Dupuy
		 		 	Title:	 	Managing Director

							
	LENDER: 	 		 	Fifth Third Bank, 
		 		 	as a Lender
				
		 		 	By:	 	/s/ Joshua Livingston
		 		 	Name:	 	Joshua Livingston
		 		 	Title:	 	Officer

							
	LENDER: 	 		 	 Bank of America, N.A., 
 as a
Lender

				
		 		 	By:	 	/s/ Khuzaim Y. Shakir
		 		 	Name:	 	Khuzaim Y. Shakir
		 		 	Title:	 	Senior Vice PresidentAgreement and Plan of Merger, dated September 19, 2008

 Exhibit 10.2 
 EXECUTION VERSION 
  
  
  
 AGREEMENT AND PLAN OF MERGER 

among 
 MEDINOTES CORPORATION,

 THE STOCKHOLDER SIGNATORIES, 
 THE STOCKHOLDERS’ REPRESENTATIVE, 
 SIRONA ACQUISITION CORPORATION 
 and 
 ECLIPSYS CORPORATION

 DATED AS OF SEPTEMBER 19, 2008 
  
  
  

 TABLE OF CONTENTS 
  

					
	 	  	 	  	 Page

		
	 ARTICLE I DEFINITIONS
	  	2
		
	 ARTICLE II THE MERGER
	  	16
	 2.1
	  	The Merger	  	16
	 2.2
	  	Closing; Effective Time	  	16
	 2.3
	  	Effects of the Merger	  	17
	 2.4
	  	Certificate of Incorporation and By-laws	  	17
	 2.5
	  	Directors; Officers	  	17
	 2.6
	  	Subsequent Actions	  	17
	 2.7
	  	Effect of Merger on the Capital Stock of MediNotes	  	18
	 2.8
	  	Dissenting Shares	  	20
	 2.9
	  	Payment for Shares, Company Options and Company Warrants	  	20
	 2.10
	  	Calculation of Net Working Capital, Closing Payment and Final Adjustments	  	24
	 2.11
	  	Dispute Resolution of Calculation of Net Working Capital, the Closing Date Cash or the Closing Date Debt	  	26
	 2.12
	  	Continuity of Interest Adjustments	  	26
	 2.13
	  	Approval	  	27
		
	 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE MAJOR STOCKHOLDERS
	  	27
	 3.1
	  	Ownership of the Shares, Company Options and Company Warrants	  	27
	 3.2
	  	Authorization, Validity, and Effect of Agreements	  	28
	 3.3
	  	No Violations; Consents	  	28
	 3.4
	  	Related Party Transactions	  	29
	 3.5
	  	Investment Intent	  	29
		
	 ARTICLE IV REPRESENTATIONS AND WARRANTIES OF MEDINOTES
	  	31
	 4.1
	  	MediNotes Existence; Good Standing	  	31
	 4.2
	  	Subsidiaries	  	31
	 4.3
	  	Capitalization	  	31
	 4.4
	  	Material Contracts; No Violation	  	32
	 4.5
	  	Financial Statements; No Undisclosed Liabilities	  	35
	 4.6
	  	Authority, No Violations; Consents	  	36
	 4.7
	  	Compliance; Permits; Litigation	  	37
	 4.8
	  	Absence of Certain Changes	  	38
	 4.9
	  	Taxes	  	39
	 4.10
	  	Certain Employee Plans	  	42
	 4.11
	  	Labor Matters	  	43
	 4.12
	  	Restrictions on Business Activities	  	45
	 4.13
	  	Real Property	  	45
	 4.14
	  	Intellectual Property	  	45
	 4.15
	  	Other Assets	  	51

  

 i 

					
	 4.16
	  	Environmental Matters	  	52
	 4.17
	  	Insurance	  	52
	 4.18
	  	Warranties	  	54
	 4.19
	  	Customers; Suppliers	  	55
	 4.20
	  	Accounts Receivable	  	56
	 4.21
	  	Accounts Payable	  	56
	 4.22
	  	Bank Accounts	  	56
	 4.23
	  	No Brokers	  	56
	 4.24
	  	Disclosure	  	57
		
	 ARTICLE V REPRESENTATIONS AND WARRANTIES OF ECLIPSYS AND MERGER SUB
	  	57
	 5.1
	  	Existence; Good Standing; Corporate Authority	  	57
	 5.2
	  	Authorization, Validity, and Effect of Agreements	  	57
	 5.3
	  	No Violation	  	58
	 5.4
	  	No Brokers	  	58
	 5.5
	  	Funds	  	58
	 5.6
	  	Valid Issuance	  	58
	 5.7
	  	Exchange Compliance	  	58
	 5.8
	  	SEC Filings; Financials; Absence of Changes	  	59
	 5.9
	  	Tax-Free Reorganization	  	59
		
	 ARTICLE VI COVENANTS
	  	59
	 6.1
	  	Conduct of Business	  	59
	 6.2
	  	Further Action	  	62
	 6.3
	  	Access to Information	  	63
	 6.4
	  	Publicity	  	63
	 6.5
	  	Expenses	  	64
	 6.6
	  	Third-Party Offers	  	64
	 6.7
	  	Restrictive Covenants	  	65
	 6.8
	  	Directors	  	67
	 6.9
	  	Stockholders’ Representative	  	67
	 6.10
	  	Employee Matters	  	68
	 6.11
	  	Release	  	69
	 6.12
	  	Confidentiality	  	70
	 6.13
	  	Covenants Regarding Contracts	  	72
	 6.14
	  	Stockholder Meeting	  	72
	 6.15
	  	Tax-Free Reorganization Status	  	72
	 6.16
	  	Second Merger	  	72
	 6.17
	  	Indemnification of Directors and Officers	  	73
	 6.18
	  	Compliance with Rule 144(c)(1)	  	73
	 6.19
	  	Termination of 401(k) Plan	  	73
	 6.20
	  	Bond Agreement Escrow	  	73
		
	 ARTICLE VII SURVIVAL; INDEMNIFICATION; REMEDIES
	  	75
	 7.1
	  	Survival of Representations and Warranties and Covenants	  	75
	 7.2
	  	Indemnification and Other Rights	  	75

  

 ii 

					
	 7.3
	  	Time Limitations	  	77
	 7.4
	  	Other Limitations	  	78
	 7.5
	  	Set-Off	  	80
	 7.6
	  	Procedures Relating to Indemnification Involving Third-Party Claims	  	81
	 7.7
	  	Other Claims	  	83
	 7.8
	  	Recovery in the Case of Strict Liability or Negligence	  	83
	 7.9
	  	Sole and Exclusive Remedy	  	83
		
	 ARTICLE VIII CONDITIONS
	  	84
	 8.1
	  	Conditions to Each Party’s Obligation to Effect the Closing	  	84
	 8.2
	  	Conditions to Obligations of Eclipsys	  	84
	 8.3
	  	Conditions to the Obligations of MediNotes and the Stockholders	  	87
		
	 ARTICLE IX TERMINATION
	  	88
	 9.1
	  	Termination by Mutual Consent	  	88
	 9.2
	  	Termination by Eclipsys or MediNotes	  	88
	 9.3
	  	Termination by MediNotes	  	89
	 9.4
	  	Termination by Eclipsys	  	89
	 9.5
	  	Effect of Termination	  	89
		
	 ARTICLE X MISCELLANEOUS
	  	90
	 10.1
	  	Entire Agreement; Assignment	  	90
	 10.2
	  	Validity	  	90
	 10.3
	  	Notices	  	91
	 10.4
	  	Governing Law	  	92
	 10.5
	  	Construction	  	92
	 10.6
	  	Counterparts	  	92
	 10.7
	  	Parties In Interest	  	92
	 10.8
	  	Prior Review and Counsel	  	92
	 10.9
	  	Waiver	  	93
	 10.10
	  	Amendments	  	93
	 10.11
	  	Specific Performance	  	93
	 10.12
	  	Further Assurances	  	93
	 10.13
	  	Cumulative Remedies	  	93
	 10.14
	  	Arbitration	  	93
	 10.15
	  	Costs and Fees	  	95

  

 iii 

 EXHIBITS 
  

			
	Exhibit A	  	Form of Certificate of Merger
	Exhibit B	  	[Intentionally Deleted]
	Exhibit C-1	  	Form of Employment Agreement (Bond)
	Exhibit C-2	  	Form of Employment Agreement (Restricted Stock)
	Exhibit C-3	  	Form of Employment Agreement (Cash)
	Exhibit C-4	  	Key Employee Details
	Exhibit D	  	Form of Legal Opinion
	Exhibit E	  	[Intentionally Deleted]
	Exhibit F	  	Form of Investor Questionnaire
	Exhibit G	  	Form of Royalty Termination Agreement
	Exhibit H	  	Form of Commission Agreement
	Exhibit I	  	Form of Consulting Agreement Termination

 SCHEDULES 
  

			
	Schedule 1(a)	  	Key Employees
	Schedule 1(b)	  	Stockholder Notes
	Schedule 1(c)	  	Accredited Investors
	Schedule 2.10	  	Hypothetical Calculation-Closing Date Net Worth
	Schedule 6.10(a)	  	Continuing Employees

 Disclosure Schedule 
  

			
	Section 3.1	  	Ownership of the Shares
	Section 4.1	  	Foreign Jurisdictions
	Section 4.3(a)(i)	  	Options and Warrants
	Section 4.4(a)	  	Material Contracts
	Section 4.5(a)	  	Financial Statements
	Section 4.7(b)	  	Permits
	Section 4.7(d)(i)	  	Litigation
	Section 4.10(a)	  	Company Benefit Plans
	Section 4.11(b)(i)	  	Employees
	Section 4.11(b)(ii)	  	Independent Contractors
	Section 4.13(a)	  	Leased Real Property
	Section 4.14(a)(i)	  	Company Registered IP
	Section 4.14(a)(ii)	  	Other Rights in Company Registered IP
	Section 4.14(b)	  	Company Licensed IP
	Section 4.14(d)(i)	  	Form of Assignment Agreements
	Section 4.14(d)(ii)	  	Software Escrow Agreements
	Section 4.14(m)	  	Software Incorporating Encryption Subroutines
	Section 4.17(a)	  	Insurance
	Section 4.17(c)	  	Material Open Claims
	Section 4.18(a)	  	Warranty Claims
	Section 4.18(b)	  	Documentation

  

 iv 

			
	Section 4.19(a)	  	Customers
	Section 4.19(c)	  	Suppliers
	Section 4.20	  	Accounts Receivable
	Section 4.21	  	Accounts Payable
	Section 4.22	  	Bank Accounts

  

 v 

 AGREEMENT AND PLAN OF MERGER 
 THIS AGREEMENT AND PLAN OF MERGER, dated as of September 19, 2008 (this “Agreement”), is entered into among Eclipsys
Corporation, a Delaware corporation (“Eclipsys”), Sirona Acquisition Corporation, an Iowa corporation and a wholly owned Subsidiary of Eclipsys (“Merger Sub”), MediNotes Corporation, an Iowa
corporation (“MediNotes”), the stockholders of MediNotes named on the signature page hereto (the “Major Stockholders”) and Danny R. Wipff (as the “Stockholders’
Representative”); 
 WHEREAS, the Boards of Directors of each of Eclipsys, MediNotes and Merger Sub have (i) determined
that the merger of Merger Sub with and into MediNotes (the “Merger”), with MediNotes surviving the Merger, and the Second Merger (as defined below), are advisable and fair to, and in the best interests of, their respective
stockholders and (ii) approved the Merger upon the terms and subject to the conditions set forth in this Agreement and pursuant to the applicable laws of the States of Iowa and Delaware; 
 WHEREAS, as soon as practicable following the Merger, Eclipsys shall cause the Surviving Corporation to be merged with and into a wholly owned limited
liability company Subsidiary of Eclipsys that is treated as a disregarded entity for tax purposes (the “Second Merger”), with such entity surviving the Second Merger as a wholly owned Subsidiary of Eclipsys; 
 WHEREAS, Eclipsys, Merger Sub, MediNotes and the Major Stockholders intend for federal income tax purposes that the Merger followed by the Second Merger
qualify as a “reorganization” described in Section 368(a) of the Code, and that this Agreement constitute a “plan of reorganization” within the meaning of Section 1.368-2(g) of the regulations promulgated under the
Code; 
 WHEREAS, as a condition to and concurrently with the execution of this Agreement, the Major Stockholders representing approximately
80% of the outstanding shares of Company Common Stock, approximately 83% of the outstanding shares of Series A Preferred Stock, 100% of the outstanding shares of Series B Preferred Stock and approximately 56% of the outstanding shares of Series C
Preferred Stock have entered into a voting agreement with Eclipsys (the “Voting Agreement”) pursuant to which such Stockholders have agreed, among other matters, to vote their Shares in favor of the approval and adoption
of this Agreement and the transactions contemplated hereby, including the Merger; and 
 WHEREAS, the parties desire to make certain
representations, warranties, covenants and agreements in connection with the Merger and to prescribe various conditions to the Merger. 
 NOW, THEREFORE, in consideration of the foregoing, and the respective representations, warranties, covenants and agreements set forth herein, and for other good and valuable consideration, intending to be legally bound, the parties hereto
agree as follows: 
  

 1 

 ARTICLE I 
 DEFINITIONS 
 As used in this Agreement: 
 “Acceptance Notice” is defined in Section 2.10(c). 
 “Accounts Payable” means all accounts payable of MediNotes. 
 “Accounts Receivable” means (a) all trade accounts receivable and other rights to payment from customers of MediNotes, and
(b) all other accounts or notes receivable of MediNotes, in each case, whether billed or unbilled. 
 “Affiliate,” as applied to any Person, shall mean any other Person directly or indirectly controlling, controlled by, or under common control with, the first Person. For the purposes of this definition,
“control” (including, with correlative meanings, the terms “controlling,” “controlled by” and “under common control with”), as applied to any Person, means the possession, directly or indirectly, of the power
to direct or cause the direction of the management and policies of that Person, whether through the ownership of voting securities, by Contract or otherwise. 
 “Aggregate Exercise Price” means the aggregate exercise price of all outstanding Company Options and Company Warrants. 
 “Aggregate Liquidation Preference” means an amount equal to the sum of the following: (i) the Series A Liquidation
Preference multiplied by the number of shares of Series A Preferred Stock outstanding immediately prior to the Effective Time; (ii) the Series B Liquidation Preference multiplied by the number of shares of Series B Preferred Stock outstanding
immediately prior to the Effective Time; (iii) the Series C Liquidation Preference multiplied by the number of shares of Series C Preferred Stock outstanding immediately prior to the Effective Time; and (iv) the Series D Cash Liquidation
Preference multiplied by the number of shares of Series D Preferred Stock outstanding immediately prior to the Effective Time. 
 “Aggregate Option Consideration” means the aggregate amount of Option Consideration payable in respect of Company Options pursuant to Section 2.7(d). 
 “Aggregate Warrant Consideration” means the aggregate amount of Warrant Consideration payable in respect of Company Warrants
pursuant to Section 2.7(e). 
 “Agreement” is defined in the introductory paragraph of this Agreement.

 “Average Market Price” means the arithmetic mean of the last sale price (or, if on any day no sale price is
reported, the average of the quoted high bid and low ask price on such day) of a share of Eclipsys Common Stock on the Nasdaq Stock Market on each of the 10 consecutive trading days ending two trading days immediately prior to the Closing Date.

  

 2 

 “Bond Agreement” means the Asset Purchase Agreement, dated February 25,
2008, by and among MediNotes, the Bond Entities, Travis Bond as Owners’ Representative and the equity owners named therein. 
 “Bond Entities” means Bond Medical Group, Bond SideWinder, LLC and Bond Technologies, L.L.C. 
 “Bond Escrow Fund” is defined in Section 6.20. 
 “Bond Medical Group”
is defined in Section 6.7(b). 
 “Business” means the business of MediNotes of developing,
marketing, selling, and licensing software for physician practice management, electronic health records and electronic prescriptions, including the Software Products, providing certain related support and services, and any incidental, related or
ancillary businesses as currently conducted or under development by MediNotes on the Closing Date.  
 “Business
Day” means any day other than a Saturday, Sunday or day on which banks in the State of New York are authorized or required to close or the national securities exchanges in the United States are closed. 
 “Capital Stock” means common stock and preferred stock, partnership interests, profits interests, limited liability company
interests or other equity, equity equivalent, or ownership interests, entitling the holder thereof to vote with respect to matters involving the issuer thereof, or to share in its profits, or to share in its distributions upon its liquidation, or
the sale or transfer of its assets, and any securities exercisable, or exchangeable for, or convertible into, such capital stock. 
 “Capitalization Update” is defined in Section 6.2(c). 
 “Cash Merger
Consideration” means the product of the Purchase Price and the Cash Percentage. 
 “Cash Percentage” is
thirty-nine percent (39%). 
 “Certificates” is defined in Section 2.9(c). 
 “Claimed Amount” is defined in Section 2.9(b). 
 “Claims” is defined in Section 6.11(a). 
 “Closing” is defined in Section 2.2(a). 
 “Closing Date” is defined in Section 2.2(a). 
 “Closing Payment” is defined in Section 2.9(a)(ii). 
 “Closing Payment Amount” is defined in Section 2.9(a)(ii). 
  

 3 

 “Closing Payment Cash” is defined in Section 2.9(a)(ii). 

“Code” means the Internal Revenue Code of 1986, as amended (or any successor thereto). 
 “Company Benefit Plans” means each of the following which is sponsored, maintained, contributed to or required to be contributed
to by MediNotes for the benefit of the current or former employees, officers or directors of MediNotes, has been so sponsored, maintained, contributed to or required to be contributed to by MediNotes prior to the Closing Date, or with respect to
which MediNotes has any liability (contingent or otherwise): (i) each “employee benefit plan,” as such term is defined in Section 3(3) of ERISA (including, but not limited to, employee benefit plans, such as foreign plans, which
are not subject to the provisions of ERISA), and (ii) each stock or stock option plan, bonus plan or arrangement, incentive award plan or arrangement, change in control, severance or termination pay plan, policy, or agreement, deferred
compensation agreement or arrangement, or supplemental income arrangement, and each other employee benefit plan, program or practice which is not described in clause (i) of this sentence. 
 “Company Capital Stock” means the Company Common Stock, the Series A Preferred Stock, Series B Preferred Stock, Series C
Preferred Stock, Series D Preferred Stock, the Company Options and the Company Warrants. 
 “Company Common Stock”
means the common stock, no par value, of MediNotes. 
 “Company IP” means any Company Licensed IP or Company Owned
IP, including Company Registered IP. 
 “Company IP Contract” is defined in Section 4.14(o). 

“Company Licensed IP” means any Intellectual Property that is owned by any other Person and that is licensed to, used or
distributed by MediNotes. 
 “Company Option” means each option issued by MediNotes to purchase Company Capital
Stock. 
 “Company Owned IP” means any Intellectual Property owned (in whole or in part) by MediNotes. 
 “Company Registered IP” means all Company Owned IP that is the subject of any registrations, or applications or filings for
registration with or by any Governmental Entity, including without limitation the United States Patent and Trademark Office, foreign patent offices, or the United States Copyright Office. 
 “Company Stockholder Approval” is defined in Section 4.6(a). 
 “Company Warrant” means each warrant to purchase Company Capital Stock issued by MediNotes. 
  

 4 

 “Confidential Information” means the disclosing party’s confidential and
proprietary information, including information concerning the disclosing party’s business, products (including, with respect to MediNotes, any source code, object code, functions, current and future design documents, documentation and
associated functions and functionality provided by and related to any Software Product), operations, employees, customers, suppliers and other technical and non-technical information and trade secrets, whenever disclosed, whether before or after the
date hereof, and whether prepared by the disclosing party, its officers, employees, agents or advisors or otherwise and irrespective of the form of communication, and all notes, analyses, compilations, studies, interpretations or other documents
which contain, reflect or are based upon, in whole or in part, the Confidential Information of another party. 
 The term “Confidential
Information” shall not include information that (i) is or becomes generally available to the public other than as a result of a disclosure by the receiving party or its representatives, (ii) was within the receiving party’s
possession prior to its being furnished to it, provided that the source of such information was not known by the receiving party to be bound by a confidentiality agreement with, or other contractual, legal or fiduciary obligation of confidentiality
to, the disclosing party with respect to such information, (iii) becomes available to the receiving party on a non-confidential basis from a source other than the disclosing party or any of its representatives, provided that such source is not
bound by a confidentiality agreement with or other contractual, legal or fiduciary obligation of confidentiality to, the disclosing party or any other Person with respect to such information, or (iv) is developed by the receiving party
independently of Confidential Information provided by the disclosing party. 
 “Confidentiality
Agreement” means that certain confidentiality agreement, dated May 2, 2008, between Eclipsys and MediNotes. 
 “Consent” means any consent, approval, authorization, waiver, permit, grant, franchise, concession, exemption or order of, registration, certificate, declaration or filing with, or report or notice to, any Person,
including in each case any Governmental Entity. 
 “Contract” means any contract, agreement, or other instrument or
understanding of any kind, including any amendment, supplement, modification, extension or renewal in respect of the foregoing, in each case, whether written or oral. 
 “Costs and fees” is defined in Section 10.15. 
 “Covenant Not
to Compete” is defined in Section 6.7(b). 
 “Current Assets” means the aggregate assets of
MediNotes that would be categorized as “current assets” on a balance sheet of MediNotes under GAAP, as of 11:59 p.m. on the Closing Date, but excluding all cash. 
 “Current Liabilities” means the aggregate liabilities of MediNotes that would be categorized as “current liabilities”
on a balance sheet of MediNotes under GAAP, as of 11:59 p.m. on the Closing Date, but excluding (i) deferred revenues, other than deferred revenues, if any, representing accruals for customer claims, (ii) the current portion of any
Final Closing Date Debt (or, for purposes of the Estimated Closing Date Net Working Capital, the Estimated Closing Date Debt) and (iii) accrued Seller Transaction Expenses unpaid as of the 

  

 5 

 
Closing (provided such expenses are less than or equal to the Stockholder Fund Amount available for payment thereof). For the avoidance of doubt, Current
Liabilities shall include any amounts payable to MediNotes’ employees as a result of or in connection with consummation of the Merger or the Second Merger, including any bonuses, but excluding severance payments, if any, resulting from
the post-Closing termination of any employee. 
 “Customer Documentation” is defined in
Section 4.18(b). 
 “Damages” is defined in Section 7.2(a). 
 “Debt” means, as to any Person, (i) any indebtedness of such Person, whether or not contingent, in respect of borrowed money
or evidenced by bonds, notes, debentures or other similar instruments or letters of credit (or reimbursement agreements in respect thereof) or banker’s acceptances or representing capitalized lease obligations, (ii) all indebtedness of
others secured by a Lien on any asset of such Person (whether or not such indebtedness is assumed by such Person), (iii) all obligations contingent or otherwise, of such Person under letter of credit or similar facilities, and (iv) to the
extent not otherwise included in clauses (i) through (iii), any guaranty by such Person of any Debt of any other Person. 
 “Disclosure Schedule” is defined in the introductory paragraph of Article III. 
 “Dissenting Shares” is defined in Section 2.8. 
 “Dissenting Share
Amount” means the product of the Per Share Consideration and the number of Dissenting Shares. 
 “Eclipsys” is defined in the introductory paragraph of this Agreement. 
 “Eclipsys Common
Stock” means the Class A common stock of Eclipsys, par value $.01 per share. 
 “Eclipsys Final
Calculations” is defined in Section 2.10(c). 
 “Eclipsys Indemnified Parties” is defined in
Section 7.2(a). 
 “Eclipsys SEC Filings” is defined in Section 5.8. 
 “Effective Time” is defined in Section 2.2(c). 
 “Effective Time Company Holder” shall mean any holder of record of any Company Capital Stock immediately prior to the Effective
Time. 
 “Employee” means employees and other persons filling similar functions. 
 “Employment Agreements” is defined in Section 8.2(l). 
  

 6 

 “Environmental Laws” means the Comprehensive Environmental Response, Compensation
and Liability Act, 42 U.S.C. § 9601 et seq., the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. § 11001 et seq., the Resource Conservation and Recovery Act, 42 U.S.C.
§ 6901 et seq., the Toxic Substances Control Act, 15 U.S.C. § 2601 et seq., the Federal Insecticide, Fungicide, and Rodenticide Act, 7 U.S.C. § 136 et seq., the Clean Air Act,
42 U.S.C. § 7401 et seq., the Clean Water Act (Federal Water Pollution Control Act), 33 U.S.C. § 1251 et seq., the Safe Drinking Water Act, 42 U.S.C. § 300f et seq., the Occupational
Safety and Health Act, 29 U.S.C. § 641 et seq., and the Hazardous Materials Transportation Act, 49 U.S.C. § 1801 et seq., as any of the above statutes have been or may be amended from time to time, all
rules and regulations promulgated pursuant to any of the above statutes, and any other Legal Requirements related to or governing Environmental Matters, as the same have been or may be amended from time to time, including any common law cause of
action providing any right or remedy with respect to Environmental Matters, and all applicable Orders, of any Governmental Entity relating to Environmental Matters. 
 “Environmental Matters” means all matters involving the prevention of or response to pollution, the handling or management of Hazardous Materials, the regulation of wetlands and other natural
resources, and the protection of the environment, noise, human health, and occupational health and safety. 
 “ERISA”
means the Employee Retirement Income Security Act of 1974, as amended (or any successor thereto). 
 “ERISA
Affiliate” means any trade or business, whether or not incorporated, under common control with MediNotes and that, together with MediNotes, is treated as a single employer within the meaning of Section 414(b), (c), (m) or
(o) of the Code. 
 “Escrow Accounts” is defined in Section 2.9(b). 
 “Escrow Agent” means Wells Fargo Bank, National Association, or such other escrow agent selected by Eclipsys and MediNotes, or
after the Closing, Eclipsys and the Stockholders’ Representative. 
 “Escrow Merger Consideration” means any
remaining portion of the escrowed funds not subject to claims and therefore released by the Escrow Agreement to the Effective Time Company Holders as provided by this Agreement and the Escrow Agreement. 
 “Estimated Closing Date Cash” means MediNotes’ good faith estimate of Final Closing Date Cash determined pursuant to
Section 2.10(a). 
 “Estimated Closing Date Debt” means MediNotes’ good faith estimate of Final
Closing Date Debt determined pursuant to Section 2.10(a). 
 “Estimated Closing Date Net Working Capital”
means MediNotes’ good faith estimate of Final Closing Date Net Working Capital determined pursuant to Section 2.10(a). 
 “Estimated Closing Date Net Working Capital Adjustment” is the amount equal to the Estimated Closing Date Net Working Capital less the Minimum Net Working Capital. 
  

 7 

 “Estimated Purchase Price” means an amount equal to (i) $42,000,000,
less (ii) the Estimated Closing Date Debt, plus (iii) the Estimated Closing Date Cash, plus (or minus if negative) (iii) any Estimated Closing Date Net Working Capital Adjustment. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended. 
 “Final Closing Date Cash” means the amount of cash of MediNotes, as of 11:59 p.m. on the Closing Date, less $1,000,000.

 “Final Closing Date Debt” means all Debt of MediNotes, as of 11:59 p.m. on the Closing Date, including capital
lease obligations and the obligations under the Stockholder Notes. 
 “Final Closing Date Net Working
Capital” means the Current Assets less the Current Liabilities determined in accordance with Section 2.10. 
 “Final Closing Date Net Working Capital Adjustment” is the amount equal to the Final Closing Date Net Working Capital less the Minimum Net Working Capital. For the avoidance of doubt, if the Final Closing Date Net
Working Capital is greater than the Minimum Net Working Capital, there shall be an increase in the Purchase Price in respect thereof, and if the Final Closing Date Net Working Capital is less than the Minimum Net Working Capital, there shall be a
decrease in the Purchase Price in respect thereof. 
 “Financial Statements” is defined in
Section 4.5(a). 
 “Fraud” means fraud or intentional misrepresentation or omission. 
 “GAAP” means United States generally accepted accounting principles. 
 “Governmental Entity” means any foreign, domestic, federal, territorial, state or local governmental authority,
quasi-governmental authority, instrumentality, court, government or self regulatory organization, commission, tribunal or organization or any regulatory, administrative or other agency, or any political or other subdivision, department or branch of
any of the foregoing which has or claims to have competent jurisdiction over the relevant Persons or its business, property, assets or operations. 
 “Hazardous Materials” means any substance or material that is defined under the Environmental Laws as a “hazardous substance,” “regulated substance,” “pollutant,”
“contaminant,” “hazardous waste,” “extremely hazardous substance,” “toxic substance,” or “hazardous material,” or that is otherwise defined in or regulated under the Environmental Laws, including,
without limitation, petroleum, asbestos-containing materials, lead-containing paint or plumbing, polychlorinated biphenyls, radioactive materials, and radon. 
 “Holdback Amount” is the amount equal to the sum of the Indemnification Amount, the Stockholder Fund Amount and the True-Up Reserve Amount. 
 “Holdback Escrow Agreement” means the Holdback Escrow Agreement, among Eclipsys, the Stockholders’ Representative and the
Escrow Agent, to be entered into concurrently with the Closing, relating to the escrow of the Holdback Amount, in the form mutually agreed by Eclipsys and MediNotes. 
  

 8 

 “Holdback Termination Date” is defined in Section 2.9(b). 

“Indemnification Amount” means (i) shares of Eclipsys Common Stock with an aggregate value of $2,562,000, valued at the
Average Market Price, plus (ii) cash, with an aggregate value of $1,638,000. For the avoidance of doubt, the cash amount shall not be less than thirty-nine percent (39%) of the Indemnification Amount. 
 “Institutional Major Stockholders” means Iowa Farm Bureau Federation, Iowa First Capital Fund II LP and Iowa Capital Corporation.

 “Instruments” is defined in Section 2.9(c). 
 “Insurance Policies” is defined in Section 4.17(a). 
 “Intellectual Property” means any patent, patent application, trademark (whether registered or unregistered), trademark
application, trade name, fictitious business name, service mark (whether registered or unregistered), service mark application, domain name, copyright (whether registered or unregistered), copyright application, mask work, mask work application,
trade secret, know-how, customer list, franchise, system, Software, including without limitation, Software development processes, practices, methods and policies recorded in permanent form, relating thereto, invention, work of authorship, design,
blueprint, engineering drawing, proprietary product, technology or other intellectual property right. 
 “Interim Financial
Statements” is defined in Section 4.5(a). 
 “Key Employees” means the employees of
MediNotes listed on Schedule 1(a). 
 “Knowledge of Eclipsys” means actual knowledge of the Chief Executive
Officer or Chief Financial Officer of Eclipsys. Actual knowledge of any matter will be deemed to include such knowledge as such person could have obtained after making reasonable inquiry and investigation of the matter. 
 “Knowledge of a Major Stockholder” means (i) actual knowledge of such Major Stockholder if such Major Stockholder is an
individual, (ii) actual knowledge of the trustee(s) of such Major Stockholder if such Major Stockholder is a trust, and (iii) the actual knowledge of any director or officer of any Institutional Major Stockholder. Actual knowledge of any
matter will be deemed to include such knowledge as such persons could have obtained after making reasonable inquiry and investigation of the matter. 
 “Knowledge of MediNotes” means the actual knowledge of Donald G. Schoen, Davin Hills or Travis Bond. Actual knowledge of any matter will be deemed to include such knowledge as such person could
have obtained after making reasonable inquiry and investigation of the matter. 
  

 9 

 “Lease” means any lease or sublease as lessee or lessor of, or option, occupancy
or space agreement relating to, real estate used, useful or held by MediNotes. 
 “Leased Real Property” is defined
in Section 4.13(a). 
 “Legal Requirement” means any federal, state, local, municipal, foreign,
international, multinational or other administrative order, constitution, law, ordinance, principle of common law, regulation, rule, statute or treaty, including any interpretation thereof by any Governmental Entity. 
 “Liability” means, with respect to any Person, any liability or obligation of such Person of any kind, character or description,
whether known or unknown, absolute or contingent, accrued or unaccrued, disputed or undisputed, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or
otherwise, whether or not the same is required to be accrued on the financial statements of such Person and whether or not the same is disclosed on any schedule to this Agreement. 
 “License-In Agreement” is defined in Section 4.14(b). 
 “Lien” means any lien (including judgment and mechanics’ liens, regardless of whether liquidated), mortgage, assessment,
security interest, easement, claim, pledge, trust (constructive or otherwise), deed of trust, option or other charge, title defect or objection, encumbrance, restriction or any other Contract having the same effect as any of the foregoing.

 “Material Adverse Effect” means with respect to any Person, or its business, one or more changes, events,
occurrences, conditions or circumstances (whether or not covered by insurance) which, individually or in the aggregate, result in a material adverse effect on or change in (i) the business, operations, assets, Liabilities, condition (financial
or otherwise), prospects, or results of operations of such Person, taken as a whole with its Subsidiaries, or its business, or (ii) the ability of such Person (and, in the case of MediNotes, the Stockholders) to timely (A) perform his or
its obligations hereunder, or (B) consummate the transactions contemplated in this Agreement and the other Transaction Documents. 
 “Material Contracts” is defined in Section 4.4(a). 
 “MediNotes” is
defined in the introductory paragraph of this Agreement, and unless the context otherwise requires, after the Effective Time shall mean the Surviving Corporation or the survivor of the Second Merger, as applicable. 
 “MediNotes Articles of Incorporation” means the Second Amended and Restated Articles of Incorporation of MediNotes as amended and
in effect on the date hereof. 
 “Merger Consideration” means the cash and Eclipsys Common Stock payable to Effective
Time Company Holders pursuant to Section 2.7 of this Agreement. 
 “Merger Sub” is defined in the
introductory paragraph of this Agreement. 
 “Minimum Net Working Capital” means $275,000. 
  

 10 

 “Non-Stock Consideration” is defined in Section 2.12. 
 “Objection Notice” is defined in Section 2.10(c). 
 “Off-the-Shelf Software” is defined in Section 4.14(b). 
 “Order” means any award, decision, injunction, judgment, decree, stipulation, order, ruling, subpoena, or verdict entered,
issued, made or rendered by any court, administrative agency or other Governmental Entity or by any arbitrator. 
 “Option
Consideration” is defined in Section 2.7(d). 
 “Participating Cash Percentage” means the
percentage calculated by dividing (A)(x) the product of (i) the Purchase Price less the Indemnification Amount and (ii) the Cash Percentage, less (y) the sum of the Stockholder Fund Amount, the True-Up Reserve Amount, the Small Holder
Cash, the Aggregate Liquidation Preference, the Aggregate Option Consideration, the Aggregate Warrant Consideration and the Dissenting Share Amount by (B)(i) the Purchase Price less (ii) the sum of the Holdback Amount, the Small Holder
Cash, the Aggregate Liquidation Preference, the Aggregate Option Consideration, the aggregate Series D Stock Liquidation Preference, Aggregate Warrant Consideration and the Dissenting Share Amount. 
 “Participating Shares” means the sum of (i) the number of shares of Series B Preferred Stock and Company Common Stock
outstanding immediately prior to the Effective Time, (ii) the number of shares of Company Common Stock for which Company Warrants are exercisable immediately prior to the Effective Time, and (iii) the number of shares of Company Common
Stock for which Company Options are exercisable immediately prior to the Effective Time. 
 “Per Share Cash
Consideration” is defined in Section 2.7(c)(ii). 
 “Per Share Consideration” means the
quotient obtained by dividing (i) the Purchase Price, plus the Aggregate Exercise Price, less the sum of (x) the Holdback Amount, (y) the Aggregate Liquidation Preference and (z) the Series D Stock Liquidation Preference (valued
at the Average Market Price), by (ii) the Participating Shares. 
 “Per Share Escrow Amount” means the quotient
obtained by dividing the Escrow Merger Consideration by the Participating Shares. 
 “Per Share Stock Consideration”
is defined in Section 2.7(c)(ii). 
 “Permits” means all licenses, permits, easements, variances,
exemptions, consents, certificates, orders, approvals and other authorizations required by applicable Legal Requirements in connection with the Business. 
 “Permitted Liens” means (i) Liens for utilities and current taxes that are not yet due and payable or that may thereafter be paid without penalty in the ordinary course of business
consistent with past practices, (ii) mechanics’, carriers’, workers’, repairers’, materialmen’s, warehousemen’s, lessor’s, landlord’s and other similar Liens arising or incurred in the ordinary course of
business with respect to which the underlying obligations are not yet due and payable 

  

 11 

 
and which do not exceed $50,000 in the aggregate, (iii) Liens arising under original purchase price conditional sales contracts and equipment leases
with third parties entered into in the ordinary course of business, (iv) easements, restrictive covenants and similar encumbrances or impediments against any of MediNotes’ assets or properties which do not materially interfere with the
Business or impair the ownership, use or operation of the assets to which they relate, or the transfer thereof, and (v) minor irregularities and defects of title which do not materially interfere with the Business or impair the ownership, use
or operation of the assets to which they relate, or the transfer thereof. 
 “Person” means any individual,
corporation, limited liability company, partnership, trust, joint venture, association, organization or other entity or group (which term shall include a “group” as such term is defined in Section 13(d)(3) of the Exchange Act) or
Governmental Entity. 
 “Privacy Regulations” is defined in Section 4.14(q). 
 “Pro Rata Portion” means with respect to each Effective Time Company Holder the quotient obtained by dividing (A) the sum of
the number of shares of Series B Preferred Stock and shares of Company Common Stock held by such Effective Time Company Holder immediately prior to the Effective Time, if any, and the number of shares of Common Stock for which Company Options and
Company Warrants held by such Effective Time Company Holder immediately prior to the Effective Time, if any, were exercisable, by (B) the Participating Shares. 
 “Purchase Price” means an amount equal to (i) $42,000,000, less (ii) the Final Closing Date Debt, plus (or minus if negative) (iii) the Final Closing Date Cash,
plus (or minus if negative) (iv) any Final Closing Date Net Working Capital Adjustment. 
 “Registered Intellectual
Property” means any Intellectual Property that is the subject of any registrations, or applications or filings for registration with or by any Governmental Entity, including without limitation the United States Patent and Trademark
Office, foreign patent offices, or the United States Copyright Office. 
 “Released Parties” is defined in
Section 6.11(a). 
 “Restrictive Covenants” is defined in Section 6.7(e). 
 “Restrictive Period” is defined in Section 6.7(b). 
 “SEC” means the United States Securities and Exchange Commission. 
 “Securities Act” means the Securities Act of 1933, as amended. 
 “Seller Transaction Expenses” means all costs and expenses (including fees of attorneys, accountants and brokers or finders) of
the Stockholders and MediNotes incurred or payable in connection with this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby, including the percentage of expenses, if any, owed to the Unrelated
Accounting Firm under Section 2.11 and all amounts owed to the brokers disclosed in 

  

 12 

 
Section 4.23, or any other broker, finder or similar agent employed by or acting on behalf of MediNotes, any Major Stockholder or any of their
respective Affiliates or agents in connection with this Agreement or any other Transaction Documents, or the transactions contemplated hereby or thereby. 
 “Series A Liquidation Preference” is defined in Section 2.7(c)(i). 
 “Series A Preferred Stock” means the Series A Convertible Preferred Stock of MediNotes. 
 “Series B Liquidation Preference” is defined in Section 2.7(c)(ii). 
 “Series B
Preferred Stock” means the Series B Convertible Preferred Stock of MediNotes. 
 “Series C Liquidation
Preference” is defined in Section 2.7(c)(iii). 
 “Series C Preferred Stock” means the
Series C Convertible Preferred Stock of MediNotes. 
 “Series D Cash Liquidation Preference” is defined in
Section 2.7(c)(iv). 
 “Series D Liquidation Preference” is defined in Section 2.7(c)(iv).

 “Series D Preferred Stock” means the Series D Non-Voting Preferred Stock of MediNotes. 
 “Series D Stock Liquidation Preference” is defined in Section 2.7(c)(iv). 
 “Settlement Agreement” means that certain Settlement Agreement and Release, entered into on the date hereof, by and among the
Bond Entities, Travis Bond, Lisa Bond, Nevestis, LLC, Primi, LLC, and MediNotes, in the form provided to Eclipsys on the date hereof. 
 “Shares” means shares of Company Common Stock, Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock. 
 “Small Holder” means all Effective Time Company Holders, other than (i) those who have executed and delivered to Eclipsys an
Investor Questionnaire, prior to the date hereof, certifying that they are an accredited investor under Regulation D of the Securities Act, and are listed as such on Schedule 1(c), and (ii) any other Effective Time Company Holder who
executes and delivers to Eclipsys an Investor Questionnaire, within five (5) Business Days after the date hereof, certifying that they are an accredited investor under Regulation D of the Securities Act, and that Eclipsys, in its sole
discretion, approves be added to such schedule within such time period. 
 “Small Holder Cash” means the aggregate
cash paid to Small Holders pursuant to Section 2.7(f). 
  

 13 

 “Software” means all of the following used, licensed or sold in the Business, but
excluding any Company Licensed IP: (i) computer programs, including any and all software implementations of algorithms, heuristics, models and methodologies, whether in source code or object code; and (ii) machine-readable databases and
compilations of data. 
 “Software Documentation” means (i) descriptions, schematics, flow-charts and other work
product used to design, plan, organize and develop Software, (ii) testing, validation and verification materials relating to Software, (iii) documentation, including user manuals; web materials; architectural, design, feature and
functionality specifications; and training materials, relating to Software, and (iv) performance metrics, bug and feature lists, build, release and change control manifests recorded in permanent form, relating to Software. 
 “Software Products” means all Software produced by MediNotes for sale or license to third parties, including, but not limited to
MediNotes e EHR, MediNotes Clinician EHR/PM Suite, MediNotes Rx, MediNotes Clinician PM and MediNotes Clinician SCM. 
 “Stock
Consideration” is defined in Section 2.12. 
 “Stock Percentage” is sixty-one percent (61%).

 “Stockholder” means a record owner of Company Capital Stock. 
 “Stockholder Fraud” means Fraud by any of the Stockholders, or Fraud by any employee or other representative or agent of
MediNotes (other than a Stockholder) as to which MediNotes had Knowledge or any of the Major Stockholders had actual knowledge. 
 “Stockholder Fund Amount” means an amount equal to $1,100,000, in cash. 
 “Stockholder
Notes” means those certain promissory notes listed on Schedule 1(b), issued by MediNotes to the Stockholders or their Affiliates. 
 “Stockholders Agreement” means that certain Amended and Restated Stockholder Agreement, dated March 07, 2008, among MediNotes and the Stockholders named therein. 
 “Stockholders’ Representative” is defined in Section 6.9. 
 “Subsidiary” means, with respect to any Person, any corporation, limited liability company, partnership, joint venture or other
entity of which such Person (either alone or through or together with any other Subsidiary), owns, directly or indirectly, securities or other interests (A) the holders of which are generally entitled to at least 50% of the vote for the
election of the board of directors or other similar governing body of such corporation or other legal entity, or otherwise having the power to direct the business and policies of that Person, or (B) representing at least 50% of the outstanding
Capital Stock of such corporation or other legal entity. 
 “Survival Period” is defined in
Section 7.1(a). 
  

 14 

 “Surviving Corporation” is defined in Section 2.1, and unless the
context otherwise requires, after the effective time of the Second Merger, shall mean the survivor of the Second Merger. 
 “Tax” means (A) all federal, state, local, foreign, and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding,
payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest and any penalties, additions to tax or
additional amounts with respect thereto, (B) any Liability for payment of amounts described in clause (A) whether as a result of transferee Liability, joint and several liability for being a member of an affiliated, consolidated, combined
or unitary group for any period, or otherwise through operation of law, and (C) any Liability for the payment of amounts described in clauses (A) or (B) as a result of any tax sharing, tax indemnity or tax allocation agreement or any
other express or implied Contract to indemnify any other Person. 
 “Tax Return” means any return, declaration,
report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof. 
 “Testing Price” is defined in Section 2.12. 
 “Third-Party
Acquisition” means (i) the acquisition by a Person, other than Eclipsys and its Affiliates, of any of the Capital Stock or assets or property of MediNotes, or any interest therein, whether by issuance, or sale or other disposition
of Capital Stock, sale, lease, license or other disposition of assets, merger or otherwise, other than sales or licenses of products to customers in the ordinary course of business consistent with past practice, or (ii) any other transaction
that would interfere with or delay the Closing or the ability of MediNotes to operate the Business and control its assets substantially as operated and controlled by MediNotes on the date hereof. 
 “Third-Party Claim” is defined in Section 7.6(a). 
 “Threatened” a claim, proceeding, dispute or other matter shall be deemed to have been “threatened” if any demand or
statement has been made, or any other notice has been given, that would lead a prudent person to conclude that such a claim, proceeding, dispute or other matter is reasonably likely to be asserted, commenced or otherwise pursued; in each case either
made in writing or orally to Donald G. Schoen, Davin Hills or Travis Bond, or to any other person if Donald G. Schoen, Davin Hills or Travis Bond has been informed or would have been informed after making reasonable inquiry; provided that such duty
to make reasonably inquiry shall not be required to be made any more frequently than in conjunction with MediNotes certifying as to the accuracy of its representations and warranties made herein, which are as of the date of this Agreement and the
Closing. 
 “Transaction Documents” means, collectively, this Agreement, the Holdback Escrow Agreement, the Voting
Agreement, the Employment Agreements, the Royalty Termination Agreement, the Commission Agreement, the Investor Questionnaires and the letter of transmittal of each Stockholder, and all certificates contemplated to be delivered hereunder.

  

 15 

 “True-Up Reserve Amount” means an amount equal to $250,000, in cash. 

“Unrelated Accounting Firm” is defined in Section 2.11. 
 “Valuation Date” is defined in Section 2.12. 
 “Value of Stock Consideration” is defined in Section 2.12. 
 “WARN Act” is defined in Section 6.10(c). 
 “Warrant Consideration” is defined in Section 2.7(e). 
 “Warranty Claim” means any claim based upon any theory of product liability, strict liability, negligence, misrepresentation,
product defect, breach of warranty (express or implied), and any other similar claims that relates to the products and services of MediNotes, including the Software Products. 
 “Year-End Financial Statements” is defined in Section 4.5(a). 
 ARTICLE II 
 THE MERGER

 2.1 The Merger. Upon the terms and subject to the conditions of this Agreement, at the Effective Time and in accordance with
the laws of the State of Iowa, Merger Sub shall be merged with and into MediNotes pursuant to which (a) the separate corporate existence of Merger Sub shall cease, (b) MediNotes shall be the surviving corporation in the Merger (the
“Surviving Corporation”) and shall continue its corporate existence under the laws of the State of Iowa as a wholly owned Subsidiary of Eclipsys (until the Second Merger occurs), (c) all of the properties, rights,
privileges, powers and franchises of MediNotes will vest in the Surviving Corporation, and all of the debts, liabilities, obligations and duties of MediNotes will become the debts, liabilities, obligations and duties of the Surviving Corporation;
and (d) all of the properties, rights, privileges, powers and franchises of Merger Sub will vest in the Surviving Corporation, and all of the debts, liabilities, obligations and duties of Merger Sub will become the debts, liabilities,
obligations and duties of the Surviving Corporation. 
 2.2 Closing; Effective Time. 
 (a) The closing of the Merger (the “Closing”) shall take place on the second Business Day following the
satisfaction or, to the extent permitted by applicable law, waiver of all conditions to the obligations of the parties set forth in Article VIII (other than such conditions as may, by their terms, only be satisfied at the Closing or on
the Closing Date, subject to such satisfaction or waiver), by telecopy exchange of signature pages with originals to follow by overnight delivery, or in such other manner or at such place as the parties hereto may agree in writing. The day on which
the Closing takes place is referred to as the “Closing Date.” 
  

 16 

 (b) As soon as practicable on the Closing Date, and immediately prior to the Closing, the
parties shall cause a certificate of merger substantially in the form attached as Exhibit A (the “Certificate of Merger”) to be executed and filed with the Secretary of State of the State of Iowa. 
 (c) The Merger shall become effective upon the filing of the Certificate of Merger with the Secretary of State of the State of Iowa or at
such other time as the parties shall agree and as shall be specified in the Certificate of Merger. The date and time that the Merger shall become effective is herein referred to as the “Effective Time.” 
 2.3 Effects of the Merger. 
 (a) The Merger shall have the effects provided for herein and in the applicable provisions of Iowa Legal Requirements. 
 (b) Each share of common stock of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted into and exchanged for one (1) validly issued, fully paid and nonassessable share of common stock of the
Surviving Corporation. Each stock certificate of Merger Sub evidencing ownership of any such shares of common stock of Merger Sub shall thereafter evidence ownership of such shares of common stock of the Surviving Corporation. 
 2.4 Certificate of Incorporation and By-laws. From and after the Effective Time, (a) the Articles of Incorporation of Merger Sub, as in
effect immediately prior to the Effective Time shall be the articles of incorporation of the Surviving Corporation, until amended in accordance with the provisions thereof and applicable law, and (b) the by-laws of Merger Sub, as in effect
immediately prior to the Effective Time shall be the by-laws of the Surviving Corporation, until amended in accordance with the provisions thereof and applicable law. 
 2.5 Directors; Officers. From and after the Effective Time, (a) the directors of Merger Sub serving immediately prior to the Effective Time shall be the directors of the Surviving Corporation until the
earlier of their resignation or removal or until their respective successors are duly elected and qualified, as the case may be, and (b) the officers of Merger Sub serving immediately prior to the Effective Time shall be the officers of the
Surviving Corporation until the earlier of their resignation or removal or until their respective successors are duly elected and qualified, as the case may be. 
 2.6 Subsequent Actions. If, at any time after the Effective Time, the Surviving Corporation shall consider or be advised that any deeds, bills of sale, assignments, assurances or any other actions or things are
necessary or desirable to vest, perfect or confirm of record or otherwise in the Surviving Corporation its right, title or interest in, to or under any of the rights, properties or assets of either MediNotes or Merger Sub acquired or to be acquired
by the Surviving Corporation as a result of or in connection with the Merger or otherwise to carry out this Agreement, the officers and directors of the Surviving Corporation shall be authorized to execute and deliver, in the name of and on behalf
of MediNotes or Merger Sub, as applicable, all such deeds, bills of sale, assignments and assurances and to take and do, in the name and on behalf of each of such corporations or otherwise, all such other actions and things as such 

  

 17 

 
officers or directors may deem necessary or desirable to vest, perfect or confirm any and all right, title and interest in, to and under such rights,
properties or assets in the Surviving Corporation or otherwise to carry out this Agreement. Notwithstanding anything contained herein to the contrary, all rights granted to and obligations of the Surviving Corporation hereunder shall also be for the
benefit and the obligation of the survivor of the Second Merger. 
 2.7 Effect of Merger on the Capital Stock of MediNotes.

 (a) Notwithstanding anything to the contrary in this Section 2.7, at the Effective Time, by virtue of the
Merger and without any action on the part of Eclipsys, Merger Sub or MediNotes, each Share that is held by Eclipsys, MediNotes or any Subsidiary of Eclipsys or MediNotes immediately prior to the Effective Time, shall be cancelled and extinguished
without any consideration paid therefor or in respect thereof. 
 (b) Notwithstanding anything to the contrary in this
Section 2.7, at the Effective Time, Dissenting Shares shall be treated in accordance with Section 2.8. 
 (c) Subject to Section 2.7(f), at the Effective Time, by virtue of the Merger and without any action on the part of Eclipsys, Merger Sub, MediNotes or the Stockholders, each Share that is issued and outstanding immediately prior
to the Effective Time (other than any Dissenting Shares and any Shares cancelled pursuant to Section 2.7(a)) shall be cancelled and extinguished and shall be converted automatically into the right to receive, subject to the terms and
conditions set forth in this Agreement (subject to the holdback of the Holdback Amount), the following consideration: 
 (i)
each share of Series A Preferred Stock will be converted only into the right to receive $.71 in cash, plus an amount equal to any accrued and unpaid dividends (the “Series A Liquidation Preference”); 
 (ii) each share of Series B Preferred Stock will be converted into the right to receive (a) $4.75 in cash, plus an amount equal to
any accrued and unpaid dividends (the “Series B Liquidation Preference”), (b) cash equal to the product of the Per Share Consideration and the Participating Cash Percentage (the “Per Share Cash
Consideration”), (c) a number of shares of Eclipsys Common Stock equal to the quotient obtained by dividing (x) the Per Share Consideration less the Per Share Cash Consideration by (y) the Average Market Price (the
“Per Share Stock Consideration”) and (d) the Per Share Escrow Amount; 
 (iii) each share of
Series C Preferred Stock will be converted only into the right to receive $4.75 in cash, plus an amount equal to any accrued and unpaid dividends (the “Series C Liquidation Preference”); 
 (iv) each share of Series D Preferred Stock will be converted only into the right to receive $800 (the “Series D Liquidation
Preference”), of which (A) the Cash Percentage shall be payable in cash (the “Series D Cash Liquidation Preference”) and (B) the Stock Percentage shall be payable in shares of Eclipsys Common Stock
(with such number of shares of Eclipsys Common Stock equal to such stock portion value, divided by the Average Market Price) (the “Series D Stock Liquidation Preference”); and 
  

 18 

 (v) each share of Company Common Stock will be converted into the right to receive
(a) the Per Share Cash Consideration, (b) the Per Share Stock Consideration and (c) the Per Share Escrow Amount. 
 (d) At the Effective Time, each Company Option then outstanding shall, whether or not then vested, by virtue of the Merger and without any action on the part of the holder thereof, be cancelled and converted without exercise only into and,
subject to the terms and conditions set forth in this Agreement, represent only the right to receive (subject to the holdback of the Holdback Amount), with respect to each share of Company Common Stock then subject to purchase under such Company
Option: 
 (i) cash equal to the Per Share Consideration less the exercise price per share of such Company Option
(“Option Consideration”); and 
 (ii) the Per Share Escrow Amount. 
 (e) At the Effective Time, each Company Warrant then outstanding shall by virtue of the Merger and without any action on the part of the
holder thereof, be cancelled and converted without exercise only into and, subject to the terms and conditions set forth in this Agreement, represent only the right to receive (subject to the holdback of the Holdback Amount), with respect to each
share of Company Common Stock then subject to purchase under such Company Warrant: 
 (i) cash equal to the Per Share
Consideration less the exercise price per share of such Company Warrant (“Warrant Consideration”); and 
 (ii) the Per Share Escrow Amount. 
 (f) Notwithstanding anything to the contrary in this Section 2.7,
Small Holders will receive the entire amount of consideration to which they are each entitled in respect of the Merger entirely in cash. Notwithstanding anything to the contrary in this Agreement, if after deduction from the Cash Merger
Consideration of the cash portion of the Holdback Amount, the payment of cash to the Small Holders pursuant to the foregoing sentence and the payment of cash to holders of the Company Options and Company Warrants pursuant to the foregoing, the
amount of the Cash Merger Consideration remaining is insufficient to pay the Aggregate Liquidation Preference entirely in cash, the Series A Liquidation Preference, Series B Liquidation Preference, Series C Liquidation Preference and Series D Cash
Liquidation Preference may be paid ratably in Eclipsys Common Stock to the extent the Aggregate Liquidation Preference exceeds the Cash Merger Consideration available after such deductions, and to the extent the holders of such shares of preferred
stock are not Small Holders. For purposes of calculating the amount of Merger Consideration payable to each Effective Time Company Holder pursuant to this Section 2.7, all amounts payable in cash to such Effective Time Company Holder
shall be aggregated and rounded up to the nearest whole cent, all shares of Eclipsys Common Stock payable to such Effective Time Company Holder shall be aggregated and rounded down to the nearest whole share. No fractional shares of Eclipsys Common
Stock will be issued by virtue of the Merger, but in lieu thereof each Effective Time Company Holder that would otherwise be entitled to a fraction of a share of Eclipsys Common Stock (after 

  

 19 

 
aggregating all fractional shares of Eclipsys Common Stock that otherwise would be received by such holder) shall, upon surrender of such holder’s
Certificate(s) or Instruments or in the case of a lost, stolen or destroyed Certificate or Instrument, upon delivery of an affidavit (and bond, if required) pursuant to Section 2.9(f), receive from Eclipsys an amount of cash (rounded to
the nearest whole cent), without interest, equal to the product of: (i) such fraction, multiplied by (ii) the Average Market Price (less any applicable withholding tax). 
 (g) Escrow Merger Consideration, if any, will be paid: (i) in cash, to Small Holders and holders of Company Options and Company
Warrants with respect to such Company Options and Company Warrants; and (ii) in cash and Eclipsys Common Stock, to all Effective Time Company Holders (other than (A) Small Holders, and (B) in respect of Series A Preferred Stock,
Series C Preferred Stock or Series D Preferred Stock, each of which do not entitle the holder to any portion of the Escrow Merger Consideration), as set forth in the Escrow Agreement. 
 2.8 Dissenting Shares. Notwithstanding anything in this Agreement to the contrary, Shares (other than any Shares to be cancelled pursuant to
Section 2.7(a)) outstanding immediately prior to the Effective Time and held by an Effective Time Company Holder who has not voted in favor of the Merger or consented thereto in writing and who has properly asserted dissenters’
rights in accordance with Division XIII of the Iowa Business Corporation Act (“Dissenting Shares”) shall not be converted into or be exchangeable for the right to receive a portion of the Merger Consideration unless and until
such Effective Time Company Holder fails to perfect or withdraws or otherwise loses such holder’s right to appraisal and payment thereunder. If, after the Effective Time, any such Effective Time Company Holder fails to perfect or withdraws or
loses such holder’s right to appraisal, such Dissenting Shares shall thereupon be treated as if they had been converted as of the Effective Time into the right to receive the portion of the Merger Consideration, if any, to which such holder is
entitled pursuant to Section 2.7(c), without interest. MediNotes shall give Eclipsys (a) prompt notice of any demands received by MediNotes for appraisal of Shares, attempted written withdrawals of such demands, and any other
instruments served pursuant to Iowa law and received by MediNotes relating to a stockholders’ rights to appraisal with respect to the Merger and (b) the opportunity to direct all negotiations and proceedings with respect to any exercise of
such appraisal rights under Iowa law. MediNotes shall not, except with the prior written consent of Eclipsys, voluntarily make any payment with respect to any demands for payment for Capital Stock of MediNotes, offer to settle or settle any such
demands or approve any withdrawal of any such demands. 
 2.9 Payment for Shares, Company Options and Company Warrants. 
 (a)(i) At or prior to the Effective Time, Eclipsys shall, or shall cause the Surviving Corporation to, make available to ComputerShare
(the “Paying Agent”), for the benefit of the Effective Time Company Holders, the Closing Payment. 
 (ii) The “Closing Payment” shall consist of: (A) a number of shares of Eclipsys Common Stock equal to the quotient of (x) the Closing Payment Amount less the Closing Payment Cash divided by (y) the
Average Market Price; and (B) the Closing Payment Cash. The “Closing Payment Amount” shall be an amount equal to the 

  

 20 

 
Estimated Purchase Price, less the sum of the Holdback Amount and the Dissenting Share Amount. The “Closing Payment Cash” shall be an
amount equal to (A) the product of (x) the Estimated Purchase Price less the Indemnification Amount and (y) the Cash Percentage, less (B) the sum of the True-Up Reserve Amount, the Stockholder Fund Amount and the Dissenting Share
Amount. 
 (iii) The cash component of the Closing Payment shall be invested at the discretion, and for the benefit, of
Eclipsys or the Surviving Corporation, as the case may be, pending payment therefor by the Paying Agent to the Effective Time Company Holders. Earnings from such investments shall be the sole and exclusive property of Eclipsys or the Surviving
Corporation, as the case may be, and no part thereof shall accrue to the benefit of Effective Time Company Holders. 
 (iv) If
any Shares become Dissenting Shares after the payment by Eclipsys or the Surviving Corporation to the Paying Agent of the Closing Payment, Eclipsys may instruct the Paying Agent to, and the Paying Agent shall promptly upon receipt of such
instruction, remit to Eclipsys the portion of the Closing Payment allocable to such Dissenting Shares. 
 (b) At the Closing,
Eclipsys shall deposit or cause to be deposited the Holdback Amount with the Escrow Agent. The Holdback Amount shall be held and invested in, and distributed out of, three (3) separate escrow accounts, all as provided in the Holdback Escrow
Agreement and this Agreement (the “Escrow Accounts”). The Escrow Account for the Indemnification Amount shall be used to pay Damages, if any, to the Eclipsys Indemnified Parties. The Escrow Account for the Stockholder Fund
Amount shall be available to pay Seller Transaction Expenses and to reimburse the Stockholders’ Representative for out-of-pocket costs and expenses incurred in the performance of his or her duties hereunder, including fees of attorneys and
accountants employed by the Stockholders’ Representative necessary to discharge his or her duties as Stockholders’ Representative. Notwithstanding the foregoing, the Stockholders’ Representative may direct in writing that certain
Seller Transaction Expenses be paid at Closing, rather than such amounts being paid into the Escrow Account for the Stockholder Fund Amount. The Escrow Account for the True-Up Reserve Amount shall be used to pay to Eclipsys any shortfall if the
Estimated Purchase Price exceeds the Purchase Price, with the balance of any amount not so used being transferred to the Escrow Account for the Stockholder Fund Amount upon written instructions of the Stockholders’ Representative to the Escrow
Agent, which may be given any time after payments pursuant to Section 2.10(d) have been made. Promptly following the date that is 456 days after the Closing Date (the “Holdback Termination Date”), Eclipsys and the
Stockholders’ Representative shall give joint written instructions to the Escrow Agent to (A) retain any portion of the Escrow Account for the Indemnification Amount subject to good faith pending claims by Eclipsys under this Agreement or
the other Transaction Documents (the “Claimed Amount”) as of such date, and (B) pay any remaining part of the funds in such Escrow Account to the Effective Time Company Holders according to Section 2.7(g).
Any Claimed Amount unpaid at the Holdback Termination Date shall be paid pursuant to the Holdback Escrow Agreement upon a final resolution of the applicable claim. Promptly following the Holdback Termination Date, the Stockholders’
Representative shall give written instructions to the Escrow Agent to pay any remaining part of the funds in the Escrow Account for the Stockholder Fund Amount to the Effective Time 

  

 21 

 
Company Holders according to Section 2.7(g). The interests of the Effective Time Company Holders in the Escrow Accounts shall not be assignable
or transferable, whether directly, indirectly or by operation of law, except in the event of death to an Effective Time Company Holder’s estate, personal representative or heirs by will or the laws of descent and distribution; provided,
however, that as a condition to any such transfer the transferee(s) shall hold such interests subject to the terms and conditions of this Agreement and the Holdback Escrow Agreement and the transferee(s) shall execute and deliver to Eclipsys and
the Escrow Agent an agreement in form and substance satisfactory to Eclipsys agreeing to be bound by the terms and conditions of this Agreement and the Holdback Escrow Agreement. 
 (c) As promptly as practicable after the Closing Date, Eclipsys or the Surviving Corporation, shall cause the Paying Agent to mail to each
Effective Time Company Holder whose Company Capital Stock was converted with the right to receive the consideration described in Section 2.7: (i) a letter of transmittal in form acceptable to Eclipsys; and (ii) instructions for
surrendering certificates that represented Shares immediately prior to the Effective Time (“Certificates”) and any instruments representing Company Options or Company Warrants (“Instruments”), in
exchange for payment therefor (other than holders of Certificates representing Dissenting Shares). Upon surrender of a Certificate for cancellation to the Paying Agent or such other agent or agents as may be appointed by Eclipsys, together with such
letter of transmittal duly executed and delivered, the holder of such Certificate shall become entitled to receive in exchange therefor (as promptly as practicable thereafter), the consideration specified in Section 2.7(c). Upon
surrender, such Certificate will be cancelled. Upon receipt of a duly executed and delivered letter of transmittal by Eclipsys and any associated Instrument, the holder of Company Options or Company Warrants will become entitled to receive (as
promptly as practicable thereafter) consideration therefor in accordance with Section 2.7(d) or Section 2.7(e), as applicable. No portion of any Merger Consideration will be paid to the holder of any Shares, Company Options
or Company Warrants until a letter of transmittal has been validly executed and delivered pursuant hereto, with all Certificates and related Instruments. Payment pursuant to this Section 2.9(c) will be made ratably by the Paying Agent
from the Closing Payment, provided that if at the time of any payment hereunder, the Final Closing Date Net Working Capital, the Final Closing Date Cash and the Final Closing Date Debt shall have been determined pursuant to
Section 2.10(d), such payment hereunder shall be based on any adjusted amounts pursuant to the provisions of Section 2.10(d). If payment in respect of any Certificate or Instrument is to be made to a Person other than the
Person in whose name such Certificate or Instrument is registered, it shall be a condition of payment that the Certificate or Instrument so surrendered shall be properly endorsed or shall otherwise be in proper form for transfer, that the signatures
on such Certificate or Instrument or any related stock power shall be properly guaranteed and that the Person requesting such payment shall have established to the satisfaction of Eclipsys and the Paying Agent that any transfer and other Taxes
required by reason of such payment to a Person other than the registered holder of such Certificate or Instrument have been paid or are not applicable. Until surrendered in accordance with the provisions of this Section 2.9, any
Certificate (other than Certificates representing Shares described in Section 2.7(a) and any Dissenting Shares) or Instrument shall be deemed, at any time after the Effective Time, to represent only the right to receive (upon execution
and delivery as described herein) the portion of the Merger Consideration payable with respect thereto, including cash, without interest, as contemplated herein. 
  

 22 

 (d) At the Effective Time, the stock transfer books of MediNotes shall be closed and
there shall thereafter be no further registration of transfers of any Shares, Company Options or Company Warrants, or any conversion or exercise thereof. If, after the Effective Time, a Certificate or Instrument (other than a Certificate
representing Shares described in Section 2.7(a)) is presented to the Surviving Corporation, it shall be cancelled and exchanged as provided in this Section 2.9 (subject to Section 2.8 with regard to Dissenting
Shares). 
 (e) All Merger Consideration paid upon conversion of the Shares in accordance with the terms of this
Article II and all Merger Consideration deposited with the Escrow Agent pursuant to Section 2.9(b), in each case, subject to adjustment as set forth in Section 2.10, shall be deemed to have been paid in full
satisfaction of all rights pertaining to such Shares. From and after the Effective Time, the holders of Certificates shall cease to have any rights with respect to the Shares represented thereby, except as otherwise provided herein or by applicable
law. 
 (f) If any Certificate (other than a Certificate representing Dissenting Shares) or Instrument shall have been lost,
stolen or destroyed, upon the making of an affidavit of that fact by the holder thereof, the Surviving Corporation shall pay or cause to be paid in exchange for such lost, stolen or destroyed Certificate or Instrument the relevant portion of the
Merger Consideration payable in respect thereof pursuant to Section 2.9(c) for the Shares, Company Options or Company Warrants represented thereby; provided, however, that the Surviving Corporation or the Paying Agent may, in
their discretion, require the delivery of a satisfactory indemnity. 
 (g) Promptly following the date that is 180 days after
the Effective Time, Eclipsys shall be entitled to require the Paying Agent to deliver to it any funds and other property (including any interest or other income received with respect thereto) that had been made available to the Paying Agent and that
have not been disbursed to Effective Time Company Holders, and any Certificates, Instruments or other documents relating to the Merger in its possession, and thereafter such holders shall be entitled to look to Eclipsys only as general creditors
thereof with respect to any portion of the Merger Consideration payable upon due surrender of their Certificates or Instruments, without interest. Notwithstanding anything to the contrary in this Section 2.9, to the fullest extent
permitted by Legal Requirements, none of the Paying Agent, Eclipsys or the Surviving Corporation shall be liable to any holder of a Certificate or Instrument for any amount properly delivered to a public official pursuant to any applicable abandoned
property, escheat or similar Legal Requirements. 
 (h) The amount of the Merger Consideration payable to holders of Shares,
the Company Warrants and the Company Options and any other applicable numbers or amounts, shall be adjusted as necessary to reflect appropriately the effect of any stock split, reverse stock split, stock dividend (including any dividend or
distribution of securities convertible into Shares), reorganization, recapitalization, reclassification or other like change with respect to Company Capital Stock occurring or having a record date on or after the date hereof and prior to the
Effective Time. 
  

 23 

 2.10 Calculation of Net Working Capital, Closing Payment and Final Adjustments. 
 (a)(i) The Current Assets, the Current Liabilities, the Final Closing Date Net Working Capital, the Estimated Closing Date Net Working
Capital, the Final Closing Date Debt, the Estimated Closing Date Debt, the Final Closing Date Cash and the Estimated Closing Date Cash shall be calculated, as applicable (A) consistent with the hypothetical calculations set forth in Schedule
2.10; (B) consistent with the practices and policies of MediNotes used in preparing the Financial Statements; and (C) with all normal and recurring accounting entries reflected therein and all errors and omissions corrected.

 (ii) Each line item component or subcomponent of the Current Assets, Current Liabilities, the Final Closing Date Debt, the
Estimated Closing Date Debt, the Final Closing Date Cash and the Estimated Closing Date Cash shall be calculated in conformity with GAAP. 
 (iii) For purposes of calculating the Current Assets, the Current Liabilities, the Final Closing Date Net Working Capital, the Estimated Closing Date Net Working Capital, the Final Closing Date Debt and the Estimated
Closing Date Debt, such calculation shall not take into account (A) the impact of any purchase accounting adjustments relating to Eclipsys’s acquisition of MediNotes, including any write-up or write-down of assets or liabilities resulting
from such purchase accounting, or (B) any Seller Transaction Expenses unpaid as of the Closing Date, provided such expenses are (y) less than or equal to the Stockholder Fund Amount available for payment thereof and (z) paid on or
before the date that is 59 days after the Closing Date. 
 (iv) At least two Business Days prior to the Closing Date,
MediNotes shall provide Eclipsys with its good faith estimate of the Seller Transaction Expenses that will not be paid on or before the Closing Date. The Stockholders’ Representative shall give prompt written instructions to the Escrow Agent to
pay any of the Seller Transaction Expenses not paid on or before the Closing Date out of the Stockholder Fund Amount within 59 days after the Closing Date. If the Seller Transaction Expenses exceed the amount in the Stockholder Fund Amount, the
portion, if any, of such excess paid by Eclipsys to the creditors thereof shall be reimbursed to Eclipsys by the Stockholders in their Pro Rata Portion, in cash, or, at Eclipsys’s option, paid to Eclipsys from the Escrow Account for the
Indemnification Amount. 
 (b) At least five Business Days prior to the Closing Date, MediNotes shall deliver to Eclipsys its
good faith calculations of the Estimated Closing Date Net Working Capital, the Estimated Closing Date Cash and the Estimated Closing Date Debt. Within two Business Days after receipt of such calculations, Eclipsys shall provide MediNotes with
Eclipsys’s written comments thereto, and MediNotes shall in good faith consider any such comments. Estimated Closing Date Net Working Capital, Estimated Closing Date Cash and Estimated Closing Date Debt shall be as agreed by the parties,
provided that if they do not agree, then such amounts shall be as calculated by MediNotes, provided further that if the Estimated Purchase Price exceeds $42,000,000, then if Eclipsys so elects, the Closing will be delayed until the parties
agree on the Estimated Purchase Price. 
  

 24 

 (c)(i) Within 60 days following the Closing, Eclipsys shall prepare and deliver to the
Stockholders’ Representative a balance sheet of MediNotes as of the Closing Date showing Eclipsys’s good faith determination of the Final Closing Date Net Working Capital, the Final Closing Date Cash and the Final Closing Date Debt (the
“Eclipsys Final Calculations”). 
 (ii) On or before the date which is 15 days after the date of
Eclipsys’s delivery to the Stockholders’ Representative of the Eclipsys Final Calculations, the Stockholders’ Representative shall deliver to Eclipsys a notice of objection, stating in reasonable detail the grounds for such objection
and signed by the Stockholders’ Representative (an “Objection Notice”), or a notice of acceptance signed by the Stockholders’ Representative (an “Acceptance Notice”), with respect to the
Eclipsys Final Calculations. Eclipsys shall provide the Stockholders’ Representative and any accountants and other representatives engaged by the Stockholders’ Representative, upon reasonable advance notice, access to such books and
records of MediNotes relating to the Eclipsys Final Calculations as may be reasonably requested by the Stockholders’ Representative. 
 (iii) The Eclipsys Final Calculations shall be final and binding on the parties if an Acceptance Notice is delivered to Eclipsys or if no Objection Notice is delivered to Eclipsys with respect to such amounts within
the 15 day period required by Section 2.10(c)(ii). If an Objection Notice is delivered, the potential dispute with respect to the Eclipsys Final Calculations shall be resolved as set forth in Section 2.11, and the Final
Closing Date Net Working Capital, the Final Closing Date Cash or the Final Closing Date Debt, to the extent in dispute, determined pursuant to such procedures, in addition to the undisputed amounts, shall be final and binding on the parties.

 (d) Upon determination of the Final Closing Date Net Working Capital, the Final Closing Date Cash and the Final Closing
Date Debt pursuant to Section 2.10(c), Eclipsys shall determine the Purchase Price. If the Purchase Price exceeds the Estimated Purchase Price, then Eclipsys shall deposit with the Paying Agent an amount in cash (subject to
Section 2.12), equal to the difference (less a ratable portion attributable to any Dissenting Shares), which the Paying Agent shall distribute to the holders of Participating Shares (other than holders of Dissenting Shares) according to
Section 2.7. If the Purchase Price is less than the Estimated Purchase Price, then the Stockholders’ Representative shall provide written instructions to the Escrow Agent to pay that shortfall in cash to Eclipsys out of the True-Up
Reserve Amount, and if the shortfall exceeds the True-Up Reserve Amount, such excess will be paid to Eclipsys by the Effective Time Company Holders in their Pro Rata Portion, if any, in cash, or, at Eclipsys’s option, paid to Eclipsys from the
Indemnification Amount. Payments pursuant to this Section 2.10(d) shall be made in cash (subject to Section 2.12) by wire transfer of immediately available funds within five Business Days after, as applicable, the delivery of the
Acceptance Notice, the expiration of the 15 day period, if no Objection Notice is delivered, the agreement of the parties after consultation, or the issuance by the Unrelated Accounting Firm of its final report pursuant to Section 2.11.
Notwithstanding anything contained herein to the contrary, if the Purchase Price exceeds the Estimated Purchase Price, but in an amount less than $250,000, then Eclipsys shall deposit with the Escrow Agent, for addition to the Escrow Account for the
Indemnification Amount, such difference. Further, if the Purchase Price exceeds the Estimated 

  

 25 

 
Purchase Price by more than $250,000, but the Paying Agent has paid to Effective Time Company Holders more than 50% of the Closing Payment, then Eclipsys may
make such payment directly to the Effective Time Company Holders, in its discretion. 
 2.11 Dispute Resolution of Calculation of Net
Working Capital, the Closing Date Cash or the Closing Date Debt. If an Objection Notice is given with respect to any or all of the Eclipsys Final Calculations, the Stockholders’ Representative and Eclipsys shall consult with each other with
respect to the objection. If Eclipsys and the Stockholders’ Representative are unable to reach agreement within 15 days after an Objection Notice has been given, any unresolved disputed items shall be promptly referred to the Dallas, Texas
office of such nationally recognized independent accounting firm, or economic consulting or valuation firm, as is mutually agreed to by Eclipsys and the Stockholders’ Representative (the “Unrelated Accounting Firm”). The
Unrelated Accounting Firm shall be directed to render a written report on the unresolved disputed issues as promptly as practicable (but in no event later than 45 days following submission of the matter to the Unrelated Accounting Firm) and to
resolve only those issues of dispute set forth in the Objection Notice (subject to any items resolved by the parties after consultation pursuant to the first sentence of this Section 2.11). In resolving any disputed issues relating to
the Eclipsys Final Calculations, the Unrelated Accounting Firm shall act as experts and not as arbitrators. The resolution by the Unrelated Accounting Firm of the disputed amount, and the undisputed amounts, shall be final and binding on the parties
for purposes of determining the Final Closing Date Net Working Capital, the Final Closing Date Cash and the Final Closing Date Debt, and the amounts owed by the parties under Sections 2.10(d), if any. The Effective Time Company Holders shall
promptly pay the entire amount of the expenses of the Unrelated Accounting Firm if the Unrelated Accounting Firm determines Eclipsys to be correct in its determination, net in the aggregate, of the Final Closing Date Net Working Capital, the Final
Closing Date Cash and the Final Closing Date Debt. Eclipsys shall promptly pay the entire amount of the expenses of the Unrelated Accounting Firm if the Unrelated Accounting Firm determines the Stockholders’ Representative to be correct, net in
the aggregate, in his or her determination of the Final Closing Date Net Working Capital, the Final Closing Date Cash and the Final Closing Date Debt. If neither Eclipsys nor the Stockholders’ Representative is correct, then Eclipsys and the
Effective Time Company Holders shall share the expenses of the Unrelated Accounting Firm in such proportion as the Unrelated Accounting Firm may determine appropriately reflects the relative accuracy of their respective determinations. If the
Effective Time Company Holders are obligated to pay some or all of the expenses of the Unrelated Accounting Firm, the Stockholders’ Representative shall give written instructions to the Escrow Agent to make any such payment out of the Escrow
Account for the Stockholder Fund Amount. If the remaining funds in the Escrow Account for the Stockholder Fund Amount are insufficient to make such payment, such additional cash as may be required to make such payment shall promptly be paid to the
Unrelated Accounting Firm by the Effective Time Company Holders in their Pro Rata Portion, or, if the Effective Time Company Holders fail to do so, the expenses or the portion of the expenses of the Unrelated Accounting Firm allocable to the
Effective Time Company Holders may, at Eclipsys’s option, be paid from the Escrow Account for the Indemnification Amount. 
 2.12
Continuity of Interest Adjustments. Notwithstanding anything in this Agreement to the contrary, if the product of (A) the number of shares of Eclipsys Common Stock to be issued in the Merger in exchange for Shares (without taking account
of any shares of Eclipsys 

  

 26 

 
Common Stock that is transferred into the Escrow Account) (the “Stock Consideration”) and (B) the Testing Price of Eclipsys
Common Stock as reported on the Nasdaq Stock Market for the trading session that closes immediately before the Effective Time (or other applicable valuation date under Treasury Regulation Section 1.368-1(e)(2) for purposes of testing the
continuity of interest requirement under Treasury Regulation Section 1.368-1(e)) (such date the “Valuation Date” and such product the “Value of Stock Consideration”) is less than 40% of the sum of
the Value of Stock Consideration and the amount of Non-Stock Consideration (as defined below), then the amount of Non-Stock Consideration shall be reduced and the number of shares of Eclipsys Common Stock issued in the Merger in exchange for Shares
shall be increased pro rata based on the cash consideration to which any Effective Time Company Holder is otherwise entitled pursuant to the Merger so as to cause such percentage to be equal to 40%. The additional shares of Eclipsys Common Stock to
be issued in lieu of cash in exchange for Shares pursuant to the preceding sentence shall be determined using a per share value equal to the Average Market Price. For purposes of this paragraph, the “Non-Stock Consideration”
shall mean (a) any cash consideration paid pursuant to the Merger (including cash included in the Holdback Amount and any adjustment payment pursuant to Section 2.10(d)), (b) any cash and the fair market value of any property
that is distributed, transferred or paid by MediNotes to its stockholders (whether in a redemption transaction or as a dividend distribution) in connection with the Merger, and (c) any other cash or property (other than shares of Eclipsys
Common Stock) that is transferred, paid or distributed by Eclipsys (or any Person related to Eclipsys within the meaning of Treasury Regulation Section 1.368-1(e)(3)) to holders of Shares in exchange for such Shares in connection with the
Merger (including any payments of expenses incurred in connection with the disposition of fractional shares in the Merger). The “Testing Price” shall be the lowest trading price of the Eclipsys Common Stock on the Valuation
Date. 
 2.13 Approval. The receipt of the Company Stockholder Approval shall be deemed to constitute approval of all arrangements
relating to the transactions contemplated hereby and to the provisions hereof binding upon the Stockholders and the Effective Time Company Holders. 
 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF THE MAJOR 
 STOCKHOLDERS 
 Except as set forth in the disclosure schedule delivered to
Eclipsys concurrent herewith, that is arranged in Sections corresponding to the numbered and lettered Sections contained in this Agreement (the “Disclosure Schedule”), each Major Stockholder, severally but not jointly, and
only as to itself, represents and warrants to Eclipsys, as of the date of this Agreement and as of the Closing Date, as follows: 
 3.1
Ownership of the Shares, Company Options and Company Warrants. Such Major Stockholder is the sole record and beneficial owner of the Shares, Company Options and Company Warrants set forth next to such Stockholder’s name in
Section 3.1 of the Disclosure Schedule, has good and valid title in such Shares, Company Options and Company Warrants, free and clear of all adverse claims and other Liens, and its interests in MediNotes represented by such Shares,
Company Options and Company Warrants shall be transferred to Eclipsys in the Merger free and clear of all adverse claims and other Liens (other than Liens arising from the actions of Eclipsys). Such Shares are duly registered in the name of such
Major Stockholder on 

  

 27 

 
the stock register of MediNotes. Such Company Options and Company Warrants are duly registered in the name of such Major Stockholder on the option or warrant
register of MediNotes, as applicable. Except for this Agreement, the Stockholders Agreement and the Voting Agreement, the Shares are not subject to any voting trust or stockholder agreement or other similar Contract, including any such Contract
restricting or otherwise relating to the voting, dividend rights or disposition of the Shares. 
 3.2 Authorization, Validity, and Effect
of Agreements. Such Major Stockholder has all requisite right, capacity, power and authority to execute and deliver this Agreement and the other Transaction Documents to be executed and delivered by such Major Stockholder and to consummate the
transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered by such Major Stockholder and constitutes, and the other Transaction Documents to be executed by such Major Stockholder (when executed and delivered
pursuant hereto) will constitute, the valid and legally binding obligations of such Major Stockholder, enforceable in accordance with their respective terms, subject to applicable bankruptcy, insolvency, moratorium, fraudulent conveyance,
reorganization or other similar laws relating to creditors’ rights and general principles of equity, whether in equity or at law. 
 3.3
No Violations; Consents. 
 (a) The execution and delivery by such Major Stockholder of this Agreement, and the other
Transaction Documents and the consummation of the transactions contemplated herein and therein in accordance with the terms hereof and thereof do not and will not (i) violate any settlement agreement, Order or material Legal Requirement
applicable to such Major Stockholder, or such Major Stockholder’s properties or assets, or (ii) violate, or conflict with, or result in a material breach of any provision of, or constitute a material default (or an event which, with notice
or lapse of time or both, would constitute a material breach or default) under, any of the terms, conditions or provisions of any Contract to which such Major Stockholder is a party or by which such Major Stockholder’s assets or properties are
bound (including the Shares). 
 (b) No Consent is required to be made by or with respect to such Major Stockholder in
connection with the execution, delivery and performance of this Agreement and the other Transaction Documents, or the consummation of the transactions contemplated hereby and thereby. 
 (c) There are no pending or Threatened lawsuits, arbitrations, proceedings, investigations or other claims against such Major Stockholder
that would be reasonably expected to prevent or materially alter or delay the transactions contemplated by this Agreement and the other Transaction Documents. 
 (d) If the Major Stockholder is not an individual, neither the execution and delivery by such Major Stockholder of this Agreement or the
other Transaction Documents, nor the consummation by such Major Stockholder of the transactions contemplated herein and therein in accordance with the terms hereof and thereof, will conflict with or result in a breach of any provisions of its
articles of incorporation or by-laws, trust agreement or other governing documents. 
  

 28 

 3.4 Related Party Transactions. 
 (a) Neither such Major Stockholder nor any Affiliate or any immediate family member thereof: 
 (i) has, or at any time since January 1, 2007 had, any interest in any assets or property (whether real, personal, or mixed and
whether tangible or intangible), used by MediNotes, or otherwise used in or pertaining to the Business; 
 (ii) owns, or at
any time since January 1, 2007 has owned (of record or as a beneficial owner) Capital Stock or other financial interest in, any Person that (A) has, or at anytime since January 1, 2007 had, business dealings with MediNotes or a
material financial interest in any transaction with MediNotes, or (B) is, or at anytime since January 1, 2007 has, engaged in activities that are, or could reasonably be expected to become, competitive with the Business, except in each
case for (1) the acquisition of Company Capital Stock or (2) ownership (of record or as a beneficial owner) of less than one percent (1%) of the outstanding capital stock of any Person that is publicly traded on any national or
foreign stock exchange, or the over-the-counter market; or 
 (iii) is, or since January 1, 2007 was, a party to any
Contract with, or has any claim or right against, MediNotes, with the exception of (x) any applicable Stockholder Note, (y) the Stockholders Agreement and agreements to purchase Shares, all of which have been fully performed or will be
extinguished on or before the Effective Time, and (z) as to Travis Bond only, (A) the royalty agreement entered into by MediNotes and the Bond Entities, dated December 8, 2007, which was terminated and of no further force and effect
on February 25, 2008, and (B) the royalty agreement entered into by MediNotes with the Bond Entities, pursuant to the Bond Agreement, under which MediNotes has performed all obligations required to be performed by it and is not in breach
or default thereunder. 
 (b) There are no Contracts between (i) such Major Stockholder, or his or its Affiliates (other
than MediNotes), or, if applicable, any immediate family member of such Major Stockholder, on the one hand, and (ii) any officer, director or employee of MediNotes, on the other hand, provided that if such Major Stockholder is an Institutional
Major Stockholder, the representations in this Section 3.4(b) shall be made to the Knowledge of such Institutional Major Stockholder. 
 (c) If the Major Stockholder holds a Stockholder Note, MediNotes is not in default with respect to such Stockholder Note, nor do any facts or circumstances exist that will, or with notice or lapse of time would,
constitute a default under any such Stockholder Note. 
 3.5 Investment Intent. 
 (a) Such Major Stockholder represents and acknowledges to Eclipsys that the Stock Consideration to be received by such Major Stockholder
pursuant to this Agreement is being acquired by such Major Stockholder for its own account and not with a view to the distribution thereof. 
  

 29 

 (b) Such Major Stockholder, alone or together with the Persons it has retained to advise
it with respect to the transactions contemplated hereby and the proposed investment in the Stock Consideration to be received by such Major Stockholder pursuant to this Agreement, has such knowledge and experience in business and financial matters
that it is capable of evaluating the merits and risks of such proposed investment. Such Major Stockholder acknowledges and understands that the Stock Consideration has not been registered under the Securities Act and therefore, cannot be sold
without registration under the Securities Act or pursuant to an exemption from the registration requirements of the Securities Act. 
 (c) Each Major Stockholder understands that shares of Eclipsys Common Stock issued in certificate form as part of the Merger Consideration will bear, and any other document that evidences uncertificated shares delivered as part of the
Merger Consideration will bear, the following legend: 
 “THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR UNDER STATE SECURITIES LAWS, AND SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED UNLESS SUCH SALE OR TRANSFER WILL BE EFFECTED IN ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AT THAT TIME
AMENDED, AND SUCH STATE SECURITIES LAWS, OR IN ACCORDANCE WITH AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND SUCH STATE SECURITIES LAWS, WHICH MAY THEN BE AVAILABLE THERETO.” 
 (d) Such Major Stockholder understands that Eclipsys will remove such legend and transfer restriction only in the event that (i) such
Major Stockholder transfers the Stock Consideration received as Merger Consideration pursuant to and in the manner provided for in an effective registration statement covering the transfer or sale of such shares, or (ii) such Major Stockholder
shall have delivered to Eclipsys a letter from the staff of the SEC, or an opinion of counsel in form and substance satisfactory to Eclipsys to the effect that such legend is not required under or for the purposes of the Securities Act and any
applicable state securities laws or (iii) counsel to Eclipsys has advised Eclipsys that shares that would be subject to removal of the transfer restriction represent only such number of shares of Eclipsys Common Stock as such Major Stockholder,
in a single transaction, could then sell under Rule 144 promulgated under the Securities Act. 
 (e) Such Major Stockholder
has delivered to Eclipsys an Investor Questionnaire in the form attached hereto as Exhibit F, and the information set forth in such Investor Questionnaire is true, correct and complete. Such Major Stockholder understands that Eclipsys will
rely on such Investor Questionnaire and the other representations of such Major Stockholder set forth herein in issuing the Stock Consideration to be received as Merger Consideration by such Major Stockholder. 
  

 30 

 ARTICLE IV 
 REPRESENTATIONS AND WARRANTIES OF MEDINOTES 
 Except as set forth in the Disclosure Schedule,
MediNotes represents and warrants to Eclipsys, as of the date of this Agreement and as of the Closing Date, as follows: 
 4.1 MediNotes
Existence; Good Standing. MediNotes is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Iowa. MediNotes is licensed or qualified to do business as a foreign corporation and in good standing in
each of the jurisdictions listed on Section 4.1 of the Disclosure Schedule. MediNotes is not required to be licensed or qualified to do business as a foreign corporation under the laws of any other jurisdiction, except where the lack of
such license or qualification would not reasonably be expected to have a Material Adverse Effect on MediNotes or the Business. MediNotes has all requisite corporate power and authority to own, operate and lease its properties and assets and carry on
its business as now conducted. The copies of the MediNotes Articles of Incorporation and by-laws previously delivered, or made available, to Eclipsys are true, correct and complete, and such documents are in full force and effect and have not been
supplemented or amended since they were delivered or made available to Eclipsys. 
 4.2 Subsidiaries. MediNotes does not hold, nor has
it ever held, directly or indirectly, any Capital Stock of any other Person. There are no obligations or other Contracts, contingent or otherwise, of MediNotes to make any investment (in the form of a loan, capital contribution or otherwise) in any
other Person. 
 4.3 Capitalization. 
 (a) The authorized Capital Stock of MediNotes consists solely of 50,000,000 shares of Company Common Stock, of which 3,473,959 shares are issued and outstanding on the date hereof, and 25,000,000 shares of preferred
stock, of which (i) 1,250,000 shares are designated as Series A Preferred Stock, of which 422,654 shares are issued and outstanding on the date hereof, (ii) 1,100,000 shares are designated as Series B Preferred Stock, of which 936,842
shares are issued and outstanding on the date hereof, (iii) 1,000,000 shares are designated as Series C Preferred Stock, of which 729,271 shares are issued and outstanding on the date hereof, and (iv) 1,000 shares are designated as
Series D Preferred Stock, of which no shares are issued and outstanding on the date hereof. The Shares, Company Options and Company Warrants are held of record by the Persons and in the amounts set forth in Section 4.3(a)(i) of the
Disclosure Schedule, and except as set forth therein, there is no Capital Stock of MediNotes outstanding. The parties acknowledge that the outstanding shares set forth above may change prior to the Closing Date as a result of (A) conversion of
shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock outstanding on the date hereof according to the terms of such preferred stock or exercise of the Company Options and Company Warrants outstanding on the
date hereof according to terms of such Company Options or Company Warrants, as the case may be, in each case for shares of Company Common Stock, and (B) the issuance of 1,000 shares of Series D Preferred Stock pursuant to the terms and
conditions of the Settlement Agreement, and MediNotes agrees to provide the Capitalization Update on or before the Closing Date, which shall set forth an accurate and complete update of all such changes through the Closing Date, arising after the
date hereof in the holders of 

  

 31 

 
MediNotes Capital Stock, or the number and class of shares of MediNotes Capital Stock held by any such holder. Except for the Stockholders Agreement, the
Settlement Agreement and the Company Options and Company Warrants set forth in Section 4.3(a)(i) of the Disclosure Schedule, and the rights granted to Eclipsys and Merger Sub under this Agreement, there are no outstanding obligations of
MediNotes, contingent or otherwise, to issue, sell or transfer or repurchase, redeem or otherwise acquire, or that relate to the holding, voting or disposition of, or that restrict the transfer of, the issued or unissued Capital Stock of MediNotes.
Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock is convertible into one share of Company Common Stock. Shares of Series D Preferred Stock are not convertible. 
 (b) All issued and outstanding Shares are duly authorized, validly issued, fully paid and nonassessable, and none of such Shares has been
issued in violation of or, except as specified in the Stockholders Agreement, is subject to, any option, call, right of first refusal, preemptive, subscription or similar right. Except for the Settlement Agreement, the Company Options set forth in
Section 4.3(a)(i) of the Disclosure Schedule and the Company Warrants set forth in Section 4.3(a)(i) of the Disclosure Schedule, there are no options, warrants, calls, subscriptions, convertible securities, convertible debt
or other rights or other Contracts which obligate MediNotes to issue, or MediNotes or any of the Stockholders to transfer, any Capital Stock of MediNotes. The outstanding Company Capital Stock has been issued in compliance with all applicable Legal
Requirements. 
 (c) MediNotes does not have any outstanding bonds, debentures, notes or other obligations, the holders of
which have the right to vote (or which are convertible into or exercisable or exchangeable for securities having the right to vote) with its Stockholders on any matter and there are no equity equivalent interests in the ownership or earnings, or
distributions upon liquidation or sale of assets, of MediNotes. 
 (d) MediNotes is not in default or breach (and no event has
occurred which with notice or lapse of time or both, would constitute a breach or default) of any term or provision of the MediNotes Articles of Incorporation or its by-laws. 
 4.4 Material Contracts; No Violation. 
 (a) Except for the Contracts listed in Section 4.4(a) of the Disclosure Schedule, MediNotes is not a party to, and none of its assets or properties is bound by, any: 
 (i) Contract that involves performance of services or delivery of Software or other products of MediNotes or any other Person, except for
Contracts providing for payments by or to MediNotes of less than $25,000 in any instance or $100,000 in the aggregate; 
 (ii)
Contract with or obligation to any Governmental Entity, including but not limited to development agreements; 
 (iii) Contract
for the future purchase of materials, services or equipment (A) with a future Liability potentially in excess of $25,000 in any instance or $100,000 in the aggregate, or (B) that are not cancelable by MediNotes on no more than 60
days’ notice without liability, penalty or premium; 
  

 32 

 (iv) license, option, escrow agreement or other Contract relating in whole or in part to
Company IP, other than licenses contained in Contracts entered into in the ordinary course of business, consistent with past practice, with resellers and other customers of MediNotes for the delivery of Software or other products of MediNotes;

 (v) lease, sublease or similar Contract under which (A) it is a lessor or sublessor of real property owned by any
other Person, or makes available for use to any Person, any portion of any premises otherwise occupied, leased or subleased by it, or (B) it is a lessee or sublessee of, or holds or uses any real property owned by any other Person; 

(vi) lease, sublease or similar Contract under which (A) it is a lessee or sublessee of, or holds or uses, any machinery,
equipment, vehicle or other tangible personal property owned by any Person, or (B) it is a lessor or sublessor of, or makes available for use by any Person, any tangible personal property owned or leased by it, except in each case for Contracts
providing for payments by or to MediNotes of less than $25,000 in any instance or $100,000 in the aggregate; 
 (vii) Contract
with any of its officers, directors or employees or any of its former officers, directors or employees, including employee policies of MediNotes (including any severance pay or change in control agreement or policy of MediNotes to provide such
payments, and whether such payments are payable upon a termination that is voluntary or non-voluntary); 
 (viii) employee
collective bargaining agreement or other Contract with any labor union; 
 (ix) covenant not to compete or other Contract
restricting, or imposing requirements related to, the conduct or location of its business; 
 (x) management, consulting,
financial advisory or other similar type of Contract; 
 (xi) Contract under which it has borrowed any money from, or issued
any Debt to, any Person; 
 (xii) Contract under which it or any other Person has guaranteed Debt or other obligations
directly or indirectly; 
 (xiii) Contract that grants or contemplates the granting of a security interest in any of its
assets or property; 
 (xiv) Contract not entered into in the ordinary course of business; 
 (xv) Contract providing for indemnification of any Person; 
  

 33 

 (xvi) power of attorney; 
 (xvii) Tax sharing or Tax allocation agreement; 
 (xviii) joint venture or partnership agreement or similar Contract; 
 (xix) Contract (A) that commits MediNotes to make any fixed or contingent payment or expenditure or any related series of fixed or
contingent payments or expenditures totaling more than $100,000 in the aggregate, or (B) that does not terminate pursuant to its terms within one year of the date hereof, and is not cancelable by MediNotes within one year without liability,
penalty or premium; 
 (xx) Contract providing for the purchase or other acquisition of any business or operations of another
Person, whether through merger, stock purchase, asset purchase or otherwise; or 
 (xxi) any other Contract that is material
to it that is not otherwise listed in Section 4.4(a) of the Disclosure Schedule. 
 The Contracts listed on
Section 4.4(a) of the Disclosure Schedule, or required to be listed thereon, are referred to herein as the “Material Contracts.” 
 (b)(i) Each of the Material Contracts is valid, binding and in full force and effect and is enforceable against MediNotes, and to the
Knowledge of MediNotes, the other parties thereto, in accordance with its terms, subject to applicable bankruptcy, insolvency, moratorium, fraudulent conveyance, reorganization or other similar laws relating to creditors’ rights and general
principles of equity, whether in equity or at law, (ii) MediNotes has performed all material obligations required to be performed by it under the Material Contracts and it is not (with or without the lapse of time or the giving of notice, or
both) in breach or default in any material respect thereunder, (iii) to the Knowledge of MediNotes, (A) no other party to any Material Contract is (with or without the lapse of time or the giving of notice, or both) in breach or default in
any material respect thereunder, and (B) no event has occurred or circumstance or condition exists (with or without the lapse of time or the giving of notice, or both) that may contravene, conflict with, or result in a violation or breach of
any Material Contract, result in the termination or in a right of termination or cancellation of, or accelerate the performance required by, or result in the triggering of any payment obligations under, or result in the creation of any Lien upon any
of the assets or properties of MediNotes under, or result in being declared void, voidable, or without further binding effect, or result in any other modification of or trigger any right or obligation under, any Material Contract or provisions
thereof; (iv) no party to any Material Contract has given any written notice of an alleged breach thereof or otherwise Threatened such a breach; and (v) MediNotes has not received any written notice that any party to any Material Contract
intends to cancel or terminate such Material Contract, to renegotiate such Material Contract, or to exercise or not exercise any options thereunder, and no such intent to cancel, terminate, renegotiate or exercise has been otherwise Threatened.

 (c) Neither the execution and delivery by MediNotes of this Agreement and the other Transaction Documents, nor the
consummation of the Merger and Second Merger, and any other transactions contemplated herein and therein in accordance with the terms hereof and 

  

 34 

 
thereof, will violate, or conflict with, or result in a breach of any provision of, or constitute a material default (or an event that, with notice or lapse
of time or both, would constitute a breach or default) under, or result in the termination or in a right of termination or cancellation of, or accelerate the performance required by, or result in the triggering of any payment obligations under, or
result in the creation of any Lien upon any of the assets or properties of MediNotes under, or result in being declared void, voidable, or without further binding effect, or result in any other modification of or trigger any right or obligation
under, any Material Contract or provision thereof. 
 (d) No Consent of any party to a Material Contract is required in
connection with the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the Merger and Second Merger, and any other transactions contemplated hereby and thereby. 
 (e) True, complete and accurate copies (or, as to oral Contracts, written summaries of the terms), of the Material Contracts entered into
on or prior to the date hereof have been provided to Eclipsys, or will be provided to Eclipsys within five Business Days after the date hereof, and true, complete and accurate copies (or, as to oral Contracts, written summaries of the terms) of any
Material Contracts entered into after the date hereof and prior to or on the Closing Date will be provided to Eclipsys promptly after being so entered into. There are no terms of any Material Contract not set forth in the copies thereof provided to
Eclipsys. The terms and conditions of all of the Material Contracts were negotiated at arm’s length. 
 4.5 Financial Statements; No
Undisclosed Liabilities. 
 (a) Section 4.5(a) of the Disclosure Schedule sets forth true and complete copies
of (i) MediNotes’ balance sheet, and related statement of income, statement of cash flows and changes in stockholders equity as of and for the twelve-month periods ended December 31, 2007, 2006, and 2005, in each case audited by LWBJ,
LLP, independent certified public accountants, with such accountant’s unqualified reports attached thereto (the “Year-End Financial Statements”), and (ii) MediNotes’ balance sheet and related statement of
income and cash flows as of and for the six months ended June 30, 2008 (the “Interim Financial Statements”). The Year-End Financial Statements and the Interim Financial Statements are collectively referred to herein as
the “Financial Statements”). 
 (b) The Financial Statements (i) were prepared by MediNotes in
accordance with the books and records of MediNotes, (ii) are true, correct and complete in all material respects, and (iii) reflect the consistent application of all accounting principles, practices and methods of MediNotes throughout the
periods thereof, except as disclosed therein, and (iv) fairly present the financial condition and results of operation of MediNotes as of the dates and for the periods covered thereby, all in accordance with GAAP (consistently applied, except
as disclosed therein). The Financial Statements do not contain any material items of a special or nonrecurring nature, except as expressly stated therein. No financial statements of any other Person are required by GAAP to be included in the
financial statements of MediNotes. 
  

 35 

 (c) There are no Liabilities of MediNotes other than: (i) Liabilities accrued on the
balance sheet dated as of June 30, 2008; and (ii) current Liabilities incurred and unpaid since June 30, 2008 that have been incurred in the ordinary course of business consistent with past practice, are accrued on the balance sheet
of MediNotes as of the Closing Date, and are included in the calculations of the Estimated Current Liabilities, Estimated Closing Date Net Working Capital, Final Current Liabilities and the Final Closing Date Net Working Capital, as applicable.
Deferred revenue amounts indicated on the balance sheet dated as of June 30, 2008 do not, and Current Liabilities will not, reflect reserves for Threatened claims against MediNotes or claims that, to the Knowledge of MediNotes, are likely to be
made against MediNotes. 
 (d) None of the Stockholders or MediNotes have been advised by any independent certified public
accountant of MediNotes that there is a significant deficiency or material weakness in the design or operation of MediNotes’ internal controls. 
 4.6 Authority; No Violations; Consents. 
 (a) MediNotes has full corporate power and
authority to execute and deliver this Agreement and each of the Transaction Documents to which it will be a party and, subject to obtaining approval of the Stockholders, voting separately by each class and series representing a majority of the
outstanding Company Common Stock, the Series A Preferred Stock, the Series B Preferred Stock and the Series C Preferred Stock, respectively (the “Company Stockholder Approval”), to perform its obligations hereunder and
thereunder and to consummate the transactions contemplated hereby and thereby. The execution, delivery and performance by MediNotes of this Agreement and each of the Transaction Documents to which MediNotes will be party and the consummation by
MediNotes of the transactions contemplated hereby and thereby have been duly and validly authorized by the Board of Directors of MediNotes. Except for obtaining the Company Stockholder Approval, no other corporate proceedings on the part of
MediNotes are necessary to authorize the execution, delivery or performance of this Agreement or any other Transaction Document or to consummate the transactions contemplated hereby and thereby. This Agreement has been, and upon their execution each
of the other Transaction Documents to which MediNotes will be a party will have been, duly executed and delivered by MediNotes. This Agreement constitutes, and upon their execution each of the Transaction Documents to which MediNotes will be a party
will constitute, the legal, valid and binding obligations of MediNotes, enforceable against MediNotes in accordance with their respective terms, subject to applicable bankruptcy, insolvency, moratorium, fraudulent conveyance, reorganization or other
similar laws relating to creditors’ rights and general principles of equity, whether in equity or at law. 
 (b) The
execution and delivery by MediNotes of this Agreement, and the other Transaction Documents and the consummation of the transactions contemplated herein and therein in accordance with the terms hereof or thereof will not: 
 (i) conflict with or result in a breach of any provisions of the MediNotes Articles of Incorporation or its by-laws; or 
 (ii) violate any settlement agreement, Order or material Legal Requirement applicable to MediNotes, or its properties or assets; or

  

 36 

 (iii) result in the imposition of any Lien upon or with respect to any of the assets or
properties owned or used by MediNotes. 
 (c) No Consent is required to be made by or with respect to MediNotes in connection
with the execution, delivery and performance of this Agreement and the other Transaction Documents, and the consummation of the transactions contemplated hereby and thereby. 
 4.7 Compliance; Permits; Litigation. 
 (a) MediNotes is, and at all times has been, in compliance in all material respects with all settlement agreements, material Permits, Orders, and material Legal Requirements to which it or any of its properties,
assets, operations or business is subject and all non-governmental restrictions as to its property or asset use. To the Knowledge of MediNotes, no event has occurred or circumstance or condition exists that (with or without the lapse of time, the
giving of notice, or both) (A) may constitute or result in a violation by MediNotes of, or a failure on the part of MediNotes to comply in all material respects with the terms of any settlement agreement, material Permit, Order, or material
Legal Requirement, or (B) may give rise to any obligation of MediNotes to undertake or bear all or any portion of the cost of any material remedial action of any nature. Neither MediNotes nor any of the Stockholders has received any written
notice or other written communication from any Governmental Entity or other Person regarding any actual, alleged, possible or potential violation of, or failure to comply with, the terms of any settlement agreement, material Permit, Order, or
material Legal Requirement, or that give rise to any obligation of MediNotes to undertake, or bear all or any portion of the cost of, any material remedial action of any nature, and no such actual, alleged, possible or potential violation or failure
to comply or obligation has been otherwise Threatened. 
 (b) MediNotes has at all times obtained all material Permits. Except
where the failure to have a Permit would not individually or in the aggregate be material, MediNotes currently holds all of the Permits necessary to permit MediNotes to lawfully conduct and operate its business and to own and use its assets and
properties in the manner it currently operates the business and owns and uses such assets and properties, and all such Permits are in full force and effect. Section 4.7(b) of the Disclosure Schedule sets forth a list of the material
Permits held by MediNotes. No material Permit held by MediNotes (A) is scheduled to expire within the period beginning on the date hereof through six months after the Closing, or (B) will be subject to suspension, modification, revocation
or nonrenewal as a result of the execution and delivery of this Agreement and the other Transaction Documents, or the consummation of the transactions contemplated hereby and thereby. 
 (c) To the Knowledge of MediNotes, there is no proposed plan, proceeding or effort or proposed change to any Legal Requirements, whether
or not directly involving MediNotes, by any Governmental Entity or other Person which in any way challenges or would be reasonably expected to adversely affect MediNotes or the Business, including any Permits. 
 (d)(i) Section 4.7(d)(i) of the Disclosure Schedule sets forth a list and description of all pending, Threatened, or to the
Knowledge of MediNotes reasonably probable, lawsuits, arbitrations, proceedings, investigations or other claims against 

  

 37 

 
MediNotes, its officers, directors or employees (as such), or any of its properties, assets, operations or business, including but not limited to any action
which would be reasonably expected to prevent or materially alter or delay the transactions contemplated by this Agreement and the other Transaction Documents. 
 (ii) There is no lawsuit, arbitration, proceedings, investigations or other claim by MediNotes pending, threatened or contemplated against
any other Person. 
 (iii) To the Knowledge of MediNotes, no event has occurred or circumstance or condition exists that may
give rise to or serve as the basis for the commencement of any lawsuit, arbitration, proceeding, investigation or other claim described in Section 4.7(d)(i) or (ii). 
 (e) MediNotes is not a party to, and its assets and properties are not subject to, any Order, or any settlement agreement with any
Governmental Entity or arbitration tribunal or other Person. 
 4.8 Absence of Certain Changes. 
 (a) Since January 1, 2008, MediNotes has conducted its business only in the ordinary course of such business consistent with past
practice and there has not been: 
 (i) any event that has occurred or circumstance or condition that exists which,
individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect on MediNotes or the Business; 
 (ii) any declaration, setting aside or payment of any dividend or other distribution with respect to the Company Capital Stock or any redemption or repurchase of any Capital Stock of MediNotes, or, any other payment
by MediNotes of any kind to any Stockholder or any Affiliate of any Stockholder (other than salary or employment related expenses in the ordinary course of business consistent with past practice); 
 (iii) any material change in the accounting principles, practices or methods of MediNotes; 
 (iv) any amendment to the MediNotes Articles of Incorporation or its by-laws, except for amendments expressly contemplated in the Bond
Agreement; 
 (v) any increase in the salaries or other compensation payable to any officer, director or employee of MediNotes
or any increase in, or addition to, other benefits to which such officer, director or employee may be entitled (except as required by the terms of plans as in effect on the date of this Agreement and which are listed on Section 4.10(a)
of the Disclosure Schedule, as required by law, or, with respect to the employment terms of former employees of the Bond Entities who were employed by MediNotes in connection with the asset purchase transaction contemplated by the Bond Agreement,
changes made contemporaneously with and as a result of that transaction); 
  

 38 

 (vi) any material adverse change, or to the Knowledge of MediNotes, any threat of a
material adverse change, in the relations of MediNotes with, or any loss or threat of loss of, any of the suppliers or customers or employees of MediNotes; 
 (vii) any sale, assignment, transfer, license or other disposal of any Intellectual Property or interest therein, except licenses of the Software Products to customers in the ordinary course of business consistent
with past practice; 
 (viii) any termination, cancellation, amendment or waiver of any material Contract or other right
material to MediNotes, except for note and royalty cancellations expressly contemplated in the Bond Agreement; or 
 (ix) any
agreement to take any action or omit to take any action (A) described in this Section 4.8, or (B) that would constitute a breach of any of the representations and warranties of MediNotes or the Major Stockholders contained in
this Agreement. 
 (b) No actions or events have occurred that would violate the provisions of Sections 6.1(a) through
(t). 
 4.9 Taxes. 
 (a) All Tax Returns that were required to be filed by or with respect to MediNotes have been accurately prepared and timely filed. All such Tax Returns are true, correct, and complete in all respects and do not
contain a disclosure statement under Section 6662 of the Code or any predecessor provision or comparable provision of state, local or foreign Legal Requirements. MediNotes has at all times complied with applicable Legal Requirements pertaining
to Taxes, including, without limitation, all applicable Legal Requirements relating to record retention. 
 (b) MediNotes has
timely paid all Taxes that have become due or payable (without regard to whether or not such Taxes are shown on any Tax Return) and has established in the Interim Financial Statements an adequate reserve in accordance with GAAP for all Taxes (other
than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) that have accrued but are not yet due or payable as of the date of such statements. All Taxes of MediNotes accrued following the end of the
most recent period covered by the Interim Financial Statements have been accrued in the ordinary course of business and do not exceed comparable amounts incurred in similar periods in prior years, taking into account any changes in MediNotes’
operating results. The provisions for Taxes currently payable on the Interim Financial Statements are at least equal, as of the date thereof, to all unpaid Taxes of MediNotes as of the date of such statements. 
 (c) No claim has been made by any taxing authority in any jurisdiction where MediNotes does not file Tax Returns that MediNotes is or may
be subject to Tax by that jurisdiction and to the Knowledge of MediNotes no such claim is being contemplated. No extensions or waivers of statutes of limitations with respect to any Tax Returns or Taxes have been given by or requested from
MediNotes. No power of attorney has been granted by MediNotes with respect to any matter relating to Taxes. 
  

 39 

 (d) No foreign, federal, state or local Tax audits or administrative or judicial Tax
proceedings are pending, being conducted or are Threatened with respect to MediNotes and to the Knowledge of MediNotes no such action or proceeding is being contemplated. All deficiencies asserted or assessments made against MediNotes as a result of
any examinations, audits, or other proceedings by any Taxing authority have been fully paid. No issue has been raised in any such examination, audit, or other proceeding, which by application of the same or similar principles, reasonably could be
expected to result in a proposed deficiency in Taxes of MediNotes. 
 (e) There are no Liens for Taxes (other than for current
Taxes not yet due and payable) upon the assets or properties of MediNotes. No asset or property of MediNotes (i) is property that is required to be treated as being owned by any other Person pursuant to the so-called “safe harbor
lease” provisions of former Section 168(f)(8) of the Code; (ii) directly or indirectly secures any debt the interest on which is Tax exempt under Section 103(a) of the Code; or (iii) is “tax-exempt use property”
within the meaning of Section 168(h) of the Code. 
 (f) MediNotes is not a party to or bound by any closing agreement,
offer in compromise, or other Contract with any Taxing authority that could affect Taxes for which MediNotes or Eclipsys may be liable. MediNotes is not a party to or bound by any tax indemnity, tax sharing or tax allocation agreement. 

(g) MediNotes is not and has not been a member of an affiliated group of corporations, within the meaning of Section 1504 of the
Code, or a member of a combined, consolidated or unitary group for state, local or foreign Tax purposes. MediNotes has no liability for Taxes of any Person under Treasury Regulations Section 1.1502-6 or any corresponding provision of state,
local or foreign income Tax Legal Requirements, as transferee or successor, by Contract or otherwise. 
 (h) MediNotes is not
a party to any plan or other Contract that has resulted or would result, separately or in the aggregate, in connection with this Agreement, in the payment of any “excess parachute payments” within the meaning of Section 280G of the
Code. 
 (i) MediNotes has withheld and paid all Taxes required to have been withheld and paid in connection with any amounts
paid or owing to any employee, independent contractor, creditor, stockholder or other third-party. 
 (j) There is no taxable
income of MediNotes that is required under applicable Tax Legal Requirements to be reported by MediNotes for a taxable period beginning after the date hereof which taxable income was realized (and reflects economic income arising) prior to the date
hereof or relates to a transaction that occurred prior to the date hereof. MediNotes has not taken any action that is not in accordance with past practice that could defer a liability for Taxes of MediNotes from any taxable period ending on or
before the date hereof to any taxable period ending after such date. 
 (k) MediNotes will not be required to include any item
of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any (i) change in method of accounting for a taxable 

  

 40 

 
period ending on or prior to the Closing Date (including pursuant to Section 481(a) of the Code or any similar Legal Requirement),
(ii) “closing agreement” as described in Code Section 7121 (or any corresponding or similar provision of state, local or foreign Tax law) executed on or prior to the Closing Date, or (iii) installment sale or open
transaction disposition made on or prior to the Closing Date. 
 (l) MediNotes has not engaged in a transaction that
constitutes a “reportable transaction”, as such term is defined in Treasury Regulation Section 1.6011-4(b)(1). 
 (m) MediNotes is not subject to Tax, is not engaged in a business, and does not have a permanent establishment in any jurisdiction outside of the United States of America. 
 (n) MediNotes is not a party to any joint venture, partnership, or other arrangement or Contract that could be treated as a partnership
for federal income tax purposes. 
 (o) MediNotes is not, nor has it ever been, a United States real property holding
corporation, as defined in Section 897(c)(2) of the Code. 
 (p) MediNotes has not been a “distributing
corporation” or a “controlled corporation” in connection with a distribution described in Section 355 of the Code. 
 (q) None of the shares of MediNotes’ outstanding Capital Stock constitutes “restricted stock” (i.e., stock that is subject to a risk of forfeiture) for purposes of Section 83 of the Code with
respect to which an election under Section 83(b) of the Code has not been made. 
 (r) MediNotes does not currently hold,
and has not at anytime held, an interest in any Subsidiary that was organized under the laws of a jurisdiction outside the United States. 
 (s) Neither MediNotes nor, to the Knowledge of MediNotes, any of its Affiliates or shareholders has taken or has agreed to take any action that would prevent the Merger followed by the Second Merger from constituting
a reorganization qualifying under the provisions of Section 368(a) of the Code. 
 (t) All of MediNotes’
indebtedness, instruments, contracts, financial positions and other arrangements that MediNotes has treated as debt for U.S. federal income tax purposes (by deducting interest or otherwise) are properly classified as debt rather than as equity for
such purposes, and have not been treated as other than debt for any other purpose. None of MediNotes’ options and warrants are properly classified as stock of MediNotes for U.S. federal income tax purposes. 
 (u) MediNotes has not made, and will not make, any distributions to its shareholders prior to, in contemplation of, or otherwise in
connection with, the transactions contemplated by this Agreement. Neither MediNotes nor any Person related to MediNotes (as defined in Treasury Regulation Section 1.368-1(e)) has acquired or has any plan or intention to acquire any stock of
MediNotes in contemplation of the transactions contemplated by this Agreement or otherwise as part of a plan of which these transactions are part. 
  

 41 

 4.10 Certain Employee Plans. 
 (a) Section 4.10(a) of the Disclosure Schedule lists all Company Benefit Plans. With respect to each Company Benefit Plan,
true, complete and correct copies of such plans and the most recent summary plan descriptions thereof and any summaries of material modifications, if any, have been furnished to Eclipsys, along with the two most recent annual reports on
Form 5500 (including schedules) filed with the Internal Revenue Service for each Company Benefit Plan where such report is required and the most recent favorable IRS determination letter for each Company Benefit Plan that is intended to be
qualified pursuant to Section 401(a) of the Code. 
 (b) Neither MediNotes nor any ERISA Affiliate sponsors, maintains or
contributes to or has ever sponsored, maintained, contributed to, or incurred an obligation to contribute or incurred any liability (contingent or otherwise) with respect to any “multiemployer plan” (as such term is defined in
Section 3(37) of ERISA) or any other employee benefit plan that is subject to Title IV of ERISA, Part 3 of Subtitle B of Title I of ERISA or Section 412 of the Code. 
 (c) MediNotes does not provide any health, welfare or life insurance benefits to any of its former or retired employees other than
pursuant to Section 4980B of the Code or similar state laws. 
 (d) (i) Each Company Benefit Plan has been maintained and
operated in all material respects in accordance with its terms and all applicable Legal Requirements. 
 (ii) MediNotes has in
all material respects performed all obligations, whether arising by operation of any Legal Requirements or by Contract, required to be performed by it in connection with the Company Benefit Plans. 
 (iii) To the Knowledge of MediNotes, there have been no defaults or violations by any other party to the Company Benefit Plans.

 (iv) There are no actions, suits, or claims pending (other than routine claims for benefits) or Threatened against, or with
respect to, any of the Company Benefit Plans, there is no matter pending with respect to any of the Company Benefit Plans before any Governmental Entity, and to the Knowledge of MediNotes, there is no basis for any such action, suit or claim.

 (v) Each Company Benefit Plan intended to be qualified under Section 401(a) of the Code has been determined to be so
qualified by the Internal Revenue Service, and since the date of each most recent determination, no event has occurred, and no condition or circumstance exists, that has adversely affected or is reasonably likely to adversely affect such qualified
status. 
 (vi) Neither MediNotes, nor, to the Knowledge of MediNotes, any other fiduciary or party in interest of any Company
Benefit Plan has participated in, engaged in or been a party to any transaction that is prohibited under Section 4975 of the Code or Section 406 of ERISA and not exempt under Section 4975 of the Code or Section 408 of ERISA,
respectively. 
  

 42 

 (vii) MediNotes and, to the Knowledge of MediNotes, its ERISA Affiliates, have made full
and timely payment of all amounts required to be contributed or paid as expenses or accrued such payments in accordance with normal procedures under the terms of each Company Benefit Plan and applicable Legal Requirements. 
 (e) The execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated
hereby and thereby (either alone or in combination with any other action or event) will not (i) require MediNotes to make a larger contribution to, or pay greater benefits or provide other rights under, any Contract or Company Benefit Plan than
it otherwise would, (ii) create or give rise to any additional vested rights or service credits under any Contract or Company Benefit Plan, or (iii) entitle any employee, officer or director of MediNotes to severance, termination allowance
or similar payments. MediNotes is not a party to any Contract, nor has MediNotes established any other policy or practice, requiring it to make a payment or provide any other form of compensation or benefit to any person performing services for
MediNotes upon termination of such services which would not be payable or provided in the absence of the consummation of the transactions contemplated by this Agreement. 
 (f) In connection with the consummation of the transactions contemplated by this Agreement (either alone or in combination with any other
action or event), no payments of money or other property, acceleration of benefits, or provisions of other rights have or will be made under any Contract, Company Benefit Plan or otherwise that would result in the imposition of the sanctions imposed
under Section 4999 of the Code. 
 (g) Each current and former employee of MediNotes has been correctly classified for
purposes of each Company Benefit Plan as an eligible or ineligible employee and any retroactive re-classification will not affect any employee’s benefit under any Company Benefit Plan. 
 (h) Each Company Benefit Plan that is a nonqualified deferred compensation plan (as defined under Section 409A of the Code) satisfies
the applicable requirements of Sections 409A(a)(2),(3), and (4) of the Code, and has, since January 1, 2005, been operated in good faith compliance with Sections 409A(a)(2), (3), and (4) of the Code. 
 4.11 Labor Matters. 
 (a) MediNotes is not a party to, or bound by, any collective bargaining agreement or other Contract with a labor union or labor organization. There is no unfair labor practice or labor arbitration proceeding pending or Threatened against
MediNotes or relating to its business. There has not been and there are no organizational efforts with respect to the formation of a collective bargaining unit being made or threatened involving employees of MediNotes. There are no pending claims or
controversies by or between MediNotes and any of its current or former employees, no such claims or controversies are Threatened and no event has occurred or circumstances or conditions exist that would support a claim by any current or 

  

 43 

 
former employee against MediNotes. None of the Major Stockholders or MediNotes has received notice of any strikes, slowdowns, work stoppages, lockouts, or
threats thereof, by or with respect to any employees of MediNotes. MediNotes is and has always been in compliance in all material respects with all applicable Legal Requirements relating to employees and the employment of labor, including provisions
thereof relating to wages, hours, equal opportunity and collective bargaining. 
 (b) Section 4.11(b)(i) of the
Disclosure Schedule sets forth a complete and accurate list of all employees employed by MediNotes, including, the salaries or wages or other payment terms, and positions and duties of each such employee, the state in which such employee is located,
and whether such employee is required to be paid overtime pay under any applicable Legal Requirements. Each employee listed on Section 4.11(b)(i) of the Disclosure Schedule is hired “at will,” meaning MediNotes or such
employee can terminate such employment, with or without cause, at any time, without liability. Section 4.11(b)(ii) of the Disclosure Schedule sets forth a complete and accurate list of independent contractors retained by MediNotes who
(i) assisted with the development of Company IP or (ii) were paid in the aggregate more than $25,000 since January 1, 2007, indicating the purposes or projects for which each was retained. All Persons who have performed services for
MediNotes and have been classified as independent contractors, and all Persons who have performed services for MediNotes and have been classified as exempt employees not entitled to overtime pay under applicable Legal Requirements, have been at all
times properly classified as such in accordance with all Legal Requirements. The classification, job description or duties of the employees of MediNotes and independent contractors of MediNotes have not been changed. Section 4.11(b)(iii)
of the Disclosure Schedule contains a complete and accurate list of each former employee of MediNotes receiving benefits or entitled to receive benefits under any life insurance, medical insurance or other coverage or benefits offered by MediNotes
or which MediNotes is obligated to provide or fund, other than medical insurance provided pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, at no cost to MediNotes. 
 (c) To the Knowledge of MediNotes, no employee of MediNotes is a party to, or is otherwise bound by, any Contract, including any
confidentiality, noncompetition, or proprietary rights agreement, between such employee and any other Person that in any way adversely affects or will affect (i) the performance of his or her duties as an employee of MediNotes, or (ii) the
ability of MediNotes to conduct its business. No Key Employee has threatened to terminate his or her employment with MediNotes, as a result of the transaction contemplated hereby or otherwise. 
 (d) There has not been and is no pending or Threatened discrimination, wrongful termination or wage and hour proceedings, claims, charges
or complaints against or involving MediNotes before the National Labor Relations Board, the Occupational Safety & Health Administration (OSHA), the Equal Employment Opportunity Commission (EEOC), or any other Governmental Entity, and no
event has occurred or circumstances or conditions exist that would support such a claim. 
  

 44 

 4.12 Restrictions on Business Activities. 
 (a) There is no currently effective Order or Legal Requirement, or any Order, or, to the Knowledge of MediNotes, any Legal Requirement or
other action by a Governmental Entity, pending before a Governmental Entity or, to the Knowledge of MediNotes, being considered by a Governmental Entity, which has or would have the effect of restricting the conduct of the Business. 
 (b) Neither MediNotes nor any director, officer, agent, employee or, to the Knowledge of MediNotes, any consultant or contractor of
MediNotes, has directly or indirectly: (i) made any contribution, gift, bribe, rebate, payoff, influence payment, kickback, or other payment to any Person, private or public, regardless of form, whether in money, property, or services, that is
(A) illegal or (B) violates any policy of MediNotes; or (ii) established or maintained any fund or asset that has not been recorded in the books and records of MediNotes. 
 4.13 Real Property. 
 (a) Section 4.13(a) of the Disclosure Schedule provides a true, correct and complete list of all of the Contracts relating to all real property leased to MediNotes (which property includes MediNotes’ right title and
interest in any leasehold improvements thereon and personal property and fixtures therein, and in each case all of MediNotes’ rights and interest in any other rights, subleases, licenses, permits, deposits and profits appurtenant or related to
such Lease, the “Leased Real Property”). The Leased Real Property constitutes all the fee and leasehold interests in real property (A) held by MediNotes or (B) used in connection with, necessary for the conduct of,
or otherwise material to, the Business. 
 (b) MediNotes has valid and enforceable Leases relating to the Leased Real Property
under which MediNotes is entitled to occupy and use such Leased Real Property in connection with the operation of the Business, and there is no breach or default on the part of MediNotes under any such Lease or, to the Knowledge of MediNotes, any
other party to any such Lease. 
 (c) To the Knowledge of MediNotes, all of the buildings, fixtures and other improvements
respecting the Leased Real Property are in good operating condition and repair, and the operation thereof as presently conducted is not in violation of any applicable building code, zoning ordinance or other Legal Requirements. 
 4.14 Intellectual Property. 
 (a) Section 4.14(a)(i) of the Disclosure Schedule sets forth a true, complete and accurate list of the following Company Owned IP (other than trade secrets and know how): Company Registered IP, material Software and material
unregistered Trademarks, indicating for each: (i) for each item thereof the beneficial owner thereof and, if different, the record owner thereof; (ii) whether such Company Owned IP is Company Registered IP; and (iii) for Company
Registered IP, (A) the applicable registration or application, issuance or other identifying number, (B) the date, status, and applicable territories of such registration, issuance or filing, as applicable, and (C) the status,
including the date and description of any action that is due within 90 days of the date hereof in connection with such registration, issuance or filing, as applicable. 

  

 45 

 
In the case of any Company Registered IP in which a Person other than MediNotes holds an interest, Section 4.14(a)(ii) of the Disclosure Schedule
identifies such Company Registered IP and Person and accurately and fully describes the extent of such interest. All Company Owned IP was created solely by employees or contractors of MediNotes and without any participation or funding by any
Governmental Entity or other Person. No Person has an interest in any Company Owned IP that would entitle them to exploit the Company Owned IP without the consent of MediNotes and no such consents have been given by MediNotes. 
 (b) Section 4.14(b) of the Disclosure Schedule (i) sets forth a true, complete and accurate list of all Company
Licensed IP that is (A) incorporated into the products of MediNotes provided to customers or provided to customers in connection with products or services of MediNotes, (B) “resold” or sublicensed to customers by MediNotes,
(C) used by MediNotes as a development tool (excluding commercially available, non-customized software and PC applications at a cost of less than $10,000 for current use by MediNotes, such as Word or Windows, that are not incorporated into
MediNotes’ products (“Off-the-Shelf Software”)); or (D) material to the Business and is not covered under clauses (A), (B) or (C); (ii) identifies the license or other Contract pursuant to which such
Company Licensed IP is being licensed to or used by MediNotes (each, a “License-In Agreement”); (iii) sets forth, to the extent applicable, the number or quantity of copies of the Company Licensed IP that MediNotes is
permitted to use or distribute, the number or quantity that MediNotes is using or distributing, and the number or quantity that MediNotes expects to use or distribute in the next three years; and (iv) sets forth a complete and accurate list of
the amount of any remaining unused prepaid royalty and identifies those License-In Agreements under which such royalty or license fee (excluding fees for maintenance and support) was paid or may become payable by MediNotes by reason of the passage
of time, use or exploitation of Intellectual Property licensed thereunder. True, complete and accurate copies (or, as to oral Contracts, written summaries of the terms), of all License-In Agreements entered into by MediNotes on or prior to the date
hereof have been provided to Eclipsys and true, complete and accurate copies (or, as to oral Contracts, written summaries of the terms) of any License-In Agreements entered into by MediNotes after the date hereof and prior to or on the Closing Date
will be provided to Eclipsys promptly after being so entered into. There are no terms of any License-In Agreements not set forth in the copies thereof provided to Eclipsys. The terms and conditions of all of the License-In Agreements were negotiated
at arm’s length. Without limiting the foregoing, MediNotes has acquired rights to all Company Licensed IP (including without limitation Off-the-Shelf Software) in sufficient quantities and of sufficient scope to cover all of MediNotes’
past and current use(s) and copies of the Company Licensed IP and those reasonably anticipated to be needed (y) for internal use during the year after the Closing Date in accordance with current business plans, and (z) for the duration of
the terms (including during any periods subject to a renewal right) of any Contract with or binding on MediNotes or its properties pursuant to which Company Licensed IP is used by third parties. Furthermore, the rights licensed under each License-In
Agreement shall be exercisable by MediNotes on and after the Closing Date to the same extent and at the same cost as MediNotes had prior to the Closing Date, and no Person granting rights under any License-In Agreement has given notice in writing,
or such other form as permitted by such License-In Agreement, to the Major Stockholders or MediNotes or Threatened that it intends to terminate such License-In Agreement prior to the expiration of the existing term thereof or to deny any request for
an extension of such term. 
  

 46 

 (c) MediNotes has good and valid title to all of the Company Owned IP, free and clear of
any Liens except for Permitted Liens, and (i) all registrations, applications and filings for the Company Registered IP are valid, enforceable, and in full force and effect, and (ii) MediNotes has the right to enforce the Company Owned IP
against the Stockholders and third parties. MediNotes is not, and will not with the passage of time or satisfaction of conditions become, obligated to make any payment to any Person in connection with the manufacture, use, sale, importation,
distribution, display, modification or other exploitation of any Company Owned IP. MediNotes is free to make, use, modify, copy, distribute, sell, license, import, export and otherwise exploit all Company Owned IP on an exclusive basis subject only
to nonexclusive (x) use pursuant to end-user licenses granted to customers; (y) distribution rights granted to the resellers or distributors listed in Section 4.14(c) of the Disclosure Schedule; and (z) nondisclosure or
confidentiality agreements pursuant to which any Person has been granted access to Company Owned IP but in which such agreement does not grant the right to exploit such Company Owned IP; in each case of (x) through (z) in the ordinary
course of business consistent with past practice and disclosed to Eclipsys prior to the date hereof. No current or former employee, officer, director, stockholder, consultant or independent contractor of MediNotes has any valid right, claim or
interest in or with respect to any Company IP which would impair or which could give rise to the impairment of the use, distribution, license or other exploitation of the Company IP by MediNotes or Eclipsys or their successors or transferees.

 (d) MediNotes has taken reasonable measures and precautions to protect, preserve and maintain the confidentiality and
secrecy of all trade secrets and other confidential information material to the Business, including at a minimum: (i) maintaining the security of its facilities and systems so that confidential information and trade secrets are not available to
Persons who are not authorized to have access; (ii) policing the use of such information; and (iii) taking appropriate action to address any misuse, or compromise of the confidentiality of such information. None of the Major Stockholders
or MediNotes has disclosed or delivered or has permitted to be disclosed or delivered to any Person, and no Person has access to (other than employees of MediNotes who need such information in the course of their employment) or has any rights with
respect to, trade secrets and other confidential or proprietary information material to the Business, the source code or any portion or aspect of the source code related to the Software Products or otherwise material to the Business, or any
proprietary information or algorithm contained in any source code related to the Software Products or of any other Software that comprises Company Owned IP, other than instances where such trade secrets, confidential information and source code have
been disclosed subject to an agreement with any Person pursuant to which such Person is required to maintain, and has not breached, the confidentiality thereof. Without limiting the generality of the foregoing, MediNotes has in all cases
(A) required each Person who has contributed to, or participated in the creation or development of any of the Software Products or other Company Owned IP to execute and deliver to MediNotes an agreement, in the form of
Section 4.14(d)(i) of the Disclosure Schedule, or another form provided to Eclipsys prior to the date hereof, assigning all rights in the Software Products and other Company Owned IP to MediNotes, and all such agreements are in full
force and effect, and (B) marked confidential or trade secret materials as such prior to disclosure of such materials to any third-party. Section 4.14(d)(ii) of the Disclosure Schedule sets forth all Software escrow Contracts
relating to the Software Products or any other Software that comprises Company Owned IP, the parties to such escrow Contracts, and the code escrowed pursuant to such escrow Contracts. No code has ever been released pursuant to any escrow
arrangement. True, complete and accurate copies (or, as to oral Contracts, written summaries of the terms) of all such escrow Contracts have been provided to Eclipsys. 
  

 47 

 (e) (i) None of the Company Owned IP or any of the products or services of MediNotes or
the Intellectual Property used by MediNotes in its operations (including the Company Licensed IP), infringe, misappropriate, violate, dilute or constitute the unauthorized use of any Intellectual Property of any other Person, and MediNotes has not
received (A) any notice or claim (oral or written) in the past six (6) years, and no Person has Threatened during such period to provide, a notice or claim, alleging or asserting that any such infringement, misappropriation, violation,
dilution or unauthorized use is or may be occurring or has or may have occurred, or (B) any written notice or claim alleging or asserting that any such infringement, misappropriation, violation, dilution or unauthorized use is or may be
occurring or has or may have occurred. No confidential information or invention owned by any former employer of any current or former employee or consultant of MediNotes is incorporated into, used or relied upon in the products or services of
MediNotes. There is no pending or Threatened claim or demand that challenges the ownership, legality, validity, enforceability, use, exploitation or modification by MediNotes of Company Owned IP or any of the products or services of MediNotes or the
Intellectual Property used by MediNotes in its operations (including the Company Licensed IP) and, to the Knowledge of MediNotes, no facts or circumstances exist that could reasonably be expected to result in such a claim or demand. No Company Owned
IP or any of the products or services of MediNotes or the Intellectual Property used by MediNotes in its operations (including the Company Licensed IP), is subject to any outstanding Order restricting the use thereof by MediNotes or, in the case of
any Intellectual Property licensed by MediNotes to others, restricting the sale, transfer, assignment or licensing thereof by MediNotes to any Person. 
 (ii) MediNotes has the right to grant the licenses it grants in the course of its business. 
 (iii) The Company IP held by MediNotes: (A) constitutes all of the Intellectual Property used in or necessary for the conduct of the Business; and (B) constitutes all of the Intellectual Property necessary to operate the Business
after the Closing in substantially the same manner as the Business has heretofore been operated by MediNotes. No rights in any Registered Intellectual Property, and to the Knowledge of MediNotes, no rights in any Intellectual Property, in each case
other than the rights of MediNotes in the Company IP, are necessary to avoid infringing any Intellectual Property or other legal or contractual right of any Person in the conduct of the Business as currently or previously conducted, or as currently
contemplated to be conducted by MediNotes. 
 (f) All Company Registered IP is valid, enforceable to the full extent permitted
by the jurisdiction in which it is registered and in full force and effect, and all maintenance, annuity and other fees due in respect of such Company Registered IP have been fully paid and all filings applicable thereto have been properly
made. There is (i) no trademark included in the Company Registered IP that is now involved in any opposition or cancellation proceeding and no trademark that is currently used by MediNotes has been involved in any opposition or cancellation
proceeding, and (ii) no patent or patent application included in the Company Registered IP that is now involved in any interference, reissue or reexamination proceeding. 
  

 48 

 (g) To the Knowledge of MediNotes, no Person is infringing or misappropriating any
Company Owned IP in any respect or making any unlawful use of any products of MediNotes in any respect. None of the Major Stockholders or MediNotes (including its representatives) has given notice to any Person in the last three years of any such
infringement, misappropriation or unlawful use or alleged infringement, misappropriation or unlawful use. MediNotes has not initiated nor is it maintaining before a court or in an arbitration proceeding claims or causes of action against any other
Person for infringement or misappropriation by such Person of Company Owned IP (including claims for past infringement or misappropriation of Intellectual Property). MediNotes has not, during the last twelve months, threatened in a writing sent by
the legal counsel of MediNotes to initiate such proceeding. 
 (h) There has not been introduced by, or on behalf of,
MediNotes into any Company IP incorporated into or used in conjunction with any product, system, program or Software that is or was used in any product of, or that relates to the assets of, MediNotes, including the Software Products, any “back
door,” “time bomb,” “Trojan horse,” “worm,” “drop dead device,” “virus” or other software routines or hardware components designed to permit unauthorized access or to disable or erase software,
hardware or data without the consent of the user. 
 (i) The existing and currently manufactured and marketed products of
MediNotes, including the Software Products, in all material respects have the features and perform the functions described in (i) any agreed specifications, responses to requests for proposals or end user documentation, provided to customers or
potential customers of MediNotes, and (ii) any Contracts or representations made by MediNotes or its representatives (either orally or in writing) that such customers or potential customers could reasonably rely on in deciding to purchase the
products (notwithstanding any subsequent disclaimer of any representations or warranties) or would reasonably be expected to rely upon when licensing or otherwise acquiring such products, in each case, subject to subsequent changes expressly
requested by the customer and to standard error and maintenance items addressed by MediNotes in the ordinary course of business. Excluding error and maintenance items adequately addressed by MediNotes in the ordinary course of business, MediNotes
has not received any notice or complaints alleging that such products do not perform as described. There are no material errors or omissions in the design, creation, implementation or maintenance of any of the Software Products. MediNotes has
performed all material obligations (legal and contractual) required to be performed by it under the Contracts with customers and it is not (with or without the lapse of time or the giving of notice, or both) in breach or default in any material
respect thereunder, and, with respect to material obligations required to be performed under such Contracts that are not yet due, there is no reason to expect that such obligations will not be fulfilled when they become due. 
 (j) No Company Owned IP is, in whole or in part, subject to the provisions of any open source, quasi-open source or other source code
license agreement that (i) requires the distribution of source code in connection with the distribution of the licensed Software in object 

  

 49 

 
code form; (ii) prohibits or limits MediNotes or any Affiliate from charging a fee or receiving consideration in connection with sublicensing or
distributing such licensed Software (whether in source code or object code form); or (iii) allows a customer or requires that a customer have the right to decompile, disassemble or otherwise reverse engineer the software by its terms and not by
operation of law, including without limitation, any version of any of the following: (A) GNU’s General Public License (“GPL”) or Lesser/Library GPL, (B) The Artistic License (e.g., PERL), (C) the
Mozilla Public License, (D) the Netscape Public License, (E) the Berkeley software design (“BSD”) license including Free BSD or BSD-style license, (F) the Sun Community Source License, (G) an Open Source
Foundation License (e.g., CDE and Motif UNIX user interfaces), and (H) the Apache Server license. 
 (k) MediNotes
has taken all reasonable actions, including all actions customary in the United States software industry, to document any Software and its operation that is part of the Company IP, such that the Software, including the source code, and Software
Documentation: 
 (i) have been written in a clear and professional manner so that they may be understood, modified,
maintained, enhanced and debugged in an efficient manner by programmers of ordinary skill in the art and comply with all applicable contractual requirements; 
 (ii) fully describe the programming of the Software, including specifications, functional and flow diagrams, tracked changes to each
version of the Software; and 
 (iii) allow debugging of the software and addition and changes of personnel who maintain and
enhance the Software without undue experimentation and exploration. 
 (l) MediNotes has not exported or transmitted Software,
trade secrets or any other technical information, including any technical data, or the direct product of such data, to or in any country to which such export or transmission or creation is restricted by any applicable Legal Requirement, without
first having obtained all necessary and appropriate United States or other Government Entity Permit(s). 
 (m)
Section 4.14(m) of the Disclosure Schedule identifies all Software Products and any other Software that comprises Company Owned IP that incorporate encryption subroutines, listing for each applicable Software Product or other Software
the modules upon which such subroutines operate and the type of encryption employed with respect to each such module. 
 (n)
Without limiting the foregoing, the Software Products are wholly owned by MediNotes and none of the Stockholders or any third-party has any rights or interests therein. 
 (o) (i) Each Contract relating to Company IP (each, a “Company IP Contract”) is valid, binding and in full force
and effect and is enforceable by MediNotes in accordance with its terms, subject to applicable bankruptcy, insolvency, moratorium, fraudulent conveyance, reorganization or other similar laws relating to creditors’ rights and general principles
of equity, whether in equity or at law; 
  

 50 

 (ii) MediNotes has performed all material obligations required to be performed by it
under the Company IP Contracts and it is not (with or without the lapse of time or the giving of notice, or both) in breach or default in any material respect thereunder; and 
 (iii) to the Knowledge of MediNotes, no other party to any of the Company IP Contracts is (with or without the lapse of time or the giving
of notice, or both) in breach or default in any material respect thereunder. True, complete and accurate copies (or, as to oral Contracts, written summaries of the terms) of the Company IP Contracts entered into on or prior to the date hereof have
been provided to Eclipsys, and true, complete and accurate copies (or, as to oral Contracts, written summaries of the terms) of any Company IP Contracts entered into after the date hereof will be provided to Eclipsys promptly after being so entered
into. 
 (p) Neither the execution and delivery by MediNotes or the Major Stockholders of this Agreement and the other
Transaction Documents, nor the consummation of the transactions contemplated herein and therein in accordance with the terms hereof and thereof, will violate, or conflict with, or result in a breach of any provision of, or constitute a material
default (or an event that, with notice or lapse of time or both, would constitute a breach or default) under, or result in the termination or in a right of termination or cancellation of, or accelerate the performance required by, or result in the
triggering of any payment obligations under, or result in the creation of any Lien upon any of the material properties of MediNotes, or result in being declared void, voidable, or without further binding effect, any of the provisions of any Company
IP Contract. 
 (q) The Software Products will, in their intended and ordinary use, not cause the violation of any applicable
Legal Requirements restricting the collection, use, retention or distribution of personally identifiable information, including without limitation the Health Insurance Portability and Accountability Act of 1996 and the regulations issued by the
United States Department of Health and Human Services thereunder (collectively, “Privacy Regulations”). MediNotes has not violated and is not violating any Privacy Regulations, and the continuation of the Business
substantially consistent with past practices, including the continued use of all Company Owned IP, after the consummation of the transactions contemplated by this Agreement and the other Transaction Documents will not violate any Privacy
Regulations. 
 4.15 Other Assets. 
 (a) MediNotes owns beneficially and of record, and has good and valid title to, all assets reflected on the balance sheet of MediNotes as of December 31, 2007, contained in the Year-End Financial Statements, or
thereafter acquired (except those sold or otherwise disposed of since December 31, 2007 in the ordinary course of business consistent with past practice and not in violation of this Agreement), in each case subject only to Permitted Liens.

  

 51 

 (b) All the material tangible personal property used or owned by MediNotes has been
maintained in accordance with generally accepted industry practice and is in good operating condition and repair, ordinary wear and tear excepted. The assets owned or leased by MediNotes include all of the material properties and other assets
necessary to conduct the Business as currently conducted and planned by MediNotes. 
 (c) All of the books and records of
MediNotes (including without limitation, the financial records and minute books of MediNotes) are true, complete and accurate in all material respects and have been maintained in accordance with generally accepted business practices. MediNotes has
made true, complete and accurate copies of such books and records available to Eclipsys, and at the Closing, all of such books and records will be in the possession of MediNotes. 
 4.16 Environmental Matters. Except as has not and would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect on MediNotes or the Business: (a) MediNotes is now and always has been in compliance with all Environmental Laws; (b) MediNotes has all Permits necessary under Environmental Laws for the conduct and operation of the business as now
being conducted by MediNotes and, to the Knowledge of MediNotes, all such Permits are in good standing; (c) there is not now, and to the Knowledge of MediNotes there has not been, any Hazardous Material used, generated, treated, stored,
transported, disposed of, released, handled or otherwise existing on, under, about, or emanating from or to, any property owned, leased or operated by MediNotes except in compliance with all applicable Environmental Laws; (d) none of the Major
Stockholders or MediNotes has received any notice of alleged, actual or potential responsibility for, or any inquiry or investigation regarding, any release or threatened release of Hazardous Material or alleged violation of, or non-compliance with,
any Environmental Law, nor to the Knowledge of MediNotes is there any basis for such a notice or claim; (e) there is no site to which MediNotes has transported or arranged for the transport of Hazardous Material which, to the Knowledge of
MediNotes, is or may become the subject of any environmental action; and (f) no event has occurred, and no circumstance or condition exists that, with or without notice or lapse of time, or both, might form the basis of any Liability of
MediNotes pursuant to Environmental Laws. 
 4.17 Insurance. 
 (a) Section 4.17(a) of the Disclosure Schedule contains a true and complete list of all liability, property, workers’
compensation, directors’ and officers’ liability, life and other insurance policies in effect at any time since January 1, 2005, that insure or did insure the business, operations, directors, or employees of MediNotes or affect or
relate to the ownership, use or operation of any of the property or assets (both past and present) of MediNotes, whether issued to MediNotes or to any other Person for the benefit of MediNotes (collectively, the “Insurance
Policies”). For each Insurance Policy, Section 4.17(a) of the Disclosure Schedule lists (i) the names and addresses of the insurers, (ii) the names of the Persons to whom such policies have been issued (including
additional insureds), (iii) the expiration dates thereof, (iv) whether the policies are currently in effect, (v) the annual premiums and payment terms thereof, (vi) whether it is a “claims made” or an
“occurrence” policy, (vii) any self insured retention or deductible, (viii) the aggregate limit of the policy and the currently available limit, and (ix) a brief description of the interests insured thereby. MediNotes has
provided Eclipsys with true, accurate and complete copies of each Insurance Policy. 
  

 52 

 (b) With respect to Insurance Policies currently in effect: (i) the insurance
coverage provided by the Insurance Policies will not terminate or lapse by reason of consummation of the transactions contemplated by this Agreement and the other Transaction Documents; (ii) the Insurance Policies were placed with insurers who
are financially sound and reputable and, in light of the business, operations and assets of MediNotes, are in amounts and have coverages that are reasonable and customary for Persons engaged in such businesses and operations and having such assets;
(iii) the Insurance Policies are sufficient for compliance with all applicable Legal Requirements and Contracts to which MediNotes is a party or by which its property or assets are bound; and do not provide for any retrospective premium
adjustment or other experienced-based liability on the part of MediNotes; and (iv) no side agreements or other Contracts exist that alter the terms of the Insurance Policies. Each current Insurance Policy is valid and binding and in full force
and effect, no premiums due thereunder have not been paid, and none of MediNotes, the Major Stockholders or the Person to whom such policy has been issued has received any notice of cancellation or termination in respect of any such policy or is in
default thereunder. 
 (c) Section 4.17(c) of the Disclosure Schedule contains a listing of all material open
claims made or otherwise asserted by MediNotes or its officers, directors or employees against any Insurance Policy. None of the Major Stockholders nor MediNotes, nor the Person to whom any Insurance Policy has been issued has received written
notice that any insurer under such Insurance Policy is denying liability with respect to a claim thereunder or defending under a reservation of rights clause or, to the Knowledge of MediNotes, indicated any intent to do so or not to renew any such
policy. All material claims under the Insurance Policies have been filed in a timely fashion. To the Knowledge of MediNotes, the activities and operations of MediNotes have been conducted in a manner so as to conform in all material respects to all
applicable provisions of the Insurance Policies. None of MediNotes, the Person to whom any Insurance Policy has been issued or, to the Knowledge of MediNotes, any Major Stockholder, has failed to disclose any fact to the insurance companies or
failed to take any other action, the consequences of which non-disclosure or failure to take action would render any Insurance Policy void, or voidable, or suspend, impair or defeat in whole or in part the insurance coverage issued thereunder. None
of MediNotes, the Person to whom any Insurance Policy has been issued or, to the Knowledge of MediNotes, any Major Stockholder, has received (A) any refusal of coverage from any insurer from which MediNotes or such other Person sought coverage,
(B) any notice that a defense will be afforded with reservation of rights, (C) any notice of cancellation or termination or any other indication that any insurance policy is no longer in full force or effect or will not be renewed or that
the issuer of any policy is not willing or able to perform its obligations thereunder, or (D) any notice that MediNotes or such other Person is in default under any Insurance Policy; and to the Knowledge of MediNotes, no event has occurred and
no circumstance or condition exists that, with or without notice or lapse of time or both, might form the basis of any such notice or refusal. 
  

 53 

 4.18 Warranties. 
 (a) MediNotes has delivered to Eclipsys complete and accurate copies of all written warranties that are in effect with respect to
MediNotes’ products and services, including the Software Products. There have not been any material deviations from such warranties and none of the employees or agents of MediNotes (i) is authorized to undertake obligations to any customer
or to other third parties which expands such warranties, or (ii) has made any oral warranty with respect to such products or services of MediNotes. Section 4.18(a) of the Disclosure Schedule sets forth a list of all Warranty Claims
currently made in writing against MediNotes or otherwise Threatened, and MediNotes’ reasonable judgment of the estimate of the aggregate Liability of MediNotes in respect of such Warranty Claims. Such estimate was prepared in good faith, based
on the Knowledge of MediNotes, although the Major Stockholders do not provide any assurance that such aggregate Liability will not be exceeded. The foregoing sentence does not limit the Major Stockholders’ liability under
Article VII. 
 (b) Without limiting the foregoing, Section 4.18(b) of the Disclosure Schedule
includes all material documentation and other written materials pertaining to the Software Products that has been developed by or for MediNotes and distributed to any customers of MediNotes (the “Customer Documentation”). The
Software Products conform to the Customer Documentation in all material respects, and MediNotes has not made any material representations or commitments regarding features or functionality of the Software Products other than as set forth in the
Customer Documentation. 
 (c) Since January 1, 2006, no former customer has, and no current customer has at any time,
(i) made any claim or assertion that the Software Products do not conform in any material respect to commitments made by MediNotes, (ii) cancelled any Contract with MediNotes, or (iii) refused to accept, or demanded a full or partial
refund or abatement of purchase price for, Software Products delivered by MediNotes pursuant to any Contract. 
 (d) MediNotes
has not, with respect to former customers since January 1, 2006, and with respect to current customers at any time, (i) given any rebates or refunds on license, installation, or support fees that any customers have contracted to pay,
(ii) made any commitments to provide future services or Software without payment by the recipient thereof of MediNotes’ ordinary fees, other than discounts provided for in sales contracts with customers as a sales term at the time of
original sale of products, in the ordinary course of business consistent with past practice, and not as a service credit or other concession, (iii) made any commitment to deliver any specific results or outcomes to any customer, (iv) had a
material cost overrun (i.e., costs in excess of estimates) for any consulting services, or (v) committed to deliver to any customer any Software, or features or functionality thereof, that did not exist on the date the
commitment was made. 
 (e) With respect to third-party Software provided by MediNotes to customers: 
 (i) the rights provided by MediNotes to the customer are within the scope of what MediNotes is permitted to provide pursuant to
MediNotes’ Contract with the third-party provider thereof; 
 (ii) MediNotes has obtained from the customer all end-user
agreements and other commitments required by the third-party provider thereof; and 
  

 54 

 (iii) any obligations undertaken by MediNotes in respect of the third-party Software (for
example, but without limitation, representations regarding features or functionality, maintenance commitments, indemnities) are consistent with, and do not exceed, the corresponding obligations of the third-party provider thereof to MediNotes.

 4.19 Customers; Suppliers. 
 (a) Section 4.19(a) of the Disclosure Schedule sets forth a complete and accurate list of all present and past customers of MediNotes to which MediNotes supplied and provided products and/or services with
an aggregate price of more than $10,000 in 2007, or expected to be more than $10,000 in 2008, showing for each, by product and service, (i) the contractual amounts due for Software license fees, installation and training services and annual
maintenance and support and project consulting services fees and revenue for the year ended December 31, 2007, and (ii) the contractual amounts due for Software license fees, installation and training services and annual maintenance and
support and estimated project consulting services fees and anticipated revenue for the years ended December 31, 2008 and 2009. 
 (b) Since January 1, 2006, MediNotes has not received from: (i) any current or former customer any written notice or assertion of material breach, misrepresentation, breach of warranty, Software defects, design errors or
malfunctions, or other failures of MediNotes to deliver upon any promises or legal or contractual obligations, and no such assertion of breach, misrepresentation, breach of warranty, Software defects, design errors or malfunctions, or other failures
have been otherwise Threatened, nor to the Knowledge of MediNotes, has any event occurred, or does any circumstance or condition exist that, with or without the giving of notice or lapse of time, or both, might form the basis of any such notice or
assertion; or (ii) any current customer any written notice that such customer has ceased or intends to cease or terminate its use of the products or services of MediNotes, or materially reduced or intends to materially reduce such use,
whether or not as a result of the transactions contemplated hereby, or has sought to reduce the price that it pays for such products and services, and no customer has otherwise Threatened such a cessation, termination, or material reduction in use
or price; and to the Knowledge of MediNotes, no customer intends to provide such notice. 
 (c) Section 4.19(c) of
the Disclosure Schedule sets forth a complete and accurate list of all present and past suppliers of MediNotes, from which MediNotes ordered supplies or other products or services with an aggregate purchase price of more than $10,000 during the
years ended December 31, 2007 and 2006, or $5,000 during the six months ended June 30, 2008, showing for each, the type of product or service purchased, and the amount of such purchases, during such periods. 
 (d) Neither MediNotes, nor any of the Major Stockholders, has received from: (i) any current supplier or, since January 1, 2006,
any former supplier, any notice or assertion of material breach, misrepresentation, breach of warranty, or other failures of MediNotes to deliver upon any promises or legal or contractual obligations, nor to the Knowledge of MediNotes, has any event
occurred, or does any circumstance or condition exist that, with or without the giving of notice or lapse of time, or both, might form the basis of any such notice or assertion; or (ii) from any current supplier any notice that such supplier
has ceased or intends to cease or terminate supplying the products or services to MediNotes, or materially reduced or intends to 

  

 55 

 
materially reduce such supply, whether or not as a result of the transactions contemplated hereby, or has sought to increase the price that MediNotes pays
for such products and services, other than general and customary price increases in the ordinary course of business, consistent with past practice, and to the Knowledge of MediNotes, no supplier intends to provide such notice. 
 4.20 Accounts Receivable. Section 4.20 of the Disclosure Schedule sets forth the Accounts Receivable of MediNotes as of the date of
the Interim Financial Statements, with the aging of each such Account Receivable. Such Accounts Receivable represent valid obligations of the obligor thereunder and arose in the ordinary course of business of MediNotes. The Accounts Receivable of
MediNotes arising after the date of the Interim Financial Statements represent valid obligations of the obligor thereunder and arose in the ordinary course of business. All of such Accounts Receivable, that have not been paid, are collectible in the
ordinary course of business, net of the reserves shown on MediNotes’ balance sheet (including the balance sheet as of the Closing Date, upon which the Closing Date Net Working Capital shall be based, and which reserves therein shall not
represent a materially greater percentage of the Accounts Receivable than the reserves reflected in the Interim Financial Statements). 
 4.21 Accounts Payable. Section 4.21 of the Disclosure Schedule sets forth all Accounts Payable as of a date no more than five Business Days prior to the date hereof, with the date incurred, creditor and amount of each
Accounts Payable. Such Accounts Payable arose, and as of the Closing, the Accounts Payable reflected in the Estimated Closing Date Net Working Capital calculation (the list of which, in the same format as Section 4.21 of the Disclosure
Schedule, will be provided to Eclipsys on or before the Closing) and the Final Closing Date Net Working Capital calculation, will have arisen, in arm’s length transactions in the ordinary course of business of MediNotes. No Accounts Payable are
delinquent, and there are no bills representing amounts alleged to be owed by MediNotes, or other alleged obligations of MediNotes, which MediNotes has disputed or determined to dispute or refuse to pay, all or any portion thereof. 
 4.22 Bank Accounts. Section 4.22 of the Disclosure Schedule sets forth the names and locations of all banks and other financial
institutions at which MediNotes maintains accounts of any nature and the names of all persons authorized to draw thereon or make withdrawals therefrom. 
 4.23 No Brokers. Except for Joseph R. Dunham II, no broker, finder or similar agent has been employed by or acted on behalf of, directly or indirectly, MediNotes, any Major Stockholder, or any of their
respective Affiliates or agents in connection with this Agreement or the other Transaction Documents or the transactions contemplated hereby or thereby. None of MediNotes, the Major Stockholders nor any of their respective Affiliates has entered
into any arrangement or other Contract with any Person, or taken any other actions, which could obligate any Stockholder, Eclipsys, MediNotes or any of their respective Affiliates to pay any brokerage commission, finder’s fee or any similar
compensation in connection with this Agreement, the other Transaction Documents or the transactions contemplated hereby and thereby, except for the Consulting Agreement dated September 5, 2007 with Joseph R. Dunham II. 
  

 56 

 4.24 Disclosure. 
 (a) None of the information included in any information statement or proxy statement relating to the meeting of the Stockholders to be
held in connection with the Merger (the “Company Stockholders’ Meeting”), or action by written consent in lieu thereof will, at the date delivered to such Stockholders and at the date of such meeting or consent, contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements herein or therein not misleading. 
 (b) To the Knowledge of MediNotes, no representation or warranty of MediNotes or the Major Stockholders contained in this Agreement, the Transaction Documents to which it is a party or the certificates delivered
pursuant to this Agreement or such Transaction Documents, and no statement contained in the Disclosure Schedule or such certificates, contains, or will contain upon delivery as set forth herein, any untrue statement of a material fact, or omits, or
will omit upon delivery, to state any material fact necessary, in light of the circumstances under which it was or will be made, in order to make the statements herein or therein not misleading. 
 (c) To the Knowledge of MediNotes, there is no fact or circumstance existing or event that has occurred, that has specific application to
MediNotes (other than general economic or industry conditions), that has had or is reasonably likely to have a Material Adverse Effect on MediNotes or the Business that has not been set forth in this Agreement, including the Disclosure Schedule.

 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES 
 OF ECLIPSYS AND MERGER SUB 
 Eclipsys and Merger Sub, jointly and severally, represent and warrant to MediNotes, as of the date of this Agreement and as of the Closing Date, as
follows: 
 5.1 Existence; Good Standing; Corporate Authority. Eclipsys is a corporation duly incorporated, validly existing and in
good standing under the laws of the State of Delaware. Merger Sub is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Iowa. Each of Eclipsys and Merger Sub is duly licensed or qualified to do
business as a foreign corporation and is in good standing under the laws of each other state of the United States in which such qualification is required, except where the failure to be so qualified or in good standing would not have a Material
Adverse Effect on Eclipsys. 
 5.2 Authorization, Validity, and Effect of Agreements. Each of Eclipsys and Merger Sub has the
requisite corporate power and authority to execute and deliver this Agreement and the other Transaction Documents to be executed by it, and the consummation by Merger Sub of the Merger, and by Eclipsys and Merger Sub of the other transactions
contemplated herein and therein, has been duly authorized by all requisite corporate action on the part of each of Eclipsys and Merger Sub. This Agreement constitutes, and the other Transaction Documents to be executed by Eclipsys and Merger Sub
(when executed and delivered pursuant hereto) will constitute, the valid and legally binding obligations of Eclipsys and Merger Sub, respectively, enforceable in accordance with their respective terms, subject to applicable bankruptcy, insolvency,
moratorium, fraudulent conveyance, reorganization or other similar laws relating to creditors’ rights and general principles of equity, whether in equity or at law. 
  

 57 

 5.3 No Violation. Neither the execution and delivery by each of Eclipsys and Merger Sub of this
Agreement or the Transaction Documents, nor the consummation by either of Eclipsys or Merger Sub of the transactions contemplated herein and therein in accordance with the terms hereof and thereof, will: 
 (i) conflict with or result in a breach of any provisions of the certificate of incorporation or by-laws of Eclipsys or Merger Sub, as
applicable; 
 (ii) violate, or conflict with, or result in a breach of any provision of, or constitute a default (or an event
which, with notice or lapse of time or both, would constitute a default) under, or result in the termination or in a right of termination or cancellation of, or accelerate the performance required by, or result in the creation of any Lien upon any
of the material properties of Eclipsys or Merger Sub under, or result in being declared void, voidable, or without further binding effect, any of the terms, conditions or provisions of any material Contract to which Eclipsys or its Subsidiaries is a
party, or by which any of their respective assets or properties are bound; or 
 (iii) require any Consent to be made by or
with respect to Eclipsys or Merger Sub (other than approvals by their respective boards of directors, which have been obtained). 
 5.4 No
Brokers. Neither Eclipsys nor any of its Subsidiaries has entered into any Contract with any Person, or taken any other action, which may result in the obligation of any other party to this Agreement to pay any finder’s fees, brokerage or
agent’s commissions or other like payments in connection with the negotiations leading to this Agreement or the consummation of the transactions contemplated hereby, except for the engagement letter with Piper Jaffray & Co., for which
all obligations thereunder Eclipsys shall be solely liable. 
 5.5 Funds. Eclipsys will have at the Closing Date the funds necessary
to pay the cash part of the Closing Payment in accordance with this Agreement. 
 5.6 Valid Issuance. When issued pursuant to the
terms of this Agreement, the Eclipsys Common Stock constituting part of the Merger Consideration will be duly authorized, validly issued, fully paid and nonassessable, and none of such shares of Eclipsys Common Stock will have been issued in
violation of or will be subject to any Lien, option, call, right of first refusal, preemptive, subscription or similar right, other than as may be created by the actions of the recipient. 
 5.7 Exchange Compliance. Eclipsys Common Stock is registered pursuant to the Exchange Act and is listed on the Nasdaq Global Select Market.
Eclipsys has taken no action that is designed to terminate the registration of the Eclipsys Common Stock under the Exchange Act and/or the delisting of the Eclipsys Common Stock from the Nasdaq Global Select Market. Eclipsys is in compliance with
all of the presently applicable requirements for continued listing of the Eclipsys Common Stock on the Nasdaq Global Select Market in all material respects. 
  

 58 

 5.8 SEC Filings; Financials; Absence of Changes. Each Form 10-K, Form 10-Q and any other periodic
report and proxy statement required to be filed by Eclipsys under the Exchange Act, since December 31, 2007 (the “Eclipsys SEC Filings”), has been duly and timely filed by Eclipsys, and did not, at the time it was filed,
contain any untrue statement of a material fact or omit to state a material fact required to be included therein or necessary in order to make the statements therein in light of the circumstances under which they were made not misleading. The
audited financial statements and unaudited interim financial statements included or incorporated by reference in the Eclipsys SEC Filings (a) were prepared in accordance with GAAP applied on a consistent basis during the periods involved
(except that the interim financial statements do not contain footnotes and as may be indicated therein or in the notes thereto, and except as permitted by SEC rules), (b) complied as of their respective dates in all material respects with the
applicable accounting requirements and the published rules and regulations of the SEC with respect thereto (except as otherwise disclosed in the Eclipsys SEC Filings) and (c) fairly present in all material respects the consolidated financial
position of Eclipsys as of the dates thereof and the income, cash flows and changes in stockholder’s equity for the periods involved. 
 5.9 Tax-Free Reorganization. Neither Eclipsys nor, to the Knowledge of Eclipsys, any of its Affiliates, has taken or has agreed to take any action that would prevent the Merger followed by the Second Merger from constituting a
reorganization qualifying under the provisions of Section 368(a) of the Code. 
 ARTICLE VI 
 COVENANTS 
 6.1 Conduct of
Business. Except as expressly consented to in writing by Eclipsys, from the date hereof to the earlier of the termination of this Agreement or the Closing Date, MediNotes shall, and the Major Stockholders shall cause MediNotes: 
 (a) to conduct its operations according to the usual, regular and ordinary course in substantially the same manner as heretofore
conducted; 
 (b) to preserve intact its business organization and goodwill, and use its commercially reasonable efforts to
(i) keep available the services of its officers and employees, and (ii) maintain satisfactory relationships with its customers, suppliers and other Persons having business relationships with it in substantially the same manner as
heretofore maintained; 
 (c) to confer on a regular basis with one or more representatives of Eclipsys, including to report
material operational matters and any proposals of MediNotes to engage in material transactions, and to provide such other information as Eclipsys may reasonably request; 
 (d) not to amend the organizational documents of MediNotes; 
 (e) to notify Eclipsys within two Business Days of (i) any material change in the condition (financial or otherwise) of the business,
properties, assets, Liabilities or prospects of MediNotes, (ii) any material litigation or material complaints, investigations or hearings of any Governmental Entity or other Person (or communications indicating that the same may be
contemplated) against MediNotes or involving the business, operations or properties of MediNotes, or (iii) the breach in any material respect of any representation or warranty or covenant contained herein; 
  

 59 

 (f) to deliver to Eclipsys within two Business Days any material report, statement,
schedule or correspondence filed or submitted by MediNotes or with respect to MediNotes or the Business, the Major Stockholders to, or received by MediNotes or with respect to MediNotes or the Business, the Major Stockholders from, any Governmental
Entity; 
 (g) not to (i) issue any Capital Stock (other than (A) the issuance of Company Common Stock (1) upon
exercise of the Company Options and Company Warrants pursuant to the terms thereof, and (2) upon conversion of the Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock pursuant to the MediNotes Articles of
Incorporation, and (B) the issuance of 1,000 shares of Series D Preferred Stock pursuant to the terms and conditions of the Settlement Agreement), effect any stock split or combination, reclassify the Shares or otherwise change its
capitalization from that which existed on the date of the Interim Financial Statements, (ii) grant, confer or award any option, warrant, conversion right or other right to acquire any of its Capital Stock, (iii) increase any compensation
or benefits or enter into or amend any employment, severance, termination or similar Contract with any of its present or future employees, officers or directors, except for normal increases in compensation and benefits to employees consistent with
past practice, (iv) adopt any new employee benefit plan (including any stock option, stock benefit or stock purchase plan) or amend any existing employee benefit plan in any material respect, except for changes which may be required by
applicable Legal Requirements, or (v) increase the amount, or expand the scope, of any indemnification currently provided for employees, officers or directors; 
 (h) not to (i) declare, set aside or pay any dividend or make any other distribution or payment with respect to any of its Shares, or
(ii) directly or indirectly redeem, purchase or otherwise acquire any of its Shares; 
 (i) not to sell, lease or
otherwise dispose of any assets, or enter into any commitment to do so (other than licenses of its products in the ordinary course of business consistent with past practice); 
 (j) except in the ordinary course of business consistent with past practice, to use commercially reasonable efforts to maintain the assets
and properties of MediNotes in substantially the same condition existing as of the date of this Agreement; 
 (k) not to
(i) incur or assume any Debt or issue any Debt securities, (ii) assume, guaranty, endorse or otherwise become liable or responsible (whether directly, indirectly, contingently or otherwise) for the obligations of any other Person,
(iii) modify in any manner adverse to MediNotes any outstanding Debt or other obligation of MediNotes (except for entry into the Royalty Termination Agreement pursuant to which, in conjunction with and immediately after the Closing, the Secured
Promissory Note issued to MediNotes on March 13, 2008 by the Bond Entities in the principal amount of $600,000 will be cancelled), (iv) pledge or otherwise encumber any Shares, or (v) mortgage or pledge any of its assets, tangible or
intangible, or create or suffer to create any Lien of any kind in respect to such assets except in the ordinary course of business consistent with past practices; 
  

 60 

 (l) not to change any of its accounting principles or practices, except as required by
GAAP; 
 (m) not to: 
 (i) acquire (by merger, consolidation or acquisition of stock or assets) any Person or division thereof or any Capital Stock of any Person, 
 (ii) except in the ordinary course of business consistent with past practices, enter into any Contract which would be required to be
listed on Section 4.4(a) of the Disclosure Schedule if entered into prior to the date hereof, or amend or terminate any Material Contract (except for the Royalty Termination Agreement and Commission Agreement, which will be entered into
as of the Closing), or 
 (iii) authorize any new capital expenditure or expenditures (except in the ordinary course of
business consistent with past practice or pursuant to Contracts listed in Section 4.4(a) of the Disclosure Schedule), which, individually or in the aggregate, is in excess of $25,000; 
 (n) not to pay, discharge or satisfy any Liabilities, other than the payment, discharge or satisfaction in the ordinary course of business
of Liabilities reflected, reserved against or disclosed in the Interim Financial Statements or incurred in the ordinary course of business thereafter consistent with past practice; 
 (o) not to settle or compromise any pending or threatened suit, proceeding, action or claim; 
 (p) not to make any material Tax election (other than in a manner consistent with prior practice), or take any material position on any
material Tax Return filed on or after the date of this Agreement, change any method of accounting for Tax purposes, amend any material Tax Return, settle or compromise any Tax liability for an amount in excess of $10,000, in the aggregate, agree to
an extension of a statute of limitations, or fail to file in a timely manner any Tax Returns (except as to filings for which a proper extension has been obtained) that become due or fail to pay any Taxes that become due; 
 (q) not to loan or advance any amount to, or enter into any Contract or other transaction with (except the Royalty Termination Agreement
and the Commission Agreement with the Bond Entities, each of which will be entered into as of the Closing), or otherwise make any payments to any Stockholder, or any of their respective Affiliates or, with the exception of payments of salary or
expense advancement in the ordinary course of business, consistent with past practice, in their capacity as employees of MediNotes, any officer or director thereof; 
 (r) not to delay or postpone the payment of any Accounts Payable or other expenses, or accelerate collection of any Accounts Receivable,
or other receivables; 
 (s) not to take any action that would knowingly result in a breach of any representation, warranty or
covenant of MediNotes or the Major Stockholders contained in this Agreement; 
  

 61 

 (t) not to take any action or fail to take any reasonable action, or agree in writing or
otherwise to take or not take any such actions, having the same or similar effect, or being of the same or similar nature, as any of the actions described in Sections 6.1(a) through (s); 
 (u) take such action, if any, as is necessary under the terms of all Company Benefit Plans and any other documents governing the Company
Options to permit all Company Options to be treated in the Merger in accordance with Section 2.7(d); and 
 (v) take such action, if any, as is necessary under the documents governing the Company Warrants to permit all Company Warrants to be treated in the Merger in accordance with Section 2.7(e). 
 6.2 Further Action. 
 (a) Upon the terms and subject to the conditions of this Agreement, MediNotes and the Major Stockholders, on the one hand, and Eclipsys and Merger Sub, on the other hand, shall use all commercially reasonable efforts to take, or cause to be
taken, all actions, and to do, or cause to be done, all other things necessary, proper or advisable to consummate and make effective as promptly as practicable the transactions contemplated in this Agreement, to obtain and file in a timely manner
all Consents required to consummate the transactions contemplated hereby, and otherwise to satisfy or cause to be satisfied in all material respects all conditions precedent to their obligations under this Agreement. 
 (b) (i) From the date of this Agreement until the termination of this Agreement or the Closing Date, MediNotes and the Major Stockholders,
on the one hand, and Eclipsys and Merger Sub, on the other hand, shall promptly notify the other of any fact, change, circumstance, condition or occurrence that is reasonably likely to (A) materially adversely affect the ability of such party
to obtain or file any Consents required for the transactions contemplated in this Agreement and the other Transaction Documents, or (B) materially adversely affect the ability of such party to perform its covenants and agreements under this
Agreement or the other Transaction Documents. 
 (ii) Each party shall promptly notify the other parties orally and in writing
if such party becomes aware of: 
 (A) (1) the material inaccuracy at any time of any representation or warranty contained in
this Agreement of such party; or (2) the breach of any covenant or agreement under this Agreement of such party or the inability of such party to comply with or satisfy in any material respect any covenant, condition or agreement under this
Agreement; provided however, that no such notification shall affect the representations, warranties, covenants or agreements of any party or the conditions to the obligations of any party hereunder; and 
 (B) any notice or other communication from any third-party alleging that the Consent of such third-party is or may be required in
connection with the transactions contemplated in this Agreement or the other Transaction Documents or that such third-party has a right to any portion of the Purchase Price. 
  

 62 

 (c) MediNotes shall deliver a supplement to Section 4.3 on or before the
Closing Date that sets forth the capitalization of MediNotes and holders of all outstanding Capital Stock of MediNotes as of the Closing Date, which supplement, may solely reflect changes from the capitalization set forth in Section 4.3
as a result of (A) the exercise of Company Options and Company Warrants outstanding on the date hereof or conversion of shares of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock outstanding as of the date
hereof, in each case, between the date hereof and the Effective Time, provided that such exercise or conversion is in conformity with the agreements governing such exercise delivered to Eclipsys prior to the date hereof and the MediNotes Articles of
Incorporation, and the terms and conditions of this Agreement, and (B) the issuance of 1,000 shares of Series D Preferred Stock pursuant to the terms and conditions of the Settlement Agreement and this Agreement (the “Capitalization
Update”). Except for the Capitalization Update, no notice under this Section 6.2 shall affect any rights of Eclipsys under Article VII. 
 In case at any time after the Closing any further action is necessary or desirable to carry out the purposes of this Agreement, each party, including the Stockholders’ Representative, shall use its respective
commercially reasonable efforts to take or cause to be taken all such necessary or desirable action. 
 6.3 Access to Information.
From the date hereof until the earlier of termination of this Agreement or the Closing Date, upon reasonable notice and subject to applicable Legal Requirements, MediNotes shall afford Eclipsys and its accountants, counsel, and other
representatives, during normal business hours, access to all of the properties and assets, books, Contracts, and other records of MediNotes reasonably requested by Eclipsys. Eclipsys shall, and shall cause its advisors and representatives to:

 (i) conduct its investigation in such a manner that will not unreasonably interfere with the normal operations, customers
or employee relations of MediNotes; and 
 (ii) treat as confidential in accordance the terms hereof all information obtained
hereunder or in connection herewith regarding MediNotes and not otherwise known to them prior to disclosure hereunder. 
 6.4
Publicity. The initial press release relating to this Agreement shall be in the form approved by the parties. Thereafter until the Closing Date, none of MediNotes, the Major Stockholders, the Stockholders’ Representative, Eclipsys or
Merger Sub may make any public statement with respect to the transactions contemplated by this Agreement or the other Transaction Documents, without the prior written consent of Eclipsys on the one hand, and MediNotes, on the other hand, except to
the extent disclosure is legally required (including the requirements and rules of any stock exchange on which the Eclipsys Common Stock is traded), in which case MediNotes and Eclipsys shall consult with each other, and use reasonable efforts to
agree upon the text prior to any such disclosure, to the extent reasonably feasible under the circumstances. 
  

 63 

 6.5 Expenses. Except as set forth herein, all costs and expenses (including fees of attorneys,
accountants and brokers or finders) incurred in connection with this Agreement, the other Transaction Documents and the transactions contemplated hereby and thereby shall be paid by the party incurring such expenses, and if the Closing is
consummated, the Seller Transaction Expenses shall be paid in accordance with the terms and conditions of the Holdback Escrow Agreement and as set forth in Section 2.9(b) and Section 2.10(a)(iv). Without limiting the
foregoing, Eclipsys shall pay the fees and expenses of any broker engaged by Eclipsys and its Affiliates, including any disclosed in Section 5.4, and the fees and expenses of any brokers engaged by the Stockholders or their Affiliates
(including MediNotes), and including those disclosed in Section 4.23, shall be paid as part of the Seller Transaction Expenses. 
 6.6 Third-Party Offers. 
 (a) From and after the date of this Agreement, until the earlier of the Closing or
termination of this Agreement, MediNotes and each of the Major Stockholders shall, and shall cause each of their Affiliates and their respective officers, directors, employees, representatives (including, without limitation, any investment banker,
attorney or accountant) and agents to immediately cease any discussions or negotiations with any Persons with respect to any Third-Party Acquisition, and none of the Major Stockholders or MediNotes shall, or shall authorize or permit any of its
respective Affiliates or their respective officers, directors, employees, representatives (including, without limitation, any investment banker, attorney or accountant) or agents to, directly or indirectly, encourage, solicit, participate in or
initiate any inquiries, discussions or negotiations with or provide any information or access to any Person concerning any potential Third-Party Acquisition or that may reasonably be expected to lead to any Third-Party Acquisition or attempted
Third-Party Acquisition, or otherwise facilitate any effort or attempt to make or implement a Third-Party Acquisition. MediNotes shall, within 24 hours, communicate to Eclipsys the existence or occurrence and the terms of any potential Third-Party
Acquisition or contact or inquiry related to any potential Third-Party Acquisition that the Major Stockholders, MediNotes or any of their respective Affiliates, or their respective officers, directors, employees, representatives or agents, receive
in respect of such a proposed transaction, and the identity of the Person from whom such proposal, inquiry, or other contact was received. 
 (b) MediNotes and the Major Stockholders jointly and severally represent and warrant to Eclipsys that each of the Major Stockholders, MediNotes, and their respective Affiliates, officers, directors, and employees, and
to the Knowledge of MediNotes, the representatives (including, without limitation, any investment banker, attorney or accountant) and agents of the Major Stockholders and MediNotes, have terminated any and all existing discussions with third parties
relating to a Third-Party Acquisition. The Major Stockholders and MediNotes have instructed all of their respective officers, directors, employees, representatives and agents to terminate all discussions relating to a Third-Party Acquisition.

  

 64 

 6.7 Restrictive Covenants. 
 (a) The Major Stockholders recognize that the covenants of the Major Stockholders contained in this Section 6.7 are an
essential part of this Agreement and that but for the agreement of each Major Stockholder to comply with such covenants Eclipsys would not enter into this Agreement. The Major Stockholders acknowledge and agree that the covenants set forth in this
Section 6.7 are necessary to protect the legitimate business interests of the Business acquired by Eclipsys pursuant to this Agreement, including without limitation, trade secrets and other confidential information and goodwill, and that
irreparable harm and damage will be done to Eclipsys if any Major Stockholder takes any action in any way prohibited by such covenants. In addition, the Major Stockholders acknowledge that the Purchase Price is paid in part as consideration for
customer contacts and marketplace reputation developed by MediNotes for the Business and such covenants are necessary for Eclipsys to receive the full benefit of this Agreement. 
 (b) After the Closing, each Major Stockholder shall not individually, or in concert with any other Person, directly or indirectly:

 (i) engage or become interested in, as owner, employee, partner, through equity ownership (not including up to a five
percent passive equity interest in a company for which such Major Stockholder does not serve as an officer, director, employee or consultant), investment of capital, lending of money or property, rendering of services, including as a director (or
equivalent), or otherwise create or initiate, any business competitive with the Business; 
 (ii) take, or assist any other
Person in taking, any action intended to advance an interest of any competitor or potential competitor of the Business, or encourage any other Person to take such action; or 
 (iii) take, or assist any other Person in taking, any material action intended to cause any customer or prospective customer of the
Business to use the services or purchase or license the products of any competitor of the Business. 
 The covenants of the
Major Stockholders set forth in this Section 6.7(b) are referred to herein as the “Covenant Not to Compete.” 
 The Covenant Not to Compete shall cover all of the counties and other political subdivisions of the states of the United States. The Covenant Not to Compete shall bind each Major Stockholder for the three year period
immediately following the Closing Date, as the same may be extended pursuant to the terms of Section 6.7(f) (the “Restrictive Period”). The Major Stockholders agree that the duration and area for which the
Covenant Not to Compete set forth in this Section 6.7(b) is to be effective are reasonable. 
 Notwithstanding the
foregoing, nothing herein shall prohibit Travis Bond from rendering services to Bond Medical Corp., Inc., a Florida corporation (“Bond Medical Group”) for so long as the business of Bond Medical Group is solely that of
(A) acting as a reseller of products and services of MediNotes and (B) limited servicing of products competitive with those of MediNotes pursuant to servicing arrangements entered into prior to the date of the Bond Agreement (which Travis
Bond represents is the sole business of Bond Medical Group as conducted on the Closing Date). 
  

 65 

 Each of the Major Stockholders hereby acknowledges and agrees that the benefit of the
Covenant Not to Compete may be assigned by Eclipsys to any Subsidiary of Eclipsys in connection with any corporate restructuring or reorganization of Eclipsys of the Business, without the further consent of such Major Stockholder. 
 (c) In addition, and not in limitation of the prohibitions described in Section 6.7(b), for the Restrictive Period, each of
the Major Stockholders shall not, and shall cause such Major Stockholder’s Affiliates and family members not to, directly or indirectly, and shall not cause, encourage or assist any other Person to, divert or attempt to divert or take advantage
of or attempt to take advantage of any actual or potential business or opportunities of Eclipsys, MediNotes or their Affiliates of which any of the Major Stockholders become aware which relate to the Business, or any part thereof and which are
located in any county or any other political subdivision of the states of the United States of America. 
 (d) During the
Restrictive Period, each of the Major Stockholders shall not, and each Major Stockholder shall cause its Affiliates not to, and shall not, cause or encourage or assist any other Persons to, directly or indirectly: 
 (i) perform any action, activity or course of conduct consisting of or encouraging the following: (A) soliciting, recruiting or
hiring any employees of Eclipsys, MediNotes or their Affiliates; or (B) soliciting or encouraging any such employee of Eclipsys, MediNotes or their Affiliates to leave the employment of Eclipsys, MediNotes or their Affiliates; or 
 (ii) cause, solicit or encourage any customer, or contractor, subcontractor or other supplier of Eclipsys, MediNotes or their Affiliates
to terminate or adversely alter any relationship such customer or supplier may have with any of Eclipsys, MediNotes or their Affiliates. 
 Notwithstanding the foregoing, nothing herein shall prohibit general solicitations by the Major Stockholders or their Affiliates not directed at any specific employees of Eclipsys or MediNotes or their respective
Affiliates, including any newspaper advertisements. 
 (e) The covenants set forth in this Section 6.7 are in
addition to and not by way of limitation of any other duties any Major Stockholder may have to Eclipsys, MediNotes or their Affiliates. The Major Stockholders acknowledge that the covenants contained in this Section 6.7 impose a
reasonable restraint on the Major Stockholders in light of the activities and business and future plans of Eclipsys. The Major Stockholders acknowledge that if they violate any of the covenants contained in this Section 6.7
(collectively, the “Restrictive Covenants”), it will be difficult to determine the resulting damages to Eclipsys, MediNotes and their Affiliates and, in addition to any other remedies Eclipsys, MediNotes and their Affiliates
may have, Eclipsys, MediNotes and their Affiliates shall be entitled to temporary injunctive relief and permanent injunctive relief without the necessity of proving actual damages in the event of any breach or threatened breach of such covenants.
The non-prevailing party or parties shall be 

  

 66 

 
liable to pay all costs, including reasonable attorneys’ fees and expenses, that the prevailing party or parties may incur in enforcing or defending, to
any extent, any of the Restrictive Covenants, whether or not litigation is actually commenced and including litigation of any appeal. Eclipsys, MediNotes and their Affiliates may elect to seek one or more remedies at their discretion on a case by
case basis. Failure to seek any or all remedies in one case shall not restrict Eclipsys, MediNotes and their Affiliates from seeking any remedies in another situation or for a continuing breach. Such action by Eclipsys, MediNotes and their
Affiliates shall not constitute a waiver of any of their rights. 
 (f) Each of the Restrictive Covenants will be read and
interpreted with every reasonable inference given to its enforceability. However, if any term, provision or condition of the Restrictive Covenants is held by a court or arbitrator to be invalid, void or unenforceable, the remainder of the provisions
thereof shall remain in full force and effect and shall in no way be affected, impaired or invalidated. If a court or arbitrator determines that any of the Restrictive Covenants are unenforceable, in whole or in part, then the court or arbitrator
shall modify such covenant so as to make it enforceable to the fullest extent the court or arbitrator deems enforceable under the prevailing circumstances. As to each Major Stockholder, the Covenant Not to Compete shall be deemed to be a series of
separate covenants, one for each and every county or other political subdivision of the states of the United States of America, which is where the Covenant Not to Compete is intended to be effective. Any violation of the provisions of this
Section 6.7 shall automatically toll the passage of the three year period with respect to the breaching Stockholder and extend the Restrictive Period for the duration of such violations with respect to the breaching Stockholder.

 (g) At any time during the Restrictive Period, each or any of the Major Stockholders shall, within five (5) days of
the written request of Eclipsys, certify to Eclipsys in writing (in form and substance reasonably satisfactory to Eclipsys) that such Major Stockholder is in full compliance with the covenants contained in this Section 6.7. 

(h) Notwithstanding the foregoing, the Restrictive Covenants shall not apply to any Institutional Major Stockholder and its Affiliates
to the extent that such Restrictive Covenants would prevent such Institutional Major Stockholder and its Affiliates from conducting its business in the ordinary course as such business was conducted in the past; provided that this
Section 6.7(h) shall not apply to any Affiliates of such Institutional Major Stockholders, if such Affiliates are also Major Stockholders. 
 (i) Nothing contained in this Section 6.7 is intended to confer upon any individual Major Stockholder any right to employment with Eclipsys, MediNotes or their Affiliates at any time after the Closing
Date. 
 6.8 Directors. Effective as of the Closing Date, the Major Stockholders shall cause each director to resign from their
position as a director of the Board of Directors of MediNotes. 
 6.9 Stockholders’ Representative. The Stockholders shall at all
times maintain a representative (the “Stockholders’ Representative”) for purposes of taking certain actions and giving certain consents on behalf of the Major Stockholders prior to the Closing, and the Effective Time
Company Holders from and after the Closing, as specified herein. The Major 

  

 67 

 
Stockholders hereby appoint Danny R. Wipff as the initial Stockholders’ Representative, and immediately upon the approval of this Agreement by the
requisite vote or written consent of the Stockholders, each Stockholder shall be deemed to have consented to such appointment (or any then acting successor pursuant to the terms hereof) and the terms hereof. Another person shall be appointed as the
Stockholders’ Representative if the person so designated (or any successor thereof) is unwilling or unable to so act. The Stockholders’ Representative hereby accepts such appointment. Each of the Stockholders acknowledges that actions
taken, consents given and representations made by the Stockholders’ Representative on behalf of the Stockholders pursuant hereto shall be binding upon the Major Stockholders and the Effective Time Company Holders, as applicable, including all
actions under Section 7.2(b) and under the Holdback Escrow Agreement. This appointment and grant of power and authority by each Stockholder is coupled with an interest and is irrevocable and shall not be terminated by any act of any
Stockholder or by operation of law, whether by the death or incapacity of any individual Stockholder, or by the occurrence of any other event. The Stockholders’ Representative is authorized to take any action on behalf of the Major Stockholders
or the Effective Time Company Holders, as applicable, to facilitate or administer the transactions contemplated hereby, including, without limitation, amending this Agreement, and executing such other documents or instruments as the
Stockholders’ Representative deems appropriate. The Stockholders’ Representative may resign at any time, and may be removed for any reason or no reason by the vote or written consent of, as applicable, (i) if prior to the Effective
Time, the Major Stockholders holding a majority of the then outstanding aggregate fully diluted Shares held by the Major Stockholders, or (ii) from and after the Effective Time, the Effective Time Company Holders holding a majority of the
outstanding aggregate fully diluted Shares at the Effective Time. 
 6.10 Employee Matters. 
 (a) The employees of MediNotes listed on Schedule 6.10(a) will, subject to Section 6.10(b), continue as at-will
employees of MediNotes or Eclipsys or another Subsidiary of Eclipsys following the Closing, on terms to be determined by Eclipsys in consultation with MediNotes. If employment is continued by Eclipsys or another Subsidiary of Eclipsys other than
MediNotes, the new employer shall assume any accrued but unused vacation benefits as listed on Schedule 6.10(a). Employees of MediNotes who continue in the employ of MediNotes, or Eclipsys or a Subsidiary of Eclipsys, following a reasonable
transition period determined by Eclipsys in consultation with the Stockholders’ Representative, will have benefits and be employed on terms consistent with those provided by Eclipsys to its other employees at comparable levels in the
organization, including annual base compensation, as applicable based on employment level, plus an opportunity to receive equity based compensation and an annual bonus pursuant to the performance-based corporate bonus plan, if established by
Eclipsys’s Board of Directors. Following the Closing, to the extent permitted by Legal Requirements, applicable tax qualification requirements and the terms of the applicable employee benefit plans and policies of Eclipsys, and subject to any
generally applicable break in service or similar rule, Eclipsys shall recognize the years of service of each continuing employee of MediNotes with MediNotes prior to the Closing Date for purposes of vesting and eligibility to participate (but not
benefit accrual) under the employee benefit plans and policies of Eclipsys; provided, however, that such service will not be recognized if recognition would result in a duplication of benefits for the same period of service or to the extent
that such service was not recognized under the corresponding Company Benefit Plan. 
  

 68 

 (b) Nothing contained in this Agreement confers upon any employee of MediNotes any right
to continued employment or participation in any Company Benefit Plan or any employee benefit plan or policy of Eclipsys or its Subsidiaries at any time after the Closing Date, nor shall anything contained herein be deemed an amendment or
modification of any Company Benefit Plan or any employee benefit plan or policy of Eclipsys or its Subsidiaries. 
 (c)
Eclipsys shall be solely responsible for any required notice and payments under the Worker Adjustment Retraining and Notification Act of 1988 (the “WARN Act”) and any similar state statutes, and otherwise to comply with any
such statute with respect to any “plant closing” or “mass layoff” (as defined in the WARN Act) or group termination or similar event affecting any continuing employees of MediNotes occurring after the Closing Date. MediNotes
shall provide any required notice and payments under the WARN Act, and any similar state statutes, and otherwise to comply with any such statute with respect to any “plant closing” or “mass layoff” (as defined in the WARN Act) or
group termination or similar event affecting any employees of MediNotes on or before the Closing Date. 
 6.11 Release. In
consideration of the payments to the Major Stockholders by Eclipsys of their share of the Purchase Price and as a condition to the execution and delivery of this Agreement by Eclipsys, each Major Stockholder hereby gives the following general
release effective as of the Closing Date: 
 (a) Each Major Stockholder on behalf of such Major Stockholder and such Major
Stockholder’s agents, heirs, successors and assigns, hereby irrevocably and unconditionally releases, acquits and forever discharges MediNotes, Eclipsys, each of their respective Affiliates and their respective partners, members, managers,
stockholders, directors, officers and agents, and their respective successors and assigns (collectively, the “Released Parties”), to the fullest extent permitted by applicable Legal Requirements, from any and all charges,
complaints, claims, obligations, promises, agreements, controversies, damages, actions, causes of action, suits, rights, demands, remedies, costs, losses, debts, expenses and fees, of every type, kind, nature, description or character, whether known
or unknown, suspected or unsuspected, liquidated or unliquidated, that such Major Stockholder has, owns or holds, or claims to have, hold or own, including but not limited to those arising out of or in connection with (i) the Major
Stockholder’s employment, or other relationship with MediNotes, (ii) the Major Stockholder’s right to or interest in any Intellectual Property or other assets or properties of MediNotes, or (iii) the Major Stockholder’s
right to or any interest in any Contract with MediNotes, and (iv) any equity or other interests the Major Stockholder may have or claim to have in, or any other claims the Major Stockholder may have against, MediNotes or its predecessors
(collectively, the “Claims”). Each Major Stockholder represents that such Major Stockholder has not assigned or transferred or purported to have assigned or transferred to any Person any Claims. This general release set forth
in this Section 6.11 shall not affect any rights that the Major Stockholder may have which arise solely under this Agreement (including payment of the Purchase Price), or that arise after the Closing Date. 
 (b) Each Major Stockholder acknowledges and agrees that the releases made herein constitute final and complete releases of the Released
Parties with respect to all Claims. Each Major Stockholder expressly acknowledges and agrees that this general release is intended to include in its effect, without limitation, all Claims which such Major Stockholder does not 

  

 69 

 
know or suspect to exist at the time hereof, and this general release contemplates the extinguishment of any and all such Claims. Furthermore, each Major
Stockholder hereby expressly waives and relinquishes any rights and benefits that such Major Stockholder may have under any Legal Requirements, including any state law or any common law principles limiting waivers of unknown claims. Each Major
Stockholder understands that the facts and circumstances under which such Major Stockholder gives this full and complete release and discharge of the Released Parties set forth herein may hereafter prove to be different than now known or believed by
such Major Stockholder and such Major Stockholder hereby accepts and assumes the risk thereof and agrees that such Major Stockholder’s full and complete release and discharge of the Released Parties with respect to the Claims shall remain
effective in all respects and not be subject to termination, rescission or modification by reason of any such difference in facts and circumstances. 
 (c) Each Major Stockholder represents and agrees that such Major Stockholder has not filed with any Governmental Entity or arbitrator or any other Person any complaint, charge or lawsuit against any of the Released
Parties involving any Claims, and that such Major Stockholder will not do so at any time hereafter. 
 (d) Each Major
Stockholder represents and acknowledges that in executing this general release such Major Stockholder does not rely and has not relied upon any representation or statement not set forth herein made by any of the Released Parties or by any of the
Released Parties’ Affiliates, agents, representatives or attorneys with regard to the subject matter, basis or effect of this general release or otherwise. 
 (e) Without limiting the foregoing general release, each Major Stockholder agrees that such Major Stockholder will not, directly or
indirectly, (i) bring or cause to be brought, or encourage or participate in the prosecution of, any action, proceeding or suit seeking recovery by or on behalf of any Person from any Released Party of any amount in respect of, or Damages with
respect to, any of the Claims, or (ii) defend any action, proceeding or suit in whole or in part on the grounds that any or all of the terms or provisions of this Section 6.11 violate any Legal Requirements, or are illegal, invalid,
inequitable, not binding, unenforceable or against public policy. 
 6.12 Confidentiality. 
 (a) Each party and such party’s representatives shall use any Confidential Information of any other party solely for the purpose of
pursuing the transactions contemplated hereby, and shall not directly or indirectly use or exploit the Confidential Information of any other party for its own benefit or the benefit of another Person, including to create, adopt or modify products or
services which would compete with the disclosing party’s products or services. For purposes of this Agreement, Confidential Information of Eclipsys shall, from and after the Closing Date, include the Confidential Information of MediNotes and
the Business, and the Stockholders shall be subject to all obligations set forth herein with respect to such Confidential Information of Eclipsys and MediNotes. This provision is not intended to restrict independent business activities, in each case
undertaken without use of the other party’s Confidential Information and without violating the Restrictive Covenants, employment terms, or other legal or contractual duties (but this sentence does not limit the Restrictive Covenants or any
employment terms or other legal or contractual duties). 
  

 70 

 (b) Each party agrees that (i) the Confidential Information of any other party
received or otherwise held by it or generated by it or its representatives based upon such Confidential Information shall be kept confidential, (ii) except as permitted hereunder, such party and its advisors and other representatives will not
disclose any of the Confidential Information of any other party in any manner whatsoever, and (iii) such party and its representatives will use the same level of care to prohibit disclosure of the other party’s Confidential Information as
such party uses to protect its own confidential information, but in no event using less than reasonable care and diligence; provided, however, that (A) such party may make any disclosure of such information to which the other party gives
its prior written consent, and (B) any of such information may be disclosed to such party’s representatives who need to know such information for the sole purpose of pursuing the transactions contemplated hereby, and who agree to keep such
information confidential. In any event, each party shall be responsible for any breach of this Agreement by its representatives and shall, at its sole expense, take all reasonable measures (including but not limited to court proceedings) to restrain
its representatives from prohibited or unauthorized disclosure or use of the Confidential Information of any other party. 
 (c) The receiving party shall immediately notify the disclosing party upon any loss or unauthorized disclosure of the other party’s Confidential Information. 
 (d) In the event that any party or any of its representatives are requested or required (by oral questions, interrogatories, requests for
information or documents in legal proceedings, subpoena, civil investigative demand or other similar process) to disclose any of the Confidential Information of any other party, it shall provide the disclosing party with prompt written notice of any
such request or requirement so that the disclosing party may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement. If, in the absence of a protective order or other remedy or the receipt
of a waiver by the disclosing party, the receiving party or any of its representatives are nonetheless, in the opinion of its outside counsel, legally compelled to disclose Confidential Information of the disclosing party to any tribunal or else
stand liable for contempt or suffer other similar censure or penalty, the receiving party or its representative may, without liability hereunder, disclose to such tribunal only that portion of the Confidential Information of the disclosing party
that such counsel advises is legally required to be disclosed, provided that the receiving party exercises its commercially reasonable efforts to preserve the confidentiality of such Confidential Information, including, without limitation, by
cooperating with the disclosing party to obtain an appropriate protective order or other reliable assurance that confidential treatment will be accorded such Confidential Information by such tribunal. 
 (e) Each party acknowledges that the Confidential Information of the other parties has tangible value and it is further understood and
agreed that money damages would not be a sufficient remedy for any breach of the provisions set forth herein by any party or any of their representatives and that the parties hereto shall be entitled to equitable relief, including injunction and
specific performance, as a remedy for any such breach or threatened breach. Such remedies shall not be deemed to be the exclusive remedies for a breach of the provisions set forth herein, but shall be in addition to all other remedies available at
law or equity to the parties. 
  

 71 

 (f) Nothing herein shall limit the obligations of the parties under the Confidentiality
Agreement, and to the extent of any inconsistency between this Section 6.12 and the Confidentiality Agreement, the Confidentiality Agreement shall govern with respect to the parties thereto. 
 6.13 Covenants Regarding Contracts. On or before the Closing Date, unless waived by Eclipsys, MediNotes shall use reasonable efforts to obtain,
and Eclipsys shall use reasonable efforts to assist MediNotes in obtaining, all Consents required under the Material Contracts in connection with the execution, delivery and performance of this Agreement, the other Transaction Documents or the
consummation of the transactions contemplated hereby and thereby, on terms that are not materially burdensome to Eclipsys or MediNotes, and MediNotes shall deliver copies of such Consents to Eclipsys. 
 6.14 Stockholder Meeting. As soon as practicable following the date of this Agreement, MediNotes shall take all action necessary in accordance
with Iowa law and the MediNotes Articles of Incorporation and by-laws to duly call, give notice of, convene and hold the Company Stockholders’ Meeting for Stockholders to consider and vote upon the adoption and approval of this Agreement and
the transactions contemplated hereby, including the appointment of the Stockholders’ Representative, or solicit the written consent of Stockholders thereto. MediNotes will, through its Board of Directors, recommend to the Stockholders the
adoption and approval of this Agreement, shall not withdraw, modify or change such recommendation, and shall use reasonable efforts to obtain Company Stockholders’ Approval. The Major Stockholders will use reasonable efforts to secure the
Company Stockholder Approval. 
 6.15 Tax-Free Reorganization Status. 
 (a) Each of Eclipsys, Merger Sub, and MediNotes shall use its best efforts to cause the Merger followed by the Second Merger to qualify as
a “reorganization” within the meaning of Section 368(a) of the Code. None of Eclipsys, Merger Sub, and MediNotes, or their respective Subsidiaries shall take, or agree to take, any action that could prevent or impede the Merger
followed by the Second Merger from qualifying as a “reorganization” within the meaning of Section 368(a) of the Code. 
 (b) Unless otherwise required pursuant to a “determination” within the meaning of Section 1313(a) of the Code, each of Eclipsys, Merger Sub, and MediNotes shall report the Merger followed by the Second Merger as a
“reorganization” within the meaning of Section 368(a) of the Code within the manner described in Revenue Ruling 2001-46. 
 6.16 Second Merger. As soon as reasonably practicable after the Effective Time, Eclipsys shall cause the Second Merger to be effected by, among other things, approving the Second Merger as the sole shareholder of the Surviving
Corporation, adopting and causing the Surviving Corporation to adopt an agreement and plan of merger pursuant to which the Surviving Corporation shall be merged with and into a wholly owned limited liability company Subsidiary of Eclipsys that is
treated as a disregarded entity for tax purposes, with such Subsidiary being the entity surviving the Second Merger as a wholly owned Subsidiary of Eclipsys. There shall be no conditions to the Second Merger, other than the consummation of 

  

 72 

 
the Merger. It is intended that the Second Merger shall occur as described in this Section 6.16, and that the Merger and the Second Merger
together qualify as a reorganization under the provisions of Section 368(a) of the Code, and that this Agreement constitute a “plan of reorganization” within the meaning of section 1.368-2(g) of the regulations promulgated under the
Code. 
 6.17 Indemnification of Directors and Officers. 
 (a) Prior to the Effective Time, MediNotes may purchase tail coverage under its directors’ and officers’ liability insurance and
fiduciary insurance policies covering MediNotes’ directors, officers and fiduciaries, with respect to claims arising from facts or events that occur at or before the Effective Time. Eclipsys shall use, and cause MediNotes to use, commercially
reasonable efforts to keep any such tail coverage in effect for the term thereof, provided that neither Eclipsys nor MediNotes shall in any event be obligated to make payments with respect to any such policy beyond the premiums paid by MediNotes
prior to the Closing. 
 (b) This Section 6.17 is intended for the irrevocable benefit of, and to grant
third-party rights to, the directors, officers and fiduciaries of MediNotes at or prior to the Effective Time, to the extent such persons are covered by any such tail policies purchased by MediNotes prior to the Effective Time, and shall be binding
on all successors and assigns of Eclipsys. Each director, officer or fiduciary of MediNotes so covered shall be entitled to enforce the post-closing covenants of Eclipsys and MediNotes contained in this Section 6.17. 
 6.18 Compliance with Rule 144(c)(1). For so long as resales of shares of Eclipsys Common Stock issued as part of the Merger Consideration are
subject to the resale restrictions set forth in Rule 145 under the Securities Act, Eclipsys will use commercially reasonable efforts to comply with Rule 144(c)(1) under the Securities Act. 
 6.19 Termination of 401(k) Plan. Effective no later than the Business Day immediately preceding the Closing Date, MediNotes shall terminate any
and all Company Employee Plans intended to include a Code Section 401(k) arrangement (each such plan, a “Company 401(k) Plan”) pursuant to resolutions of MediNote’s Board of Directors that are substantially in the
form attached hereto as Schedule 6.19. MediNotes shall provide Eclipsys with evidence that all Company 401(k) Plans have been terminated (effective no later than the Business Day immediately preceding the Closing Date) and shall take
such other actions in furtherance of terminating any Company 401(k) Plans as Eclipsys may reasonably require. 
 6.20 Bond Agreement
Escrow. Travis Bond, as the owners’ representative under the Bond Agreement, hereby represents and covenants as follows: 
 (a) He is authorized to make the representations, warranties and covenants in this Section 6.20 under Section 11.01 of the Bond Agreement. 
 (b) The Merger Consideration received for the shares of Series C Preferred Stock (or any shares of Company Common Stock into which such
shares are converted) held in escrow pursuant to Sections 2.03 and 10.05 of the Bond Agreement (the “Bond Escrow Fund”) shall be held in escrow by Eclipsys to serve as a fund for the potential payment to MediNotes for claims
for indemnification pursuant to Article X of the Bond Agreement. This escrow shall 

  

 73 

 
terminate on March 13, 2009, the first anniversary of the closing date of the transaction contemplated by the Bond Agreement, except that any amounts in
escrow are subject to then pending claims for indemnification will continue to be held in escrow until such claims are resolved. With respect to any such claims, the portion of the Bond Escrow Fund that is shares of Eclipsys Common Stock Merger
shall be valued at the Average Market Price. 
 (c) Each of the Sellers (as defined in the Bond Agreement) shall: 

(i) Duly execute and deliver to the Paying Agent a letter of transmittal pursuant to Section 2.9(c) with respect to such
shares, directing the Paying Agent to pay the Merger Consideration with respect to such shares to Eclipsys as provided hereunder; and 
 (ii) Duly execute and deliver to Eclipsys, on or before the Closing Date, three stock powers in blank providing for the transfer of any or all of the shares of Eclipsys Common Stock held in the name of such Person in
the Bond Escrow Fund to MediNotes in respect of any claims for indemnification pursuant to Article X of the Bond Agreement. 
 (d) Notwithstanding anything contained herein, as an accommodation to the Sellers under the Bond Agreement, promptly, but in no event more than 10 days after Eclipsys receives (i) the Merger Consideration for all shares of Series C
Preferred Stock (or any shares of Company Common Stock into which such shares are converted) held in escrow pursuant to Sections 2.03 and 10.05 of the Bond Agreement, as set forth in Section 6.20(c)(i), and (ii) the letters of
transmittal and stock powers described in Section 6.20(c), Eclipsys shall deliver to Travis Bond, as owners’ representative under the Bond Agreement, fifty percent (50%) of the cash portion of the Merger Consideration received
therefor, provided that Travis Bond has provided Eclipsys with wire instructions for such transfer at least one Business Day prior to such payment. Such payment shall not limit the indemnification obligations of the Sellers under the Bond Agreement.

 (e) Promptly after March 13, 2009, or promptly after settlement of all open claims against such escrowed funds, if
later, Eclipsys shall deliver to Travis Bond, as owners’ representative under the Bond Agreement, all Merger Consideration not paid to MediNotes for indemnification pursuant to Article X of the Bond Agreement. 
 (f) Allocation of amounts distributed from the Bond Escrow Fund as described in Sections 6.20(d) and 6.20(e) is the
responsibility of Travis Bond as owners’ representative under the Bond Agreement, and MediNotes, Eclipsys and the Paying Agent, and their successors and transferees have no obligations with respect to such allocation or any actions taken or not
taken by Travis Bond. 
  

 74 

 ARTICLE VII 
 SURVIVAL; INDEMNIFICATION; REMEDIES 
 7.1 Survival of Representations and Warranties and
Covenants. 
 (a) The representations and warranties made in this Agreement shall survive for 456 days after the Closing
Date (the “Survival Period”). Notwithstanding the foregoing, the representations and warranties set forth in Sections 3.1, 3.2, 3.5, 4.3, 4.6(a), 4.9, 4.10, 4.11(b),
4.14 and 4.16 shall survive until the earlier of (i) 90 days after the expiration of the applicable statute of limitations period or (ii) the seventh anniversary of the Closing Date. The right to indemnification,
reimbursement or other remedy based upon such representations, warranties, covenants and obligations shall not be affected by any investigation conducted with respect to, or knowledge acquired (or capable of being acquired) at any time, whether
before or after the execution and delivery of this Agreement or the Closing Date. 
 (b) The covenants and agreements of the
parties contained in this Agreement shall survive the Closing indefinitely, except as expressly provided otherwise herein. 
 7.2
Indemnification and Other Rights. 
 (a) If the Closing occurs, each of the Stockholders shall, jointly and severally
(except as stated in Section 7.4(d) below), indemnify and defend Eclipsys, and its Affiliates (including MediNotes following the Closing), each of their respective officers, directors, employees, stockholders, agents and representatives,
and each of their respective successors and assigns (the “Eclipsys Indemnified Parties”) against and hold them harmless, reimburse and make them whole from and against any loss, claim, Liability, cost, damage or expense
(including reasonable legal and expert fees and expenses incurred in investigation or defense (including any appeal) of any of the same, or in asserting, preserving or enforcing its rights hereunder) actually incurred or claims suffered by any such
indemnified party (collectively “Damages”), to the extent arising from or in connection with any of the following: 
 (i) any breach or inaccuracy of any representation or warranty of MediNotes or the Major Stockholders, or any of them, contained in this Agreement, as modified by the Disclosure Schedule or any of the other
Transaction Documents (without giving effect to any supplement to the Disclosure Schedule after the date hereof, except for the Capitalization Update), provided that disclosures set forth in the Disclosure Schedules shall be disregarded with respect
to any claims arising from or in connection with any breach or inaccuracy of any of the representations set forth in Schedules 4.7(d)(i), 4.7(d)(iii), 4.11(a), 4.14(e) or 4.19(b); 
 (ii) any breach of any covenant of MediNotes prior to the Closing, or any breach of any covenant of the Major Stockholders, or any of
them, contained in this Agreement; 
  

 75 

 (iii) a Third-Party Claim arising from or in connection with the operations of the
Business before the Closing Date, including but not limited to (A) errors and omissions in design, creation, implementation or maintenance of any of the Software Products, (B) any failure of any of the Software Products to conform to
commitments made by or on behalf of MediNotes to customers or third parties before the Closing Date, and (C) any failure by MediNotes prior to the Closing Date to perform all material obligations under the Material Contracts, and in each case
notwithstanding disclosures set forth in the Disclosure Schedule; 
 (iv) any claims by any current or former employees of
MediNotes or any of its predecessors arising from or in connection with events or circumstances preceding the Closing, or arising from or in connection with the employment policies of MediNotes in place at any time prior to the Closing; and

 (v) (A) any and all Taxes of MediNotes with respect to (x) taxable periods ending on or before the Closing Date or
(y) any taxable period that commences before and ends after the Closing Date to the extent attributable to the period prior to Closing, (B) any and all Taxes arising as a result of the transactions contemplated by this Agreement;
(C) any and all costs and expenses incurred by MediNotes in connection with compliance matters relating to Taxes covered by this clause (v), including costs and expenses relating to disputes with taxing authorities, 
 provided that Eclipsys shall not be entitled to recover duplicate Damages under clauses (i) through (v), to the extent claims could be made under
more than one of such clauses. 
 The express written waiver by Eclipsys of any condition set forth in Section 8.2 based on the
inaccuracy of any representation or warranty, or on the nonperformance of or noncompliance with any covenant or obligation, will not preclude any right of Eclipsys or any other Eclipsys Indemnified Party to indemnification, payment of Damages, or
other remedy based on such representation, warranty, covenant, or obligation to the extent arising from a Third-Party Claim. For purposes of this Agreement, Damages shall include, but not be limited to, the amount by which the value of MediNotes and
the Business is less than it would have been but for a breach or inaccuracy of the representations and warranties of MediNotes or the Major Stockholders, or the failure by MediNotes or the Major Stockholders to fulfill their obligations hereunder.

 (b) Each of the Stockholders hereby (i) irrevocably appoints the Stockholders’ Representative as such
Stockholder’s agent for service of any and all legal process, summons, notices and documents which may be served in any action or proceeding under or pursuant to this Agreement, (ii) waives any requirement of personal notice or any claim
that service on the Stockholders’ Representative is invalid or insufficient to constitute valid personal service on such Stockholder, and (iii) ratifies and confirms, and agrees to be bound by, all actions taken by the Stockholders’
Representative on its behalf pursuant to the foregoing authorization. 
 (c) Eclipsys shall indemnify the Stockholders and
their Affiliates and each of their respective officers, directors, employees, stockholders, agents and representatives against and hold them harmless from any Damages to the extent arising from (i) any breach or inaccuracy of any representation
or warranty of Eclipsys contained in this Agreement or any of the other Transaction Documents; and (ii) any breach of any covenant of Eclipsys contained in this Agreement. The express written waiver by MediNotes of any condition set forth in

  

 76 

 
Section 8.3 based on the inaccuracy of any representation or warranty, or on the nonperformance of or noncompliance with any covenant or
obligation, will not preclude any right of the Stockholders to indemnification, payment of Damages, or other remedy based on such representation, warranty, covenant, or obligation to the extent arising from a Third-Party Claim. Any indemnity payment
under this Section 7.2(c) shall be satisfied, subject to compliance with Legal Requirements, with Eclipsys Common Stock to the extent necessary to preserve the status of the Merger followed by the Second Merger as a reorganization within
the meaning of Section 368(a) of the Code. 
 (d) Any payments made pursuant to this Article VII shall, except as
may otherwise be required by applicable Legal Requirements, be treated for all purposes as an adjustment to the Merger Consideration for Tax purposes. For purposes of this Article VII, shares of Eclipsys Common Stock held by the Escrow Agent
and released to Eclipsys or representing a portion of the Merger Consideration returned to Eclipsys by the Stockholders as indemnification for Damages shall be valued at the Average Market Price. 
 (e) For the sole purpose of appropriately apportioning any Taxes relating to a period that includes (but that would not end on) the
Closing Date, the portion of such Tax that is attributable to MediNotes for the part of such taxable period that ends on the Closing Date shall be (i) in the case of any Taxes other than Taxes based upon income or receipts, the amount of such
Tax for the entire Tax period multiplied by a fraction the numerator of which is the number of days in the Tax period ending on the Closing Date and the denominator of which is the number of days in the entire Tax period, and (ii) in the case
of any Taxes based upon or related to income or receipts, the amount which would be payable if the relevant Tax period ended as of the close of business on the Closing Date. Any Taxes that are the responsibility of the Stockholders pursuant to
Section 7.2(a)(v) shall be paid to Eclipsys or MediNotes no later than five (5) days prior to the due date for the payment of such Taxes and, to the extent such Taxes are not paid to Eclipsys or MediNotes on or prior to the
applicable due date, the amount of such Taxes shall bear interest at the rate of ten percent (10%) per annum or the applicable underpayment rate (if higher), commencing on the applicable due date until the date of payment. 
 7.3 Time Limitations. 
 (a) Neither Eclipsys, nor the Stockholders will have any liability (for indemnification or otherwise) with respect to any representation or warranty contained in this Agreement, other than those in Sections 3.1, 3.2,
3.5, 4.3, 4.6(a), 4.9, 4.10, 4.11(b), 4.14 and 4.16, except to the extent that on or before the last day of the Survival Period, the party seeking recovery for Damages provides notice in
writing pursuant to Section 7.6 or Section 7.7 of a claim for Damages specifying the factual basis of that claim in reasonable detail to the extent then known by such party. In such event, the party giving such notice shall
continue to have the right to recover hereunder, and to all other rights and remedies under this Agreement, with respect to the matter or matters to which such claim relates until such claim has been finally resolved and payment made, if any.

 (b) Subject to Section 7.4, a claim with respect to Sections 3.1, 3.2, 3.5, 4.3,
4.6(a), 4.9, 4.10, 4.11(b), 4.14 and 4.16, must be made at any time prior to the earlier of (i) 90 days after the expiration of the applicable statute of limitations period or (ii) the seventh
anniversary of the 

  

 77 

 
Closing Date, except to the extent that on or before such date, the party seeking recovery for Damages provides the notice in writing pursuant to
Section 7.6 or Section 7.7 of a claim for Damages specifying the factual basis of that claim in reasonable detail to the extent then known by such party. In such event, the party seeking recovery for Damages shall continue to
have the right to recover hereunder, and to all other rights and remedies under this Agreement, with respect to the matter or matters to which such claim relates until such claim has been finally resolved and payment made, if any. 
 (c) Subject to Section 7.4, a claim made under Section 7.2(a)(ii), with respect to actions of MediNotes or the
Major Stockholders prior to the Closing, or Sections 7.2(a)(iii), (iv) or (v), must be made at any time prior to the earlier of (i) 90 days after the expiration of the applicable statute of limitations period or
(ii) the seventh anniversary of the Closing Date, except to the extent that on or before such date, the party seeking recovery for Damages provides the notice in writing pursuant to Section 7.6 or Section 7.7 of a claim
for Damages specifying the factual basis of that claim in reasonable detail to the extent then known by such party. In such event, the party seeking recovery for Damages shall continue to have the right to recover hereunder, and to all other rights
and remedies under this Agreement, with respect to the matter or matters to which such claim relates until such claim has been finally resolved and payment made, if any. 
 7.4 Other Limitations. 
 (a) The Stockholders shall have no liability (for
indemnification or otherwise) with respect to any matters under this Agreement (except for all claims, rights or causes of action arising from (i) Stockholder Fraud or (ii) a breach of any of the representations and warranties contained in
Section 3.1, 3.2, 3.5, 4.3, 4.6(a), 4.9, 4.10, 4.11(b), 4.14, 4.16 and 4.23, as to which the threshold described in this Section 7.4(a) shall be inapplicable)
unless the total Damages for matters hereunder exceed $300,000; once such amount has been met, the Stockholders shall be liable for all amounts of such Damages, in excess of $200,000. 
 (b) Eclipsys will have no liability (for indemnification or otherwise) with respect to any matters under this Agreement (except for Fraud
by Eclipsys, or the representations made in Section 5.4, as to which the threshold described in this Section 7.4(b) shall be inapplicable) unless the total Damages for matters hereunder exceed $300,000; once such amount has
been met, Eclipsys shall be liable for all amounts of such Damages, in excess of $200,000. 
 (c) For purposes of this
Article VII, the representations and warranties contained herein shall not be deemed qualified by any references herein to materiality generally or to whether any such breach results or may result in a Material Adverse Effect or if a matter
be or may not be “reasonably likely” to occur. 
 (d) Any claims by the Eclipsys Indemnified Parties for claims
under Section 7.2(a)(i) though (v) shall be first made against the Escrow Account for the Indemnification Amount, which shall be funded from the Purchase Price by all Effective Time Company Holders; provided, however
that any claim by the Eclipsys Indemnified Parties against a Major Stockholder under Section 7.2(a)(i), with respect to a breach or inaccuracy of any 

  

 78 

 
representation or warranty of such Major Stockholder, or Section 7.2(a)(ii), with respect to a breach of any covenant of such Major Stockholder,
in the discretion of Eclipsys, may first be made directly against the Major Stockholder. Once the Escrow Account for the Indemnification Amount is exhausted, no Stockholder, other than the Major Stockholders, shall have any further liability under
this Article VII, but each Major Stockholder shall continue to be liable, provided however that each Major Stockholders’ liability (for indemnification or otherwise) with respect to any Damages (i) relating to (A) any
breach or inaccuracy of a representation or warranty contained in Article III or Article IV, other than those in Sections 3.1, 3.2, 3.5, 4.3, 4.6(a), 4.9, 4.10, 4.11(b),
4.14 and 4.16, or (B) any matters under this Agreement described in Section 7.2(a)(ii), with respect to actions of MediNotes or the Major Stockholders prior to the Closing, or Section 7.2(a)(iii) and
(iv), shall not exceed, in the aggregate, twenty five percent (25%) of the portion of the Purchase Price payable to such Major Stockholder, and provided, further that with respect to a breach or inaccuracy of the representations
and warranties of a Major Stockholder under Article III, such Major Stockholder shall only be liable for such Major Stockholder’s breaches or inaccuracies. Subject to the second proviso to the foregoing sentence, each Major
Stockholder shall be liable for up to one hundred percent of the portion of the Purchase Price payable to such Major Stockholder with respect to a breach of any of the representations and warranties contained in Sections 3.1, 3.2,
3.5, 4.3, 4.6(a), 4.9, 4.10, 4.11(b), 4.14 and 4.16 (and such Major Stockholder’s liability shall not be limited by anything contained in clause (i) above, even if such liability may
also relate to a claim under Sections 7.2(a)(ii), (iii) or (iv)). For purposes of calculating such caps on the liability of a Major Stockholder, any amount contributed by such Major Stockholder to the Indemnification
Amount paid to Eclipsys shall be counted towards the amount paid by such Major Stockholder. The Major Stockholders’ liability arising from claims or causes of actions arising from Stockholder Fraud, and with respect to claims arising under
Section 7.2(a)(ii) with respect to actions of a Major Stockholder after the Closing, or Section 7.2(a)(v), shall not be subject to any cap or limitation on amount, provided that (1) with respect to claims arising under
Section 7.2(a)(ii) with respect to actions of a Major Stockholder, each Major Stockholder shall only be liable for breaches by such Major Stockholder or breaches arising from the concerted action of such Major Stockholder, and
(2) with respect to Stockholder Fraud, each Major Stockholder shall only be liable if such Major Stockholder committed, or conspired to commit, such Stockholder Fraud. 
 (e) Notwithstanding anything herein to the contrary, payments to Eclipsys for Damages shall be limited to the amount of Damages, if any,
that remains after deducting therefrom (i) any insurance proceeds received by Eclipsys or MediNotes under policies in place prior to the Effective Time and any indemnity contribution or other similar payment actually recovered by Eclipsys or
MediNotes from any third-party with respect thereto, and (ii) any provision or reserve with respect to such Damages reflected as a Current Liability. Notwithstanding anything herein to the contrary, Eclipsys shall not be entitled to punitive
damages unless assessed in connection with a Third-Party Claim. 
 (f) After Eclipsys receives indemnification as provided in
this Agreement, Eclipsys shall rebate to the Escrow Agent, the Stockholders, or the Major Stockholders, as applicable, the actual cash tax benefits, if any, realized on account of the Damages to which such claim relates by Eclipsys in the first tax
year in which such Damages are reflected on Eclipsys’s Tax Returns, to the extent such benefits are readily identifiable, and provided that the tax position producing such tax benefits has not been challenged by any tax authority within 

  

 79 

 
eighteen months after the filing of the initial Tax Return reflecting the tax benefit. Any such rebate shall be paid within thirty (30) days after the
expiration of such eighteen month period, provided that any such rebate paid by Eclipsys may be recovered to the extent that the cash benefit upon which the rebate was based is subsequently invalidated by any tax authority. Notwithstanding the
foregoing, nothing in this Agreement shall limit Eclipsys’s right to determine its tax position in its sole discretion. 
 (g) The Stockholders’ remedies (for indemnification or otherwise, whether such claim is based in contract, tort or any other theory) with respect to any breach or inaccuracy of Eclipsys’s representations, warranties or covenants
in this Agreement shall be limited to those available under federal securities laws in connection with a private placement of securities under SEC Rule 506. 
 (h) Nothing herein shall limit, or be deemed to limit, the rights of Eclipsys against any Stockholder arising under the Investor
Questionnaire delivered by such Stockholder prior to the date hereof or the letter of transmittal delivered by such Stockholder as described in Section 2.9(c). 
 (i) In no event shall any Stockholder be entitled to require that any claim be made or brought against any other Person, including
MediNotes, before any claim for Damages is brought or claim is made by any Eclipsys Indemnified Party against such Stockholder or the Escrow Account for the Indemnification Amount hereunder. 
 7.5 Set-Off. In addition to any rights of set-off, off-set or other rights that Eclipsys may have at common law, by statute or otherwise, Eclipsys
shall have the right to set-off against (i) the Escrow Account for the Indemnification Amount held by the Escrow Agent pursuant to the Holdback Escrow Agreement and (ii) any amount that Eclipsys would otherwise be required to pay to any
Major Stockholder, any amounts owing by any Major Stockholder to Eclipsys pursuant to this Article VII; provided, however, that (A) notwithstanding the exercise by Eclipsys of the right to set-off described in this
Section 7.5, Eclipsys and the Stockholders shall remain obligated to first comply with their respective obligations described in Section 7.6 and Section 7.7 and (B) with respect to a breach or inaccuracy of
the representations and warranties of a Major Stockholder under Article III, Eclipsys shall only have the right to set-off against the Escrow Account for the Indemnification Amount held by the Escrow Agent pursuant to the Holdback Escrow
Agreement or any amounts that Eclipsys would be required to pay such Major Stockholder. Neither the exercise of nor failure to exercise any such right of set-off will constitute an election of remedies or limit Eclipsys in any manner in the
enforcement of other remedies available to it hereunder and the exercise by Eclipsys of the right of set-off against the Escrow Account for the Indemnification Amount held under the Holdback Escrow Agreement or other amounts Eclipsys would otherwise
be required to pay to any Major Stockholder shall not be the sole or exclusive remedy of Eclipsys for recovery of any amounts owed by the Stockholders to Eclipsys under this Article VII. 
  

 80 

 7.6 Procedures Relating to Indemnification Involving Third-Party Claims. 
 (a) In order for a party to be entitled to any indemnification provided for under this Agreement in respect of, arising out of or
involving a claim or demand made by any Person not a party to this Agreement against such party (a “Third-Party Claim”), such indemnified party must promptly notify the indemnifying party in writing, and in reasonable detail,
of the Third-Party Claim after receipt by such indemnified party of written notice of the Third-Party Claim; provided, however, that failure to give such notification will not affect the indemnification provided hereunder except to the extent
that the indemnifying party is actually prejudiced as a result of such failure. Thereafter, the indemnified party shall promptly deliver to the indemnifying party after the indemnified party’s receipt thereof, copies of all notices and
documents (including court papers) received by the indemnified party relating to the Third-Party Claim. In the event that more than one Major Stockholder is an indemnifying party hereunder, the indemnified party may provide the notices and other
communications required pursuant to this Section 7.6 solely to the Stockholders’ Representative. 
 (b) If a
Third-Party Claim is made against an indemnified party, the indemnifying party shall be entitled to participate in the defense thereof and, if it promptly so chooses and acknowledges its obligation to indemnify the indemnified party therefor, to
assume the defense thereof with counsel selected by the indemnifying party, provided that such counsel is not reasonably objected to by the indemnified party. Should the indemnifying party assume the defense of a Third-Party Claim, the indemnifying
party shall not be liable to the indemnified party for legal expenses subsequently incurred by the indemnified party in connection with the defense thereof. If the indemnifying party assumes such defense, the indemnified party shall have the right
to participate in the defense thereof and to employ counsel (not reasonably objected to by the indemnifying party), at its own expense, separate from the counsel employed by the indemnifying party, it being understood that the indemnifying party
shall control such defense. However, notwithstanding the foregoing, if Eclipsys or any of its Affiliates is an indemnified party in connection with a Third-Party Claim involving any then current employee, any then current client or supplier
(including the owner of any Intellectual Property then used in the Business), Eclipsys may control the defense, at the cost of the indemnifying party, subject to reasonable input from the indemnifying party, with reasonableness determined by
reference, among other things, to any conflicting interests between the indemnified party and indemnifying party. 
 (c) The
indemnifying party shall be liable for the reasonable fees and expenses of counsel employed by the indemnified party in connection with a Third-Party Claim for any period during which the indemnifying party has failed to assume or is not entitled to
assume the defense thereof; provided, however, that the indemnifying party shall not, in connection with any one action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general
allegations or circumstances, be liable for the fees and expenses of more than one separate firm of attorneys (in addition to one local counsel, where applicable). In connection with any Third-Party Claim, the indemnified party and the indemnifying
party shall cooperate with each other in the defense or prosecution thereof. Such cooperation shall include the retention and (upon the indemnified or indemnifying party’s request) the provision to such party of records and information which
are reasonably relevant to such Third-Party Claim, and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, including deposition or trial testimony.

  

 81 

 (d) If the indemnifying party shall have assumed the defense of a Third-Party Claim, the
indemnified party shall not have the right to settle or compromise such claim, and shall agree to any settlement, compromise or discharge of a Third-Party Claim that the indemnifying party may recommend and which by its terms obligates the
indemnifying party to pay the full amount of the liability in connection with such Third-Party Claim, which releases the indemnified party completely in connection with such Third-Party Claim, which does not impose any equitable remedies and which
the indemnified party reasonably determines would not otherwise adversely affect the indemnified party. If the indemnifying party shall not have assumed the defense of a Third-Party Claim, the indemnified party may settle, compromise or discharge,
such Third-Party Claim in good faith without the indemnifying party’s prior consent. 
 (e) Notwithstanding the
foregoing, the indemnifying party shall not be entitled to assume the defense of any Third-Party Claim (and shall be liable for the reasonable fees and expenses of counsel incurred by the indemnified party in defending such Third-Party Claim) if:

 (i) the Third-Party Claim seeks an Order or other equitable relief or relief for other than money damages against the
indemnified party which the indemnified party reasonably determines, after conferring with its outside counsel, cannot be separated from any related claim for money damages, or 
 (ii) the indemnified party reasonably determines, after conferring with its outside counsel, that joint representation would be expected
to give rise to a conflict of interest. 
 If such equitable relief or other relief portion of the Third-Party Claim can be so
separated from that for money damages, the indemnifying party shall be entitled to assume the defense of the portion relating to money damages. All claims under Section 7.2 other than Third-Party Claims shall be governed by
Section 7.7. 
 (f) Notwithstanding the foregoing, Eclipsys and MediNotes shall have the sole right to represent
the interests of MediNotes in all Tax audits and administrative and court proceedings and to employ counsel of its choice (and, to the extent relating to Taxes for which the Major Stockholders are liable pursuant to this Agreement, at the Major
Stockholders’ expense); provided, however, that, to the extent relating to Taxes for which the Major Stockholders are liable pursuant to Section 7.2, the Stockholders’ Representative shall have the opportunity to
participate, subject to the control of Eclipsys and MediNotes, at its own cost in any defense of such proceeding. Eclipsys and MediNotes shall not settle any Tax claim to the extent relating to Taxes for which the Major Stockholders are liable
pursuant to Section 7.2 without the prior written consent of the Stockholders’ Representative, which consent shall not be unreasonably withheld or delayed. If the Stockholders’ Representative consents to any such settlement,
neither the Stockholders’ Representative nor any Major Stockholder shall have any power or authority to object to the amount or validity of any claim by or on behalf of any indemnified party for indemnity with respect to such settlement.

  

 82 

 7.7 Other Claims. A claim by any party for reimbursement, make whole or other recovery for Damages
arising from any event, circumstance or condition not involving a Third-Party Claim may be asserted by written notice to the party or parties from whom such recovery is sought (or to the Stockholders’ Representative, if such recovery is sought
from more than one of the Major Stockholders) and shall be paid promptly after receipt of such notice. Notwithstanding the foregoing, no party shall be liable to any other for any punitive damages pursuant to this Section 7.7.

 7.8 Recovery in the Case of Strict Liability or Negligence. THE PROVISIONS IN THIS ARTICLE VII SHALL BE ENFORCEABLE
REGARDLESS OF WHETHER THE DAMAGES ARE BASED ON PAST, PRESENT OR FUTURE CLAIMS OR LEGAL REQUIREMENTS (INCLUDING ANY ENVIRONMENTAL LAW OR PRODUCTS LIABILITY LAW), AND REGARDLESS OF WHETHER ANY PERSON (INCLUDING THE PERSON FROM WHOM INDEMNIFICATION OR
OTHER RECOVERY IS SOUGHT) ALLEGES OR PROVES THE CONCURRENT, CONTRIBUTORY OR COMPARATIVE NEGLIGENCE OF THE PERSON SEEKING SUCH INDEMNIFICATION OR OTHER RECOVERY, OR THE SOLE OR CONCURRENT STRICT LIABILITY IMPOSED ON THE PERSON SEEKING SUCH
INDEMNIFICATION OR OTHER RECOVERY. 
 7.9 Sole and Exclusive Remedy. 
 (a) Should the Closing occur (i) the sole and exclusive remedies of Eclipsys and Merger Sub for any breach or inaccuracy of the
representations and warranties of MediNotes and the Major Stockholders under this Agreement and any other Transaction Documents (except to the extent expressly provided in such Transaction Documents), whether such claims be in contract, tort or
otherwise, shall be the remedies provided in this Article VII, and Eclipsys and Merger Sub hereby waive, from and after the Closing, any and all other remedies which may be available at law or equity for any breach or inaccuracy or
alleged breach or inaccuracy of the representations and warranties of MediNotes and the Major Stockholders hereunder, and (ii) the Stockholders’ sole and exclusive remedies for any breach or inaccuracy of the representations and warranties
of Eclipsys and Merger Sub under this Agreement and any other Transaction Documents (except to the extent expressly provided in such Transaction Documents), whether such claims be in contract, tort or otherwise, shall be the remedies provided in
this Article VII, and each of the Stockholders hereby waives, and by approval hereof by the Stockholders, shall be deemed to have waived, from and after the Closing, any and all other remedies which may be available at law or equity for
any breach or inaccuracy or alleged breach or inaccuracy of the representations and warranties of Eclipsys and Merger Sub hereunder. If the Closing does not occur, the sole and exclusive remedy of the parties shall be as set forth in
Section 9.5, and the provisions of this Article VII shall be inapplicable. 
 (b) Nothing in this
Article VII will (i) limit the right of any party to seek injunctive or other equitable relief for any breach or alleged or threatened breach of any covenant in this Agreement or any other Transaction Document, provided that the exercise
of any equitable relief shall be subject to Section 10.11, or (ii) limit the rights of the Major Stockholders to seek any remedies with respect to Fraud by Eclipsys, or Eclipsys to seek any remedies with respect to Stockholder Fraud
in connection herewith or transactions contemplated hereby (including limiting the time such claims can be made, or making such claims subject to any deductibles set forth herein). 
  

 83 

 (c) For the avoidance of doubt, the concept of “indemnity” as used in this
Article VII is intended to include claims between or among the parties to this Agreement and not involving any third-party, as well as Third-Party Claims, and the limitation set forth in this Section 7.9 of remedies for
breach or inaccuracies of representations and warranties under this Agreement is not intended to preclude claims between or among the parties, including but not limited to claims for breach of contract or Fraud, which claims are, however, intended
to be governed by this Article VII. 
 ARTICLE VIII 
 CONDITIONS 
 8.1 Conditions to Each Party’s Obligation to Effect the
Closing. The respective obligations of each party to effect the Closing and the other transactions contemplated hereby are subject to the satisfaction or waiver at or prior to the Closing Date of each of the following conditions: 
 (a) All filings with any Governmental Entity required to be made prior to the Closing Date by MediNotes, the Major Stockholders, Eclipsys,
Merger Sub or any of their respective Affiliates, and all other Consents of any Governmental Entity required to be obtained prior to the Closing Date by MediNotes, the Major Stockholders, Eclipsys, Merger Sub or any of their respective Affiliates in
connection with the execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated herein and therein by MediNotes, the Major Stockholders, Eclipsys and Merger Sub shall have been
made or obtained (as the case may be). 
 (b) No court or other Governmental Entity of competent jurisdiction shall have
enacted, issued, promulgated, enforced or entered any Legal Requirement or Order, whether temporary, preliminary or permanent that is in effect and restrains, enjoins or otherwise prohibits, materially delays, makes illegal, or would be violated
(provided that with respect to any Legal Requirement, such violation is not immaterial in light of the transactions contemplated hereby) by consummation of the transactions contemplated by this Agreement or the other Transaction Documents.

 (c) The Company Stockholder Approval shall have been validly obtained under Iowa state law, MediNotes Articles of
Incorporation and the by-laws of MediNotes. 
 8.2 Conditions to Obligations of Eclipsys. The obligations of Eclipsys to effect the
Closing are also subject to the satisfaction or waiver by Eclipsys at or prior to the Closing Date of the following conditions: 
 (a) each of the representations and warranties of MediNotes and the Major Stockholders set forth in this Agreement qualified as to materiality shall be true and correct, and those not so qualified shall each be true and correct in all
material respects, as of the date of this Agreement and as of the Closing Date (without giving effect to any amendment or supplement to the Disclosure Schedule after the date hereof, except for the Capitalization Update), except to the extent such
representations and warranties speak as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date; 
  

 84 

 (b) MediNotes and the Major Stockholders shall have performed in all material respects
all obligations required to be performed by them under this Agreement at or prior to the Closing Date; 
 (c) Eclipsys shall
have been furnished with a certificate, executed by MediNotes and the Stockholders’ Representative, dated the Closing Date, certifying as to the fulfillment of the conditions in Sections 8.2(a) and (b); 
 (d) each of the other Transaction Documents, and such further instruments of sale, transfer, conveyance, assignment, delivery or
confirmation, or any part thereof, as Eclipsys may reasonably require, shall have been fully executed and delivered by MediNotes or the Major Stockholders to Eclipsys and shall remain in full force and effect, and there shall be no default
thereunder; 
 (e) all Consents required under the Material Contracts in connection with the execution, delivery and
performance of this Agreement and the other Transaction Documents, and the consummation of the transactions contemplated hereby or thereby, shall have been obtained by MediNotes on terms that are not materially burdensome to MediNotes or Eclipsys,
shall be in full force and effect and shall have been delivered to Eclipsys; 
 (f) there shall not be pending or threatened
by any Governmental Entity any suit, action or proceeding (or by any other Person any suit, action or proceeding which Eclipsys determines in good faith has a reasonable likelihood of success): (A) seeking to obtain from Eclipsys, Merger Sub or
any Affiliate thereof, in connection with the Merger or the other transactions contemplated hereby or by the other Transaction Documents any money damages; (B) seeking to prohibit or limit the ownership or operation by Eclipsys or MediNotes, of
any material portion of the Business, or to compel Eclipsys or MediNotes to dispose of or hold separate any material portion of the Business in each case as a result of the Merger or any of the other transactions contemplated by this Agreement or by
the other Transaction Documents; (C) seeking to impose limitations on the ability of Eclipsys to acquire or hold, or exercise full rights of ownership of the Capital Stock of MediNotes, including the right to vote such Capital Stock on all
matters properly presented to the equityholders of MediNotes; (D) seeking to prohibit Eclipsys from effectively controlling in any material respect the Business; (E) claiming that such Person is a beneficial owner of, or has the right to
acquire or to obtain beneficial ownership of, any Capital Stock or assets of MediNotes or is entitled to any portion of the Purchase Price; (F) affecting a material portion of the Business, as determined by Eclipsys, in good faith; or
(G) that may otherwise have the effect of preventing, materially delaying, or otherwise materially interfering with the transactions contemplated by this Agreement and the other Transaction Documents; 
 (g) since the date of this Agreement, there shall have been no event, change, occurrence, condition or circumstance that Eclipsys
determines, in good faith, has had or is reasonably likely to have, individually or in the aggregate, a Material Adverse Effect on MediNotes or the Business; 
 (h) Eclipsys shall have received the resignations of the directors of MediNotes pursuant to Section 6.8; 
  

 85 

 (i) [deliberately deleted] 
 (j) the Escrow Agent, the Major Stockholders and the Stockholders’ Representative shall have executed the Holdback Escrow Agreement;

 (k) Eclipsys shall be reasonably assured that each of the Key Employees and other employees of MediNotes of a quantity and
having the skills sufficient for the operation of the Business are continuing their affiliation with the Business through employment with Eclipsys or MediNotes, after the Closing Date; 
 (l) each of the Key Employees shall have entered into an employment agreement, on the terms set forth in Exhibit C-4, and in
the applicable form attached hereto as Exhibit C-1, Exhibit C-2, or Exhibit C-3, or another form acceptable to Eclipsys and such Key Employee, with Eclipsys or, in the discretion of Eclipsys, a Subsidiary of
Eclipsys (including MediNotes) (the “Employment Agreements”); 
 (m) Eclipsys’ review of the
Contracts, capital structure and other legal due diligence materials provided or to be provided hereunder by MediNotes shall not have revealed any fact not disclosed in this Agreement or on the face of the Disclosure Schedule hereto that represents
or could reasonably be expected to result in a material cost or risk to Eclipsys, or a material reduction in value to Eclipsys, resulting from the Merger, and such review shall not have revealed that the Material Contracts with customers (including
resellers) vary in any material respect from the forms provided to Eclipsys on or before the date hereof; 
 (n) Eclipsys
shall have received an opinion of counsel to MediNotes in the form attached hereto as Exhibit D; 
 (o) all
required corporate action on the part of MediNotes and the Stockholders, including without limitation, approval by the board of directors of MediNotes, shall have been taken (and not rescinded) to approve the execution, delivery and performance of
this Agreement and the other Transaction Documents; 
 (p) the Merger shall be effective; 
 (q) the issuance of the Stock Consideration shall not, in the sole judgment of Eclipsys, violate any Legal Requirement; 
 (r) Eclipsys shall have received an executed Spousal Consent from the spouse of each Major Stockholder who is married on the Closing Date,
and residing in a community property state;  
 (s) the Dissenting Shares shall constitute no more than five
percent (5%) of the Shares outstanding as of the Effective Date; 
 (t) Eclipsys shall have received a certificate from
MediNotes, in form and substance reasonably satisfactory to Eclipsys, to the effect that MediNotes is not a U.S. real property holding company meeting the requirements of Treasury Regulations 1.1445-2(c)(3) and 1.897-2(h); 
  

 86 

 (u) the Stockholders Agreement shall have been terminated effective on or before the
Closing, and the Stockholders party thereto shall have waived all rights thereunder with respect to the transactions contemplated hereby; 
 (v) the Consulting Agreement, dated September 5, 2007, between MediNotes and Joseph R. Dunham II shall have been terminated effective as of the Closing pursuant to a Consulting Agreement Termination in the form
attached hereto as Exhibit I; 
 (w) the Bond Entities shall have executed and delivered the Royalty Termination
Agreement, in the form attached herein as Exhibit G; 
 (x) the parties to the Bond Agreement shall have executed and
delivered the stock powers referenced in Section 6.20; and 
 (y) Eclipsys shall have received such other
documents as Eclipsys reasonably requests evidencing the satisfaction of any condition referred to in this Section 8.2. 
 8.3
Conditions to the Obligations of MediNotes and the Stockholders. The obligations of MediNotes and the Stockholders to effect the Closing are also subject to the satisfaction or waiver by the Stockholders prior to the Closing Date of the
following conditions: 
 (a) each of the representations and warranties of Eclipsys and Merger Sub set forth in this Agreement
qualified as to materiality shall be true and correct, and those not so qualified shall each be true and correct in all material respects, as of the date of this Agreement and as of the Closing Date (except to the extent such representations and
warranties speak as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date); 
 (b) Eclipsys and Merger Sub shall have performed in all material respects all obligations required to be performed by it under this Agreement at or prior to the Closing Date; 
 (c) the Stockholders’ Representative shall have been furnished with a certificate, executed by a duly authorized officer of Eclipsys,
dated the Closing Date, certifying as to the fulfillment of the conditions in Sections 8.3(a) and (b); 
 (d) the Escrow Agent and Eclipsys shall have executed the Holdback Escrow Agreement; 
 (e) Eclipsys shall have
delivered the Closing Payment to the Paying Agent; 
 (f) Eclipsys shall have delivered the Holdback Amount to the Escrow
Agent; 
 (g) since the date of this Agreement, there shall have been no event, change, occurrence, condition or circumstance
that MediNotes and the Stockholders’ Representative determines, in good faith, has had or is reasonably likely to have, individually or in the aggregate, a Material Adverse Effect on Eclipsys; 
 (h) [deliberately deleted] 
  

 87 

 (i) there shall not be pending or threatened by any Governmental Entity any suit, action
or proceeding (or by any other Person (other than a Stockholder or any third-party alleging rights as a holder of Capital Stock of MediNotes), any suit, action or proceeding which MediNotes determines in good faith has a reasonable likelihood of
success to enjoin or prohibit the consummation of the transactions contemplated hereby, or to materially limit the rights of the Stockholders hereunder): (A) seeking to obtain from the Stockholders in connection with the Merger or the other
transactions contemplated hereby or by the other Transaction Documents money damages in excess of $100,000 that Eclipsys does not commit to pay; (B) claiming that such Person is an owner of, or has the right to acquire or to obtain ownership
of, any assets of MediNotes with a value in excess of $100,000; or (C) that may otherwise have the effect of preventing, materially delaying, or otherwise materially interfering with the transactions contemplated by this Agreement and the other
Transaction Documents; 
 (j) all required corporate action on the part of Eclipsys and Merger Sub, including without
limitation approval by the boards of directors of Eclipsys and Merger Sub, shall have been taken (and not rescinded) to approve the execution, delivery and performance of this Agreement and the other Transaction Documents; 
 (k) Eclipsys shall have executed a Commission Agreement in the form of Exhibit H and delivered such agreement to Bond Medical
Group; 
 (l) the Major Stockholders shall have received such other documents as the Stockholders’ Representative
reasonably requests evidencing the satisfaction of any condition referred to in this Section 8.3. 
 ARTICLE IX 

TERMINATION 
 9.1 Termination by
Mutual Consent. This Agreement may be terminated and the transactions contemplated hereby may be abandoned at any time prior to the Closing Date, by mutual written consent of MediNotes and Eclipsys. 
 9.2 Termination by Eclipsys or MediNotes. This Agreement may be terminated and the transactions contemplated hereby may be abandoned at any time
prior to the Closing Date by either Eclipsys or MediNotes if any Order permanently restraining, enjoining or otherwise prohibiting the Merger or the Second Merger shall be entered and such Order is or shall have become nonappealable, provided that
(i) the party seeking to terminate this Agreement shall have complied with its obligations under Section 6.2 with respect to the removal or lifting of such Order (including, with respect to MediNotes, the Major Stockholders), and
(ii) the noncompliance with this Agreement by the party seeking to terminate this Agreement (including, with respect to MediNotes, the Major Stockholders) shall not have been the proximate cause of the issuance of the Order. 
  

 88 

 9.3 Termination by MediNotes. This Agreement may be terminated and the transactions contemplated
hereby may be abandoned at any time prior to the Closing Date, by MediNotes if: 
 (a) (i) the Closing shall not have been
consummated on or before November 15, 2008 (the “Termination Date”), or 
 (ii) any of the
conditions (other than absence of material breach as addressed in Section 9.3(b)) set forth in Section 8.1 or 8.3 shall have become incapable of fulfillment; 
 provided, however, that the right to terminate this Agreement pursuant to this subsection (a) shall not be available to MediNotes if MediNotes
or the Major Stockholders or any of them has breached in any material respect their obligations under this Agreement in any manner that shall have proximately contributed to the failure referenced in this subsection (a); or 
 (b) there has been a material breach by Eclipsys or Merger Sub of any representation, warranty, covenant or agreement of Eclipsys or
Merger Sub contained in this Agreement that is not curable or, if curable, is not cured prior to the earlier of (i) 30 days after written notice of such breach is given by MediNotes to Eclipsys and (ii) the Termination Date. 
 9.4 Termination by Eclipsys. This Agreement may be terminated and the transactions contemplated hereby may be abandoned at any time prior to the
Closing Date by Eclipsys if: 
 (a) (i) the Closing shall not have been consummated on or before the Termination Date, or

 (ii) any of the conditions (other than absence of material breach as addressed in Section 9.4(b)) set forth in
Section 8.1 or Section 8.2 shall have become incapable of fulfillment; 
 provided, however, that the right to
terminate this Agreement pursuant to this subsection (a) shall not be available to Eclipsys if Eclipsys or Merger Sub has breached in any material respect its obligations under this Agreement in any manner that shall have proximately
contributed to the failure referred to in this subsection (a); or 
 (b) there has been a material breach of any
representation, warranty, covenant or agreement of MediNotes or the Major Stockholders or any of them contained in this Agreement that is not curable or, if curable, is not cured prior to the earlier of (i) 30 days after written notice of such
breach is given by Eclipsys to MediNotes, and (ii) the Termination Date. 
 9.5 Effect of Termination. Except for
termination under Section 9.1, any termination shall be effective upon receipt of written notice thereof given to Eclipsys or MediNotes, as applicable. If this Agreement is terminated, all obligations of the parties under this Agreement
will terminate, without any Liability on the part of any party hereto to any Person in respect hereof or the transactions contemplated hereby and the other Transaction Documents, and no party shall have any claim against another, whether under
contract, tort or otherwise, except that (i) Sections 6.3(ii), 6.5 and 6.12 and Article X hereof and the Confidentiality Agreement will survive, and (ii) if this Agreement is terminated by a party because of the
breach of this Agreement by another party or parties or because one or more of the conditions to the terminating party’s obligations under this Agreement is not satisfied as a result of another party’s or parties’ failure to comply
with its obligations under this Agreement, the terminating party’s 

  

 89 

 
right to pursue all legal remedies for such breach will survive such termination unimpaired, provided that MediNotes and the Major Stockholders each agree
that to the extent they have incurred any Damages in connection with termination of this Agreement as set forth in the preceding clause, the maximum liability of Eclipsys and Merger Sub (and the sole and exclusive remedy of MediNotes and the
Stockholders) for such Damages shall be limited in the aggregate to $800,000. The remedies set forth in this Section 9.5 are the sole and exclusive remedies of the parties if this Agreement is terminated, and MediNotes and the Major
Stockholders shall not be entitled to specific performance hereof. 
 ARTICLE X 
 MISCELLANEOUS 
 10.1 Entire Agreement; Assignment. 
 (a) This Agreement, including the schedules and exhibits hereto (which are incorporated herein by this reference), the other Transaction
Documents and the Confidentiality Agreement constitute the entire agreement, and supersede all prior agreements, understandings and other Contracts, both written and oral, and all contemporaneous oral agreements, understandings and other Contracts,
among the parties with respect to the subject matter hereof. Except for express representations, warranties and covenants of Eclipsys, Merger Sub, MediNotes and the Major Stockholders contained herein, or in the other Transaction Documents, there
are no representations or warranties whatsoever by or on behalf of MediNotes, the Major Stockholders, their Affiliates or agents relating to MediNotes or their ownership interests therein, on the one hand, and Eclipsys, Merger Sub and their
Affiliates or agents relating to Eclipsys or Merger Sub, on the other hand. 
 (b) Neither this Agreement nor any of the
rights, interests or obligations hereunder will be assigned by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of each of the other parties hereto; provided, however, that Eclipsys may
assign all or a portion of its rights and obligations, or those of Merger Sub, under this Agreement to any other Subsidiary of Eclipsys without the consent of MediNotes or the Major Stockholders (which assignment shall not relieve Eclipsys of any
obligation or liability under this Agreement). 
 (c) This Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and permitted assigns. 
 10.2 Validity. The invalidity or unenforceability of any
provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, each of which shall remain in full force and effect and in lieu of such invalid or unenforceable provision there shall be
automatically added as part of this Agreement a valid and enforceable provision as similar in terms to the invalid or unenforceable provision as possible, provided that this Agreement as amended, (i) reflects the intent of the parties hereto,
and (ii) does not change the bargained for consideration or benefits to be received by each party hereto. 
  

 90 

 10.3 Notices. All notices, requests, claims, demands and other communications hereunder
shall be in writing and shall be deemed to have been duly given when delivered in person, by overnight courier or facsimile (provided that such notice is delivered during regular business hours in the location of receipt, and if not, then on the
next Business Day) to the respective parties as follows: 
 If to Eclipsys: 
 Eclipsys Corporation 
 Three Ravinia Drive

 Suite 1000 
 Atlanta, GA 30348

 Fax: (404) 847-5777 
 Attn.: General Counsel 
 with a copy to (which copy shall not constitute notice): 
 Gibson, Dunn & Crutcher LLP 
 3161
Michelson Drive 
 Irvine, CA 92612 
 Fax: (949) 475-4703 
 Attn.: Michelle Hodges 
 If to MediNotes or the Major Stockholders (prior to the Closing): 
 MediNotes Corporation 
 1025 Ashworth Road, Suite 222 
 West Des
Moines, IA 50265 
 Fax: (515) 327-8856 
 Attn.: Donald G. Schoen 
 If to the Stockholders’ Representative: 
 Danny R. Wipff 
 8866 Gulf Freeway, Ste. 335

 Houston, TX 77017 
 dwipf@aol.com 
 in each case, with a copy to (which copy shall not constitute notice): 
 Fredrikson & Byron, P.A. 
 200 South
Sixth Street, Suite 4000 
 Minneapolis, MN 55402 
 Fax: (612) 492-7077 
 Attn.: Steven J. Dickinson 
 or to such other address as the Person to whom notice is given may have previously furnished to the others in writing in the manner set forth above. 
  

 91 

 10.4 Governing Law. This Agreement shall be governed by and construed in accordance with the laws
of the State of Delaware, regardless of the laws or rules that might otherwise govern under applicable principles of conflicts of laws thereof. In the event of the bringing of any action or suit by a party hereto against another party hereunder
arising out of or relating to this Agreement, which claim or suit is not subject to arbitration, as determined pursuant to Section 10.14, then in that event, the sole forum for resolving such disputes shall be the state and federal
courts located in Delaware, and each of the parties hereby irrevocably submits to such exclusive jurisdiction. This Section 10.4 shall survive any termination of this Agreement and the Closing. 
 10.5 Construction. 
 (a) The headings herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement. Unless the context clearly requires otherwise “or” is not
exclusive, and “includes” means “includes, but is not limited to.” 
 (b) Each of the parties acknowledges
that it has been represented by counsel of its choice throughout all negotiations that have preceded the execution of this Agreement and that each party and its counsel cooperated in the drafting and preparation of this Agreement and the other
Transaction Documents, and any and all drafts relating thereto exchanged between the parties shall not be construed against any party by reason of its preparation. Accordingly, any ambiguities in this Agreement will not be interpreted against any
party that may have drafted this Agreement. 
 (c) For purposes of this Agreement, “commercially reasonable efforts” will not be
deemed to require a Person to undertake extraordinary or unreasonable measures, including the payment of amounts in excess of normal and usual filing fees and processing fees. 
 10.6 Counterparts. This Agreement may be executed in counterparts, including facsimile counterparts, each of which shall be deemed to be an
original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile transmission or PDF by electronic transmission shall be effective delivery of a manually
executed counterpart to this Agreement. 
 10.7 Parties In Interest. This Agreement shall be binding upon and inure solely to the
benefit of each party hereto and, except for the Persons expressly set forth in Section 7.2 and Section 10.8, with respect to such sections, nothing in this Agreement, express or implied, is intended to confer upon any other
Person any rights or remedies of any nature whatsoever under or by reason of this Agreement, including any employee or former employee of MediNotes (or any beneficiary or dependent thereof). 
 10.8 Prior Review and Counsel. Eclipsys and Merger Sub, on the one hand, and MediNotes and the Major Stockholders jointly, on the other hand, each
represents and warrants that: (a) it was provided a fair and reasonable time in which to evaluate this Agreement and the other Transaction Documents and to negotiate their respective terms and conditions; (b) it has regularly
consulted with and received advice and counsel from one or more attorneys of its own 

  

 92 

 
choice regarding the Merger, this Agreement, the other Transaction Documents and the negotiation of each and every one of them, which attorney(s) is/are not
and was/were not any of the other party’s attorneys; (c) it has not received any legal or other substantive advice or any attorney work product from any of the other party’s attorneys (including in-house attorneys), and it has not
relied upon any comment, observation, remark, communication or information (whether oral or written) made or delivered by any of the other party’s attorneys (including in-house attorneys); and (d) it has read and fully understands this
Agreement and each of the other Transaction Documents. Each party’s attorneys (including in-house attorneys) shall be entitled to rely on the other party’s representations and warranties made in this Section 10.8 as
intended beneficiaries of such representations and warranties. 
 10.9 Waiver. No waiver of any breach of the provisions of this
Agreement will be deemed to have been made by any party, unless such waiver is expressed in writing and signed by the party against which it is to be enforced (or the Stockholders’ Representative, with respect to matters relating to all Major
Stockholders or all Stockholders). The waiver by any party of any right under this Agreement or to a remedy for the breach of any of the provisions herein shall not operate or be construed by the breaching party as a waiver of the non-breaching
party’s remedies with respect to any other or continuing or subsequent breach. 
 10.10 Amendments. No amendment or
modification in respect of this Agreement shall be effective unless it shall be in writing and signed by the parties hereto (or the Stockholders’ Representative, with respect to matters relating to all Major Stockholders or all Stockholders
after the Closing Date). 
 10.11 Specific Performance. The parties agree that irreparable damage would occur in the event any
provision of this Agreement were not performed by MediNotes or the Major Stockholders in accordance with the terms hereof and that Eclipsys shall be entitled to an injunction or injunctions to prevent breaches of this Agreement by MediNotes and the
Major Stockholders and to enforce specifically the terms and provisions of this Agreement in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to which it is entitled at law or in equity.

 10.12 Further Assurances. The parties agree (a) to furnish upon request to each other such further information, (b) to
execute and deliver to each other such other documents, and (c) to do such other acts and things, all as any other party hereto may reasonably request for the purpose of carrying out the transactions contemplated by this Agreement pursuant to
the terms hereof. 
 10.13 Cumulative Remedies. Except as expressly limited herein, the rights, remedies, powers and privileges herein
provided are cumulative and not exclusive of any other rights, remedies, powers and privileges provided by law or equity. 
 10.14
Arbitration. 
 (a) Any dispute, claim or controversy arising out of or relating to this Agreement or any other
Transaction Document (other than the Employment Agreements) or the breach, termination, enforcement, interpretation or validity thereof, including the determination 

  

 93 

 
of the scope or applicability of this Agreement to arbitrate, shall be determined by arbitration in Dallas, Texas, before a sole arbitrator; provided,
however, if the claim and any counterclaim, in the aggregate, exceed $750,000, exclusive of interest and attorneys’ fees, the dispute shall be heard and determined by three arbitrators as provided herein. If any such dispute, claim or
controversy arises at the same time and relates to the same or similar facts, claims or events as any one or more other disputes, claims or controversies, such disputes, claims or controversies (including any dispute, claim or controversy under
Section 2.11), shall, to the extent practicable, be combined in one arbitration proceeding under this Section 10.14, and in such event, the provisions of this section governing dispute resolution shall supersede any other
provisions relating to such matters in this Agreement or the other Transaction Documents. If any dispute, claim or controversy arising out of or relating to this Agreement or any other Transaction Document (other than the Employment Agreements)
arises at the same time and relates to the same or similar facts, claims or events as a dispute, claim or controversy relating to or arising out of the Employment Agreement of any Stockholder, the employment of any Stockholder by Eclipsys or any of
its Affiliates including MediNotes, such disputes, claims or controversies shall, to the extent practicable, be combined in one arbitration proceeding, and in such event, the provisions of this Agreement governing dispute resolution shall supersede
any provisions relating to such matters in the Employment Agreement between any such Stockholder and Eclipsys or any Affiliate of Eclipsys. For the avoidance of doubt, no claim under any Employment Agreement shall be governed by this provision,
unless it arises at the same time and relates to the same or similar facts, claims or events as a dispute, claim or controversy relating to or arising out of this Agreement or any other Transaction Document (other than the Employment Agreements).

 (b) Notwithstanding the foregoing, if any dispute, claim or controversy arises out of or relates to this Agreement or any
other Transaction Document (other than a dispute solely relating to any Employment Agreement), the parties shall first try to resolve their dispute through informal and good faith negotiation between an authorized officer of MediNotes (or, after the
Closing, the Stockholders’ Representative) and an authorized officer of Eclipsys, with authority to settle such dispute claim or controversy, before resorting to arbitration. Such persons shall meet for the purpose of endeavoring to resolve
such dispute, claim or controversy within ten Business Days after a written request from either MediNotes (or, after the Closing, the Stockholders’ Representative) or Eclipsys to the other. Such representatives shall discuss the problem and
negotiate in good faith in an effort to resolve the dispute promptly and without the necessity of any formal arbitration proceeding relating thereto. The location, format and duration (not to exceed three Business Days, unless mutually agreed
by such representatives) of these negotiations shall be left to the discretion of the representatives involved. If such negotiations do not lead to resolution of the underlying dispute, claim or controversy to the satisfaction of any party,
then any party may provide notice of the election to pursue resolution by arbitration as set forth herein. 
 (c) The
arbitration shall be conducted by JAMS pursuant to the Comprehensive Arbitration Rules of JAMS. All arbitrators shall be retired or former district court or appellate court judges of any United States District Court or United States Court of
Appeals, other than courts in the States of Iowa or Georgia, or such other person with such other qualifications as Eclipsys and MediNotes (or, after the Closing, the Stockholders’ Representative) may agree, and shall be selected within seven
Business Days after receipt of 

  

 94 

 
notice from one party to another that it intends to seek arbitration hereunder. The Federal Rules of Evidence shall govern the admissibility of evidence
during the arbitration. The arbitrator(s) will have no authority to award punitive or other damages not measured by the prevailing party’s actual damages, except as may be required by statute. The determination of the arbitrator(s) shall be
final and binding on the parties and a judgment on such award or determination may be entered in any court of competent jurisdiction and such judgment shall be final and non-appealable. The decision and award of the arbitrator(s) shall be
accompanied by a reasoned opinion. 
 (d) All parties covenant not to appeal or otherwise litigate or file any court action
that would seek to delay, amend, vacate or otherwise alter the determination of the arbitrator(s). 
 10.15 Costs and Fees. The
prevailing party in any arbitration or court proceeding under this Agreement, including any related appeal, will be entitled to recover its fees and costs incurred in the arbitration or proceeding (including attorneys and arbitration fees and costs)
from the non-prevailing party, provided that the arbitrator or judge has the discretion to determine that there is no prevailing party or to eliminate or reduce the prevailing party’s recovery of its costs and fees to the extent that the
arbitrator or judge determines that full recovery thereof would be unreasonable or disproportionate to the harm suffered by the prevailing party. In absence of a determination of a prevailing party, the parties shall split equally all costs and
fees. “Costs and fees” mean all reasonable pre-award expenses of the arbitration or other proceeding, including the arbitrators’ fees, administrative fees, travel expenses, out-of-pocket expenses such as copying and
telephone, court costs, witness fees, expert costs and fees, and attorneys’ fees, costs and expenses and other costs incurred in enforcing, perfecting and executing such judgment or order. For the purposes of this section, attorneys’ fees,
costs and expenses shall include all such fees, costs and expenses incurred in (i) appeals, (ii) post-judgment motions, (iii) contempt proceedings, (iv) garnishment, levy, and debtor and third-party examinations,
(v) discovery, and (vi) bankruptcy litigation. 
 [Signature page follows] 
  

 95 

 IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed as of the day and year
first above written. 
  

									
	 “ECLIPSYS”
	 		 	“MEDINOTES”
	Eclipsys Corporation,	 		 	MediNotes Corporation,
	a Delaware corporation	 		 	an Iowa corporation
					
	By: 	 	/s/ R. Andrew Eckert	 		 	By: 	 	/s/ Donald G. Schoen
	Name: 	 	R. Andrew Eckert	 		 	Name: 	 	Donald G. Schoen
	Title:	 	Chief Executive Officer	 		 	Title:	 	CEO & President

  

					
	“MERGER SUB”
	Sirona Acquisition Corporation,
an Iowa corporation
		
	By: 	 	/s/ R. Andrew Eckert
	Name: 	 		 	R. Andrew Eckert
	Title:	 		 	Chief Executive Officer

  

	
	“STOCKHOLDERS’ REPRESENTATIVE”
	
	/s/ Danny R. Wipff
	Danny R. Wipff

									
	“MAJOR STOCKHOLDERS”	 		 	
				
	By: 	 	/s/ Donald G. Schoen	 		 	Iowa Capital Corporation
					
	By: 	 	/s/ Madelyn K. Schoen	 		 	By: 	 	/s/ Terry L. Sullivan
		 	Donald G. and Madelyn K. Schoen,	 		 	Name:	 	Terry L. Sullivan
		 	as JTWRS	 		 	Title:	 	Vice President
				
	By:	 	/s/ Donald G. Schoen	 		 	Iowa Farm Bureau Federation
		 	Donald G. Schoen, an individual	 		 		 	
					
	By:	 	/s/ Madelyn K. Schoen	 		 	By:	 	/s/ Edward G. Parker
		 	Madelyn K. Schoen, an individual	 		 	Name:	 	Edward G. Parker
		 		 		 	Title:	 	General Counsel
				
	By:	 	/s/ Travis Bond	 		 	IOWA FIRST CAPITAL FUND II LP
		 	Travis Bond, an individual	 		 	  
 By:
	 	  
 Corridor Management Co. LLC,
 its General Partner

		 		 		 	 
					
	By:	 	/s/ Davin S. Hills	 		 	By:	 	/s/ Dennis C. Wangeman
		 	Davin S. Hills, an individual	 		 	Name:	 	Dennis C. Wangeman
		 		 		 	Title:	 	President
				
	By:	 	/s/ Danny R. Wipff	 		 	
		 	Danny R. Wipff, an individual	 		 		 	
				
	By:	 	/s/ Suzanne B. Schoen	 		 	
		 	     Suzanne B. Schoen,
	 		 		 	
		 	 Sole Trustee of the Sophie B. Berlin
 Revocable Trust
“B,” EIN #36-6702116
	 		 		 	
				
	By:	 	/s/ Suzanne B. Schoen	 		 	
		 	     Suzanne B. Schoen,
	 		 		 	
		 	 Sole Trustee of the Suzanne B. Schoen
 Revocable Trust
U/A 10-08-75
	 		 		 	
				
	By:	 	/s/ Robert C. Westlund	 		 	
		 	     Robert C. Westlund,
	 		 		 	
		 	 Sole Trustee of the Robert C. Westlund
 Trust U/A dated
December 28, 1993

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00149-of-00352.parquet"}]]